Salmon in Pregnancy Study (SIPS): the effects of increased oily fish consumption on maternal nutrient intake, fatty acid status and
immunity by Kremmyda, Lefkothea-Stella
University of Southampton Research Repository
ePrints Soton
Copyright © and Moral Rights for this thesis are retained by the author and/or other 
copyright owners. A copy can be downloaded for personal non-commercial 
research or study, without prior permission or charge. This thesis cannot be 
reproduced or quoted extensively from without first obtaining permission in writing 
from the copyright holder/s. The content must not be changed in any way or sold 
commercially in any format or medium without the formal permission of the 
copyright holders.
  
 When referring to this work, full bibliographic details including the author, title, 
awarding institution and date of the thesis must be given e.g.
AUTHOR (year of submission) "Full thesis title", University of Southampton, name 
of the University School or Department, PhD Thesis, pagination
http://eprints.soton.ac.ukUNIVERSITY OF SOUTHAMPTON 
 
INSTITUTE OF HUMAN NUTRITION, DEVELOPMENTAL ORIGINS OF 
HEALTH AND DISEASE 
 














Salmon in Pregnancy Study (SIPS): The effects of increased oily fish 

























Thesis for the degree of Doctor of Philosophy 
 
August 2010 
   I 
UNIVERSITY OF SOUTHAMPTON 
ABSTRACT 
INSTITUTE OF HUMAN NUTRITION, DEVELOPMENTAL ORIGINS OF HEALTH AND 
DISEASE 
SCHOOL OF MEDICINE 
Doctor of Philosophy 
SALMON IN PREGANCY STUDY (SIPS): THE EFFECTS OF INCREASED OILY FISH 
CONSUMPTION ON MATERNAL NUTRIENT INTAKE, FATTY ACID STATUS AND 
IMMUNITY 
By Lefkothea-Stella Kremmyda 
 
The prevalence of childhood atopic diseases (eczema, asthma, allergies, hay-fever) has increased 
during the last 30 years. Epidemiological studies link higher fish intake during pregnancy with 
lower risk of atopy in the offspring. Oily fish provide the long chain (LC) n-3 polyunsaturated 
fatty acids (PUFA) eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), as well as 
vitamin  D  and  antioxidants  (selenium).  Fish  oil  provides  EPA  and  DHA  and  fish  oil 
supplementation during pregnancy alters offspring immunity in a way that would be consistent 
with lowered risk of atopy. There are no studies of oily fish intervention in pregnancy. 
The Salmon in Pregnancy Study (SIPS) is the first randomised controlled trial of oily fish 
intervention during pregnancy. The main outcome measures of SIPS were the clinical signs of 
atopy in the offspring (not reported here). The current thesis presents and discusses results of 
SIPS mainly relating to the mother. The hypotheses examined here are that increased oily fish 
consumption  during  pregnancy  will:  a)  increase  maternal  LC  n-3  PUFA  intake  b)  increase 
maternal LC n-3 PUFA status, c) alter maternal immunity, which may influence the developing 
foetal immune system in a way that would decrease atopy risk for the offspring.  
Pregnant women (n = 123) with high risk of having atopic offspring and with low habitual 
intake of oily fish (≤ 2/month) were randomised at 20 weeks of pregnancy to either consuming 2 
portions/week of farmed salmon (n = 62) or continuing their habitual diet (n = 61) until the end 
of pregnancy. The women attended a clinic at weeks 20 (n = 123), 34 (n = 110), and 38 (n = 91) 
of pregnancy at which fasting blood samples were collected for fatty acid and immunological 
analysis, and a food frequency questionnaire (FFQ) was administered (at 20 and 34 weeks). At 
delivery, placenta and umbilical cord tissue were collected for fatty acid analysis. Mothers were 
followed-up at 3 months postpartum when the FFQ was administered (n = 88). Maternal plasma, 
peripheral  blood  mononuclear  cell  (PBMC),  placenta  nad  umbilical  cord  tissue  fatty  acid 
compositions were determined by gas chromatography (GC). Maternal immune cell subsets were 
determined by flow cytometry (FACS); ex-vivo cytokine production by PBMC in response to 
stimulants  (allergens,  mitogen,  and  toll-like  receptor  (TLR)  ligands)  was  determined  by 
cytometric bead array (CBA) and FACS; and eicosanoid (prostaglandin (PG) E2) production by 
PBMC was determined by enzyme-linked immunosorbent assay (ELISA).  
Subjects complied with the salmon intervention and this increased their intakes of EPA, 
DHA,  vitamin D and  selenium. The  salmon  intervention prevented the pregnancy-associated 
depletion  in LC n-3 PUFA and resulted  in  higher LC n-3 PUFA status in  maternal plasma, 
maternal  PBMC,  placenta  and  cord  tissue.  Effects  of  pregnancy  on  many  of  the  immune 
parameters assessed here were identified. However, the salmon intervention had only limited 
impact on maternal immunity as measured here, and thus it cannot be concluded whether the 
intervention would have an effect on the immune system of the offspring. 
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1  General Introduction 
 
 
   2 
This introduction aims to provide information on fatty acids (Section 1.1), the immune 
system (Section 1.2), immune system changes during pregnancy and the early life origins 
of  atopic  disease  (Section  1.3),  the  link  between  fatty  acids  and  the  immune  system 
(Section 1.4), the scientific evidence available concerning the effects of increased intake of 
long-chain n-3 fatty acids during early life on immune system development and atopic 
disease (Section 1.5), leading to the hypotheses and aims of this PhD thesis (Chapter 2). 
 
1.1  Fatty Acids: Structure, Nomenclature, Types, Dietary 
Sources, and Metabolism 
The  aim  of  this  section  is  to  provide  introductory  information  about  fatty  acids 
including their nomenclature, structure, and metabolism, as well as dietary sources and 
intakes and current recommendations. 
1.1.1  Structure of fatty acids 
Lipids are organic compounds composed of a carbon skeleton with mainly hydrogen 
and oxygen substitutions, and include fatty acids and their esters with alcohols such as 
glycerol or cholesterol. 
Fatty  acids  are  the  main  components  of  dietary  lipids.  They  are  carboxylic  acids, 
varying in chain length from one to more than 30 carbons. Their structure is RCOOH, 
where R can be a hydrogen in formic acid, a methyl group (CH3) in acetic acid, or a longer 
hydrocarbon chain of up to more than 30 methylene (CH2) groups and a terminal methyl 
group. The absence of double bonds in the hydrocarbon chain of a fatty acid defines it as 
saturated, whereas an unsaturated fatty acid contains one or more double  bonds  in the 
hydrocarbon chain. Fatty acids with one double bond in the hydrocarbon chain are termed 
monounsaturated fatty acids (MUFA) and those with two or more double bonds in the 
hydrocarbon chain are termed polyunsaturated fatty acids (PUFA).   3 
1.1.2  Physicochemical properties of fatty acids 
In general, saturated fatty acids have a higher melting point than unsaturated fatty 
acids,  and  unsaturated  fatty  acids  with  a  greater  degree  of  unsaturation  have  a  lower 
melting  point  than  those  with  fewer  double  bonds.  Also,  fatty  acids  with  a  longer 
hydrocarbon chain usually have a higher melting point. Therefore, PUFA are usually more 
easily  liquefied  than  saturated  fatty  acids  or  MUFA.  Unsaturation  results  in  structural 
variety  in  fatty  acids  and  allows  for  isomerisation.  A  saturated  fatty  acid  occupies,  in 
general, less space than an unsaturated fatty acid of the same length. This is because the 
insertion of double bounds increases the curvature of the unsaturated fatty acid causing it 
to occupy a greater area. When the two hydrogens at the double bond are on the same side 
of the molecule as each other the bond is termed cis-unsaturated and when the hydrogens 
are on the opposite side of the double  bond to one another the  bond  is termed trans-
unsaturated. This leads to different orientation of the adjoining carbons across the double 
bond. A cis-fatty acid molecule has a curved structure whereas a trans-fatty acid does not. 
Thereby  the  physicochemical  properties  of  a  trans-fatty  acid  are  closer  to  those  of  a 
saturated fatty acid. Lastly, most naturally occurring PUFA have a methylene (CH2) group 
between the two double bonds. This methylene interruption of the double bonds can be lost 
when bonds move one carbon closer as a result of particular metabolic processing of fatty 
acids or of industrial processing of fats and oils for use in the food industry. These isomers 
are termed conjugated.  
1.1.3  Nomenclature of fatty acids 
Individual fatty acids have both common and systematic names, as well as a shorthand 
notation that reflects the number of carbons, the number of double bonds and the position 
of the first double bond from the methyl-terminus. Because of the methylene interruption 
of the double bonds in PUFA, the position of the rest of the double bonds is assumed and 
not referred to in the shorthand notation. The n- notation is also referred to as ω or omega. 
For example, the shorthand notation 18:1n-9 refers to the common MUFA oleic acid which 
has 18 carbons and one double bond at the ninth carbon from the methyl-terminus. Table 
1.1 presents the nomenclature and dietary sources of common fatty acids.   4 
 
Table 1.1 Nomenclature and typical sources of fatty acids 
Systematic name  Common name  Shorthand 
notation 
Typical sources 
Saturated fatty acids       
Dodecanoic  Lauric  12:0  Coconut oil 
Tetradecanoic  Myristic  14:0  Milk 
Hexadecanoic  Palmitic  16:0  Milk, eggs, animal fats, meat, 
palm oil 
Octadecanoic  Stearic  18:0  Milk, eggs, animal fats, meat, 
cocoa butter 
Monounsaturated fatty acids 
9-Hexadecanoic  Palmitoleic  16:1n-7  Animal fats, vegetable oils 
9-Octadecanoic  Oleic  18:1n-9  Animal fats, olive oil 
Polyunsaturated fatty acids 








γ-Linolenic  18:3n-6  Evening primrose oil 
5,8,11-Eicosatrienoic  Mead  20:3n-9  Synthesised from oleic acid 




Arachidonic  20:4n-6  Synthesised from linoleic 
acid, marine algae 
5,8,11,14,17-
Eicosapentaenoic 
Eicosapentaenoic  20:5n-3  Fish, fish oils, marine algae 
4,7,10,13,16,19-
Docosapentaenoic 
Docosapentaenoic  22:5n-3  Fish, fish oils, marine algae 
4,7,10,13,16,19-
Docosahexaenoic 
Docosahexaenoic  22:6n-3  Fish, fish oils, marine algae 
Modified from (1)   5 
 
1.1.4  Synthesis and metabolism of fatty acids 
Fatty acids can also be categorised into general groups according to the length of their 
chain. Short-chain fatty acids contain less than 8 carbons, medium-chain fatty acids contain 
8-14 carbons, and fatty acids with more than 14 carbons are termed long-chain and are the 
main constituents of dietary fat.  
Long-chain fatty acids can either be taken directly from the diet, or can originate by 
complete synthesis from acetyl-coenzyme A in the cytosol, or by chain elongation of a pre-
existing shorter chain fatty acid. Saturated fatty acids and most MUFA can be synthesised 
in mammals from non-fat precursors, such as glucose or amino acids.  
However, not all fatty acids can be synthesised de novo (from acetate) in mammals, as 
they cannot insert double bonds before carbon 9 in oleic acid. More specifically, mammals 
cannot convert oleic acid (18:1n-9) into linoleic acid (18:2n-6), or linoleic acid into α-
linolenic acid (18:3n-3). Linoleic and α-linolenic acids are the primary dietary cis-PUFA 
and,  because  they  cannot  be  synthesised  de  novo,  their  intake  from  food  sources  is 
essential. Thus linoleic and α-linolenic acids are termed essential fatty acids. What is more, 
mammalian tissues cannot interconvert n-6 and n-3 fatty acids. Only plants are capable of 
these conversions.  
However, elongases and desaturases in mammalian cells are able to extend and insert 
further double bonds into linoleic and α-linolenic acids taken from the diet, these fatty 
acids  acting  as  precursors  of  the  families  of  n-3  and  n-6  fatty  acids.  In  particular, 
docosahexaenoic acid (DHA; 22:6n-3) and eicosapentaenoic acid (EPA; 20:5n-3) can be 
made  by  elongation  and  desaturation  of  α-linolenic  acid,  and  arachidonic  acid  (ARA; 
20:4n-6) can be made by elongation and desaturation of linoleic acid. Derivatives of the 
essential fatty acid metabolism may be described as conditionally essential. The structures 






Linoleic acid ︵18:2n-6 ︶
Arachidonic acid ︵20:4n-6  ︶
H3C
α-Linolenic acid ︵18:3n-3 ︶
COOH H3C
Eicosapentaenoic acid ︵20:5n-3 ︶
COOH
H3C
Docosahexaenoic acid ︵22:6n-3 ︶ 
Figure 1.1 Structure of n-3 and n-6 polyunsaturated fatty acids 
 
Figure 1.2 describes the metabolism of n-6 and n-3 polyunsaturated fatty acids. These 
metabolic pathways are not so efficient in mammals (2), although reasons for this are not 
yet clear. The two families of fatty acids (n-3 and n-6) have different affinities for the 
desaturation and elongation enzymes. The metabolic pathway is principally based in the 
endoplasmic reticulum and has also been demonstrated to occur in mitochondria. The last 
step of the pathway is more complex, since the existence of Δ4-desaturase in animals has 
not  been  proven,  and  it  appears  that  fatty  acids  undergo  a  second  elongation,  Δ6-
desaturation and a final chain shortening in peroxisomes (3, 4).  
Linoleic acid is the predominant PUFA in the diet and in the body, accounting for 12-
15% of adipose tissue fatty acids (5, 6). In cell membranes, linoleic and arachidonic acids 
are the principal n-6 PUFA, and DHA is the principal n-3 PUFA (3, 7).   7 
 
Figure 1.2 Metabolism of n-3 and n-6 polyunsaturated fatty acids 



















































β-oxidation   8 
 
1.1.5  Sources of n-6 and n-3 fatty acids 
Linoleic and α-linolenic acids are found in plant tissues and plant oils. Linoleic acid 
comprises  over  50%,  often  up  to  80%,  of  the  fatty  acids  found  in  corn,  sunflower, 
safflower and soybean oils. Other plant oils, such as rapeseed and soybean oil, also contain 
α-linolenic acid but in smaller amounts (between 5 and 15% of total fatty acids). Flaxseed 
oil contains a high proportion of α-linolenic acid. Table 1.2 describes the linoleic and α-
linolenic acid contents of various plant oils, seeds and nuts. 


























1 Data taken from (8) 
  Polyunsaturated fatty acids, g per 100 g total fatty acids
1 
Food  α-Linolenic acid (18:3n-3)  Linoleic acid (18:2n-6) 
Oils 
Corn oil  0.90  50.40 
Evening primrose oil  0.12  68.81 
Peanut oil  0  31.00 
Rapeseed oil  9.60  19.70 
Safflower oil  0.10  73.90 
Sesame oil  0.30  43.10 
Soyabean oil  7.30  51.50 
Sunflower oil  0.10  63.20 
Walnut oil  11.5  58.40 
Nuts and Seeds 
Almonds  0.27  10.19 
Brazil nuts  0  25.43 
Hazelnuts  0.12  6.50 
Peanuts  0.35  12.75 
Poppy seeds  0.45  27.20 
Pumpkin seeds  0.13  21.58 
Sesame seeds  0.15  25.35 
Sunflower seeds  0.09  28.06 
Walnuts  7.47  39.29   9 
The long-chain n-3 PUFA EPA and DHA are found in oily fish and fish oils. White 
fish, like cod, have flesh that is very low in fat as these fish accumulate fat in their liver. 
Oily fish have fat in their flesh and its amount is related to their diet, stage of maturation, 
season  and  breeding  cycle,  after  breeding  the  fat  content  falls  considerably.  Oily  fish 
contain 5-20% fat in their flesh as opposed to white fish which contain only 1-2% fat. Oily 
fish include sardines, salmon, pilchards, mackerel, herring, and trout, whether fresh, frozen 
or canned. Fresh tuna is also an oily fish. However, unlike other canned oily fish, canned 
tuna is not regarded as oily, as processing of tuna during canning reduces its fat content. 
Table 1.3 lists common oily and non-oily fish and their n-3 and n-6 PUFA contents.  
 
   10 
 




1 PUFA, polyunsaturated fatty acid(s); EPA, eicosapentaenoic acid; DPA, docosapentaenoic acid; DHA, 
docosahexaenoic acid; ARA, arachidonic acid; Tr, traces.
 
2 Data taken from (9) 
3 Data taken from (10) cited in (11) 
4 Figure reflects total long chain (LC) n-3 PUFA content, not total n-3 PUFA as in other fish types 
5 Data taken from (8)
  Total fat and polyunsaturated fatty acids, g per 100 g fish
1 






















2  13.2  2.17  1.83  0.32  0.51  0.11  0.69  0.18  0.29  0.04 
Kippers, fresh
2  17.7  3.86  3.52  0.24  1.15  0.10  1.34  0.24  0.18  0.03 
Mackerel, fresh
2  16.1  3.27  2.78  0.51  0.71  0.12  1.10  0.22  0.30  0.07 
Salmon, fresh
3   11.0
5  3.10
5  2.70
4    1.20  0.20  1.30       
Salmon, canned 
in brine
2  7.8  2.24  1.85  0.27  0.55  0.14  0.86  0.08  0.13  0.11 
Sardines, canned 
in oil, drained
2  14.1  4.94  2.27  2.60  0.89  0.10  0.82  0.36  2.54  0.04 
Sprats, fresh
2  11.0  3.04  2.68  0.31  0.93  0.10  1.35  0.08  0.11  0.07 
Trout, rainbow, 
fresh
2  5.2  1.73  1.32  0.41  0.23  0.09  0.83  0.06  0.34  0.03 
Tuna, fresh
3      1.50
4    0.30  0.10  1.10       
Non-oily Fish 
Cod, fresh
2  0.7  0.28  0.26  0.02  0.08  0.01  0.16  Tr  Tr  0.02 
Haddock, fresh
2  0.6  0.20  0.17  0.03  0.05  0.01  0.10  Tr  0.01  0.01 
Plaice, fresh
2  1.4  0.35  0.32  0.01  0.16  0.04  0.10  0  0  0 
Tuna, canned in 
brine, drained
2  0.6  0.21  0.17  0.04  0.02  0.01  0.14  0  0.01  0.02 
Fish products and Fish dishes 
Fish cakes
2  3.9  0.93  0.33  0.60  0.05  0.01  0.09  0.18  0.58  0.01 
Fish fingers, 
cod
2  7.8  1.38  0.17  1.28  0.04  0  0.03  0.10  1.21  0 
Scampi, breaded
2  0.90  0.20  0.06  0.14  0  0  0  0.06  0.14  0 
Taramasalata
2  52.9  15.14  5.00  10.81  0.14  0.05  0  4.43  10.52  0 
Crustacea and Molluscs 
Crab
2  5.50  1.36  1.10  0.24  0.47  0.08  0.45  0.02  0.02  0.12 
Mussels
2  2.70  0.76  0.68  0.08  0.41  0.02  0.16  0.02  0.02  0.05 
Oysters
2  1.30  0.41  0.37  0.05  0.14  0.02  0.16  0.01  0.02  0.01 
Prawns
2  0.60  0.13  0.11  0.03  0.06  Tr  0.04  0  0.01  0.01 
Squid
2  1.70  0.61  0.45  0.16  0.13  0.01  0.29  0  0.12  0.01   11 
 
1.1.6  PUFA and fish consumption in the UK 
Typical adult intakes of linoleic and α-linolenic acids in the UK are 10-15 and 0.75-
1.5 g/day respectively (12). The NDNS data (collected in 2000-2001) for adults aged 19-64 
years (in the total of the population, including non-consumers of fish) show that mean 
consumption  of  total  fish  is  217  g/week  (about  1.55  portions/week),  of  which  white 
(including fish products and dishes) was 103 g/week and oily fish (excluding canned tuna) 
50  g/week  (about  0.36  portion/week)  (12).  Amongst  those  consuming  fish,  mean 
consumption of total  fish was 304 g/week, of  which white  fish and oily  fish was 221 
g/week and 194 g/week, respectively. The fish mainly consumed were canned tuna (27%), 
fresh cod (25%), fresh haddock (9%), fresh salmon (9%), and canned and smoked salmon 
(8%). Only a very small percentage of the fish consumers consumed sardines, pilchards, 
mackerel, trout, herring and fresh tuna. During the period of the NDNS survey 74% of the 
participants  did  not  consume  oily  fish  (excluding  canned  tuna),  65%  did  not  consume 
coated and/or fried white fish and 82% did not consume other white fish and their dishes. 
The NDNS data were collected based on a seven day dietary record (12). 
The results of the most recent NDNS (2008/2009) showed similar results. Women 
aged 19-64  years (including  non-consumers) consume on average 7 g/day (49 g/week) 
coated and fried white fish, 15 g/day (105 g/week) other white fish, shellfish and tinned 
tuna, and 11 g/day (77 g/week) of oily fish. The same report, showed that amongst female 
consumers of oily fish (29% of women) aged 19-64 years old daily consumption was 39 
g/day (273 g/week or 2 portions/week) (13). This data shows that over 70% of women 
aged 19-64 years do not consume any oily fish, although within the 30% of consumers 
consumption is in accordance with the minimum recommendation.  
The most recent NDNS data (13) did not report on intake of LC n-3 PUFA. However, 
the previous NDNS results (12) showed that mean intake of EPA plus DHA for adults in 
the UK was 244 mg/day from fish and animal sources (12). Since about 70% of the adult 
population do not eat oily fish, this is an overestimate of true average intake which is likely 
to be 100  mg/day (14) or less (15). Also, according to NDNS (2008/2009) 2% of the 
population aged 19-64 years is vegetarian (13). However, it has been previously shown 
that the percentage of women in the UK who are vegetarians may be as high as 12% (12). 
Exclusion of meat and fish can result in low intake of EPA and DHA among pregnant 
vegetarian  women.  The  intake  of  DHA  among  pregnant  vegetarian  women  has  been 
estimated to be around 10-30 mg/day (16, 17).   12 
 
1.1.7  Recommendations for dietary intake of LC n-3 PUFA and fish 
It is recommended that for infants, children and adults linoleic acid should provide at 
least 1% of total energy and α-linolenic acid at least 0.2% of total energy (18). The current 
recommendation for EPA and DHA intake is at least 450 mg/day (11). Also, it has been 
recommended that DHA intake should be at least 200 mg/day in women of reproductive 
age (19). To achieve this  level of  intake, the  Committee on Medical  Aspects of  Food 
Policy (COMA) recommended eating at least two portions of fish, of which one should be 
oily,  weekly  (11).  The  average  fish  portion  size  for  adults  is  defined  140  g,  and  the 
estimate used for long-chain n-3 PUFA (EPA and DHA) content of an average oily fish is 
1.5-2 g/100 g and for an average white fish 0.3 g/100 g. The long-chain n-3 PUFA content 
of shellfish is about 0.4 g/100 g (12).  
The current recommendation for fish consumption for pregnant women and women of 
childbearing  age  is  the  same  as  the  recommendation  given  for the  general  population. 
However, pregnant women and women of reproductive age should not consume more than 
a total of two portions of oily fish and tinned tuna per week because of the possible high 
levels of mercury in these fish. For the same reason, pregnant women are advised to avoid 
eating shark, marlin and swordfish (11).  
The demand for long-chain PUFA for the development of the mammalian brain is 
high. Preformed long-chain PUFA, particularly DHA and EPA, may need to be provided in 
the diets of infants to meet the high requirements of rapidly growing tissues and organs 
(11). The mother is the primary source of these fatty acids for the foetus and breast-fed 
infant. The current mean dietary intake of DHA in the UK can be estimated around 100 
mg/day for adult women, and for those individuals who do not consume fish, or who are 
consuming a low fat diet the intake is likely to be less (12). It has been recommended that 
pregnant women need to consume 300 mg DHA/day (20). Koletzko et al. (21) concluded 
that pregnant and lactating women should aim to achieve an average dietary intake of at 
least 200 mg DHA/day. Intakes of up to 1 g DHA/day or 2.7 g/day long-chain n-3 PUFA 
have been used in randomised clinical trials in pregnant women without significant adverse 
effects. According to data reviewed by the Scientific Advisory Committee on Nutrition in 
2004 (11), there is some evidence that for many women there is a marginal status for n-3 
PUFA during pregnancy and lactation. However, there is a lack of agreed markers which 
are  suitable  for  defining  n-3  PUFA  status.  The  markers  usually  reported  relate  to 
concentrations of fatty acids within the circulation. They may be expressed as total fatty   13 
acids or related to their concentrations  in different circulating pools. Concentrations of 
fatty acids in maternal or umbilical blood have been used as measures of n-3 PUFA status 
during pregnancy. These measures have been related to maternal dietary intake (22), as 
well as to pregnancy outcomes (gestation duration, infant growth) (23-26). What is more, 
during pregnancy a woman must also meet the additional demands related to the accretion 
of  maternal,  placental,  and  foetal  tissues.  Although,  the  formation  of  DHA  and  EPA 
appears to be tightly regulated, a marginal state for many women during pregnancy and 
lactation cannot be excluded. The additional demands for EPA and DHA or other fatty 
acids during a normal pregnancy have not been adequately defined. It was concluded that 
the extent of dietary dependence on  increased  levels of consumption of n-3 PUFA, or 
specifically DHA, to improve pregnancy outcome needs to be demonstrated (11) 
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1.2  The Immune System 
The aim of this section is to present an overview of the components and the activities 
of the immune system. The text books ‘Immunology’ by Roitt, Brostoff, Male (27), and 
‘Immunobiology’ by Janeway (28) are recommended for further reading. 
Immunity  is  the  defence  system  of  the  body,  acting  to  protect  the  host  from 
pathogenic agents in the environment, such as bacteria, viruses, fungi and parasites, and 
other  potential  insults.  It  consists  of  complex  pathways  of  recognition,  response, 
elimination  and  memory,  and  it  is  divided  into  the  innate  (natural)  and  the  acquired 
(specific or adaptive) immune system (28). The immune response, in most cases, requires 
the coordination of the two types of immunity. All cells of the immune system originate in 
the bone marrow and result from the differentiation of stem cells (27).  
1.2.1  Innate Immunity 
Innate immunity has no memory and thus is not dependent on prior exposure to an 
infectious agent. It is the first line of defence against pathogens. The components of the 
innate immune system are the physical barriers of the body (skin, mucous membranes, 
lysozyme,  stomach  acid,  commensal  bacteria),  soluble  mediators  (macrophage  derived 
cytokines),  circulating  molecules  (complement),  and  phagocytic  cells  (granulocytes 
(neutrophils,  basophils, eosinophils),  monocytes,  macrophages), and  natural killer cells. 
Granulocytes, monocytes and macrophages are involved in pathogen killing, in clearing up 
cellular and tissue debris, and in tissue repair (29). Phagocytic cells are the main cellular 
component of the innate immune system. They express on their surface receptors specific 
for bacterial surface antigens or structures. Phagocytosis is triggered by the binding of the 
antigen or structure to its receptor. The pathogenic microorganism can then be destroyed 
by  complement  or  by  toxic  substances  (superoxide  radicals,  hydrogen  peroxide)  (30). 
Bacterial lipopolysaccharide (LPS; known also as endotoxin) is an important exogenous 
trigger. LPS is a component of the cell wall of Gram-negative bacteria. The role of natural 
killer  cells  is  also  important  as  they  also  have  receptors  on  their  surface  and  release 
cytotoxic proteins against microorganisms (31). 
1.2.2  Acquired Immunity 
Acquired  immunity  distinguishes  a  pathogenic  agent  as  foreign  to  the  host  by 
specifically  recognising  antigens  derived  from  the  pathogen.  The  components  of  the 
acquired immune system also consist of physicochemical barriers (cutaneous and mucosal 
immune  systems,  antibodies  in  mucosal  secretions),  soluble  mediators  (lymphocyte   15 
derived  cytokines),  circulating  molecules  (antibodies),  and  cells  (lymphocytes). 
Lymphocytes are the main cellular component of the acquired immune system and are 
divided  into  T-  and  B-lymphocytes.  Before  being  released  into  the  bloodstream,  B-
lymphocytes develop and mature in the bone marrow, whereas T-lymphocytes undergo 
maturation in the thymus. After they are released into the circulation, lymphocytes enter 
peripheral lymphoid organs: lymph nodes, the spleen, mucosal lymphoid tissue, tonsils, 
and  gut-associated  lymphoid  tissue.  Lymphoid  organs  are  organised  to  promote  the 
interaction  of  cells  and  pathogens,  and  thus  immune  responses  occur  mainly  in  these 
organs (29).  
The characteristics of the acquired immune response are that it is specific, diverse, has 
memory, and is self-regulated (32). The specificity of acquired immunity is attributed to 
the fact that each lymphocyte carries surface receptors specific for a single antigen. The 
acquired  immune  system  is  characterised  by  diversity  since  lymphocytes  recognise  an 
extremely wide variety of antigens (approximately 10
11). As a result, a small number of 
lymphocytes are able to recognise a specific antigen. For this reason the immune system 
has developed immunologic memory through clonal expansion (33). A single lymphocyte, 
after interacting with a specific antigen, proliferates giving rise to a clone of lymphocytes 
which are able to recognise and destroy the source of this antigen. The effectiveness of the 
acquired immune system becomes evident over several days after initial activation, and 
also  persists  some  time  after  removing  the  antigen  that  triggered  the  response. 
Immunologic memory results in higher effectiveness and flexibility of the immune system 
in case of re-exposure to the same antigen. The last feature of the acquired immune system, 
self-regulation,  reflects  its  ability  to  re-establish  homeostasis  through  communication 
between cells (7).   16 
 
1.2.3  B-Lymphocytes and humoral immunity 
B-lymphocytes produce antibodies, which are immunoglobulins that are specific for a 
single antigen. This form of immunity, which is performed exclusively by B-lymphocytes 
and deals with extracellular pathogens, is termed humoral immunity. The antibodies on the 
surface  of  the  B-lymphocyte  bind  with  their  specific  antigen  and  this  causes  B-
lymphocytes to proliferate and to differentiate into plasma cells, which in turn secrete large 
amounts of specific antibodies (33).  
Immunoglobulins  are  proteins  consisting  of  two  identical  heavy  chains  and  two 
identical light chains. There are five major classes of immunoglobulin (IgA, IgD, IgG, IgM 
and  IgE)  and  five  types  of  heavy  chain  respective  to  each  class  of  immunoglobulins. 
Antibodies can bind to microogranisms or toxins and prevent them from attaching to host 
cells.  Also,  antibodies  activate  complement  proteins  in  plasma  which  promote 
phagocytosis  of  bacteria.  Antibodies  enable  opsonisation,  the  process  through  which 
antigens and phagocytes interact. Antibodies possess binding sites for both the antigen and 
the receptors on the surface of phagocytic cells, and thus act like a link between these two. 
The  antibody  class  determines  the  type  of  the  phagocytic  cell  that  it  will  bind  with. 
Eosinophils are specific for IgE, and macrophages and neutrophils are specific for IgM and 
IgG. Because of the fact that antibodies are produced through very specific pathways, but 
promote the response of the innate immune system to destroy the pathogen, they form a 
bridge between acquired and innate immunity (29). 
1.2.4  T-Lymphocytes and cell-mediated immunity 
In  contrast  to  humoral  immunity,  cell-mediated  immunity  deals  with  intracellular 
pathogens, specifically viruses and some bacteria. Cell-mediated immunity is carried out 
by T-lymphocytes. T-lymphocytes use antigen-specific T-cell receptors (TCR) expressed 
on  their  surface  to recognise  antigens  presented  to them  on  the  surface  of  an  antigen 
presenting  cell  (APC),  which  ingest  the  pathogen  proteins  and  digest  them  into  small 
peptides. Thus, this type of acquired immunity is cell-mediated. The peptide fragments 
derived from the pathogen are transported to the surface of the APC and expressed there in 
conjunction  with  proteins  termed  major  histocompatibility  complex  (MHC),  after 
migration  of  the  cells  to  the  regional  lymph  nodes;  in  man  MHC  is  termed  human 
leukocyte antigen (33). The combination of the pathogen peptide fragment with the MHC 
is recognised by T-lymphocytes. There are two classes of MHC, MHC class I and MHC 
class II. MHC I binds peptides that are produced within the host cell cytosol originating   17 
from pathogen proteins (from viruses and certain bacteria). MHC II binds peptides that 
originate from pathogens that have been phagocytosed by macrophages or endocytosed by 
APC  (macrophages,  dendritic  cells,  B-lymphocytes).  MHC  I  bound  peptides  are 
recognised  by  T-lymphocytes  expressing  CD8,  whereas  MHC  II  bound  peptides  are 
recognised by T-lymphocytes expressing CD4 (34).  
Activation of the TCR results in proliferation of T-lymphocytes, and also synthesis 
and secretion of the cytokine interleukin-2 (IL-2) from them. IL-2 has an autocrine activity 
promoting  further  proliferation  and  differentiation  of  T-lymphocytes.  The  expanded  T-
lymphocytes  can  migrate  to  sites  of  infection,  injury  or  tissue  damage.  Cytotoxic  T-
lymphocytes (CD8
+) are stimulated by intracellular pathogens and they secrete cytotoxic 
enzymes which lyse the target cell, or secrete the antiviral cytokine interferon-γ (IFN-γ), or 
induce  apoptosis  of  target  cells  (35).  Helper  T-lymphocytes  (CD4
+)  are  stimulated  by 
extracellular pathogens and they induce the phagocytic activity of macrophages, and also 
proliferation of B-lymphocytes and antibody secretion from them (36).  
The  secretion  of  cytokines  by  antigen-activated  CD4
+  T-lymphocytes  causes 
recruitment of neutrophils and monocytes from the bloodstream to the site of infection, and 
also activation of monocytes. This type of cell-mediated immunity is termed delayed-type 
hypersensitivity (DTH), and is the primary defence against intracellular bacteria. The DTH 
may  be  caused  by  contact  with  chemicals  and  environmental  antigens.  Intradermal 
injection of microbial antigens also leads to DTH and has been used as a rapid in vivo 
marker of cell-mediated immunity (32).  
Some aspects of the immune system may have undesirable consequences, such as host 
tissue damage by inflammatory mediators secreted by macrophages which are toxic not 
only  to  pathogens.  Therefore,  self-regulation  of  immune  responses  needs  to  be  highly 
effective (37).   18 
 
1.2.5  Cytokines 
 
Cells  of  the  immune  system  communicate  either  by  direct  cell  to  cell  contact 
involving adhesion  molecules or by producing chemicals which act as signals  between 
cells. Cytokines are the most important chemical messengers produced. They are proteins 
which may have multiple activities on different cell types and they can regulate the activity 
of  the  cell  that  produced  them  or  of  other  cells.  Cytokines  regulate  the  development, 
growth or activity of target cells by binding to specific receptors on their surface (38). 
Some of the most important cytokines are tumour necrosis factor-α (TNF-α), IL-1, IL-
6 and IL-8 produced by monocytes and macrophages. These cytokines are mediators for 
both the acquired and innate immune system, and thus they are a link between the two 
(39). Some of the actions of these cytokines are to activate monocytes, macrophages and 
neutrophils to eliminate infectious agents or tumour cells, to increase adhesion molecule 
expression  on  the  surface  of  neutrophils  and  endothelial  cells,  to  stimulate  T-  and  B-
lymphocyte  proliferation,  and  to  initiate  the  production  of  other  proinflammatory 
cytokines.  The  actions  of  inflammatory  cytokines  are  opposed  by  anti-inflammatory 
cytokines such as IL-10 and by receptor antagonists such as IL-1 receptor antagonist.  
Inflammatory cytokines also mediate the systemic effects of inflammation, and their 
production is an important response to infection. However their overproduction has been 
shown to play an important role in some of the symptoms of chronic inflammatory diseases 
such as rheumatoid arthritis, inflammatory bowel diseases and psoriasis (40). 
 
1.2.6  Th1 and Th2 cell responses 
 
Helper  T-cells  play  an  important  role  in  the  accumulation  and  activation  of 
eosinophils and mast cells, and IgE production by B-cells. These characterise disorders 
which are associated with chronic inflammation. Thus, helper T-cells are believed to be 
important in the pathogenesis of allergic disease (41). Helper T-cells that encounter antigen 
for  the  first  time  produce  mainly  IL-2.  These  cells  may  differentiate  into  a  Th0  cell 
population, which may further differentiate into helper T type 1 (Th1) or helper T type 2 
(Th2) cells. These are the two broad categories that T-cells can be divided into and this is 
based on the different range of cytokines produced by them. Another, type of helper T-
cells is the T-regulatory (T-reg) cells which produce IL-10 and play an important role in 
regulating the balance between Th1 and Th2. In addition, the differentiation of Th0 (naïve)   19 
cells depends on cytokines. Specifically, the development of Th1 cells is mediated by IL-
12 and IFN-γ, whereas the development of Th2 cells is mediated by IL-4 (42, 43).  
As  mentioned  above  these  two  types  of  cells  have  a  specific  profile  of  cytokine 
production and thus they induce different immune responses. Th1 cells produce IL-2 and 
IFN-γ.  These  activate  macrophages,  NK  cells,  cytotoxic  T-lymphocytes  and  B-
lymphocytes leading to cell-mediated immune responses against intracellular pathogens, 
and they are regarded as proinflammatory cytokines (44). Th1 activity is mostly induced by 
infection with bacteria, viruses and fungi. Inflammatory conditions, such as rheumatoid 
arthritis, psoriasis, and multiple sclerosis, are frequently associated with a bias towards 
Th1 cytokine responses (45). 
Th2 cells produce IL-4, IL-5, IL-10 and IL-13. IL-4 stimulates IgE production by B-
cells  (antibody  responses)  and  IL-5  activates  eosinophils.  IL-10,  together  with  IL-4, 
suppresses cell-mediated immune responses by Th1 cells, and thus these cytokines may be 
regarded as anti-inflammatory (37). On the other hand, cytokines produced by Th1 cells, 
suppress Th2 cell activity. Th2 responses induce humoral immune responses, such as IgE-
mediated activation of mast cells and baseophils to eliminate extracellular antigens (such 
as antigens of helminthic parasites). Biased responses towards Th2 have been associated 
with allergy development (43).  
Cells with typical distinct Th1 and Th2 profiles have been demonstrated in mice. In 
humans, although some cells might have typical responses, there is no distinct division 
between the two types of cells. Helper T-cells in humans produce a mixture of Th1 and 
Th2 cytokines  in  various proportions (44). Consequently, helper T-lymphocytes can  be 
‘Th1 dominant’ (inflammatory conditions) or ‘Th2 dominant’ (allergy), and the dominant 
activity antagonises the non-dominant one, leading to polarisation towards the dominant 
phenotype.  
More recently, a novel helper T-cell subset which produces IL-17 has been identified 
as a distinct population from Th1 and Th2. These cells have been termed Th17 and they 
are the result of naïve T-cell differentiation though the effect of IL-1, IL-6, and IL-23. 
Th17  cells  have  been  shown  to  be  involved  in  the  pathogenesis  of  infectious  and 
autoimmune diseases leading to their exacerbation. Their existence has led to revision of 
the classic Th1/Th2 paradigm (46). There is evidence, although with discrepancies, that 
Th17 cells (as well as T-reg cells) may also contribute to the pathogenesis of some types of 
atopic  diseases  that  have  been  considered  to  be  Th2-mediated.  Specifically,  the 
observations on Th17 have provided with a new insight into the pathogenesis of ‘non-Th2-
type’ asthma (i.e.  ‘non-eosinophilic’/  ‘neutrophilic’ asthma) (41). Figure 1.3 represents 










Figure 1.3 T-cell polarizing capacity of dendritic cells (DC), and the development and cytokine profiles 
of type 1 helper T-cells (Th1), type 2 helper T-cell (Th2), IL-17-producing helper T- cell (Th17) or T-
regulatory cells (T-reg), and their roles in regulating physiological and pathological responses 
iDC, immature DC; mDC, mature DC; Th0; naïve helper T-cell; ICAM, intercellular adhesion molecule; IL, 
interleukin; IFN, interferon; TGF; transforming growth factor; APC, antigen presenting cell; Ig, 
immunoglobulin; DTH, delayed type hypersensitivity. 
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1.2.7  Inflammation 
 
Inflammation is part of the innate immune system response to infection or injury, and 
is characterised by redness, swelling, heat and pain. These are caused by increased blood 
flow and permeability across the blood capillaries, which allow large molecules (cytokines, 
complement, antibodies) and leukocytes to cross the endothelial wall and move to the point 
of infection or injury. Inflammation functions to eliminate invading pathogens and toxins, 
and to repair damaged tissue. The responses that occur during inflammation must be well 
controlled. The movement of cells into the infected site is induced by the up-regulation of 
adhesion  molecules  such  as  intercellular  adhesion  molecule  1  (ICAM-1),  vascular  cell 
adhesion molecule 1 (VCAM-1), and E-selectin on the surface of endothelial cells. These 
responses allow leukocyte binding and subsequent diapedesis (7).  
The  earliest  cells  to  appear  at  inflamed  sites  are  granulocytes,  with  monocytes, 
macrophages and lymphocytes appearing later. Activated macrophages and monocytes that 
arrive at the  inflamed site  form a range of  inflammatory  mediators such as cytokines, 
eicosanoids, nitric oxide, matrix metalloproteinases, reactive oxygen species, and kinins. 
These mediators are involved in pathogen destruction and communication between cells. 
They are also responsible for the systemic effects of inflammation on brain (fever, reduced 
appetite), on skeletal muscle (proteolysis), on adipose tissue (lipolysis), and on liver (acute 
phase protein synthesis). These inflammatory mediators provide the link between innate 
and acquired immune responses (5). 
Uncontrolled  inflammatory  responses  can  cause  damage  to  host  tissues.  Such 
inappropriate responses are characterised by hyperexpression of endothelial and leukocyte 
adhesion molecules, appearance of soluble forms of adhesion molecules in the circulation, 
appearance of leukocytes in unusual sites, and overproduction of inflammatory mediators.   22 
 
1.2.8  The Immune system in health and disease: inappropriate 
immune responses 
 
The functioning of the immune system is vital to maintain health and protect the body 
from pathogenic agents, injuries, and cancer cells. However, the immune system may in 
some individuals develop undesirable responses (48). One of these is the recognition and 
rejection of transplants which are being treated by the immune system as sources of foreign 
antigens.  Another  example  is  a  dysfunction  in  the  ability  of  the  immune  system  to 
distinguish between ‘self’ and ‘non-self’, resulting in diseases such as rheumatoid arthritis, 
psoriasis  and  multiple  sclerosis.  These  are  autoimmune  inflammatory  conditions,  since 
host tissues are being attacked, and they are characterised by chronic inflammation and a 
dysregulated Th1 response. 
High  concentrations  of  TNF-α,  IL-1β,  and  IL-6  are  implicated  in  some  of  the 
pathologic responses that occur in endotoxic shock, in acute respiratory distress syndrome, 
and in chronic inflammatory diseases such as rheumatoid arthritis and inflammatory bowel 
disease. Chronic overproduction of TNF-α and IL-1 can cause adipose tissue and muscle 
wasting  and  loss  of  bone  mass.  These  effects  may  account  for  alterations  in  body 
composition seen in cancer cachexia (40). 
Normally, the immune system develops tolerance towards self-antigens, by destroying 
self-recognising  T-  and  B-lymphocytes  before  maturation,  or  by  a  mechanism  termed 
clonal anergy. These mechanisms can be disrupted because of a range of immunological 
abnormalities and genetic predisposition leading to autoimmune inflammatory diseases.  
On the other hand, dysregulation of Th2 immune responses results in atopic diseases, 
including  allergies,  hay-fever,  allergic  rhinitis,  eczema  and  asthma.  In  this  case,  the 
immune system is sensitised to usually harmless antigens from the environment, such as 
components of foods, pollens, house dust mite, animal fur, and these antigens are termed 
allergens.  Inappropriate  recognition  of  and/or  responses  to  allergens  includes  IgE 
production by B-lymphocytes at initial exposure (40). The produced IgE binds to specific 
receptors on the surfaces of mast cells and basophils. This process is termed sensitisation. 
When the  individual  is re-exposed to the allergen,  it will  interact with the bound IgE, 
leading to cell activation and production of inflammatory mediators, especially histamine 
and the Th2 cytokines, IL-4, IL-5 and IL-10. 
Finally,  inflammation  is  now  recognised  to  play  a  role  in  the  pathology  of  other 
diseases, such as cardiovascular disease and neurodegenerative diseases of aging. Also, 
because of the  fact that adipose tissue  is a  source of  inflammatory cytokines, obesity,   23 
metabolic syndrome, and Type 2 diabetes are believed to have an inflammatory component 
(7). 
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1.3  Early origins of atopic disease 
 
1.3.1  Introduction 
The aim of this section is to highlight that gene-environment interactions influence the 
development  of  atopic  disease  and  that  these  interactions  begin  in  early  life.  Health, 
nutrition and environmental exposures of the mother during pregnancy may influence the 
development of allergic diseases in the offspring.  
The  genetic  component  of  allergic  diseases  is  well  established.  Twin  and  family 
studies  have  shown  the  strong  heritability  of  allergy  (49-52).  What  is  more,  single 
nucleotide polymorphisms affecting Th2 pathways have been related to atopic disease (53-
56). While, these polymorphisms contribute to the higher risk of developing allergy and 
allergic  inflammation,  their  presence  in  the  genome  does  not  necessarily  lead  to 
development of allergic disease (57). Most atopic diseases have their origins in early life, 
their signs appear in early infancy and their progression is apparent all the way through 
childhood (58-62). 
1.3.2  Foetal immune responses 
Neonates are not immunologically naïve, and in fact immune responses are evident 
from early foetal life. Events that occur during foetal life contribute to the development of 
atopic disease. Neonates with  higher risk of developing atopy appear to have different 
immune responses at birth from those with no family history of atopy and those who do not 
go on to develop atopic diseases (63).  
Stem cells can be found in the human yolk sac at 21 days. The first lymphocytes are 
found in the thymus by the week 9 of gestation. Lymphocytes are also found in different 
organs like the lungs and the gut (14 weeks gestation). B-cells are present in circulation by 
16 weeks gestation. What is more, the complete process of immune sensitisation is known 
to occur in the neonate, and antigen-specific responses at birth are not unusual. Antibody 
responses (IgG, IgM) can be detected in neonates after antigen exposure of the mother or 
of the foetus during pregnancy. Also, it has been shown that circulating blood mononuclear 
cells can specifically proliferate as a response to allergens from 22 weeks gestation (64). 
Specific  responses  of  the  foetus  to  common  environmental  factors  increase  with 
progression of the pregnancy, and at birth most neonates are able to mount such responses. 
It has been shown that strong proliferative specific responses to an allergen at birth are   25 
associated  with  a  higher  risk  of  developing  inappropriate  immune  responses  to  that 
allergen later on in childhood (64). 
1.3.3  Immune responses in pregnancy 
Maternal  cell-mediated  immune  responses  to  foetal  and  paternal  antigens  are 
suppressed  during  the  course  of  pregnancy,  and  this  allows  the  normal  progression  of 
pregnancy.  The  balance  of  the  maternal  immune  response  is  shifted  away  from  cell-
mediated immunity to humoral immunity, which is less damaging. This shift in balance of 
maternal immunity is a result of cytokines produced from tissues in the foeto-placental 
unit, which are characteristic of Th2 responses (64). The Th2 cytokines produced in normal 
pregnancy  may  also  lead  to  biased  suppression  of  Th1  responses.  Thus,  immunologic 
changes during pregnancy lead to polarization towards Th2 and T-regulatory responses 
(64, 65). 
Cytokines produced by decidual tissues include IL-1α, IL-1β, IL-6, IL-13, IL-4, and 
IL-10. The production of these Th2 and regulatory cytokines is regulated by the interaction 
between the mother, the placenta and the foetus. Also, the cytokines produced modulate 
foetal immunity so that the immune responses detected in neonates are biased towards the 
Th2 phenotype, so that the immune system of the foetus is polarised towards the same 
direction (Th2/T-regulatory) as in the pregnant woman (66). This is balanced by the rapid 
postnatal maturation of Th1 responses. Thus, although immune system maturation begins 
in utero, it continues during the first two years of life with appropriate antigen exposure. 
Th2  and  T-regulatory  cytokines  can  be  detected  in  the  amniotic  fluid  during  the 
second trimester of pregnancy. As the foetus swallows amniotic fluid, these cytokines will 
be swallowed by the foetus. Also, there is some aspiration of the amniotic fluid, through 
the permeable skin of the foetus, into mucosal surfaces of the respiratory tract during foetal 
respiratory movements (63). 
The immune system of the foetus is not fully functional and its gastrointestinal tract is 
sterile. The gut becomes colonised after exposure to bacteria during birth and postnatally 
from the mother’s skin, immunologic factors in breast milk, and antigens in formulas and 
weaning foods. Furthermore, it has been shown that immune active cells (macrophages, 
dendritic cells, T- and B-lymphocytes) are present in the foetal gut from early gestation. 
Maturation of these cells in the foetal gut possibly results from exposure to cytokines as 
well as food and inhalant allergens in the amniotic fluid (67).   26 
Antibodies of maternal origin (IgG and IgE) can be detected in the amniotic fluid from 
early gestation. Since receptors for these antibodies exist in the foetal gut, it is possible that 
their presence in the amniotic fluid facilitates the uptake of antigens by APC, and thus 
promotes sensitisation to allergens present in the amniotic fluid even in low concentrations 
(68). Therefore, the formation of IgE and IgA starts in utero and leads to the development 
of specific T-cell responses against environmental and food antigens particularly during 
the third trimester of pregnancy. Antigen-reactive T-cells can be detected in the cord blood 
of almost all infants supporting the idea of early sensitisation (69).  
The foetus can also be exposed to antigens via its circulation during the third trimester 
of  pregnancy.  IgG  linked  to  antigens  and  allergens  are  actively  transported  across  the 
placenta into the foetal blood stream. Higher exposure to allergens during pregnancy leads 
to higher production of allergen-specific IgG antibodies in the mother. Higher IgG levels to 
specific allergens are associated with lower risk of sensitisation to these allergens in the 
offspring. The relationship between the risk of allergic sensitization in the offspring and 
maternal exposure during pregnancy is a bell shaped curve (70). Thus, reducing exposure 
to  allergens,  such  as  house  dust  mite,  during  pregnancy  might  have  adverse  effects 
increasing the risk of sensitisation to these specific allergens. On the contrary, high levels 
of exposure to allergens during pregnancy may be protective for the offspring. 
Consequently, the concentration of the antigen to which the foetus is exposed during 
pregnancy, and the timing, the nature (bound to IgG or free), and the route of exposure 
affect the development or not of sensitization and clinical outcomes of atopy (64). 
1.3.4  Early life nutrition and development of atopic disease 
Epidemiological data show that the incidence of diseases with an immunological basis 
has increased dramatically over the past three to four decades especially in westernised 
environments  (71,  72).  For  example,  the  incidence  of  atopic  diseases  has  increased, 
particularly  among  children  (73,  74).  This  increased  incidence  has  been  related  to 
environmental  changes  that  have  occurred  during  the  past  years.  Leibowitz et  al.  (75) 
suggested that high levels of sanitisation at home during childhood are associated with 
higher risk of multiple sclerosis. Strachan (76) observed that the order of birth and size of 
the family were inversely associated with the risk of allergic rhinitis. This finding led to the 
hygiene hypothesis, according to which infections within households in early childhood 
have  a  protective  role  against  allergic  rhinitis  (76).  Bach  (77,  78)  has  reviewed  the 
evidence  and  mechanisms  supporting  that  the  main  factor  of  increased  prevalence  of 
allergic and autoimmune diseases in industrialised countries is the decreased incidence of   27 
infectious  diseases  over  the  past  30-40  years.  Figure  1.4  shows  that  the  incidence  of 
infectious  diseases  has  decreased  and  this  may  be  related  to  the  increase  in  immune 
disorders (figure from (77)). 
 
Figure 1.4 Inverse relation between the incidence of infectious diseases and immune system disorders 
from 1950 to 2000 
Figure from (77) 
 
However, some of the most important environmental changes that have occurred over 
the last decades are dietary. Changes in diet that have occurred during the last 30-40 years 
that have been related to increased sensitisation of the immune system to allergens include 
the  increased  intake  of  n-6  PUFA  followed  by  a  subsequent  decrease  in  n-3  PUFA. 
Specifically, Black & Sharp (79) and Hodge et al. (80) were the first to argue that the 
increased incidence and prevalence of childhood allergic disease has coincided with the 
increased  intake  of  n-6  PUFA  (linoleic  acid).  Also,  the  lower  intake  of  antioxidant 
vitamins and minerals, and changes in diet that have lead to an altered pattern of the gut 
microflora have been associated with the increased rates of atopic disease (47, 81).  
Maternal  intake  of  fruit  and  vegetables  (antioxidant  intake),  and  fish  (n-3  PUFA 
intake) during pregnancy will determine maternal antioxidant and n-3 PUFA status, which 
may subsequently determine the status of these nutrients in the neonate. It has been shown 
that n-3 PUFA status in maternal blood and breast milk is lower in mothers of children 
who go on to develop atopy (82-88). Also, it has been shown that cord blood levels of EPA 
and DHA are lower and ARA is higher in infants who develop atopy later on in life and 
also in infants of atopic mothers (89-91). Additionally, low cord selenium and iron have 
been associated with the development of atopic diseases in the offspring (92). Moreover, 
atopic infants have been shown to have a different gut microflora compared to non-atopic 
infants (47, 81). Thus maternal n-3 PUFA and antioxidant status, as well as maternal gut   28 
microflora, may be important in determining the development of atopy in the offspring. 
This  underlines  the  importance  of  the  early  life  environment  and  maternal  diet  during 
pregnancy in the development of atopic disease (81).  
Prescott and Dunstan (93) have recently reviewed the effects of dietary LC PUFAs on 
early  immune development and their potential role  in  immune disease development or 
prevention. The potential effects of LC-PUFA may be of great importance during early 
life. Potential pathways through which LC-PUFA could influence immune programming 
include  effects  on:  local  tissue  factors  (production  of  lipid-derived  inflammatory 
mediators,  oxidative  stress),  neonatal  APC  function,  T-regulatory  cell  function,  T-cell 
function, B-cell function (antibody production), and end-organ factors (affecting clinical 
phenotype). The review concluded that the relevance of these effects to the prevention of 
disease is not clear, and that intervention studies during pregnancy are needed in order to 
address  more definitely the potential  beneficial  effects of early  LC-PUFA exposure on 
allergy prevention in the offspring (93). 
In conclusion, nutrition in early life may affect immune development by providing: 
antigens to which the immune system will acquire tolerance, nutrients which can modulate 
immune responses (such as n-3 PUFA and antioxidants), and factors that influence the 
intestinal flora (such as dietary fibre, prebiotics and probiotics) (47). 
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1.4  Fatty Acids and the Immune system 
This part of the introduction aims to present the possible mechanisms by which fatty 
acids may affect immune responses.  
There  are  many  studies  of  fatty  acids  and  the  immune  system.  These  have  been 
reviewed elsewhere (2, 5, 7, 94, 95). The clearest mechanism by which fatty acids can 
influence the immune system is by altering eicosanoid patterns and this will be described 
in sections 1.4.1-1.4.3. The present PhD thesis examined T cell responses in the blood of 
pregnant  women  and  whether  these  are  modulated  by  consumption  of  salmon. As  the 
pattern of production of Th1 and Th2 cytokines has been measured in the current thesis, an 
overview of the literature on this topic will be provided (section 1.4.4).  
1.4.1  Eicosanoids 
 
The link between fatty acids and the immune system relates to the composition of 
immune  cell  membrane  phospholipids.  The  fatty  acid  composition  of  cell  membrane 
phospholipids  can  influence  various  membrane  activities,  which  can  influence  cellular 
responses. For example, the fluidity of the membrane is regulated in part by the fatty acid 
composition  of  its  constituent  phospholipids.  Membrane  fluidity  is  important  for  the 
activity  of  membrane  proteins  such  as  receptors,  transporters  and  enzymes.  The 
responsiveness of immune cells to a stimulus can be altered by membrane fluidity. What is 
more,  the  production  of  intracellular  signals,  such  as  diacylglycerol  (DAG),  inositol 
phosphates, and ceramide, from membrane phospholipids, is dependent on the activity of 
phospholipase enzymes which can be altered by the fatty acid composition of the substrate 
phospholipids. Another group of  mediators, the eicosanoids, are generated from PUFA 
released from cell membrane phospholipids. Consequently, the fatty acid composition of 
immune cells is important for the regulation of the responses and functions of these cells. 
Eicosanoids, as indicated by their name, are a group of mediators whose precursors 
are 20-carbon atom PUFA (ARA, 20:4n-6; EPA, 20:5n-3). These PUFA are contained in 
the  phospholipid  bilayer  of  cell  membranes,  with  ARA  being  contained  in  most  cell 
membranes in relatively large amounts. Eicosanoid synthesis involves PUFA mobilisation 
from the cell membrane by various phospholipase enzymes, most notably phospholipase 
A2. The free PUFA is converted by cyclooxygenase enzymes (COX) into prostaglandins 
(PG), thromboxanes (TX) and related compounds, or by lipoxygenase enzymes (LOX) into   30 
leukotrienes (LT) and related compounds. Figure 1.5 presents the synthesis of eicosanoids 
from PUFA (7). 
 
 
Figure 1.5 Synthesis of eicosanoids from arachidonic acid and eicosapentaenoic acid (EPA) 
COX, cyclooxygenase; HEPE, hydroxyeicosapentaenoic acid; HETE, hydroxyeicosatetraenoic acid; HPETE, 
hydroperoxyeicosatetraenoic acid; HPEPE, hydroperoxyeicosapentaenoic acid; LOX, lipoxygenase; LT, 
leukotriene; PG, prostaglandin; TX, thromboxane. 
Adopted from (7) 
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ARA is the principal precursor of eicosanoids. However, different cell types produce 
different compounds belonging to each class of eicosanoids. Monocytes and macrophages 
produce large amounts of PGE2 and PGF2, neutrophils produce moderate amounts of PGE2 
and mast cells produce PGD2. The LOX enzymes have a tissue-specific distribution. The 
5-LOX enzyme is mainly found in mast cells, monocytes, macrophages, and granulocytes, 
and 12- and 15-LOX in epithelial cells. 
Eicosanoids are the key link between fatty acids and the immune system. They are 
involved in modulating the intensity and duration of inflammatory and immune responses 
(96, 97). The effects of eicosanoids may vary even if these have the same precursor, and in 
addition, a single eicosanoid may have opposing effects on different cell types. The overall 
physiological effect of eicosanoids will be determined by the nature of cells producing 
them, the nature of the stimulus, their concentrations, the timing of their production, and 
the sensitivities of target cells. For example, ARA is the precursor of different mediators 
(PGE2, LTB4) which sometimes have opposing effects to one another. PGE2 has various 
proinflammatory effects (increases vascular permeability,  vasodilatation, pain, oedema), 
but  at  the  same  time  exhibits  immunosuppressive  and  anti-inflammatory  effects 
(suppresses lymphocyte proliferation, inhibition of IFN-, TNF-α and IL-1 production). 
Recent studies have shown that PGE2 induces the production of IL-6 by macrophages (98), 
induces COX-2 in fibroblast cells and subsequently stimulates its own production (98), 
inhibits 5-LOX leading to decreased production of 4-series LT (99), and induces 15-LOX 
promoting  the  formation  of  lipoxins  (99,  100),  which  have  been  shown  to  have  anti-
inflammatory effects (101, 102). LTB4 also has proinflammatory effects such as increase of 
vascular permeability and enhancing the production of inflammatory cytokines, but also 
inhibits lymphocyte proliferation. Table 1.4 lists the anti- and pro-inflammatory effects of 
two different eicosanoids (7).   32 
 
Table 1.4 Pro- and anti-inflammatory effects of prostaglandin E2 and leukotriene B4  
 
LOX, lipoxygenase; LT, leukotriene; IL, interleukin; TNF, tumour necrosis factor; Ig, immunoglobulin; Th1, 
helper T-cell type 1; Th2, helper T-cell type 2 
Adapted from (7, 103) 
 
Eicosanoid  Pro-inflammatory effects  Anti-inflammatory effects 








Increases vascular permeability  
Increases vasodilatation  
Enhances pain 
Promotes Th2-type response 
Promotes IgE production by B-cells 
Inhibits Th1-type response 
Inhibits production of TNF-α and IL-1β 
Inhibits T-cell proliferation 
Inhibits 5- and 15-LOX 
 







Increases of vascular permeability 
Enhances of local blood flow 
Chemotactic agent for leukocytes 
Induces release of lysosomal enzymes 
Induces of release of reactive oxygen 
species by granulocytes 
Increases production of TNF-α, IL-1β 
Promotes IgE production by B-cells 
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1.4.2  Arachidonic acid and inflammatory mediators 
The amount of ARA in immune cells can be increased by including ARA in the diet of 
rats (104), or by increasing its intake from the diet in humans (105). Increasing the dietary 
intake of linoleic acid (18:2n-6) may also increase the amount of ARA in immune cells, 
although this is not well defined in humans and studies are contradictory (7, 106). 
Animal feeding studies have shown that increasing the amount of ARA in immune 
cells is related to increased production of eicosanoids, such as PGE2, by these cells (104). 
The  effects  of  increased  dietary  ARA  intake  on  immune  processes  have  been  little 
investigated in humans. It has been shown that modest increase of ARA intake in humans 
results  in  increased  production  of  proinflammatory  eicosanoids  (PGE2  and  LTB4)  by 
endotoxin stimulated mononuclear cells (107). However, it was shown that the production 
of inflammatory cytokines (TNF-α, IL-1β, IL-6) by these cells was not affected (107, 108). 
Furthermore, T-cell responses, the generation of reactive oxygen species (superoxide) by 
neutrophils and monocytes (108), and the concentrations of adhesion molecules (VCAM-1, 
ICAM-1, E-selectin) in plasma were not affected (108). 
1.4.3  LC n-3 PUFA and eicosanoid production 
Increased dietary intake of EPA and DHA results in increased proportions of these 
fatty acids in immune cell membranes phospholipids (106, 109, 110). The incorporation of 
long-chain n-3 PUFA occurs in a dose-response fashion and is accompanied by decreased 
levels of  ARA  in  immune cell  membranes (110). Consequently, there  is  less  substrate 
available  for the  synthesis of  ARA-derived eicosanoids. In accordance to this,  fish oil 
supplementation of the human diet has been shown to result in decreased production of 
PGE2 (111, 112), TXB2 (113), LTB4 (109, 114), 5-hydroxyeicosatetraenoic acid (5-HETE) 
(109, 114), and LTE4 (115) by inflammatory cells.  
Furthermore, EPA can be converted to 3-series PG and TX, and 5-series LT, by COX 
and 5-LOX respectively. Fish oil supplementation of the human diet has been shown to 
result  in  increased  production  of  LTB5,  LTE5  and  5-hydroxyeicosapentaenoic  acid  (5-
HEPE)  by  inflammatory  cells  (109,  114,  115),  although  it  was  more  difficult  to 
demonstrate  the  production  of  PGE3    (116).  EPA-derived  eicosanoids  have  a  slightly 
different structure and are less biologically potent than their ARA-derived analogues, and 
some of them exhibit anti-inflammatory effects (PGE3, LTB5). The decreased production 
of ARA-derived eicosanoids, followed by an increase in EPA-derived eicosanoids as a   34 
result of fish oil consumption, has led to the idea that fish oil may have anti-inflammatory 
effects and may influence the function of the immune system. 
Recent  studies  have  demonstrated  the  production  of  a  novel  group  of  mediators, 
termed E-series resolvins. These compounds are produced when EPA acts as a substrate 
for COX-2 and appear to have anti-inflammatory actions. (117-119). Moreover, DHA also 
competitively inhibits ARA metabolism acting as a substrate for COX-2, giving rise to 
DHA-derived mediators termed D-series resolvins, docosatrienes and neuroprotectins, that 
appear  to  be  anti-inflammatory.  These  novel  inflammatory  mediators  may  be  of  great 
importance for a variety of conditions (95, 120). 
1.4.4  Effects of fish oils on T-cell function 
The effects of dietary  fish oils cannot be predicted based on the EPA and  DHA-
derived eicosanoids produced. As mentioned above, dietary n-3 PUFA decrease production 
of ARA-derived eicosanoids (PGE2), and they give rise to eicosanoids and eicosanoid-like 
mediators (E- and D-resolvins) with varying actions. Because of the effects of eicosanoids 
on Th1 and Th2 responses and lymphocyte proliferation, it could be speculated that fish 
oils  could  influence  T-cell  functions  through  the  production  of  eicosanoids.  However, 
because  fish oils  may affect the production of a  mixture of anti- and proinflammatory 
mediators,  it  is  not  possible  to  predict their  precise effect  on  immunomodulation.  The 
influence  of  fish  oils  on  T-cell  functions  and  Th1/Th2  cytokine  production  have  been 
reviewed  in  detail elsewhere (1, 47, 121). The  results of the  most significant  in  vitro, 
animal  feeding and  human supplementation studies  in this area are summarised  in this 
section. 
It has to be mentioned at this point that most human studies used blood lymphocytes 
as  a  mixture  with  monocytes.  These  preparations  are  described  as  peripheral  blood 
mononuclear cells (PBMC) and they contain typically 85-90% lymphocytes and 10-15% 
monocytes (121). Proliferation in response to mitogens is the most widely used test of 
lymphocyte  function.  Mitogens  used  to  stimulate  T-lymphocyte  proliferation  are 
concanavalin  A  (Con  A)  and  phytohaemagglutinin  (PHA).  Proliferative  response  is 
determined  either  by  measuring  the  increase  in  number  of  cells  or  by  measuring  the 
incorporation of [
3H]thymidine into the DNA.  
In  vitro  studies  have  shown  that  adding  EPA  and  DHA  in  culture  inhibits  the 
production of IL-2 and proliferation of lymphocytes (1, 121). In the study of Soyland et al. 
EPA  and  DHA  exerted  a  strong  dose-dependent  inhibitory  effect  on  proliferation  of   35 
mitogen- or antigen-stimulated human T-cells in vitro. COX and LOX inhibitors did not 
affect the anti-proliferative effect of EPA (122). In the study of Khalfoun et al. (123, 124) 
it was shown that EPA and DHA had no effect on PHA-induced lymphocyte agglutination, 
but they strongly inhibited the lymphocyte proliferative response to PHA. This inhibition 
was dose-dependent and more potent with DHA than EPA. However, EPA and DHA did 
not inhibit IL-2 stimulated lymphocyte proliferation (124). Similarly, in another in vitro 
study on human lymphocytes, it was shown that the proliferative response to mitogens 
(PHA,  Con  A)  was  inhibited  in  a  dose-dependent  manner  (125).  Furthermore,  the 
inhibition of T-cell proliferation was associated with decreased production of IL-2, TNF-α, 
and IFN-γ. Calder et al. (126) showed that PGE2 concentrations in the medium taken from 
lymphocytes  cultured  in  the  presence  of  EPA  and  DHA  were  not  associated  with  the 
inhibitory  effects of these  fatty acids on  lymphocyte proliferation.  Also, PGE3 did  not 
inhibit lymphocyte proliferation, except at high concentrations. Lymphocyte proliferation 
was  not affected by  inclusion of  inhibitors of phospholipase  A2, COX or LOX  in the 
cultures.  Thus,  inhibition  of  lymphocyte  proliferation  by  n-3  PUFA  appears  to  be 
independent of eicosanoid production (122, 126). The results of these studies show that in 
vitro n-3 PUFA influence T-cell function by inhibiting proliferation and IL-2 production 
but that the effects probably do not involve a change in eicosanoid profiles. 
The results of animal feeding studies showed high levels dietary fish oil decreased 
lymphocyte proliferation (127, 128), and resulted in lower production of IL-2 and IFN-γ 
(128,  129).  In the  study  of  Jolly  et  al.  (128)  murine  T-cell  function  was  examined  in 
response to a low fat, short term (10 days) diet enriched with EPA or DHA. It was shown 
that Con A-induced T-cell proliferation in splenocyte cultures was suppressed by dietary 
EPA  and  DHA,  and  this  suppression  appeared  to  be  mediated  by  a  reduction  in  IL-2 
secretion. This  study showed that even at  lower  levels of  intake,  both EPA and DHA 
inhibit lymphocyte proliferation and IL-2 production (128). The study of Wallace et al. 
(129) compared the effects of different types of oils (coconut, safflower, fish oil) with a 
low fat diet fed to mice for 6 weeks. IFN-γ production was decreased by safflower or fish 
oil feeding. IL-4 production was lowest by lymphocytes from fish-oil fed mice, although it 
was not significantly affected by diet. The ratio of Th1/Th2 cytokine production (IFN-γ/IL-
4) was lower from lymphocytes of mice fed safflower or fish oil diets. Also, IL-2, IFN-γ, 
and IL-4 mRNA levels were lowest in cells from mice in the fish oil diet group. The ratio 
of IFN-γ  mRNA/IL-4  mRNA  was  lowest  in cells of  mice  fed  fish oil. In vitro results 
showed  that  the  n-3  PUFA  found  in  fish  oil  were  the  most  potent  inhibitors  of  IL-2 
production. It was concluded that n-3 PUFA inhibit production of Th1-type cytokines with   36 
little effect on Th2 type cytokines. In the study of Sanderson et al. (130) rats were fed for 
12 weeks with different high fat diets (coconut, olive, safflower, evening primrose, or fish 
oil) or a low fat diet. It was shown that after feeding with fish oil mitogen-stimulated 
spleen lymphocyte proliferation was inhibited (130, 131). Therefore, the results of animal 
feeding studies show that fish oil decreases  lymphocyte proliferation and  skews T-cell 
responses away from the Th1-type response (121). 
Human supplementation studies with EPA and DHA have shown differential effects 
on lymphocyte functions. Meydani et al. (111) showed that supplementation of healthy 
volunteers with fish oil providing 2.4 g EPA plus DHA/day for three months resulted in 
decreased  PHA-stimulated  proliferation  of  lymphocytes  and  also  decreased  IL-2 
production in women aged 51-68 years (but not in younger women aged 23-33 years). In 
another study of Meydani et al. (132) it was shown that supplementation of a low fat diet 
with 1.2 g EPA plus DHA/day decreased T-cell proliferation in subjects older than 40 
years  old.  Another  study  provided  2  or  4  g  EPA  plus  DHA/day,  and  this  resulted  in 
decreased  PHA-stimulated  PBMC  proliferation  in  healthy  volunteers  and  in  newly 
diagnosed Type 1 diabetic patients (133). Moreover, Gallai et al (134) showed that 5.2 
g/day EPA plus DHA decreased IL-2 and IFN-γ production by stimulated PBMC. In the 
study of Thies et al. (105) 1 g EPA plus DHA/day (720 mg EPA plus 280 mg DHA) for 12 
weeks decreased lymphocyte proliferation, but did not affect IL-2 or IFN-γ production in 
healthy subjects aged 55-75 years. In the study of Endres et al. (135) it was shown that 
supplementation  with  EPA  and  DHA  resulted  in  suppressed  synthesis  of  IL-2  from 
stimulated PBMC 10 weeks after the end of supplementation, and also suppressed PHA-
induced proliferation of PBMC. However, the effect of n-3 PUFA on IL-2 production was 
no  longer  evident  at  the  end  of  the  study  (135).  Consequently,  several  studies  have 
demonstrated  that  dietary  n-3  PUFA  supplementation  in  humans  significantly  reduces 
lymphocyte proliferation to mitogens. 
On  the  contrary,  there  are  a  number  of  studies  that  showed  no  effects  of  human 
supplementation  with  n-3  PUFA.  Specifically,  it  was  reported that  supplementation  of 
healthy subjects with 3.2 g EPA plus DHA/day for 12 weeks did not alter lymphocyte 
proliferation and IL-2 and IFN-γ production (106). However, the authors stated that the 
lack  of  effects  might  have  been  associated  with  the  level  of  α-tocopherol  in  the 
supplement. One study has reported that moderate dose of fish oil supplementation (0.3, 1 
and 2 g EPA plus DHA/day) for 4 consecutive weeks each (total of 12 weeks) increased T-
cell proliferation and IFN-γ production (112).    37 
Finally, there are a few studies investigating the effects of DHA alone. The study of 
Kelley et al. (107, 136) found no effect of supplementation of men aged 20-40 years with 6 
g DHA/day for 90 days on lymphocyte proliferation or the number of T-cells producing 
IL-2. What is more, another study showed that supplementation with 720 mg DHA/day did 
not affect lymphocyte proliferation or IL-2 and IFN-γ production in healthy subjects aged 
55-75  years  (105,  108).  These  studies  show  that  either  high  or  low  levels  of  DHA 
supplementation alone do not affect T-cell proliferation and cytokine production. 
In conclusion, both in vitro and animal feeding studies showed that n-3 PUFA inhibit 
T-cell proliferation  and production of IL-2 and  IFN-γ. Human  supplementation studies 
indicate that high levels of fish oil supplementation may inhibit T-cell responses. However, 
lower levels of supplementation do not exhibit such effects. Studies that have used levels 
of supplementation between the previous two levels had conflicting results. Inconsistency 
in results may be related to differences in subject characteristics (age, gender, health status, 
background diet), study design (dose and duration of supplement), as well as to differences 
in experimental methods (cell preparation, cell culture, cytokine assays) (121). All in all, 
the  evidence  available  shows  that  fish  oils  may  affect  T-cell  responses  and  function 
independently  of  eicosanoid  production.  Figure  1.6  summarises  the  anti-inflammatory 
effects of LC n-3 PUFA discussed in this part.    38 
 
 
Figure 1.6 Anti-inflammatory effects of long-chain n-3 polyunsaturated fatty acids 
AA; arachidonic acid; COX, cyclooxygenase; LOX, lipoxygenase; EPA, eicosapentaenoic acid; DHA, 
docosahexaenoic acid; IL, interleukin; IFN-γ, interferon-γ 
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↑ Generation of E- and D-
series, resolvins, docosanoids 
and neuroprotectins 
Effects on cell membrane 
structure (fluidity, protein 
acylation, lipid rafts) 
Cell signalling 
↓ Inflammation 
↓ T-cell proliferation 
↓ IL-2 and IFN-γ 
production from T-cells   39 
1.4.5  Fish oil and chronic inflammatory diseases 
1.4.5.1  Th1 responses 
Chronic inflammatory conditions that are related to Th1-type response dysregulation 
are  characterised  by  inappropriate  production  of  ARA-derived  eicosanoids  (PGE2  and 
LTB4) and inflammatory cytokines. Since n-3 PUFA from fish oil act to decrease ARA-
derived eicosanoid production, it has been suggested that fish oils may have a preventive 
or therapeutic role for these diseases. Supplementation trials have been conducted for most 
of these diseases. Clinical trials provide good evidence of the anti-inflammatory effects of 
fish  oils  on  rheumatoid  arthritis  (137-139)  and  inflammatory  bowel  diseases  (Crohn’s 
disease and ulcerative colitis) (140, 141), and are associated with clinical improvements. 
However, the therapeutic effect of fish oils on other conditions, such as multiple sclerosis 
and systemic lupus erythematosus, is not clearly evident (142-144). 
1.4.5.2  Th2 responses: fish oil and atopic disease 
Atopic  diseases,  which  are  also  associated  with  dysregulation  of  the  Th2-type 
response, are associated with production of ARA-derived eicosanoids such as PGD2, LTC4, 
LTD4 and LTE4 (produced by mast cells to mediate pulmonary inflammation in asthma). 
What is more, PGE2 regulates the activities of macrophages and lymphocytes, inhibits the 
production of Th1-type cytokines (IFN-γ, IL-2) without affecting the production of Th2-
type  cytokines  (IL-4,  IL-5),  regulates  T-cell  lymphocyte  differentiation  promoting  the 
development of the Th2 phenotype (145), and stimulates B-cells to produce IgE (146). 
Thus,  ARA-derived  eicosanoids  have  been  suggested  to  play  an  important  role  in  the 
aetiology of asthma, and in addition, PGE2 may be involved in the development of allergic 
disease.  The  hypothesis  that  has  evolved  is  that  an  increased  intake  of  n-6  PUFA 
accompanied by a low intake of n-3 PUFA has played a causal role in increased asthma 
incidence in the last 30 to 40 years (79, 80). 
A  number  of  studies  have  been  conducted  investigating  the  possible  therapeutic 
affects of  fish oils on  asthma, after  its development. It has  been reported that fish oil 
supplementation in patients with asthma has anti-inflammatory effects, such as decreased 
4-series LT production (147-149) and leukocyte chemotaxis (148, 149). Uncontrolled and 
open-label trials of fish oil have also shown clinical benefit of fish oil on asthma (150). 
Schachter et al. (150) and Woods et al. (151) have reviewed randomised controlled and 
other type of supplementation trials of fish oil in asthmatic patients. Woods et al. (151) 
concluded that there was no consistent effect on forced expiratory volume in one second or   40 
peak  flow  rate,  both  measures  of  lung  function,  or  on  asthma  symptoms,  asthma 
medication  use  or  bronchia  hyper-reactivity.  Similarly,  in  the  review  conducted  by 
Schachter et al. (150), it was concluded that the efficacy of n-3 PUFA supplementation as 
a treatment for asthma in adults and children is not clearly evident. However, there are 
some studies which show that there may be subgroups of asthmatic subjects who benefit 
greatly  and  others  who  do  not  benefit  from  long-chain  n-3  PUFA  (151,  152).  Further 
studies are needed to be conducted in this area in order to provide strong evidence of the 
potent therapeutic effects of fish oils on asthma.  
There are biochemical indicators showing that there is an inverse relationship between 
n-3 status and atopic disease. A study showed that EPA, docosapentaenoic acid, and DHA 
proportions  were  higher  in  the  umbilical  cord  serum  phospholipids  from  non-allergic 
compared to allergic mothers (91). Higher n-3 PUFA in breast milk were associated with a 
decreased likelihood of atopy in the infants (82). Non-atopic children between 12 to 15 
years old had higher proportion of DHA and of total n-3 PUFA in serum phospholipids 
compared to children with asthma and/ or atopic dermatitis (153). It is now recognised that 
sensitisation  to  allergens  occurs  early  in  life  (69).Thus,  maternal  diet  may  be  very 
important in determining predisposition to atopy. Studies investigating early exposure to 
long-chain n-3 PUFA show in overall modulation of the development of atopic diseases. 
These studies are reviewed in Section 1.5. 
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1.5  Atopy risk in infants and children in relation to early 
exposure to fish, oily fish, or LC n-3 PUFA: A systematic 
review 
This review collates the evidence available on the effects of fish intake and fish oil 
supplementation of pregnant or lactating mothers on immune and atopy outcomes in their 
offspring, as well as the effects of fish intake and fish oil supplementation during infancy 
or childhood on immune and atopy outcomes on those infants/children. This review has 
been  recently  published  by  Kremmyda  L.S.,  Vlachava  M.,  Noakes  P.S.,  Diaper  N.D., 
Miles E.A., and Calder P.C. in Clinical Reviews in Allergy and Immunology (103).  
1.5.1  Epidemiological studies relating early fish exposure to atopy 
outcomes in infancy or childhood 
The aim of this section is to describe and interpret epidemiological studies on the 
effects of maternal fish intake during pregnancy or lactation on atopic/allergic outcomes in 
the  offspring  of  those  mothers,  as  well  as  the  effects  of  fish  intake  during 
infancy/childhood on atopic/ allergic outcomes in those infants/children. 
1.5.1.1  Studies investigating the effect of maternal fish intake during 
perinatal life on atopic outcomes in infants or children 
 
Table 1.5 includes all studies published to the present that investigate the association 
between maternal fish intake in perinatal life and atopic/allergic outcomes in the offspring 
of  those  mothers.  The  studies  were  identified  through  Ovid  Medline  (1950-2009)  and 
Embase  (1980-2009)  databases  performing  and  combining  searches  with  the  following 
keywords:  fish  intake,  oily  fish  intake,  maternal,  pregnancy,  atopy,  allergy,  asthma, 
eczema, childhood, infancy. Five studies were identified investigating maternal fish intake 
during  pregnancy  and  one  study  investigating  maternal  fish  intake  during  lactation  in 
relation to atopic outcomes in infants or children. 
Studies investigating the effect of maternal fish intake during pregnancy on 
atopic outcomes in infants or children 
 
Study design 
Out  of  the  five  studies  which  examined  the  effect  of  maternal  fish  intake  during 
pregnancy three studies were prospective cohort (154-156), one study was case-control 
(157), and one study was retrospective cohort (158). All five studies had large sample   42 
sizes, with the largest being in the studies of Willers et al. (156) and Sausenthaler et al. 
(154). The age range of children taking part in these studies was  between 2-16  years. 
Children who took part in the three prospective cohort studies were followed-up for 6, 2 
and 5 years (154-156) for each study respectively.  
Table 1.5 presents only statistically significant results referring to maternal fish intake 
in relation to atopic or allergic outcomes in infants or children. Other results reported by 
these studies that were either not significant or not related to fish intake are not included 
here.  
Exposure measures 
Regarding the quality and the method of assessing fish intake during pregnancy, three 
of the five studies used a food frequency questionnaire (FFQ) (155, 157, 158) and two used 
a semi-quantitative FFQ (154, 156). FFQ varied in frequency categories and also in time 
point  of  administration  [during  pregnancy  (156),  shortly  after  birth  (154,  155)  or 
retrospectively  a  long  time  after  birth  (157,  158)]  and  way  of  administration  [self-
administered (156) or interviewer-administered (154, 155, 157)]. 
Two of the studies examined the effect of total fish consumption during pregnancy on 
childhood/infancy atopic outcomes (154, 157, 158). Three studies examined the effect of 
different fish categories (155-157), and two of them found statistically significant results 
for oily fish (156, 157). It has to be pointed out that, although Romieu et al. (155) found a 
statistically significant protective effect of total fish intake, they did not assess the impact 
of different types of fish because of the small number of participants reporting intake of 
oily  fish  only.  Regarding  fish  consumption  frequency,  Salam  et  al.  (157)  observed 
statistically  significant  results  when  comparing  the  effects  of  ‘monthly  intake’  versus 
‘never’  whereas  the  other  four  studies (154-156,  158) observed  statistically  significant 
results  when  comparing  the  effects  of  different  weekly  consumption  frequencies. 
Analysing different types of fish and consumption frequencies could possibly explain the 
heterogeneity in the extent of the protective effect between the studies. 
The smallest decreases in childhood/infancy atopic risk were found in those studies 
comparing the effect of two different weekly consumption frequencies of total fish (154, 
155).  On  the  contrary,  studies  observing  a  greater  decrease  in  risk  made  comparisons 
between  the  effect  of  weekly  versus  ‘less  than  monthly’  or  ‘never’  consumption 
frequencies (156, 158).   43 
Moreover, the definition of ‘oily fish’ was not consistent if it existed, which gives rise 
to the issue of dietary exposure misclassification. For example, Salam et al. (157) defined 
oily fish as those with > 2% fat specifying which types of fish are included in this category. 
Other studies which gave a definition of oily fish were those of Romieu et al. (155) and 
Willers et al. (156).  
Generally, FFQ is an effective method of assessing nutrient intakes during pregnancy 
in observational studies of fairly large sample sizes. However, a complete picture of the 
rest of the diet is needed in order to identify other food categories/items related to the 
outcome measure or that could be possible confounding factors. In this way, apart from 
fish categories it is important other major food categories/food items to be considered so as 
to control for other components of the diet, such as total energy intake, dietary fat and 
antioxidant intake. A FFQ reflecting total and oily fish intake throughout pregnancy and 
which is not administered retrospectively after delivery (in order to reduce recall bias) nor 
is self-administered would be ideal. 
Confounding factors 
 
All of the studies adjusted for most recognized confounding factors. Romieu et al. 
(155) included type of fish as a confounding factor and Sausenthaler et al. (154) adjusted 
for  all  dietary  variables  included  in  their  FFQ.  Three  of  the  studies  controlled  for 
breastfeeding (154, 156, 157). All five studies controlled for maternal atopy/asthma and 
all, with the exception of Salam et al. (157), controlled for maternal smoking. It should be 
mentioned  that,  because  fish  consumption  may  be  a  marker  of  specific  lifestyle,  it  is 
important for the studies to adjust  for socio-economic  factors such  as  social class and 
parental education, as well as smoking. All of the studies in Table 1.5 have adjusted for 
most of these confounding factors. 
Outcome measures 
There  was  great  heterogeneity  among  the  five  studies  with  regard  to  outcome 
measures and their assessment. Salam et al. (157) focused on asthma, Calvani et al. (158) 
focused on allergic sensitisations, while Sausenthaler et al. (154), Romieu et al. (155), 
Willers et al. (156) included various outcome measures such as eczema, atopic wheeze, 
allergic sensitisation, or hay-fever. Also, each of the studies assessing clinical outcomes 
used a parental questionnaire which most of the times asked for doctor-diagnosis and gave 
clear definitions of each outcome. Although doctor-diagnosed atopic diseases may be more   44 
valid,  limited  access  to  health  care  may  result  in  under-diagnosis  of  atopic  disease, 
especially when these are mild or at early stages (157). 
Results 
There is consistency between the findings of these five studies since each of them 
identified beneficial associations between maternal fish intake during pregnancy and atopic 
or  allergic  outcomes  in  children.  However,  in  the  study  of  Salam  et  al.  (157)  the 
association between maternal oily fish intake and children’s risk of developing asthma was 
greater  in  children  whose  mothers  had  asthma  compared  to  children  of  non-asthmatic 
mothers (p for interaction = 0.02). On the contrary, Calvani et al. (158) observed that the 
protective  effect  of  increased  oily  fish  intake  during  pregnancy  against  offspring  food 
sensitisation was greater for children of non-allergic mothers compared to those of allergic 
mothers  (p  for  trend  =  0.002).  However  this  was  not  the  case  for  offspring  inhalant 
sensitisations. It is not clear why these findings are different.  
Moreover, in the prospective cohort study conducted by Romieu et al. (155), although 
a beneficial association was observed initially for the whole sample, after stratifying by 
breast-feeding,  increased  fish  consumption  during  pregnancy  decreased  the  risk  of 
persistent wheeze at 6 years of age decreased among the non-breastfed infants whereas no 
protective effect was observed among the breastfed infants. 
The large cohort studies conducted by Sausenthaler et al. (154, 156) and Willers et al. 
concluded similar associations: high (≥ 1 time/week) vs. low maternal fish intake during 
pregnancy was associated with decreased doctor-diagnosed eczema. However the decrease 
in the study of Willers et al. (156) was greater than that in the study of Sausenthaler et al. 
(154)  (43%  vs.  25%  respectively).  This  might  be  related  to the  fact  that the  study  of 
Willers et al. (156) followed-up children for a longer period, allowing for manifestations of 
atopic disease to be revealed at the stage of clinical assessment. Willers et al. (156) also 
showed that there was a 72% decrease in doctor-diagnosed hay-fever in children born to 
mothers with higher oily fish intake (but not total fish intake) during pregnancy.  
Across these five studies, the extent of the protective effect is highly variable. Fish 
intake resulted in decrease in childhood or infancy atopy which ranged between 25% and 
95%. However, most decreases in atopic risk ranged between 40% and 80%. These five 
studies  provide  strong  evidence  of  protective  effect  of  maternal  fish  intake  during 
pregnancy, however heterogeneous was the extent of the protective effect.   45 
 
The effect of maternal fish intake during lactation on atopic outcomes in the 
infant 
The last study of Table 1.5 conducted by Hoppu et al. (159) assessed maternal dietary 
intake one month after birth (during lactation) and atopic dermatitis development in the 
infant at four timepoints. The primary objective of the study was to examine the effect of 
breast  milk  fatty  acid  composition  on  atopic  dermatitis  during  the  first  year  of  life. 
Although  high  percentage  of  EPA  in  breast  milk  was  related  to  lower  risk  of  atopic 
dermatitis,  fish  consumption  frequency  during  lactation  was  not  associated  with  breast 
milk  EPA  content.  This  may  be  explained  by  the  fact  that  breast  milk  fatty  acid 
composition  is determined  more  by  fatty  acids  accumulated  in  maternal adipose tissue 
during pregnancy rather than dietary intake of fatty acids during lactation (160, 161). The 
authors  stated  that  maternal  fish  intake  during  pregnancy  would  have  been  more 
appropriate to investigate in relation to breast milk composition (159). 
 
Summary 
All five epidemiological studies investigating the effect of maternal fish intake during 
pregnancy  on  atopic  or  allergic  outcomes  in  infants/children  of  those  pregnancies 
concluded protective associations. However, the protective effect varied widely between 
25% and 95% and this might be attributed to differences in study design i.e. confounding 
factors adjustments, statistical analysis, definition of atopic outcome in infants/children and 
their mothers, method of atopy evaluation, method of collecting dietary information, oily 
and/or  total  fish  definition  as  well  as  categories  of  consumption  frequencies  used  for 
comparisons.  The  one  study  investigating  the  effects  of  maternal  fish  intake  during 
lactation did not observe any significant associations, suggesting that prenatal maternal fish 
oil  supplementation  (during  pregnancy)  might  be  more  beneficial  in  association  to 
reducing  atopy  risk  in  the  offspring,  as  this  is  more  likely  to  determine  fatty  acid 
composition of breast milk and thus provision of n-3 PUFA to the infant. 
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Table 1.5 Maternal fish intake during perinatal life and atopic/allergic outcomes in infants and children of those mothers 
Study  Study population 
and design 
Exposure measures and exposure 
assessment 
Outcome measures and 
confounding factors 
Findings 
Salam et al 2005 
(157) 





th  grade) and 
their mothers/ guardians 
 
Nested case-control 
study in the Children’s 
Health Study 
 
Public schools in 
southern California, 
USA 
Maternal fish consumption during pregnancy-
retrospective assessment (1999-2001) 
 
oily fish (> 2% fat) 
non-oily fish (≤ 2% fat) 
fish fingers (‘fish sticks’) 
canned fish 
 




at least 1/month 
Parental report of physician-diagnosed by 
age 5 years: any asthma, early transient 
asthma, early persistent asthma, late-onset 
asthma (1993-1995)  
 
Confounding factors: maternal asthma, 
race/ethnicity, maternal age, maternal 
education, gestational age, number of 
siblings, exclusive breast feeding for four 
months, other fish categories 
 Asthmatic mothers: at least monthly oily fish consumption 
during pregnancy vs. never decreased risk of any asthma 
in children (OR 0.20; 95% CI 0.06-0.65, p-trend= 0.006).  
 Asthmatic and non-asthmatic mothers together: maternal 
oily fish consumption at least monthly was protective for 
early persistent asthma in children (OR 0.45; 95% CI 
0.23-0.91, p-trend 0.04) 
Fish fingers consumption increased risk of any asthma (OR 
2.04; 95% CI 1.18-3.51, p-trend= 0.01) 
 Children of non-asthmatic mothers were not benefited from 
maternal oily fish consumption during pregnancy. 
 
No associations were found for the rest of the fish categories   47 
Study  Study population 
and design 
Exposure measures and exposure 
assessment 
Outcome measures and 
confounding factors 
Findings 
Calvani et al 2006 
(158) 
295 allergic and 693 
non-allergic mothers 
and their children 
(median age 5 years, 






General Hospitals in 
Rome, Italy 
Maternal intake of fish, butter, margarine 
during pregnancy 
 
Retrospectively assessed by parental report via 
standardised questionnaire  
 
1 time/month or less 
1 time/week 
2-3 times/week or more 
 
 
Atopy in children: SPT to inhalant and food 
allergens (at hospital)  
 
Confounding factors: age, gender, 
oculorhinitis, eczema, age of gestation, 
maternal smoking, paternal atopy, maternal 
occupation, butter and margarine intake  
 
 Non-allergic mother group:  
-A reduction in risk of food sensitisations in offspring to 
mothers with fish intake during pregnancy ‘1 time/week’ 
(OR 0.22; 95% CI 0.08-0.55, p-trend= 0.002) and ‘2-3 
times/week or more’(OR 0.23; 95% CI: 0.08-0.69, p-trend= 
0.002) compared to 1 time/month or less 
 
-Intake of fish ‘1 time/week’ and ‘2-3 times/week or more’ 
reduced milk sensitisation (OR 0.15; 95% CI 0.04-0.59 and 
OR 0.05; 95% CI 0.00-0.54 respectively) and egg 
sensitisation (OR 0.26; 95% CI 0.09-0.76 and OR 0.33; 95% 
CI 0.10-1.07 respectively) 
 
-No associations with inhalant sensitisation 
 
 Allergic mother group: no associations between maternal 
intake of fish during pregnancy and children food or 
inhalant sensitisation 
 
 Whole study population (adjusted also for maternal atopy):  
-Increased consumption of fish was associated with 
decreased prevalence of positive SPT for foods (p-trend= 
0.008) 
 
-Fish intake 1 time/week vs. ≤ 1 time/month decreased risk 
of food sensitisation (OR 0.34; 95% CI 0.15-0.75, p= 0.007)   48 
Study  Study population 
and design 
Exposure measures and exposure 
assessment 
Outcome measures and 
confounding factors 
Findings 
Romieu et al 2007 
(155) 
 
Antenatal Clinics in 
Manorca, Spain 
462 pregnant women 
and their offspring 













Interviewer administered FFQ; 3 months after 
delivery 
 
weekly intake  
 
 
Parental report: doctor-diagnosed eczema 
(at age 1 year), atopic wheeze and persistent 
wheeze (at age 6 year) 
SPT (at age 6 years) 
IgE (at age 4 years) 
 
Confounding factors: maternal asthma, type 
of fish, smoking during pregnancy, 
maternal atopy, gender, maternal social 
class, gestational age 
An increase in maternal fish intake during pregnancy from 
once per week to 2.5 times per week was associated with 
lower risk of eczema at age 1 year (OR 0.73; 95% CI 0.55-
0.98, p= 0.036), positive SPT to HDM at 6 years (OR 0.68; 
95% CI 0.46-1.01, p= 0.058) and atopic wheeze at age 6 
years (OR 0.55; 95% CI 0.31-0.96, p= 0.034)  
 
Weekly maternal fish intake during pregnancy was lower for 
infants with: eczema at 1 year (p= 0.050), positive SPT for 
HDM at 6 yr (p= 0.048), atopic wheeze at 6 years (p= 0.028) 
 
Stratification by breastfeeding: for an increase in fish intake 
during pregnancy from 1 time/week to 2.5 times/week the 
risk of persistent wheeze at 6 years decreased by 90% (OR 
0.10; 95% CI 0.02-0.69, p< 0.05) only among the non-
breastfed infants. 
Sausenthaler et al 
2007 (154) 
 
4 German cities 
 
2641 mothers and their 
infants followed up to 
age 2 years  
 
Prospective cohort in 
the Influences of 
Lifestyle Factors on the 
Immune System and the 
Development of 
Allergies in Childhood 
Study (LISA)  
Maternal diet during the last 4 weeks of 
pregnancy including fish 
 
 
Semi-quantitative FFQ administered shortly 
after delivery  
 
high (1-2 times/week) 
low (<1 time/week) 
Parental report of lifetime doctor-diagnosed 
eczema at age 2 years  
 
Allergic sensitisation (IgE)  
 
Confounding factors: study area, sex, 
maternal age at delivery, smoking during 
2
nd or 3
rd trimester of pregnancy, parental 
education, exclusive breastfeeding for ≥4 
months, family history of atopy, season of 
birth, all dietary variables from FFQ 
High maternal fish intake vs low was associated with 
decreased doctor-diagnosed eczema risk in children at 2 
years (OR 0.75; 95% CI 0.57-0.98, p< 0.05)   49 
Study  Study population 
and design 
Exposure measures and exposure 
assessment 
Outcome measures and 
confounding factors 
Findings 







1212 pregnant women 
and their children 
followed up to age 5 
years  
 
Prospective cohort  
 
 
Maternal diet during pregnancy including fish; 




oily fish  
 
Semi-quantitative FFQ:  
 
Version 5.4 of the Scottish Collaborative 
Group FFQ; sent by post and self-administered 






Parental report of asthma, atopic eczema, 
wheezing, hay-fever in children at 5 years 
(ISAAC core questions) 
 
Spirometry and SPT (only on small number 
of children)  
 
Confounding factors: maternal age of 
leaving full-time education, paternal social 
class, maternal age, maternal smoking 
during pregnancy, smoking in the home 
during childhood, energy intake, maternal 
asthma, maternal atopy, birth weight, 
presence of older siblings, child’s gender, 
breastfeeding. 
Beneficial associations:  
Maternal total fish intake ≥1/week vs. never decreased risk 
of: doctor-diagnosed eczema (OR 0.57; 95% CI 0.35-0.92, p-
trend= 0.008), current treated eczema (OR 0.58; 95% CI 
0.32-1.06, p-trend= 0.028), and ever having eczema (OR 
0.68; 95% CI 0.43-1.10, p-trend= 0.050) 
 
Maternal oily fish intake ≥1/week vs. never decreased risk of 
doctor-diagnosed hay-fever (OR 0.28; 95% CI 0.06-1.19, p-
trend= 0.043) 




34 atopic mothers and 
their infants followed up 
to age 1 year 
 
 
Breast milk fatty acids; samples taken 1 month 
postpartum when infants were exclusively or 
predominantly breastfed  
 
Maternal atopic disease (asthma, allergic 
rhinitis, atopic dermatitis) assessed with 
questionnaire and SPT; 35-36 weeks of 
gestation 
 
Maternal dietary intake (4-consequative-day 
food records) and questionnaire on maternal 
dietary habits including fish consumption 
frequency; 1 month postpartum reflecting 




> 1 time/week 
Clinical examination at ages 1, 3, 6, 12 
months and SPT at 12 months  
 
Atopic dermatitis during the 1
st year of life 
(Hanifin criteria) 
Maternal frequency of fish consumption during pregnancy 
was not related to breast milk EPA content. 
 
The ratio SFA/PUFA was higher in breast milk consumed by 
infants developing atopic dermatitis compared to those 
remaining healthy (4.3 vs. 3.1; p=0.05) 
 
Total n-3 PUFA (% of total fatty acids) was lower in the 
breast milk of mothers whose infants developed atopic 
dermatitis than of those whose infants remained healthy 
(1.61% vs. 2.17%; p=0.05) 
 
EPA (% of total fatty acids) was lower in breast milk 
consumed by infants who developed atopic dermatitis during 
the 1
st yr of life compared to those who did not (0.10 vs. 
0.15; p=0.02) 
  
OR, odds ratio; CI, confidence interval; PUFA, polyunsaturated fatty acid(s); SFA, saturated fatty acid(s); HDM, house dust mite; FFQ, food frequency questionnaire; ISAAC; International 
Study of Asthma and Allergies in Childhood; SPT, skin prick testing; DHA, docosahexaenoic acid; EPA, eicosapentaenoic acid; Ig, immunoglobulin; vs.,versus.   50 
1.5.1.2  Studies investigating the effects of fish intake during infancy or 
childhood on atopic outcomes in those infants or children 
Table  1.6  summarises  all  identified  observational  studies  that  investigate  the 
association  between  fish  intake  during  infancy  or  childhood  and  atopic  or  allergic 
outcomes  in  those  infants  or  children.  Studies  were  identified  through  Ovid  Medline 
(1950-2009) and Embase (1980-2009) databases performing and combining searches with 
the  following  keywords:  fish  intake,  oily  fish  intake,  pre-school  children,  childhood, 
infancy, atopy, allergy, asthma, eczema. Fourteen epidemiological studies were identified. 
The  evidence  provided  by  these  studies  is  less  consistent  and  there  is  a  greater 
heterogeneity in study designs, exposure, outcome measures and results compared to the 
epidemiological studies of Table 1.5.  
Nine studies observed a beneficial effect of fish intake during childhood/ infancy and 
atopic  outcomes  in  those  children/infants  (162-169).  Two  of  the  studies  observed  a 
negative effect of fish intake on childhood atopy (170, 171), and three studies observed no 
associations (172-175). All studies had large sample sizes, although there was a wide range 
of sample sizes amongst the studies. 
The  studies  of  Table  1.6  are  discussed  according  to  whether  they  observed  a 
protective, negative or a null effect. 
 
Studies showing a protective effect of fish 
Study design 
Of the studies that found a beneficial association between fish intake during infancy/ 
childhood and atopic outcomes, three were prospective cohort (164, 167, 175), two studies 
were case-control (162, 163), and four were cross-sectional (165, 166, 168, 169). The age 
range of children taking part in these studies was between 1 and 18 years (at the time point 
that outcomes were measured). Because of the wide age range of the study population 
differences  in the extent of the  beneficial effect can  be expected. Some of the studies 
measured exposure and outcome at a much older age (162, 163, 165, 166) than others (164, 
167, 168, 175). Two of the prospective cohort studies followed-up infants to age 4 years 
(164, 167), whereas Alm et al. (175) followed-up infants to age 1 year.   51 
Exposure measures 
Studies  were  inconsistent  as  far  as  exposure  assessment  is  concerned.  All  three 
prospective cohort studies (164, 167, 175) determined the time point of fish introduction 
during the first year of life using a parental questionnaire. In addition Kull et al. (167) 
collected information on fish consumption frequencies. The cross-sectional study of Kim et 
al. (166) and Antova et al. (169) used a parental FFQ, that of Chatzi et al. (168) used a 
semi-quantitative  FFQ  and  the  other  cross-sectional  study  used  parental  report  of  fish 
consumption without frequencies (165). The retrospective case-control study of Dunder et 
al. (163) used a 48-hour recall of intake and the case-control study of Hodge et al. (162) 
used a parental FFQ (although consumption frequency categories were not used in their 
analysis). 
The ideal method of collecting information on fish consumption would be a FFQ with 
various food categories/items reflecting intake during the past 12 months, including time of 
introduction of fish into diet and different types of fish consumed (oily, non-oily). Also, 
ideally  the  questionnaire  should  be  repeated  in  different  time  points  in  the  case  of 
prospective cohort studies which have a long period of follow-up. In this way changes in 
the fish eating patterns of the children could be identified and related with allergy/atopy 
risk. 
Oily fish consumption was recorded in only some of the studies (162, 168, 175). The 
rest of the studies recorded only total fish intake without specifying the types of fish. In the 
study of Hodge et al. (162) fresh oily fish consumption had a greater beneficial effect on 
current asthma than total fish consumption (74% versus 48% respectively). The ‘Infants of 
Western  Sweden’  study  of  Alm  et  al.  (175)  collected  information  on  the  fish  usually 
consumed and this was categorised into two different types of fish (lean and oily). The vast 
majority of the infants consumed lean fish, and in the univariate analysis it was shown that 
eating lean fish reduced eczema risk by 19% at one year of age (OR 0.81, 95% CI 0.68-
0.97, p = 0.025), but the effect was lost in the multivariate analysis (175). However, Chatzi 
et al. (168) did not identify any significant association for any of the subgroups of fish 
included in their FFQ. 
Confounding factors 
The different studies controlled for different confounding factors. Kim et al. (166) and 
Antova et al. (169) adjusted for all other dietary information collected in the study. Alm et 
al. (175) performed a multivariate analysis, after identifying significant risk factors in the   52 
univariate analysis, and adjusted for ‘atopic reasons’ for not having furry animals and for 
cow’s milk allergy. Chatzi et al. (168) controlled for total energy intake and for maternal 
fish  intake  during  pregnancy  which  was  recorded  using  the  Spanish  version  of  the 
validated European Prospective Investigation into Cancer and Nutrition (EPIC)-Norfolk 
FFQ. Maternal smoking was controlled in the studies of Hodge et al. (162), Nafstad et al. 
(164), Andreasyan et al. (165), Alm et al. (175), and Kull et al. (167), and passive smoking 
was  controlled  in  the  study  of  Antova  et  al.  (169).  Parental  history  of  atopy  and 
breastfeeding was controlled  for  in the studies  of Nafstad et al. (164), Kull et al. and 
Chatzi et al. (168), and parents’ allergy was controlled in the study of Antova et al. (169). 
Hodge et al. (162), Alm et al. (175), and Nafstad et al. (164) adjusted for atopy/respiratory 
infection  in  early  life.  It  should  be  emphasised  that  issues  related  to  the  methods  of 
collecting the information about confounding factors and the validity of this information 
need to be considered when interpreting the results of these studies. 
Outcome measures and findings 
Atopic outcome definitions and assessment methods differed between studies. Three 
of the studies performed skin prick testing (SPT) (162, 165, 168) and one study determined 
specific IgE to identify sensitisation (167). In the study of Alm et al. (175) no clinical test 
or biochemical measurement of allergy was conducted. Clinical outcomes measured in all 
of  the  studies  were  assessed  with  parental  questionnaires.  However  parents  were  not 
always asked for doctor-diagnosis. Clinical outcomes in all of the studies were generally 
well defined. 
The reduction in atopy/allergy risk due to fish intake ranged between 22% and 80%. 
However,  the  risk  reduction  in  most  cases  was  between  50%  and  60%,  providing 
consistent  evidence  for  the  protective  effects  of  fish  consumption  during  childhood/ 
infancy on atopy/ allergy. The study of Antova et al. (169) showed that low fish intake, 
compared with higher intake, increased the risk of respiratory symptoms by 21% (current 
wheeze). 
Nafstad et al. (164) observed a protective effect of introduction of fish early into diet 
on  allergic  rhinitis  for  the  whole  study  population,  but this  protective  effect  remained 
significant  only  among  children  who  were  breastfed  for  more  than  6  months,  without 
parental hay-fever or asthma, with early life atopic eczema, or without an episode of lower 
respiratory tract infection during the first year of life. Similarly, in the other prospective 
cohort study of Kull et al. (167), although there was a dose-dependent reduction in risk of   53 
atopic  outcomes  with  increased  fish  consumption  frequency,  the  protective  effect  was 
significant only for children without parental allergy. Additionally and in contrast to the 
study  of  Nafstad  et  al.  (164),  in  the  study  of  Kull  et  al.  (167)  the  results  remained 
significant only for children without eczema and/or recurrent wheeze during the first year 
of life. Interestingly, introducing fish early during the first year of life (age 3-8 months) 
was more beneficial than introducing fish later on (age ≥ 9 months) and this was associated 
with a lower risk of eczema at 4 years of age (167). This agrees with the findings of Alm et 
al. (175) who found that the introduction of fish before 9 months of age had a protective 
effect on eczema at infants at one year, lowering the risk by 24% at 1 year of age. All the 
rest of the studies which identified a protective effect conducted their analysis for the study 
population as a whole.  
Studies showing a negative effect of fish 
Study design 
Two  studies  were  identified  that  found  a  negative  effect  of  fish  consumption  on 
atopic/allergic outcomes in children/infants (170, 171). Both studies had a cross-sectional 
study design, measuring exposure and outcome at the same time point. This study design is 
not strong enough to infer causality. All sample sizes can be considered as large enough. 
Compared to the studies that identified a positive effect, these studies were conducted in 
older children.  
Exposure measures 
Both  studies  used  a  FFQ.  The  FFQ  in  the  studies  of  Takemura  et  al.  (171)  was 
completed by parents. The study of Huang et al. (170), apart form the FFQ, also used a 24-
h  recall  and  compared  the  effect  between  quartiles  of  intake  rather  than  consumption 
frequencies.  Also, the study conducted by Huang et al. (170) included oily  fish  in the 
questionnaire. 
Confounding factors 
Takemura et al. (171) adjusted for parental atopy, and children’s fruit and vegetable 
intake. Huang et al. (170) adjusted for the level of urbanisation and dietary factors in the 
multivariate analysis. None of these two studies adjusted for socio-economic factors. As 
mentioned previously, these are very important since fish intake may be associated with a 
specific lifestyle. In addition, a possible confounding factor could be parental beliefs about 
when specific food items should be introduced in their infants’ diet, which can change   54 
dietary  initiation  of  a  food  item.  For  example,  parents  may  avoid  or  promote  the 
introduction certain foods if they believe that this could help prevent allergy development. 
Outcome measures and findings 
As far as the atopic outcome measures are concerned, in the study of Takemura et al. 
(171) questionnaires about atopy were answered by parents whereas in the study of Huang 
et  al.  (170)  questionnaires  were  answered  by  children.  Both  studies  were  focused  on 
clinical outcomes and included a component of doctor-diagnosis of atopic outcomes in 
their  questionnaires.  The  study  of  Huang  et  al.  (170)  excluded  subjects  with  atopic 
symptoms who were not doctor-diagnosed. This could potentially lead to misclassification 
of atopy since some of the subjects may not have access to the health care system or may 
have a premature form of the disease that might limit the revealing of clinical observation 
of atopy. 
In the study of Takemura et al. (171), comparing children with current asthma and 
healthy children there were no differences in fish consumption frequencies. However, the 
increase in risk (12% for current asthma) was significant when comparing the effect of fish 
intake 1-2 times/month with that of fish intake 1-2 times/week. Also, the authors showed 
that the risk of current asthma increased with increasing fish intake (p for trend = 0.0349).  
Although the univariate analysis Huang et al. (170) showed that higher oily fish intake 
was associated with  higher prevalence of doctor diagnosed asthma,  in the  multivariate 
analysis this association was no longer significant. Also, no associations were found for 
total fish, seafood and shellfish intake and allergic rhinitis or asthma.  
Studies showing no effect of fish 
 
Study design 
Of  the  three  studies  that  did  not  identify  any  statistically  significant  asssociations 
between fish intake and atopic or allergic outcomes in infants/children, two of the studies 
were prospective cohort (173, 174) and one study was case-control (172). All studies were 
conducted in children older than 1 year of age. Hijazi et al. (172) collected fish intake data 
at age 12 years, Farchi et al. (173) at age 6-7 years and Wijga et al. (174) at age 2 years.    55 
Exposure measures  
All three studies used a parental/maternal FFQ. The study of Farchi et al. (173) was 
the only one including oily fish (mentioned as ‘blue fish’) and ‘pasta with oily fish’. The 
other two  studies  collected  information  only  on  consumption  frequencies  of  total  fish. 
Also, frequency categories (often, sometimes, rarely, never) in the study of Hijazi et al. 
(172) were not clearly defined in the questionnaire. What is more, the two prospective 
cohort studies (173, 174) did not include monthly fish consumption frequencies in their 
analysis. In contrast, they only compared weekly consumption frequencies which may not 
have allowed for significant associations to be identified. 
Outcome measures and findings 
As far as the outcome measures are concerned, the two prospective cohort studies 
(173,  174)  assessed  atopic  outcome  based  on  the  International  Study  of  Asthma  and 
Allergies  in  Childhood  (ISAAC)  questionnaires  completed  by  parents.  The  ISAAC 
questions were also used in the study of Hijazi et al. (172), but they were answered by the 
children themselves. Two of the studies (172, 174) reported results of univariate analysis. 
Although the two prospective cohort studies had a large sample size, their follow-up lasted 
only for 1 year which may not have been long enough to allow for allergy/ atopy outcomes 
to be revealed. It has to be mentioned that the cross-sectional data recorded in 1980 during 
the case-control study, nested in the follow-up study of Dunder et al. (163), identified a 
null association between fish consumption and any atopic diseases (in 1980). However, as 
mentioned above, the retrospective follow-up showed a protective effect of fish. In the 
same study the cross-sectional data of 1986 were not presented. 
Summary 
Overall, the evidence from epidemiological studies investigating the effects of fish 
intake during infancy and childhood on atopic outcomes in those infants or children is 
inconsistent. However, the majority of these studies (nine of 14) showed a protective effect 
of fish intake during infancy or childhood on atopic outcomes in those infants/children. 
The reduction in atopy/allergy risk amongst these studies ranged between 22% and 80%. 
This  could  be  attributed  to  the  fact  that  studies  differed  in  study  design,  control  of 
confounding  factors,  exposure  and  outcome  measure  assessment.  Also,  it  has  to  be 
underlined that some of the studies performed subgroup analysis (for example Kull et al. 
(167) and Nafstad et al. (164)) which may increase the risk of finding chance associations. 
There were only three studies that did not observe any associations (172-174), and two   56 
studies (170, 171) that observed increased risk of atopy with higher fish consumption (12% 
increase of risk for current asthma (171)), although the study of Huang et al. (170) did not 
show any significant results in the multivariate analysis. Therefore, based on the evidence 
available  from  epidemiological  studies,  it  cannot  be  clearly  concluded  with  absolute 
certainty whether fish consumption during infancy or childhood can be protective towards 
atopic disease development in those infants/children, although a number of studies would 
support that conclusion. 
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Table 1.6 Fish intake during infancy/ childhood and atopic or allergic outcomes in those infants/ children 
Study  Study 
population and 
design 
Exposure measures and 
exposure assessment 
Outcome measures and 
confounding factors 
Findings  










Dietary intake of children including 
fish (reflecting intake over the last 
year) 
 
total fish (all categories) 
fish fingers 
canned fish 
total fresh fish 
fresh oily fish (>2% fat) 
fresh non-oily fish (≤2% fat)  
 
FFQ completed by parents 
(Commonwealth Scientific and 




Assessed 6 months before dietary information 
was collected: AHR (by exercise), SPT, recent 
wheeze (parental questionnaire) 
 
Current asthma: presence of both recent 
wheeze and AHR  
 
Confounding factors: Sex, ethnicity, country 
of birth, atopy, respiratory infection in the first 
2 years of life, parental smoking or asthma 
history 
Unadjusted analysis: 
Total fresh fish (OR 0.50; 95% CI 0.27-0.92, p< 0.05) and oily 
fresh fish (OR 0.29; 95% CI 0.13-0.67, p< 0.01) associated with 
reduced risk of current asthma 
 
Adjusted analysis: 
Oily fresh fish associated with reduced risk of current asthma 
(OR 0.26; 95% CI 0.09-0.72, p< 0.01) 




(rural and urban 
areas) 
114 asthmatic and 202 
non-asthmatic children; 
aged 12 years (from a 






Dietary intake including fish; at age 12 
years 
 
-Maternal completion of  
semi-quantitative FFQ 







Asthma ever, wheeze in the last 12 months 
(ISAAC questions answered by the children)  
SPT 
 
Cases: both asthma and wheeze 
 
Confounding factors: social class, place of 
residence, nationality, sex, maternal education, 
family history of asthma or allergy, positive 
SPT 
Univariate analysis:  
The frequency of eating fish was not significantly related to ever having 
asthma or wheezing in the last 12 months 
 
   58 
Study  Study 
population and 
design 
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Findings  
Dunder et al 2001 
(163) 
 




control nested in the 9-
year follow-up (1980-
1989): 60 atopic and 
1293 non-atopic 
children aged 3, 6, 9, 
12, 15, 18 years.  
 
2. Case-control: 
231 atopic and 231 non-
atopic children (1980); 
mean age 10.3 years  
 
154 atopic and 154 non-
atopic children (1986) 
 
(pairs matched for age, 




Dietary intake including fish intake 
(standardised to energy intake); in 
1980 and 1986 
 




Serum fatty acids 
 
Physician diagnosed: allergic rhinitis, allergic 
dermatitis, asthma (parental questionnaires in 
1980, 1986, 1989) 
 
Atopic disease: one or more of the above 
diseases 
 
Confounding factors: age, sex, region, 
maternal education 
  Follow-up: children who developed atopic diseases in 1989 had 
consumed less fish in 1980 compared to those who remained healthy (3.2 
vs 6.6 g/1000 Kcal; p< 0.001) 
 
  Cross-sectional data in 1980: fish consumption was not associated with 
atopic disease, atopic dermatitis, allergic rhinitis, or asthma  
 
  Serum EPA and DHA were lower in children with atopic dermatitis in 
1980 (1.11 vs 1.22; p= 0.01 and 0.64 vs. 0.69; p= 0.01 respectively) and 
1986 (0.91 vs 1.02; p= 0.02 and 0.55 vs. 0.61; p= 0.01 respectively) 
 
 






Survey in Taiwan 
 







Dietary intake including fish during 





other seafood  
 
24-h recall and FFQ; administered to 
children  
 
Quartiles of intake 
 
 
Physician-diagnosed: allergic rhinitis, asthma; 
(questionnaire to children) 
 
Confounding factors: age, levels of 
urbanisation 
 
FFQ variables used in the multivariate model: 
liver, deep-fried foods, oily fish, butcher’s 
meat 
  Univariate analysis: Higher intake of oily fish (1
st vs. 4
th quartile of 
intake) was associated with higher prevalence (1.5% vs. 4.9%) of 
doctor diagnosed asthma (p= 0.01) 
 
  Multivariate analysis: total and oily fish intake were not associated 
with asthma or allergic rhinitis  
 
  There was no association between any fish category intake and 
allergic rhinitis 
 
  No associations found for shellfish and other seafood and outcome 
measures   59 
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Children aged 6-15 
years: 1673 currently 






FFQ including fish, completed by 









Current asthma (parental questionnaire of the 
American Thoracic Society and Division of 
Lung Diseases adopted by the Japan 
Environment Agency) 
 
Current asthma: doctor-diagnosed asthma with 
symptoms and treatment during the past 2 
years 
 
Confounding factors: age, gender, parental 
history of asthma, vegetable and fruit intake 
Higher prevalence of asthma among subjects who ate fish 1-2 times/wk 
compared to those who ate fish 1-2 times/month (OR 1.117; 95% CI 
1.005-1.241, p= 0.041).  
 
Increasing frequency of fish intake was associated with increased risk of 
current asthma (p-trend= 0.0349) 
Antova et al 2003 
(169) 
 















Dietary intake of fish, fresh fruit and 
fresh vegetable (parental FFQ; 




Winter cough , persistent cough, wheeze ever, 
current wheeze (parental questionnaires, 
ISAAC) 
 
Confounding factors: age, sex, area, pets, 
indoor moisture, gas oven for heating, 
additional gas heating, passive smoking, 
maternal education, paternal occupation, 
parental allergy, respondent, overcrowding, all 
tested nutritional factors 
Low fish intake (<1/month) compared with higher (≥1/month) was 
associated with increased risk of persistent cough (OR 1.18; 95% CI 1.04-
1.34, p= 0.01), wheeze ever (OR 1.14; 95% CI 1.03-1.34, p= 0.01), and 
current wheeze (OR 1.21; 95% CI 1.06-1.39, p= 0.01)    60 
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Farchi et al 2003 
(173) 
 
Italian Studies on 
Respiratory 
Disorders in 
Children and the 
Environment 
(SIDRIA), part of 
the ISAAC 
4104 children aged 6-7 
years, followed-up for 
one year 
 
Prospective cohort  
 
 
Dietary intake including fish (at 1 year 
follow-up) 
 
pasta with fish: tuna, mackerel, 
sardines, salmon, anchovies 
 
oily (‘blue’) fish: tuna, mackerel, 
sardines, salmon, anchovies 
 






12 month occurrence of: wheeze, shortness of 
breath with wheeze, allergic rhinitis symptoms 
(parental completion; ISAAC questions at 
baseline and questionnaire at 1 year follow-
up) 
 
Confounding factors: sex, study area, paternal 
education, household crowding, maternal or 
paternal smoking, dampness or mould, 
parental asthma 
Univariate analysis: 
Neither oily fish nor ‘pasta with fish’ were associated with 12 month 
occurrence of wheeze, shortness of breath with wheeze or allergic rhinitis    61 
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Nafstad et al 2003 
(164) 
 
Oslo Birth Cohort 
Study, Norway 
2531 infants followed 
up to age 4 years  
 
Prospective cohort  
 
 
Introduction of various kinds of food 
including fish into diet during the year 
1 of life 
 
 
Parental questionnaires at age 1  
year (no quantitative information)  
 
Yes (and month of introduction) 
No  
Doctor-diagnosed current asthma and allergic 
rhinitis (parental questionnaire administered at 
4 years) 
 
Confounding factors: parental atopy, atopic 
eczema at 0-6 months of age, gender, parity, 
birth weight, maternal age at delivery, birth 
order, uterus-related pregnancy complications, 
keeping pets at home when child was born, 
episode of lower respiratory tract infections 
during year 1 of life, maternal education, 
family income per year, maternal smoking at 
the end of pregnancy, length of breastfeeding. 
The risk of allergic rhinitis was lower in children who had fish during the 
first year of life compared to children who had fish later in life (OR 0.45; 
95% CI 0.28-0.74) 
 
Among children who were breastfed for >6 months, those who had fish 
during year 1 of age had lower asthma risk (OR 0.56; 95% CI 0.36-0.87) 
and allergic rhinitis risk (OR 0.28; 95% CI 0.15-0.52) 
 
Among children without parental hay fever or asthma, those who had fish 
during year 1 of age had lower asthma risk (OR 0.50; 95% CI 0.30-0.83) 
and allergic rhinitis risk (OR 0.47; 95% CI 0.25-0.86) 
 
Among children with early life atopic eczema, there was a decreased risk 
of asthma (OR 0.47; 95% CI 0.23-0.97) and allergic rhinitis (OR 0.32; 
95% CI 0.15-0.69) with any fish consumption during year 1  
 
Among children without an episode of lower respiratory tract infection 
during the first year of life, those who had fish during year 1 of age had 
lower allergic rhinitis risk (OR 0.39; 95% CI 0.24-0.66) compared to 
those who had none  
 
The risk of having doctor-diagnosed atopic eczema with symptoms during 
the 4
th year of age was reduced in children who consumed fish during 
year 1 of life compared to those who did not (OR 0.66; 95% CI 0.52-0.84) 




and Incidence of 
Asthma and Mite 
Allergy (PIAMA) 
birth cohort study, 
Netherlands 
2978 children, aged 2 






Dietary intake including fish during 




Rarely: <1 time/week 
Regularly: 1-5 times/week 
Daily: 6-7 times/week 
Doctor-diagnosed ever asthma, doctor-
diagnosed recent asthma (last 12 months), 
recent wheeze (parental questionnaire based 
on ISAAC); posted at age 3 years 
 
Confounding factors: sex, birth weight, 
presence of older siblings, parental allergy, 
maternal level of education, breastfeeding for 
at least 8 weeks, smoking in the home and 
during pregnancy, region, parental asthma  
Univariate analysis: 
Eating fish at least once a week was not associated with ever asthma, 
recent asthma or recent wheeze 
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Children’s total fish intake at age 8 





SPT, asthma, hay-fever, wheeze, eczema 
(ISAAC questionnaire to parents)  
 
Confounding factors: sheepskin and plastic 
mattress use during infancy, sex, number of 
siblings at 8 years, bottle feeding at 1 month, 
any maternal smoking during pregnancy 
Fish intake was associated with decreased risk of ryegrass-pure 
sensitisation (OR 0.37; 95% CI 0.15-0.90, p= 0.03) 
 
Fish intake was associated with decreased risk of asthma linked to 
ryegrass-pure sensitisation (OR 0.20; 95% CI 0.04-0.90, p= 0.04), and the 
risk of hey-fever linked to ryegrass-pure sensitisation (OR 0.25; 95% CI 
0.08-0.78, p= 0.02) 
 
Fish consumption was associated with a greater reduction in risk for 
ryegrass-pure sensitisation in comparison to the risk reduction for HDM-
pure sensitisation (OR 0.20; 95% CI 0.05-0.79) 













Dietary intake of specific food 
categories including fish (parental 











Assessment of allergens in the school 
environment  
 
Doctor-diagnosed asthma, current asthma (last 
12 months), wheeze, daytime breathlessness, 
night-time breathlessness, self-reported atopic 
sensitisation to cat, dog, pollen, food  
 
Questions obtained from the European 
Community Respiratory Health Survey; 
parental completion in co-operation with the 
child 
 
Confounding factors: age, gender, and all 
other dietary factors 
For an increase of fish intake by one frequency category there was a 
decreased risk of doctor-diagnosed asthma (OR 0.54; 95% CI 0.35-0.84, 
p< 0.01), current asthma (OR 0.51; 95% CI 0.31-0.84, p< 0.01), and 
night-time breathlessness (OR 0.36; 95% CI 0.17-0.78, p< 0.05) 
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3619 infants followed 





Infant’s consumption frequency and 
time of introducing fish during the 1
st 
year of life  
 






>1 time/ week 
 
Regular fish consumption defined as 
≥2-3 times/week 
Assessed at age 4 years (occurrence during 
last 1-2 years): asthma, eczema, allergic 
rhinitis, persistent allergic disease, 
sensitisation (IgE) 
 
Any allergic disease: at least one of asthma, 
eczema, allergic rhinitis 
 
Multiple allergic diseases: more than two 
 
Confounding factors: parental allergic disease, 
maternal age, maternal smoking, breastfeeding 
Dose-dependent reduced risk for asthma (p-trend= 0.03), eczema, allergic 
rhinitis and sensitisation (p-trend< 0.001) with increased in fish 
consumption frequency 
 
Introducing fish at age 3-8 months reduced risk for asthma (OR 0.73; 95% 
CI 0.55-0.97), eczema (OR 0.77; 95% CI 0.64-0.92), allergic rhinitis (OR 
0.77; 95% CI 0.60-0.97) and sensitisation (OR 0.78; 95% CI 0.64-0.95) 
compared to introducing fish at or after age 9 months 
  
  Among children without eczema and /or recurrent wheeze during the 1
st 
year of life: fish consumption ≥2 times/month compared to ≤1 
time/month during the first year of life was associated with reduced risk 
of any allergic disease (OR 0.76; 95% CI 0.61-0.94), eczema (OR 0.78; 
95% CI 0.60-1.00), rhinitis (OR 0.60; 95% CI 0.43-0.83), sensitisation 
(OR 0.76; 95% CI 0.57-1.00), persistent eczema (OR 0.48; 95% CI 0.32-
0.68), persistent rhinitis (OR 0.43; 95% CI 0.23-0.79) and multiple 
allergic disease (OR 0.56; 95% CI 0.35-0.89) at age 4 years 
 
  Fish consumption ≥2 times/month compared to ≤1 time/month during 
the first year of life was associated with reduced risk of sensitisation (OR 
0.52; 95% CI 0.35-0.76, p< 0.01) only in children without parental 
allergy 















fried/ coated fish 
seafood 
 
Parental completion of semi-
quantitative FFQ (modified Harvard 
questionnaire)  
 
Current wheeze, atopic wheeze (parental 




Confounding factors: gender, maternal and 
parental asthma, maternal and paternal atopy, 
maternal smoking, BMI at 6.5 years, maternal 
and paternal education and social class, 
breastfeeding, fish intake during pregnancy, 
number of siblings 
There was inverse association between children’s total fish intake ≥ 60 
gr/day and atopy (OR 0.43; 95% CI 0.21-0.90, p< 0.05) 
 
Subgroups of fish were not significantly associated with atopy 
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Food frequency data including fish 




A few times per year 
1-3 times per month 
1-3 times per week 
3+times per week 
 
Lean fish (cod, haddock) 
Salmon 
Flatfish 
Mackerel or herring 
Paternal report of eczema. Parental report of 
food allergy diagnosed by a physician at 6 and 
12 months of age 
 
Multivariate analysis was performed for those 
risk factors that were significant in the 
univariate analysis: maternal eczema, sibling 
with eczema, bird in the home, introduction of 
fish before 9 months of age. Also adjusted for 
‘atopic reasons’ for not having furry pets and 
for cow’s milk allergy 
 
  Multivariate analysis:  
 
-Introducing fish before 9 months of age reduced the risk of developing 
eczema at 1 year of age (OR 0.76; 95% CI 0.62-0.94, p= 0.009) 
-No influence of the type of fish (lean/oily) consumed 
 
  Univariate analysis: Usually eating lean fish reduced the risk of 
eczema at 1 year of age (OR 0.81; 95% CI 0.68-0.97, p= 0.025)- this 
was not significant in the multivariate analysis 
OR, odds ratio; CI, confidence interval; PUFA, polyunsaturated fatty acid(s); HDM, house dust mite; FFQ, food frequency questionnaire; ISAAC, International Study of Asthma and 
Allergies in Childhood; SPT, skin prick testing; DHA, docosahexaenoic acid; EPA, eicosapentaenoic acid; Ig, immunoglobulin; AHR, airway hyper-responsiveness; vs, versus. 
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1.5.2  Intervention studies investigating the effect of early fish oil 
exposure on atopic outcomes in infancy or childhood 
In general, randomised controlled trials (RCT) or experimental/intervention studies are 
study designs that provide the highest level of testing of cause and effect. This section reviews 
the literature published to present on RCT of fish oil supplementation in pregnancy, lactation 
or infancy/childhood and allergic outcomes in infants/children of those pregnancies or those 
infants/children (Table 1.7 and Table 1.8). The studies were identified through Ovid Medline 
(1950-2009) and Pubmed (1950-2009) databases by searching with the following keywords: 
fish oil, fish supplements, fish-oil capsules, EPA, DHA, trial, maternal, pregnancy, lactation, 
atopy, allergy, asthma, eczema, dermatitis, hayfever, pre-school children, childhood, infancy. 
1.5.2.1  Randomised controlled trials investigating the effects of fish oil 
supplementation during pregnancy or lactation on immune or atopic 
outcomes in the offspring of those pregnancies 
Table  1.7  summarizes  RCT  of  maternal  fish  oil  supplementation  during  early  life 
(pregnancy and lactation) and immune or allergic outcomes in the offspring during infancy or 
childhood; five such studies were identified. One study investigated the effects of n-3 PUFA 
supplementation during pregnancy and many scientific papers have been published on this 
study (22, 176-182), of which six (22, 176-179, 182) refer to clinical allergic outcomes in the 
offspring or immune markers that may modulate these outcomes (Table 1.7). A second study, 
also  investigating the effects of fish oil  supplementation during pregnancy on the immune 
system of the mother and the offspring, has recently published two papers (183, 184) of which 
one (183) is  included  in Table  1.7. A  third study was conducted on lactating women  and 
associated the maternal fish oil  intervention with allergic biomarkers, but not with clinical 
outcomes in the children (185). The fourth trial, conducted by Olsen et al. (186) investigated 
the effects of fish oil intake in the last trimester of pregnancy and followed up the children to 
assess asthma-related diagnosis at 16 years of age. The fifth study investigated the effects of n-
3 fatty acid supplementation both during pregnancy and lactation, on infant allergy risk. This 
trial  has  published  up  to  present  two  relevant  papers,  one  looking  at  the  effects  of  the 
supplementation on the offspring during the first year of life (187) and the other at the effects 
of the supplementation during pregnancy on the immune system of the mother (188).   66 
Study Design 
The study by Dunstan and colleagues (22, 176-182) was conducted in Australia and was a 
double-blinded RCT starting at week 20 of pregnancy. The study of Krauss-Etschmann et al. 
(183) was a European multicenter (Germany, Spain, Hungary) 2-factorial double-blinded RCT 
starting at week 22 gestation. This study was conducted by the Nutraceuticals for Healthier 
Life (NUHEAL) study group. The study by Lauritzen et al. (185) was conducted in Denmark 
and  it  was  also  a  double-blinded  parallel  group  RCT  including  women  from  The  Danish 
National Birth Cohort. In this study, the women were supplemented during lactation and their 
children  were  followed  up  to  2.5  years  of  age.  The  study  by  Furuhjelm  et  al.  (187)  was 
conducted in Sweden and was a RCT as well starting at 25
th week of gestation up to 3-4 
months of breastfeeding. The study of Olsen et al. (186), conducted in Denmark, was a double 
blinded  RCT  with  stratification  by  maternal  fish  intake  at  baseline  (low/  medium/  high), 
conducted from week 30 gestation to delivery, and children were followed up at 16 years of 
age. 
Furuhjelm et al. (187) compared marine n-3 fatty acid supplementation with soy oil as 
placebo. The studies of Dunstan et al. (22, 176-182), Lauritzen et al. (185), and Olsen et al. 
(186) compared marine n-3 fatty acid supplementation with olive oil as placebo. However, in 
the study of Lauritzen et al. (185) there was a third group of women which was a high-fish-
intake reference group and did not receive any supplement. In the study of Olsen et al. (186) 
there was also a third group which was a control group and which received no oil capsules. 
Krauss-Etschmann  et  al.  (183)  included  four  groups:  DHA-rich  fish  oil,  5-methyl-tetra-
hydrofolic acid (5-MTHF, 400 µg/day), both, or placebo. All were provided in a milk-based 
drink. The placebo was a plain milk-based supplement of minerals and vitamins recommended 
for  pregnancy.  For  the  intervention  groups,  fish  oil  and/or  5-MTHF  were  added  into  the 
placebo supplement. All groups received supplement with similar energy value, protein, fat 
and carbohydrate content,  and  identical  content in  rest of  vitamins and  minerals. Detailed 
analysis of individual fatty acids of the placebo and fish oil supplement was provided by the 
authors, and there were not significant differences in linoleic and α-linolenic acid between 
them.  
The main inclusion criterion for the women who participated in the study by Dunstan et 
al. (22) was the presence of atopy: all women had a history of physician diagnosed allergic 
rhinitis  and/or  asthma  and  one  or  more  positive  skin  prick  tests  (SPT)  to  six  common   67 
allergens. The subjects’ habitual dietary intake did not exceed two fish meals per week as 
assessed using a semi-quantitative FFQ prior to the study. In the study of Krauss-Etschmann et 
al.  (183)  subjects  were  healthy  pregnant  women  (including  both  atopic  and  non-atopic 
subjects). Only women who did not use fish oil, folate and vitamin B12 supplementation after 
week 16 gestation were included in the study. Mothers that took part in the Danish study (185) 
were healthy and non-atopic. Estimation of their habitual LC n-3 PUFA (g/day) intake was 
conducted using a semi-quantitative 300 item FFQ and only women with an intake below the 
population  median  (<  0  .4  g/day)  were  randomized.  Women  with  an  intake  in  the  upper 
quartile (> 0.8 g/day) were used as a reference group. In the study of Olsen et al. (186) the 
women were healthy at study entry (atopic and non-atopic), and those with fish allergy were 
excluded. Food intake was assessed at baseline by a simple FFQ that categorised women in 
low,  medium and high habitual intake of fish. In the study of Furuhjelm et al. (187) both 
atopic and non-atopic women were included (family history of allergy assessed by interview 
and doctor diagnosis and IgE positive test) and those with fish or soy allergy were excluded. 
Only women that planned to breastfeed their offspring were included in the study. At baseline 
(25  weeks  of  gestation)  3-day  dietary  diaries  were  conducted  and  PUFA  nutrients  were 
calculated.  In  both  groups  levels  of  EPA  and  DHA  intake  were  0.2g/day  and  0.1  g/day 
respectively, while in the placebo group the LA intake was about 7 g/day (187). 
Although the window of early life that the intervention took place differed between the 
five studies (pregnancy and/ or lactation), the duration of intervention period prenatally was 
similar for the three studies between week 20 of gestation to delivery (22), between week 22 
of gestation to delivery (183), and between 30 weeks of gestation to delivery (186). For one 
study supplementation occurred only postnatally, during the first 4 months of lactation (185) 
and for the study conducted by Furuhjelm et al. supplementation occurred perinatally, started 
in  pregnancy  (25
th  week)  and  finished  in  lactation  (average  3-4  months  of  breastfeeding) 
(187).  
It has to be noted that the fish oil supplements used contained high amounts of long chain 
n-3 PUFAs and supplementation dosages differed between the three studies. Women in the 
fish oil group in the study of Dunstan et al. (22) received 3.7 g/day of n-3 PUFAs with 56% as 
DHA and 27.7% as EPA. The control group received 4 g/day of olive oil. In the study of 
Krauss-Etschmann et al. (183) women received a lower dose of fish oils: 0.5 g/day DHA and 
0.15 g/day EPA. Women in the study of Olsen et al. (186) received 2.7 g/day EPA plus DHA,   68 
while the placebo group (one of the 2 control groups) received 4 g/day olive oil. In the trial of 
Furuhjelm et al. (187) the pregnant women assigned to the intervention group consumed 1.6 
g/d EPA and 1.1 g/d DHA while the placebo group consumed 4.5 g/day soy oil containing 
mainly linoleic acid. Mothers in the study of Lauritzen et al. (185), were supplemented with 
4.5 g/day of fish oil which provided 1.5 g/day of EPA plus DHA or with 4.5 g/day of olive oil. 
It has to be noted that the supplementation in the studies of Dunstan et al. (22), Furuhjelm et 
al. (187), and Olsen et al. (186) was in the form of capsules, in the study of Krauss-Etschmann 
et al. (183) in the form of powder stirred into a milk-based drink, whereas in the study of 
Lauritzen et al. (185) the fish oil was incorporated into muesli bars, home-made cookies and 
capsules.  
Subject follow-up and compliance 
In  the  study  of  Dunstan  et  al.,  85%  of  the  women  that  took  part  in  the  intervention 
completed the study. Compliance was monitored by measuring the incorporation of EPA and 
DHA into the cell membranes of erythrocytes (178). 
In the European multicenter study (183), there is no reference to subject compliance rates. 
However, this trial has published results on DHA and EPA incorporation in the mother and 
offspring (184). In this paper it is mentioned that left over sachets of the supplement were 
asked  to  be  returned.  Also,  compliance  was  assessed  in  standardised  questionnaires  at  30 
weeks gestation, and at delivery by asking each subject how many days of dosing she had 
missed. The drop-out rate was 13.18% (270 of the 311 recruited pregnant women completed 
the study) (184).  
In the study conducted by Furuhjelm et al. (187) the overall dropout from gestation week 
25 till delivery was 17%, however the dropout was higher in the fish oil group (23%) than in 
the control group (12%). After birth, 52 infants were followed up in the fish oil group at and 
65 infants followed up in the control group. This means that the dropout in the fish oil group 
was  25%  in  the  control  13%,  while  overall,  the  attrition  rate  was  19%.  Authors  did  not 
comment on compliance, apart from the fact that the research nurses contacted the mothers 
twice during the last part of pregnancy to remind them of the supplementation/placebo (187). 
In the study of Olsen et al. (186) children were followed up and assessed in terms of 
asthma  and  other  related  allergic  symptoms  at  16  years  of  life.  The  follow  up  rate  was 
extremely high, as 522 were included in analyses 16 years after the intervention. According to   69 
the authors compliance was optimised by returning and weighing the empty boxes of capsules 
at three times, so that the researchers estimated amounts of capsules consumed (186). 
Lauritzen  et  al.  (185)  stated  that  the  overall  self-reported  compliance  with  exclusive 
breastfeeding in both groups was on average 91% (range 67-100%, n = 64). The follow-up 
rates at 2.5 years of age in the randomized groups and in the high-fish-intake reference group 
were 72% and 58%, respectively, but in total, the follow-up rate at 2.5 years of infants’ age in 
comparison to the baseline subjects’ recruitment was 48% (101 infants out of 211 pregnant 
women). However, the follow-up women had significantly better compliance with exclusive 
breastfeeding in the intervention groups compared to the follow-up women in the reference 
group (89 versus 85%, p = 0.020) (185). 
Confounding factors 
In the study of Dunstan and colleagues, so as to minimise potential confounding factors at 
randomization, the groups were stratified by parity (no previous term birth child versus one or 
more), pre-pregnancy BMI, age and maternal allergy (allergic rhinitis or asthma). Results were 
adjusted for gender, parity and method of delivery (178). Dunstan et al. (22) reported that 
background maternal dietary intake of fatty acids assessed by FFQ was not different between 
the two groups at study entry or at 30 weeks gestation. 
In the study of Krauss-Etschmann et al. (183), after randomization the women in different 
groups did not differ significantly in parity, height, weight at study entry, smoking habits, or 
social demographic characteristics. Also, data on dietary habits were obtained at study entry 
(184).  However,  data  on  their  dietary  intake  were  not  presented  nor  controlled  for.  The 
neonates did not differ significantly in sex, birth weight, length, Apgar score, and parental 
history of allergy. For the purposes of this analysis only 158 mother-child pairs were available. 
Their characteristics did not differ from those of the main trial (n = 311). The analysis of this 
study  was  adjusted  for  study  centre  (reference  Hungary)  and  maternal  percentage 
weight/weight DHA at week 20 gestation (baseline). Confounding factors controlled for were 
gravity, parity, delivery mode, and maternal smoking at 20 and 30 weeks gestation.  
Olsen et  al. (186) did not  control  for any  factors  but randomisation was stratified  by 
maternal habitual fish intake (low, medium and high).   70 
Furuhjelm  et  al.  (187)  made  adjustments  in  their  analysis  for  allergic  symptoms  in 
children  for  the  following  factors:  linoleic  and  arachidonic  acid  levels  in  maternal 
phospholipids at inclusion, breastfeeding fully until 6 months, number of siblings, exposure to 
tobacco smoke, maternal allergic symptoms and eczema in family (187). 
Lauritzen et al. (185) did not control for confounder factors in their analysis. However 
they  assessed  subjects’  compliance  with  exclusive  breastfeeding,  and  they  found  no 
differences  in characteristics of children (2.5  years) between the  groups (sex, parity, birth 
weight, duration and degree of  breastfeeding, age, height, weight, family history of atopy, 
eczema, wheezing, food allergy, plasma IgE). 
Findings of the studies 
Findings of the Australian fish oil supplementation study (22, 176-182) 
Maternal fish oil supplementation resulted in higher EPA and DHA status and lower AA 
status in cord blood erythrocytes (180) and in breast milk (179, 181). Cord blood plasma and 
urinary F2-isoprostane concentrations, considered to be markers of lipid peroxidation, were 
lower  in the fish oil group (176), suggesting that maternal fish oil  supplementation during 
pregnancy might be protective against oxidative stress in the infants of atopic mothers soon 
after birth.  A  number  of  immunologic effects of  maternal  fish  oil  supplementation during 
pregnancy were reported. These include significantly lower cord plasma IL-13 concentrations 
(178), a tendency towards lower cord blood mononuclear cell cytokine responses to allergens 
which was significant for IL-10 in response to cat allergen (22), and lower LTB4 production 
and higher LTB5 production by cord blood neutrophils (182). Cord plasma IL-13 and cord 
neutrophil LTB4 production were inversely related to n-3 PUFA status. Although breast milk 
IgA, soluble CD14 and cytokines were not different between fish oil and control groups, IgA 
concentration was positively correlated with breast  milk  DHA (179). Denburg et al. (177) 
showed an altered cord blood hemopoietic progenitor phenotype in the fish oil group: there 
was an increased number of cord blood CD34
+ progenitors and an increased number of IL-5 
responsive cord blood eosinophil/basophil colony forming units. The number of CD34
+ cells 
in cord blood significantly increased the risk of atopic eczema in infants at 1 year of age, and 
cord blood progenitor IL-5 responsiveness increased the risk of atopic eczema and recurrent 
wheeze  significantly.  Paradoxically,  these  findings  suggest  that  fish  oil  supplementation 
during pregnancy may actually favour the development of atopic disease in the offspring. In   71 
contrast to this conclusion, infants in the fish oil group were significantly less likely (OR 0.09) 
to have severe atopic dermatitis at 1 year of age and were three times less likely to have a 
positive SPT to egg at 1 year of age (OR 0.34) (22). It has to be noted that this study was not 
statistically powered to assess effects on clinical outcomes. Analysis at 2.5 and 5 years of age 
would provide a more reliable assessment of such clinical outcomes. In addition, the small 
sample  size  makes  this  study  an  “exploratory”  study.  Larger  scale  studies  are  needed  for 
neonatal  clinical  assessment  and  to  investigate  the  effects  of  n-3  PUFA  supplementation 
during  pregnancy  and/or  early  life  in  relation  to  allergy  prevention  in  children  of  those 
pregnancies. 
Findings of the European multicenter pregnancy supplementation study (183) 
As  mentioned  above,  the European  multicenter study  measured  the  effects of  fish oil 
supplementation during pregnancy on maternal and cord blood plasma concentrations of EPA 
and DHA. It was shown that fish oil supplementation with or without 5-MTHF resulted in an 
increased proportion of DHA and EPA in maternal plasma at 30 weeks of gestation and at 
delivery and of DHA in cord blood plasma compared with placebo (184). What is more, fish 
oil supplementation increased the percentage of DHA in placenta phospholipids (p = 0.008). 
However, placental ARA was not significantly different between the groups (189). 
Fish  oil  supplementation  during  pregnancy  was  associated  with  decreased  mRNA 
expression of IL-4, IL-13 and CCR4 and decreased frequencies of NK cells and CCR3
+ CD8
+ 
T cells in cord blood (183). Moreover, mRNA levels of IL-1 and IFN-γ in maternal blood at 
delivery  were  decreased  after  fish  oil  supplementation.  In  contrast,  mRNA  levels  of  the 
regulatory cytokine TGF-β were higher in both maternal blood at delivery and in cord blood 
following maternal supplementation (183). Thus, it was shown that fish oil supplementation 
during pregnancy downregulates Th1 responses in the mother and Th2 responses in the foetus. 
These results are in line with the observations made by Dunstan et al. (178) of lower cord 
blood  IL-13  concentrations  after  maternal  fish  oil  supplementation.  In  addition,  Krauss-
Etschmann et al. (183) showed that the decrease in cord blood IL-13 mRNA levels was more 
pronounced in non-allergic mothers. No clinical assessments of the infants from this study 
have been reported.    72 
Findings of the Danish follow up study (186) 
 
Olsen et al. (186) conducted the supplementation trial in 1992 and related late pregnancy 
fish oil supplementation to prolonged gestation. After 16 years, they followed up the offspring 
of those mothers that participated in the trial and assessed the prevalence of asthma-related 
diagnosis,  as  well as atopic dermatitis or  allergic rhinitis  in those  children  after  obtaining 
information on occurrences of those allergic diagnoses from the Danish patient registry. The 
odds ratios  for asthma (all types) and allergic asthma were  both  lower (by  63% and 87% 
respectively) in the fish oil group in comparison to the olive oil group (control). There was a 
lower prevalence of asthma (all types), atopic dermatitis or allergic rhinitis (by 57%) and of 
allergic asthma, atopic dermatitis or allergic rhinitis (by 69%) in the fish oil group compared 
to  control.  Finally,  stratification  by  maternal  fish  intake  at  baseline  (low/medium/high) 
resulted in small number of cases and did not have any significant effect on the results (186).  
 
Findings of the Swedish pregnancy and lactation study (187, 188) 
 
Warstedt et al. (188) showed that plasma phospholipid EPA and DHA increased in the 
fish-oil-treated women during pregnancy with similar changes seen in both atopic and non-
atopic women. Lipopolysaccharide (LPS)-induced PGE2 secretion from whole blood cultures 
was decreased in the majority of the fish oil group (188). However, the mean decrease in the 
fish oil group was not significant, in contrast to the PGE2 production in the control group that 
increased  significantly. The  non-significant decrease  of PGE2  secretion  in the  intervention 
group was probably due to the observation of higher secretion at baseline from the mothers 
that were randomized to the fish oil group compared to those allocated in the placebo group. 
The change in PGE2 production differed significantly between the two groups (p = 0.002) and 
the decrease in PGE2 secretion in the n-3 supplementation group was more pronounced among 
non-atopic  women  (but  not  significant).  As  far  as  secretion  of  LTB4,  chemokines  and 
cytokines, no changes were observed with supplementation. Finally, Warstedt et al. showed 
that  the  changes  in  LPS-induced  PGE2  production  in  the  intervention  group  correlated 
positively  with  changes  in plasma  phospholipid  AA  and  negatively with changes  in  EPA, 
which was even stronger among the non-atopic (188).   73 
Furuhjelm  et  al.  (187)  associated  the  fish  oil  supplementation  during  pregnancy  and 
lactation (25 weeks gestation to 3-4 months lactation) with atopic clinical outcomes in the 
offspring at 6 months and 1 year of age. The prevalence of any positive SPT and of a positive 
SPT  to  egg  in  the  infants  at  1  year  of  age  was  significantly  lower  in  the  fish  oil  group 
compared to the placebo. IgE associated eczema (eczema in the presence of detectable IgE 
antibodies or positive SPT towards egg, milk or wheat) and food allergy (reaction to egg or 
milk) during the first year of life were significantly lower in the fish oil group. In a regression 
analysis, after controlling for the confounding factors, it was found that the risk of developing 
any positive SPT, a positive SPT to egg or IgE associated eczema was three to four times less 
in the fish oil group compared to the placebo. The risk of developing food allergy was reduced 
10 times in the fish oil group in comparison to the control. These significant effects were seen 
in the offspring of non-allergic mothers but not of allergic mothers (187).  
Findings of the ‘Danish National Birth Cohort’ (185) 
Erythrocyte n-3 PUFA at 4 months were higher in infants whose mothers received fish oil 
during  lactation  compared  to  control.  Differences  in  erythrocyte  fatty  acid  composition 
between the groups were no longer evident at 2.5 years of age. The study was not powered to 
look at clinical outcomes, such as atopic sensitization, and no differences in atopic outcomes 
or in plasma IgE were observed between the groups. No association was found between in 
vitro cytokine production and plasma IgE levels and there was also no significant association 
between plasma IgE and eczema, wheezing or food allergy, although both associations tended 
to be positive (185).  
Summary 
 
Dunstan et al. (178) showed that maternal fish oil supplementation resulted in higher n-3 
PUFA status (higher EPA and DHA in cord blood erythrocytes) and lower n-6 PUFA status in 
the neonates. Krauss-Etschmann et al. (183) demonstrated that fish oil supplementation during 
pregnancy results in higher levels of DHA in both maternal and cord blood. These studies 
reported effects of maternal fish oil supplementation during pregnancy on cord blood immune 
markers  (blood  cytokine  mRNA,  plasma  cytokines,  LTB4  production  from  neutrophils, 
cytokine production by mononuclear cells) and an altered cord blood hemopoietic progenitor 
phenotype. These immunologic effects might be expected to impact on allergic sensitization 
and on the  development of  atopic  disease. Indeed, Dunstan et  al.  (22) reported beneficial   74 
effects on atopic outcomes as a result of maternal fish oil supplementation during pregnancy 
(less-severe atopic dermatitis, lower risk of positive SPT to egg). The Danish study of Olsen et 
al. (186) identified that fish oil supplementation in late pregnancy is associated with a marked 
reduction  in atopic manifestations in the offspring at age 16 years, suggesting a long-term 
effect of any immunologic changes that occurred in pregnancy and early life of those children. 
The  study conducted  in  Sweden  (187, 188)  involved  fish  oil  supplementation during  both 
pregnancy and lactation. Again, expected effects on n-3 PUFA status were observed and these 
were  associated  with  differences  in  PGE2  production.  The  latter  might  be  expected  to 
influence Th2 polarization. Indeed, infants from mothers in the fish oil group had reduced risk 
of developing allergic sensitization to egg, IgE-associated eczema and food allergy during the 
first year of life. The Danish study of maternal fish oil supplementation during lactation (185) 
is the only one of these studies investigating immune outcomes in the offspring beyond birth. 
Infants of lactating mothers who received fish oil supplementation had a higher n-3 PUFA 
status at 4 months of age and IFN-γ production at 2.5 years of age was higher in the fish oil 
group, an observation which may reflect faster maturation of the immune system. This study 
did not assess clinical outcomes.  
Thus, it is clear that fish oil supplementation during pregnancy and lactation results in 
higher provision of n-3 PUFA to the offspring and so  in a higher n-3 PUFA status in the 
offspring. Early fish oil provision is associated with immunologic changes in cord blood and 
such changes  may persist. These studies suggest clinical effects of early fish oil provision 
including reduced sensitization to common food allergens and reduced prevalence and severity 
of atopic dermatitis in the first year of life, again with a possible persistence until adolescence 
with a reduction in eczema, hay fever, and asthma. The observations of these studies need to 
be  confirmed  by  future  trials  powered  adequately  to  examine  clinical  outcomes  in  the 
offspring later on in life in order to be able to draw more definite conclusions and to inform 
recommendations. 
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Table 1.7 Maternal fish oil supplementation during pregnancy or lactation and allergic outcomes in infants/ children of those pregnancies 
Study and 
study design 
Subjects  Intervention  Exposure 
period 
Outcome measures  Findings 
Barden et al 2004 
(176) 
Dunstan et al 2003 
(178) 
Dunstan et al 2003 
(22) 
Dunstan et al 2004 
(179)  
Denburg et al 2005 
(177) 










n= 40 FO  
n= 43 Control  
FO: 4 g fish 
oil/day (capsules) 
providing 3.7 
g/day n-3 PUFA 
(56% DHA, 27,7% 
EPA) 
 
Control: 4 g olive 
oil/day (capsules) 
providing 66.6% 
oleic acid (<1% n-
3 PUFA) 





Plasma cytokine concentrations (IL-4, 
IL-5, IL-6, IL-10, IL-12, IL-13, TNF-α, 
TNF-γ) 
 
Markers of APC function (HLA-DR 
expression and cytokine responses) 
 
Mononuclear cell cytokine responses to 
allergens and mitogen (IL-5, IL-10, IL-
13, INF-γ) 
 
Plasma total IgE 
 
CD34




+ cell expression of cytokine (IL-
5Rα, IL-3Rα) or chemokine receptors 
(CXCR4, CCR3) 
 
Eosinophil/Basophil colony forming 
units  
 
Leuktriene production by stimulated 
neutrophils  
 
In breast milk (3 days post-partum): 
immunomodulatory factors - sCD14, 
IgA, cytokines (IL-5, IL-6, IL-10, 
TNF-α and IFN-γ) 
 
Clinical outcomes at 1 year of age: SPT 
 
Symptoms of atopic disease (asthma, 
wheeze, food allergy, atopic dermatitis) 
 
Maternal FO associated with: 
 




HLA-DR expression on APC was not different between 
the groups 
 
Lower cord blood mononuclear cell cytokine responses 
(statistically significant only for IL-10 in response to cat 




A higher percentages of cord blood CD34




+ cell expression of cytokine and 
chemokine receptors was not different between groups 
 
 
More IL-5 responsive colony forming units (p< 0.003) 
 
Lower cord blood neutrophil LTB4 production (p= 0.031) 
 
 
No differences were observed in breast-milk IgA, sCD14, 
and cytokines between the groups 
 
 
Lower likelihood of a positive SPT to egg (OR 0.34, 95% 
CI 0.11-1.02, p= 0.055) 
 
Less severity in those infants with atopic dermatitis (OR 
0.09, 95% CI 0.01-0.94, p= 0.045) 
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Study and 
study design 
Subjects  Intervention  Exposure 
period 
Outcome measures  Findings 
Krauss-Etschmann 












This analysis on 
subcohort  
 
n= 45 FO 
n= 49 5-MTHF 
n= 49 FO + 5-
MHTF 
n= 50 Control 
4 groups: 
1. FO: 0.15 g EPA 
+ 0.5 g DHA/day 
2. 5-MTHF 
3. FO + 5-MTHF 




FO and 5-MTHF 
added to control 
supplement 
From week 22 
of pregnancy 
until delivery 
Th1/Th2 related molecules in maternal 
blood at delivery and in CB: mRNA 
expression of CCR4, IL-13, IL-4, 
CRTH2, CXCR3, INF-γ, IL-1, TGF-β  
 
Cord blood lymphocyte subsets 
Maternal FO was associated with: 
 
Higher TGF-β mRNA in maternal blood at birth and in 
cord blood (both p< 0.001) 
 
Lower INF-γ and IL-1 mRNA in maternal blood at birth 
(both p< 0.001) 
 
Lower IL-4, IL-13, and CCR4 mRNA in cord blood ( all 
p< 0.001) 
 
Lower proportions of NK  and CCR3
+ CD8
+ T-cells in 
cord blood (p< 0.001 and p< 0.04, respectively) 
























followed up at 16 
years after birth 
3 groups: 
1.FO: 4 g/day: 
32% EPA, 23% 
DHA, provided 2.7 
g/day marine n-3 
PUFA 
 
2. Control: olive 
oil capsules (4 
g/day; 72% oleic 
acid, 12% LA) 
 
3. No oil capsules 
From week 30 
of pregnancy 
until delivery 
Offspring asthma-related diagnosis at 
16 years of age: 
allergic asthma, asthma of mixed type, 
atopic dermatitis or allergic rhinitis  
 
Data taken from the National patient 
registry in Denmark 
Maternal FO was associated with: 
-Lower risk of asthma (OR 0.37; 95% CI 0.15-0.92, p= 
0.03) 
-Lower risk of allergic asthma (OR 0.13; 95% CI 0.03-
0.60, p= 0.01)  
-Lower risk of asthma all types, atopic dermatitis or 
allergic rhinitis (OR 0.43; 95% CI 0.19-0.96, p= 0.04) 
-Lower risk of allergic asthma, atopic dermatitis or 
allergic rhinitis (OR 0.31; 95% CI 0.11-0.84, p= 0.02) 
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Study and 
study design 
Subjects  Intervention  Exposure 
period 
Outcome measures  Findings 
Warstedt et al. 
2009 (188) 

























1. FO: 1.6 g EPA + 
1.1 g DHA/day  
 




From week 25 
of pregnancy 




Maternal outcomes: production of 
eicosanoids (PGE2 and LTB4), 
cytokines (IFNγ, IL-5, IL-6, ΤΝF, IL8, 
IL10) and chemokines (CCL2, CCL3) 








Clinical examinations of infants: 
 
-Skin prick testing to cow’s milk, egg, 
and wheat at 6 and 12 months of age 
 
-IgE associated eczema and food 
allergy at 3, 6, and 12 months of age 
 
Plasma specific IgE to egg/milk/wheat 
at age 3 and 12 months  
 
 
From week 25 gestation until 1 week post-partum: 
-LPS-induced PGE2 secretion decreased in 64% of the FO 
supplemented mothers and increased in 77% of those in 
the control group (p= 0.002). 
-The decreased PGE2 production was more pronounced 
among non atopic (80%) than atopic mothers (69%) (not 
significant) 
-LPS-induced maternal cytokine and chemokine secretion 
was not affected.  
 
Maternal FO was associated with: 
-Lower prevalence of food allergy (2% vs. 15% in control 
group, p<0.05) 
-Lower prevalence of IgE-associated eczema (8% vs. 24% 
in control group, p<0.05). 
-Lower prevalence of any positive SPT (15% vs. 32% in 
control group, p= 0.04) 
-Lower prevalence of positive SPT to egg (12% vs. 29% 
in control group, p= 0.02) 
 
Logistic regression analysis revealed that maternal FO 
was associated with: 
-Reduced risk of developing any positive SPT (OR=0.36, 
95% CI 0.14-0.95, p< 0.05), a positive SPT to egg 
(OR=0.31, 95% CI 0.11-0.89, p< 0.05), and IgE-
associated eczema (OR=0.22, 95% CI 0.06-0.81, p< 0.05) 
during the first year of life 
 
-The risk of developing food allergy was 10 fold lower in 
the FO group compared to control group (OR=0.09, 95% 
CI 0.01-0.74, p<0.05)   78 
Study and 
study design 
Subjects  Intervention  Exposure 
period 
Outcome measures  Findings 








mothers with fish 




n= 37 FO 
n= 28 Control 
 
n= 26 Lactating 
women with fish 





1. 4.5 g FO/day 
providing 1.5 
g/day of LC n-3 
PUFA  
 
2. Control: olive 
oil 
 
3. Women with 
high fish 






made cookies, or 
capsules 
 
First 4 months 
of lactation 
Cytokine production in endotoxin-
stimulated whole-blood cultures at 2.5 
years of age  
 
Infant plasma IgE levels at 2.5 years of 
age  
 
Parental report of allergy diagnosis or 
tendency to allergy 
Maternal FO was associated with: 
higher IFN-γ production (p= 0.034) and a higher ratio of 
IFN-γ to IL-10 (p= 0.019) 
RCT, randomized control trial; OR, odds ratio; CI, confidence interval; SD, standard deviation; FA, fatty acid(s); PUFA, polyunsaturated fatty acid(s); LC, long chain; FO, fish 
oil; 5-MTHF, 5-methyl-tetra-hydrofolic acid; SPT, skin prick testing; DHA, hocosahexaenoic acid; EPA, eicosapentaenoic acid; ARA, arachidonic acid; NK, natural killer 
cell(s); APC, antigen presenting cell(s); HLA-DR, human leukocyte antigen-DR; sCD14, soluble CD14; Eo/BCFU, eosinophil/basophil colony forming unit(s); Ig, 
immunoglobulin; IFN, interferon; IL, interleukin; TNF, tumour necrosis factor; TGF-β, transcription growth factor β; LPS, lipopolysaccharide; vs., versus. 
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1.5.2.2  Randomized controlled trials investigating the effects of fish oil 
supplementation during infancy/childhood on allergic outcomes in 
those infants/children 
Table 1.8 summarizes the randomized controlled trials of fish oil supplementation during 
infancy/childhood on allergic outcomes in those infants/ children; five studies were identified. 
Six scientific papers have been published on the Childhood Asthma Prevention Study (CAPS), 
of which one describes extensively the study protocol (190). Table 1.8 summarizes the results 
of  CAPS  at  18  months  (191,  192),  at  3  years  (193),  and  at  5  years  of  age  (194,  195). 
Damsgaard  et  al.  (196)  also  studied  the  impact  of  n-3  PUFA  supplementation  in  infants. 
Studies  done  by  Hodge  et  al.  (197),  Nagakura  et  al.  (198),  and  Vaisman  et  al.  (199) 
investigated the effect of fish oil supplementation in older children. 
Study design 
Both the CAPS (190) and the study of Hodge et al. (197) were conducted in Australia, the 
study of Nagakura et al. in Japan (198), the study of Vaisman et al. (199) in Israel, and the 
study of Damsgaard et al. (200) in Denmark. Infants (aged 6 months) who participated in the 
CAPS (190) were at high risk of developing asthma, whereas infants (aged 9 months) who 
took part in the Danish study (200) were not selected according to atopy. Children (aged 8 to 
12 years) who participated in the study of Vaisman et al. (199) were healthy, but those in the 
studies of Hodge et al. (197) and Nagakura et al. (198) (aged 8 to 12 years and 4 to 17 years, 
respectively) were asthmatic. 
All five trials were controlled, comparing fish oil with placebo. The placebos used in the 
studies varied. The CAPS (190) used capsules containing sunola oil, a monounsaturated fatty 
acid rich oil which also contained 7% n-6 PUFA, and dietary modification. Damsgaard et al. 
(200) used milk or formula without added oils. Hodge et al. (197) used capsules containing a 
mixture of palm, olive, and safflower oils and also replaced usual dietary fat by sunflower oil. 
Nagakura et al. (198) used capsules containing olive oil and Vaisman et al. (199) used canola 
oil blended in chocolate spread as a placebo. According to these strategies, the five studies 
provided  different  sources  and  amounts  of  n-6  PUFA  to  the  control  group.  The  mode  of 
provision of fish oil and the dose of LC n-3 PUFAs given differed among the five studies 
(Table 1.8). In the CAPS tuna oil was given in capsules in an amount that was related to the 
age of the infant/child: the capsules were added into milk formula if infants had started bottle 
feeding before 6 months of age, or into formula and weaning foods after 6 months of age. At   80 
the highest possible dose infants received 3.6 mg DHA and 0.8 mg EPA per kilogram of body 
weight (190). Also canola oil  and  canola  oil-based  margarine were used to lower  the  n-6 
PUFA intake in the fish oil group, with the aim of achieving a dietary ratio of n-6 to n-3 fatty 
acids of 5. In the Danish study (200) liquid fish oil was used providing a mean daily intake of 
571 mg EPA plus 381 mg DHA, although the range of intakes was wide, and it was advised to 
mix the oil into milk or formula. Hodge et al. (197) used fish oil capsules providing 1.2 g EPA 
plus DHA/day and replaced the usual dietary fat sources with canola oil and canola oil-based 
margarine. Nagakura et al. (198) used fish oil capsules with the number consumed adjusted 
according to body weight: thus daily intakes were in the range of 17 to 26.8 mg EPA and 7.3 
to 11.5 mg DHA per kg body weight; the heaviest children consumed about 1.4 g EPA plus 
DHA/day. Finally, Vaisman et al. (199) provided fish oil in chocolate spread delivering 300 
mg EPA plus DHA/day and in addition provided some canola oil. Three of the studies (197-
199) were double-blinded, while the CAPS (190) was single-blinded, and the Danish study 
(200) was not blinded. The CAPS study included also a house dust mite (HDM) exposure 
modification as a separate arm (190).  
The  duration  of  supplementation  varied  between  the  studies:  3  months  (199,  200),  6 
months (197), 10 months (198), 5 years (190). Finally, infants and children taking part in these 
five studies were supplemented during different periods of life. The CAPS study conducted 
the intervention from onset of bottle feeding (or 6 months of age) to 5 years of age (190). The 
study of Damsgaard et al. (200) supplemented infants between months 9 and 12 of life. Hodge 
et al. (197), Nagakura et al. (198), and Vaisman et al. (199) conducted the intervention on 
children of a wide age range (8-12, 4-17, and 8-12 years of age, respectively). The differences 
in duration and dose of fish oil supplementation and in the ages of study subjects among the 
studies makes direct comparison difficult and may be a source of heterogeneity of findings. 
Sample size, subject follow-up and compliance 
Regarding the sample size, in the CAPS study it is possible that failure to show a clinical 
benefit resulted from lack of power (194). In the study of Damsgaard et al. (200), it was 
recognized that sample size was small and that the rate of completion with blood samples was 
low. Finally, in the study conducted by Hodge et al. (197), authors suggested that significant 
changes in TNF-α production may have had been detected if the sample size was larger.   81 
In the CAPS study, 68% of the children remaining in the study (excluding those lost to 
follow-up) were available for assessment and had their blood taken at 18 months of age. At 5 
years of age, 84% of the children that participated in the randomized cohort were available for 
assessment. In the study of Damsgaard et al. (200), the attrition rate was 32% (30 subjects out 
of  94  dropped  out),  and  the  completion  rate  was  88%  (and  it  did  not  differ  significantly 
between the groups). In the study of Hodge et al. (197) 6 children out of 45 dropped out at 
baseline (13% withdrawal). Vaisman et al. (199) did not have any dropouts. In the study of 
Nagakura et al. (198) only one child out of 30 dropped out.  
In the CAPS, the moderate compliance rates might be related to the no association effect 
of the intervention on allergic outcomes at 3 and 5 years of age. In the CAPS, compliance was 
assessed my counting the number of capsules used. The proportion of parents who reported to 
have remembered to use the study spreads and oils all or most of the time of the study was 
88%, and this proportion was not different between groups (194). However, when the weight 
change of the used capsule containers was measured, the median adherence to oil capsules 
during the period after age 2.5 years was only 56% and was higher in the control versus the 
fish oil group (62% vs. 51%, p = 0.004).  
Damsgaard et al. (200) asked volunteers to return remaining bottles and report any waste. 
Damsgaard et al. (200) reported that mean fish oil consumption was 3.4 ml/day (range 0.8-5 
ml/day), which was according to the advice given to the subjects (1-2 teaspoons/day of the oil 
supplement into milk or formula). Hodge et al. (197) assessed compliance by counting the 
number of unused capsules by the participants and by food diary records repeated at 3 time 
points after dietary modification and supplementation. Mean number of capsules taken per day 
was 3 instead of 4 (for both groups), and there were no children with an average of less that 2 
capsules per day. Moreover, subject compliance was confirmed by the observed changes in 
plasma EPA levels over the whole period of the trial. Vaisman et al. (199) ensured compliance 
of the participants by recording the empty containers of chocolate spread in both groups on a 
weekly basis. However, the compliance rate was not reported. In the study of Nagakura et al. 
(198) compliance was controlled within the hospital setting.  
Confounding factors 
Potential  confounders  in  the  CAPS  study  include  those  related  to the  family  (age  of 
parents, socioeconomic status, ethnicity, parental smoking, number and age of siblings), the   82 
home environment, lifestyle and diet (intake of potential allergens,  foods high in  n-3 fatty 
acids), duration of breastfeeding, and maternal diet during late pregnancy and breastfeeding 
(including fish eating habits, oils/margarines use, organ meat eating habits as well as use of 
vitamin/ mineral supplements) (190). The clinical setting (hospital) in the study carried out by 
Nagakura et al. (198), and the fact that subjects stayed in the hospital ward for almost 85% of 
the intervention, was ideal as the environment was controlled both for nutrients and allergens. 
However, in this study the two groups differed significantly in the amount of medication used 
for acute asthma attacks during the study. In the Danish study, sex, parity and breastfeeding 
duration were tested as covariates because they are known to modify immune function and 
development of allergies. In the formula groups, parents were asked to use formulas with a 
ratio of 18:2n-6 to 18:3n-3 of about 8:1 (200). 
Hodge et al. (197) assessed the dietary intake of children using dietary records of 1 week 
(at baseline, 3 months, and 6 months after intervention). It was found that the fish oil group ate 
significantly more fresh fish than the control group (370 ± 148 vs. 109 ± 70 g/month, p = 
0.0045). Oil and margarine use did not differ between the two groups throughout the study. 
However, as with the studies of Nagakura et al. (198) and Vaisman et al. (199), the study of 
Hodge et al. (197) did not control for fish intake or for any other confounding factors in their 
analyses.  
Outcomes measures 
The CAPS assessed clinical outcomes of allergic diseases in children at three different 
time points (18 months, 3 years, and 5 years of age) (194). Primary outcomes were asthma and 
cough  at  3  years  of  age,  and  probable  current  asthma  at  5  years  of  age.  Wheeze  was  a 
secondary  outcome  measure  at  5  years  of  age  (Table  1.8).  Clinical  outcomes  were  also 
measured in the study conducted by Hodge et al. (197) in which lung function, atopy and 
asthma severity were assessed. Asthma severity and lung function were assessed in the study 
of  Nagakura et al. (198).  In contrast,  blood immune  markers were determined,  instead of 
clinical outcomes, in the trials conducted by Vaisman et al. (199) and Damsgaard et al. (200). 
Blood immune markers were also determined in the CAPS study and in the study of Hodge et 
al. (197).  
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Findings of the studies 
 
 
Findings of the CAPS (190-195) 
In the CAPS, Alqmvist et al. (195) reported that dietary and plasma LC n-3 PUFA were 
significantly higher in the intervention group in comparison to the control group at all ages. 
Also, plasma n-6 PUFA levels were lower in the fish oil group. At 18 months of age there was 
decreased prevalence of wheeze in the fish oil group and higher plasma n-3 PUFA levels were 
associated with lower bronchodilator use, irrespective of supplementation group (191, 192). 
Follow-up at 3 years of  age suggested fish oil supplementation from infancy to childhood 
could reduce allergic sensitization and airway disease at early age, as fish oil supplementation 
reduced cough, but not wheeze (193). However, no effect was reported on the other end-points 
measured such as eczema, serum IgE or doctor diagnosis of asthma. At 5 years of age there 
was no significant effect of fish oil intervention on any of the clinical outcomes relating to 
lung function (194), allergy (194), or asthma (195). The CAPS (194) was the first study to 
examine the effects of dietary modification of n-3/n-6 balance during infancy and childhood, 
on the incidence of asthma or allergic disease in children. It should be noted that the infants 
who participated in that study had a family history of asthma, which put them in higher risk of 
developing asthma. Possible reasons for the lack of beneficial effects of LC n-3 PUFA on the 
incidence of any allergic outcome at 5 years of age may be related to suboptimal adherence to 
and/or  implementation  of  intervention  (50%  and  56%  compliance  in  the  intervention  and 
control group, respectively), as well as to the dose of fish oil supplementation, loss to follow-
up and lack of power. 
Findings of Damsgaard et al. (200) 
Damsgaard et al. (200) showed that fish oil increased erythrocyte n-3 PUFA status. There 
was a borderline significant effect of fish oil on IFN-γ production by whole blood cultures, 
which increased, but there were no other significant effects on markers of innate immunity or 
inflammation, although there was a non-significant tendency of a reduced IL-10 production. 
These effects could indicate a decrease in Th2 responses, with possible implications for the 
development of allergies (185, 196), but clinical outcomes were not assessed.   84 
Findings of Hodge et al. (197) 
In the study of Hodge et al. (197) fish oil supplementation increased plasma phospholipid 
n-3 PUFA status. TNF-α production by isolated mononuclear cells decreased significantly in 
the  fish  oil  group  but  was  not  different  from  that  in  the  control  group  at the  end  of  the 
intervention. There was no effect of fish oil on lung function or asthma severity.  
Findings of Nagakura et al. (198) 
Nagakura et al. (198) showed that fish oil increased plasma EPA status and significantly 
reduced asthma severity score (by about 70% by month 10) and improved lung function in 
children  (the  provocative  concentration  of  acetylcholine  causing  a  20%  fall  in  the  forced 
expiratory volume in 1 second was increased from an average of 980 µg/mL at baseline to an 
average of 1850 µg/mL at month 10).  
Findings of Vaisman et al. (199) 
Vaisman et al. (199) found that long term supplementation of moderate amounts of n-3 
fatty acids to the diets of children increased the production of all cytokines measured (TNF-α, 
IL-1β,  IL-6,  IL-10,  IL-1rα)  in  both  unstimulated  and  LPS-stimulated  mononuclear  cell 
cultures. Clinical outcomes were not assessed. No baseline data on population characteristics 
or diet were given. Both of the groups were provided with canola oil (which is high in the n-3 
PUFA α-linolenic acid). Also, the amounts of n-3 and n-6 fatty acids (mg/day) coming from 
the oil added to the chocolate spread were not reported for the control group. 
Summary 
 
Provision of long-chain n-3 PUFA in the form of fish oil to infants or children increases 
the status of those fatty acids in plasma (191, 193-195, 197) and blood cells (196). Fish oil 
consumption may induce effects on the immune system in infants (196) and older children 
(197, 199). In children with asthma, fish oil did not affect lung function or asthma severity in 
the study conducted in Australia (197), but significantly improved lung function and asthma 
severity in the study conducted in Japan (198). These latter two studies had similar sample 
sizes. The study of Nagakura et al. (198) used a lower dose of n-3 PUFA than that of Hodge et 
al. (197), and so this does not explain the differences in outcome observed between these two 
studies. The study of Nagakura et al. (198) was of longer duration than that of Hodge et al.   85 
(197) and did not identify a significant effect of fish oil on asthma score or lung function until 
month 6 of the intervention; the study of Hodge et al. (197) was of 6 months duration. The 
studies of Damsgaard et al. (196) in healthy infants and of Vaisman et al. (199) in healthy 
children did not report clinical outcomes. The CAPS, conducted in infants at risk of allergic 
disease, is the largest of these studies and involved the longest period of supplementation. This 
study reported some protective effects of fish oil in these infants at 18 months and 3 years of 
age, but these effects did not persist until 5 years at age (194, 195). Lack of persistence may be 
due to reduced compliance over time, loss to follow-up, lack of power, or the presence of 
confounding factors.  
Thus, it is clear that fish oil supplementation during infancy or childhood results in higher 
n-3 PUFA status in those infants or children. Such early fish oil provision may be associated 
with immunologic changes in the blood but it is not clear if these are of clinical significance 
and  whether  they  persist.  Fish  oil  supplementation  in  infancy  may  decrease  the  risk  of 
developing some manifestations of allergic disease, but this benefit may not persist as other 
factors come into play. It is not clear whether fish oil can be used to treat children with asthma 
as the two studies conducted to date (197, 198) give divergent results. Further studies are 
needed to identify immunologic and clinical effects of fish oil in infants and in children and to 
identify protective and therapeutic effects and their persistence.   86 
1.5.3  Final summary and conclusions of the systematic review 
It is considered that n-3 PUFA will protect against atopic sensitization and against the 
clinical  manifestations  of  atopy.  Evidence  to  examine  this  has  been  acquired  from 
epidemiologic studies investigating associations between fish intake in pregnancy, lactation, 
infancy, and childhood and atopic outcomes in  infants and children  and from intervention 
studies with fish oil supplements in pregnancy, lactation, infancy, and childhood and atopic 
outcomes in infants and children All five epidemiological studies investigating the effect of 
maternal fish intake during pregnancy on atopic or allergic outcomes in infants/children of 
those pregnancies concluded protective associations. One study  investigating the effects of 
maternal  fish  intake  during  lactation  did  not  observe  any  significant  associations.  The 
evidence from epidemiological studies investigating the effects of fish intake during infancy 
and childhood on atopic outcomes in those infants or children is inconsistent, although the 
majority of the studies (nine of 14) showed a protective effect of fish intake during infancy or 
childhood  on  atopic  outcomes  in  those  infants/children.  Fish  oil  supplementation  during 
pregnancy and lactation or during infancy of childhood results in a higher n-3 PUFA status in 
the infants or children. Fish oil provision to pregnant women is associated with immunologic 
changes in cord blood and such changes may persist. Studies performed to date indicate that 
provision of fish oil during pregnancy may reduce sensitization to common food allergens and 
reduce prevalence and severity of atopic dermatitis in the first year of life, with a possible 
persistence until  adolescence  with a  reduction  in  eczema,  hay  fever, and  asthma.  Fish oil 
provision to infants or children may be associated with immunologic changes in the blood but 
it is  not clear whether these are of clinical  significance and whether they persist. Fish oil 
supplementation  in  infancy  may  decrease  the  risk  of  developing  some  manifestations  of 
allergic disease, but this benefit may not persist as other factors come into play. It is not clear 
whether fish oil can be used to treat children with asthma as the two studies conducted to date 
give  divergent results.  Further studies  of  increased  long-chain  n-3  PUFA  provision during 
pregnancy, lactation, and infancy are needed to more clearly identify the immunologic and 
clinical effects in infants and children and to identify protective and therapeutic effects and 
their persistence (103). 
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Table 1.8 Fish oil supplementation during infancy/ childhood and allergic outcomes in those infants/ children 
Study and 
study design 





Mirhshahi et al 
2003 (191) 











616 Infants with 
family history of 
asthma (at least one 
parent or sibling with 
asthma) 
 
554 Children of 616 
completed the study 
at 18 months 
 




1. HDM reduction, placebo supplement 
 
2. No HDM reduction, placebo supplement  
 
3. HDM reduction, FO supplement  
 
4. No HDM reduction, FO supplement  
 
FO group: 500 mg/day tuna oil capsules (37% 
n-3 PUFA, 6% n-6, 24% MUFA, 28% SFA, 
5% minor FA), plus canola margarines and oil 
(16% n-6, 40% n-9, 6% n-3 PUFA) 
From 6 months 
old or onset of 
bottle-feeding 











minor FA), plus 
margarines and 
oil (40% n-6, 
20% n-9, 1.2% 
n-3) 
 
Outcomes at 18 
months of age 
At age 18 months: 
 
Total serum IgE 
 
Lymphocyte cytokine 






wheeze, cough, asthma 
history, eczema 
 





High n-3 PUFA exposure tended to 
lower serum IgE 
 
FO was associated with a 9.8% 
absolute reduction (95% CI 1.5-18.1, 
p= 0.02) in the prevalence of any 
wheeze, and a 7.8% absolute 
reduction (95% CI 0.5-15.1, p= 0.04) 
in prevalence of wheeze for more than 
1 week 
 
High n-3 PUFA exposure was 
associated with a reduction in wheeze 
ever (p-trend 0.031), doctor visits for 
wheeze (p-trend 0.047), 
bronchodilator use (p-trend <0.001) 
and nocturnal coughing (p-trend 
0.032) 
 
After adjusting for breastfeeding and 
smoking during pregnancy, the 
highest n-3 PUFA exposure was only 
protective for bronchodilator use (OR 
0.46, 95% CI 0.30-0.71, p< 0.0001) 
 







526 Children of 616 
completed the study 
at 3 years of age  
As above  As above 
 
Outcomes at 3 
years of age 
At 3 years: 





wheeze, cough, asthma 
history, eczema 
 
Clinical assessment for 
eczema 
 
FO was associated with a 10% 
reduction in the prevalence of cough 
(95% CI, 3.7-16.4, p= 0.003) in atopic 
children 
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Study and 
study design 





Marks et al 2006 
(194) 







516 Children of 616 
completed the study 





Results at 5 
years of age 
At 5 years: 





wheeze, cough, asthma 
history, rhinitis, eczema 
 









FO supplementation did not have any 
effect on the outcome measures at 5 
years of age 
 
 













n= 13 FO 
n= 20 Control 
 
Infant Formula 
n= 20 FO 
n= 11 Control 
4 Intervention groups: 
 
Cow’s milk and FO 
Cow’s milk only 
Infant formula and FO Infant formula only  
 
Mean fish oil consumption 3.4 mL/day (571 
mg EPA and 381 mg DHA) 
 
Between 9 and 
12 months of 
age 
 
Plasma IgE, CRP, sIL-
2R concentrations 
 
Production of  TNF-α, 
IFN-γ, and IL-10 in 
whole-blood cultures  
 
Fecal IgA at 10 months 
of age 
FO supplementation: 
Increased induced IFN-γ production 
(p= 0.05) and tended to decrease IL-
10 production (p= 0.08)  
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Study and 
study design 













children aged 8-12 
years 
 
n= 20 FO 
n= 19 Control 
Intervention: 
4 fish oil capsules (0.18g EPA, 0.12g 
DHA/capsule) providing 1.2 g/day n-3 PUFA 
Diet: canola oil and canola-oil based 
margarines and salad dressing  
 
Control:  
4 capsules (0.45g safflower, 0.45g palm, 0.1 g 
olive oil/capsule)  
Diet: sunflower oil 
and sunflower-oil based margarines and salad 
dressing 
6 months  Circulating eosinophil 
numbers 
 
Production of TNF-α by 
stimulated blood 
mononuclear cells  
 





Asthma severity (record 
of expiratory flow rate, 
symptoms, medication) 
FO decreased TNF-α production 
compared to baseline (p= 0.026) but 
the magnitude of change between FO 
and control groups was not significant 
(p= 0.075) 
 









children aged 4-17 
years 
 
n = 15 FO 
n = 14 Control 
Intervention: 300 mg fish oil in capsules (84 
mg EPA, 36 mg DHA)  
 
Control: 300 mg olive oil capsules 
 
The number of capsules were adjusted to body 
weight: 
daily dosages of EPA and DHA were 17.0-26.8 
and 7.3-11.5 mg/Kg body weight, respectively. 
10 months  Asthma scoring 
(observation by 







FO was associated with: 
Decreased severity of asthma  at 6, 7, 
8, 9, 10 months after administration 
compared to baseline (p< 0.05) 
 
Improved lung function (lower 
responsiveness to acetylcholine) at 6, 











21 Healthy children 
aged 8-12 years 
 
n = 7 FO 
n = 14 Control 
 
Intervention: 300 mg/day n-3 PUFA (180 mg 
EPA, 120 mg DHA) + 700 mg canola oil 
 
Control: 1 g of canola oil  
 
 
Oils were blended in chocolate spread 
3 months  Cytokine production 
(IL-1β, TNF-α, IL-6, 





FO supplementation associated with 
higher cytokine production in 
unstimulated and stimulated cultures 
RCT, randomized control trial; CAPS; Childhood Asthma Prevention Study; OR, odds ratio; CI, confidence interval; FA, fatty acid(s); PUFA, polyunsaturated fatty acid(s); 
MUFA, monounsaturated fatty acid(s); SFA; saturated fatty acid(s); FO, fish oil; SPT, skin prick testing; HDM; house dust mite; DHA, docosahexaenoic acid; EPA, 
eicosapentaenoic acid; ARA, arachidonic acid; sCD14, soluble CD14; CRP, C-reactive protein; Ig, immunoglobulin; IFN, interferon; IL, interleukin; TNF, tumour necrosis 
factor; AHR, airway hyper-responsiveness; FVC, forced vital capacity; FEV1, forced expiratory volume in 1 second; LPS, lipopolysaccharide, vs., versus. 



















2  Salmon in pregnancy study (SIPS): aims, research 
hypotheses, study design and baseline characteristics 
of participants 
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2.1  Aims of the study and research hypotheses 
 
There is a theoretical basis by which increased early exposure to long chain (LC) n-
3 polyunsaturated fatty acids (PUFA), as found in oily fish and fish oils, should lower the 
risk of atopy and its manifestations including asthma. The literature review in Section 1.5 
indicates that the effects of  maternal  fish oil supplementation during pregnancy on the 
immune system of the mother and the offspring, as well as on atopic disease development, 
have  not  been  clearly  demonstrated,  although  there  is  some  evidence  for  benefits. 
However,  epidemiological  studies  provide  a  fairly  strong  evidence  base  that  fish 
consumption by pregnant women is protective against atopy development in their offspring 
(103). While it is widely considered that this is because fish provide LC n-3 PUFA, fish 
also provide other nutrients such as vitamin D and selenium. It is possible that it is these 
nutrients or the combination of these nutrients with LC n-3 PUFA that is important. To 
examine this further early intervention with fish is required.  
It is recommended that pregnant women and women of reproductive age should 
consume  oily  fish  but  not  more  than  two  portions  weekly,  due  to  of  the  presence  of 
contaminants in some fish (11). Other population subgroups are recommended to consume 
up to four portions of oily fish per week, or more if the individual wishes to do so (2). The 
level  of  contaminants  in  oily  fish  can  be  greatly  reduced  by  aquaculture  using  feed 
resources that are low in contaminants.  
There are no published intervention trials with fish during pregnancy. The Salmon 
in Pregnancy Study (SIPS) is the first single blind (investigator) randomised controlled 
trial with oily fish (in this case farmed salmon) in pregnant women. SIPS specifically 
focuses on pregnant women whose offspring are at risk of developing atopic disease, with 
one aim being to identify whether there is an effect on atopy outcomes in the offspring. 
SIPS is registered on the clinicaltrials.gov website with identifier number NCT00801502, 
and official title: ‘The Effects of Oily Fish in Pregnancy on Markers and Manifestations of 
Allergic Diseases in Infants at Risk of Atopy’. 
(http://clinicaltrials.gov/ct2/show/NCT00801502?term=sips&rank=2). 
The overarching SIPS hypothesis, as stated on clinicaltrials.gov, is that “increased 
consumption of oily fish during pregnancy by women at risk of having offspring who will 
develop atopy will increase their LC n-3 PUFA and antioxidant status and that of their   92 
developing  baby  and  will  ameliorate  the  development  of  atopic  markers  and 
manifestations in the infants”. 
 
The primary outcome measure of SIPS, as stated on clinicaltrials.gov is:  
  Omega-3 fatty acid status in maternal and umbilical cord plasma [Time frame: 
weeks 20, 34 and 38 of pregnancy and at birth (in cord)]  
The secondary outcome measure of SIPS, as stated on clinicaltrials.gov are:  
  Antioxidant status in maternal and umbilical cord blood [Time frame: weeks 20, 34 
and 38 of pregnancy and at birth 
  Allergic sensitisation of infants [Time frame: 6 months of age] 
 
The core SIPS investigators were: 
 
Professor Philip P. Calder   Program Coordinator and Principal 
Investigator 
Dr Elizabeth A. Miles         Senior Investigator 
Dr Paul S. Noakes          Postdoctoral Investigator 
Mrs Norma D. Diaper, MSc        Senior Research Nurse 
Miss Maria Vlachava, MSc        PhD student and Nutritionist 
Miss Lefkothea-Stella Kremmyda, MSc    PhD student and Nutritionist 
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The present thesis presents data from only part of SIPS. The aims of the work described in 
this thesis are: 
a)  to  increase  oily  fish  consumption  from  a  habitually  low  intake  (≤  2 
portions/month)  to  the  recommended  maximum  level  of  intake  (two 
portions/ week) during pregnancy, in women whose offspring is at a risk of 
developing atopic disease; 
b)  to  investigate  the  effect  of  increased  oily  fish  consumption  on  maternal 
blood and tissue LC n-3 PUFA status; 
c)  to  investigate  the  effect  of  increased  oily  fish  consumption  on  maternal 
immunity, which may potentially influence the developing foetal immune 
system and atopy risk of the offspring. 
The research hypotheses examined on this thesis are:  
that  increased  consumption  of  salmon  during  pregnancy  by  women  with  high  risk  of 
having an atopic offspring will:  
a)  increase maternal LC n-3 PUFA intake; 
b)  increase maternal LC n-3 PUFA status;  
c)  alter maternal  immunity, which  may potentially  influence the developing 
foetal  immune  system,  in  a  way  that  would  decrease  atopy  risk  for  the 
offspring  
The work addressing each of these three research hypothesis is described, and the findings 
presented and discussed, separately in Chapters 3, 4 and 5, respectively. 
The work described presented in this thesis was conducted by me, L.-S. Kremmyda, 
as a  member of the SIPS research team. The tasks described  here were primarily  my 
responsibility, although their completion required collaboration with the activities of the 
rest of the SIPS investigators and I acknowledge them for this. In addition, I was involved 
to an extent in other activities until the end of the study and these activities and their 
results are not described in this thesis. Briefly, other activities that I performed but were 
not  my  primary  responsibility  (and  so  are  not  reported  here)  were:  making  maternal 
anthropometry measurements including body composition using bioelectrical impedance; 
preparation of maternal erythrocytes, plasma and serum to be analysed by other research 
centres  (for  contaminant,  antioxidant,  vitamin,  hormone,  amino  acid,  oxidative  stress 
marker, and inflammatory marker analyses); preparation of placenta and umbilical cord   94 
tissue  and  umbilical  cord  vein  and  artery  for  immunohistochemistry;  processing  of 
umbilical cord blood for anlyses including fatty acids and immune markers; collection of 
urine, faecal (maternal and infant) and breast milk samples at various time points during 
clinics and home visits; administration of infant food frequency questionnaire at 6 months 
of age. 
 
2.2  Study design 
A hundred and twenty three (123) pregnant women whose baby had a high risk of 
being  atopic  and  with  a  self-reported  low  habitual  intake  of  oily  fish  were  randomly 
assigned  to  consume  two  portions  of  oily  fish  (salmon)  per  week  or to  continue  their 
habitual diet low in oily fish, from week 20 of gestation until the end of their pregnancy. 
The study was single blind (investigator only), randomised and controlled (vs. habitual 
diet). 
Eligibility criteria for inclusion in the study were:  
1.  In the early stages of pregnancy 
2.  Habitual intake of ≤ 2 portions of oily fish per month (excluding tinned tuna) 
3.  Family  history  of  atopy  within  the  last  5  years  (including  asthma,  atopic 
dermatitis (itchy rash/eczema), seasonal rhinitis (hay-fever), perennial rhinitis 
(other allergies)) in any first degree relative: mother, father or sibling of the 
foetus 
4.  Not consuming fish oil supplements 
5.  Aged between 18-40 years. 
Exclusion criteria were: 
1.  Habitual consumption of oily fish (> 2 portions of oily fish per month excluding 
tinned tuna) 
2.  Use of fish oil supplements within the previous 3 months 
3.  Use of non-steroidal anti-inflammatory drugs (NSAID) (e.g. aspirin, diclofenac, 
ibuprofen, voltarol) 
4.  Multiple pregnancy 
5.  Not  willing  for  essential  identifiable  information  being  stored  for  tracking 
purposes 
6.  Participation in another research study   95 
7.  Known diabetic  
8.  Known to suffer  from auto-immune disease, e.g., multiple  sclerosis, thyroid 
disease, systemic lupus erythematosis 
9.  Having a learning disability 
10.  Having a terminal illness 
11.  Having a mental health problem. 
Ethics approval for the study was obtained from the Southampton and South West 
Hampshire Research Ethics Committee (07/Q1704/43).  
2.3  Subject follow-up and data collection 
Subjects taking part in the study were seen at 13, 19-20, 32-34, and 38 weeks of 
pregnancy and at several time points after they had given birth. At 13 weeks gestation 
subjects were screened for eligibility during their routine ultrasound scan appointment at 
the Southampton Women’s Survey Ultrasound Unit (SWS UU) of Princess Anne Hospital 
in Southampton, UK. Prior to their appointment, pregnant women had received an initial 
information sheet about the SIPS (Appendix A), along with their appointment notes sent by 
the SWS UU. Subjects were initially approached by a researcher of the SIPS team and 
were asked if they would like to hear more about the study and be screened for eligibility. 
Subjects who agreed to be screened were asked to sign a consent form for initial screening 
(Appendix B). Initial screening included a health and lifestyle questionnaire administered 
by the researcher including questions on eligibility criteria, measurement of weight and 
height  (Appendix  C),  and  body  composition  measurement  performed  by  bioelectrical 
impedance.  
Subjects who were eligible for the study were provided with a second information 
sheet (Appendix D), the study was further explained to them and their intention to take part 
in  the  study  irrespective  of  randomization  group  was  confirmed.  Subjects  who  were 
interested in the study but had a preference for either of the two groups were not included 
in the study. At 15 weeks of pregnancy subjects were phoned to be reminded about the 
study, discuss any concerns and confirm their next appointment at 19-20 week pregnancy 
at SWS UU, and they were randomly assigned in one of the two groups, intervention or 
control.  A  randomisation  plan  was  created  through  the  website 
http://www.randomization.com, which randomises each subject (in the order that they were 
found to be eligible) to one of the two groups by using the method of randomly permuted 
blocks.   96 
The  overall  SIPS  study  was  powered  according  to  two  outcomes:  fatty  acid 
composition  of  maternal  plasma  phospholipids  and  infant  sensitisation  to  at  least  one 
common allergen by skin prick testing (SPT). The power calculations were based initially 
on 50 subjects per group, however because of anticipated withdrawals, recruitment target 
was raised to 60 subjects per group so as to have approximately the number of women (50) 
in each group that would achieve statistical significance at the end of the intervention. 
Specifically, a sample size of 50 per group was anticipated to have a 99% power to detect 
differences in maternal plasma eicosapentaenoic acid (EPA) phospholipids with p < 0.05 
(90% power to detect with p < 0.001). A sample size of 50 per group would have a 70% 
power to detect differences  in  infant sensitisation to allergens (by SPT) with p < 0.05 
(Appendix E) 
Subjects attended the 19-20 week appointment in the fasted state. They were asked to 
sign  the  consent  form  for  participating  in  the  SIPS  (Appendix  F).  This  appointment 
included  an  ultrasound  scan,  weight  measurement  and  body  composition  analysis  with 
bioelectrical  impedance,  a  researcher-administered  health  and  lifestyle  questionnaire 
(Appendix G), blood collection (see section 4), urine collection, and administration of a 
food frequency questionnaire (FFQ) covering the past three months (Appendix H). Women 
were given breakfast after blood sample collection and before the FFQ was administered. 
Subjects in the intervention group were provided with a cook book with salmon recipes 
and a fish diary to record their consumption of the study salmon (and any other fish they 
may consume), how it was cooked, and whether there were any leftovers from the standard 
portion (Appendix I). Subjects in the control group were provided with a general cook 
book  including  information  on  healthy  eating  during  pregnancy,  and  a  fish  diary 
(Appendix J) to record their fish consumption (type, way of cooking, portion size).  
The fasting appointments at 32-34 and 38 weeks of pregnancy were identical to the 
one at 19-20 weeks of pregnancy, except that at week 38 a stool sample was also collected 
and there was no FFQ administration or body composition measurements.  
The health and lifestyle questionnaire was administered by an appropriately trained 
member of the SIPS team at 13, 20, 32-34, and 38 weeks of pregnancy. This included 
questions on medication, use of nutritional supplements/vitamins/minerals in the previous 
4 weeks, physical activity, smoking, alcohol consumption, atopic symptoms of the mother, 
father and sibling(s) (only at 13 weeks), pet ownership, visiting households with pets, oily 
and  non-oily  fish  consumption  frequencies  (only  at  13  weeks),  level  of  education  and 
occupation (only at 20 weeks), and problems with eating the salmon if in the intervention   97 
group  (at  32-34  and  38  weeks)  (Appendices  C,  G,  K,  L).  Physical  activity  questions 
incorporated in the health and lifestyle questionnaire included questions on frequency of 
performing physical activities of different intensity (vigorous, moderate, gentle exercise), 
as well as hours spent sleeping/lying down, sitting, standing/walking over a typical 24 h 
day, and walking speed at present. The questions reflected average physical activity in the 
past three months from the time point of the interview. The questions were adopted form 
the SWS questionnaire for estimating physical activity, which has been used before on 
women in Southampton (201-203).  
Height was measured at 13 weeks gestation using a stadiometer. Subjects were asked 
to remove their shoes and stand straight. The head was placed in the Frankfort Plane, such 
that an imaginary line joining the upper margin of the external auditory meatus and the 
lower border of the orbit of the eye was horizontal. The measurement was taken once and 
to the nearest 0.1 cm. Weight and body composition were measured using a MC-180MA 
Tanita, at 13, 20, 32-34, and 38 weeks gestation. This is a bioelectrical impedance device 
using  multi-frequency 8-electrodes to measure  body  composition. This  method enables 
measurement of impedance per segment – in other words for the whole body, right leg, left 
leg, right arm or left arm. The results of body composition measurement are not included 
in this thesis.  
Midwives at the Princess Anne Hospital, Southampton and the rest of the birth centres 
(if a subject was planning to deliver in a birth centre different from the Princess Anne 
Hospital  or  at  home)  were  provided  with  information  about the  study  and  were  given 
laminated instructions to remind them to store the whole placenta and umbilical cord at 
4˚C after delivery (see section 4). They were asked to contact the SIPS team once a sample 
was collected. 
Subjects were followed up at 3 months post-partum when the FFQ was administered 
to them by an appropriately trained nutritionist during home visits. 
Finally,  both the  mother and the  father of the  infant who attended the clinic at 6 
months post-partum were skin prick tested to specific allergens. Skin prick test (SPT) was 
performed by the research nurse of the study (N.D. Diaper) on the flexor aspect of the 
forearm using a standardized technique and allergen extracts, as well as histamine as a 
positive control and a negative control (glycerine diluent) (Soluprick SQ, ALK Abello). A 
drop of each allergen and control was introduced at 90° into the epidermis using a lancet, 
without drawing blood. A wheal diameter of ≥3 mm greater than the negative control was   98 
considered positive 15  minutes after the application of the allergen extracts. Table 2.1 
presents  the  allergens  and  controls  used.  The  potency  is  expressed  in  ‘Histamine 
Equivalent in skin Prick testing’ (HEP) which is related to the allergenic activity of the 
allergen. 
Table 2.1 Allergens used in skin prick testing (SPT) 
Type  Strength 
Negative Control  Glycerine diluent 
Positive Control  10 mg/ml 
Dermatophagoides pteronyssinus  10 Hep 
Felis domesticus (cat)  10 Hep 
Canis familiaris (dog)  10 Hep 
6 Grass mix   10 Hep 
3 Tree mix  10 Hep 
Aspergillus fumigatus  1:20 w/v 
Alternaria alternata   1:20 w/v 
Cladosporium herbarum  1:20 w/v 
Penicillum notatum   1:20 w/v 
 
2.4  Study salmon  
The  salmon  used  in  the  study  were  farmed  in  Norway  using  high  quality  feed 
ingredients in order to be low in contaminants (dioxins and dioxin-like polychlorinated 
biphenyls  (PCB),  dichloro  diphenyl  trichloroethanes  (DDT)  and  heavy  metals  (arsenic, 
cadmium, mercury, lead)). Salmon were farmed until they averaged 4 kg in weight and 
were then killed; a total of 2280 kg (gutted) of salmon were produced. They were then 
filleted into 150 g portions and the portions frozen in vacuum sealed bags in Norway, from 
where it was shipped to Southampton and stored at -30˚C (Figure 2.1). The salmon were 
delivered to the intervention group, on a monthly basis, with enough to cover intake of two 
portions (150 g/portion) per week by the pregnant women and their partners. After delivery 
salmon were stored in home freezers. 
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Figure 2.1 Vacuum sealed salmon as delivered to the pregnant women 
 
Frozen portions of salmon were analysed by the National Institute for Nutrition and 
Seafood  Research,  Norway.  Thirty  (30)  portions  of  frozen  portions  were  randomly 
sampled for analysis. The individual portions were pooled into 3 samples of 10 portions 
each  for analysis of  nutrient and undesirable content. Table 2.2 presents the  fatty  acid 
content of the tailored salmon with data expressed as g/100 g of total fatty acids, as g/kg of 
salmon fillet, and as g/per standard 150 g portion of salmon. The sum of EPA plus DHA 
was 1.73 g/portion and these two fatty acids provided 10.6% of the total fatty acids in the 
salmon. Table 2.3 presents selected vitamin, mineral, total protein and fat content in the 
tailored salmon expressed as per kg of salmon, as well as per standard 150 g portion of 
salmon. Table 2.4 presents selected contaminant and heavy metal content of the salmon, 
expressed  also  per  standard  portion  of  salmon.  As  a  result  of  the  controlled  farming 
environment and the high quality feeds used, the contaminant content of the salmon fillets 
was low, with two portions providing far less than the provisional tolerable weekly intake 
(see Table 2.6).    100 
 
Table 2.2. Fatty acid composition of tailored salmon  
(mean ± standard deviation; n = 3) 
Fatty acid  % of total fatty acids  g/kg fillet  g/150 g fillet 
C14:0  2.3 ± 0.1  2.4 ± 0.3  0.36 
C16:0  12.3 ± 0.3  13.2 ± 0.7  1.98 
C18:0  3.3 ± 0.1  3.6 ± 0.2  0.54 
Sum of SFA  18.6 ± 0.3  20.1 ± 1.2  3.02 
C16:1n-7  2.5 ± 0.1  2.7 ± 0.3  0.41 
C18:1n-9  33.1 ± 0.4  35.7 ± 2.5  5.31 
C18:1n-7  2.7 ± 0.1  2.9 ± 0.2  0.44 
C20:1n-9  2.8 ± 0.1  2.9 ± 0.4  0.44 
Sum of MUFA  43.3 ± 0.4  46.8 ± 3.8  7.02 
C18:2n-6  11.6 ± 0.2  12.5 ± 1.1  1.88 
C20:2n-6  1.2 ± 0.1  1.3 ± 0.1  0.20 
C20:4n-6  1.3 ± 0.1  1.4 ± 0.1  0.21 
Sum of n-6 PUFA  14.3 ± 0.1  15.4 ± 1.2  2.31 
C18:3n-3  7.4 ± 0.3  7.9 ± 0.3  1.19 
C18:4n-3  0.6 ± 0.1  0.7 ± 0.1  0.11 
C20:4n-3  1.1 ± 0.1  1.2 ± 0.1  0.18 
C22:5n-3  2.1 ± 0.1  2.3 ± 0.2  0.35 
C20:5n-3 (EPA)  3.5 ± 0.2  3.8 ± 0.4  0.57 
C22:6n-3 (DHA)  7.1 ±0.1  7.7 ± 0.5  1.16 
Sum of EPA + DHA  10.6  11.5  1.73 
Sum of n-3 PUFA  22.0 ± 0.2  23.7 ±1.5  3.56 
Sum of total PUFA  36.5 ± 0.2  39.4 ± 2.7  5.91 
Total Fatty Acids  100 ± 0.00  107.9 ± 7.8  16.19 
n-3 PUFA/n-6 PUFA  1.53 ± 0.02 
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Table 2.3. Vitamin, mineral, total protein and total fat content of tailored salmon  
(mean ± standard deviation; n = 3) 
Vitamins   g/g fillet  mg/150 g fillet 
α-tocopherol   27.3 ± 0.1  4.1 
γ-tocopherol  10.9 ± 1.2  1.6 
Vitamin A (sum of retinols)  0.039 ± 0.006  0.006 
Vitamin D3  0.093 ± 0.001  0.014 
Vitamin K1  < 1  
Vitamin K2  < 1 
 
Minerals   mg/kg fillet  mg/150 g fillet 
Iodine  0.044 ± 0.008  0.006 
Iron  2.49 ± 0.21  0.373 
Selenium  0.288 ± 0.008  0.043 
Zinc  2.85 ± 0.06  0.428 
  g/kg fillet  g/150 g fillet 
Total protein  203 ± 2  30.5 
Total fat   109 ± 6  16.4 
 
Table 2.4. Contaminant and heavy metal content of tailored salmon  
(mean + standard deviation; n = 3) 
Compound  Per kg fillet  Per 150 g fillet 
Sum of dioxin and dl-PCB  0.35 ± 0.06 pg WHO TEQ/g  52.5 pg 
Sum of DDT   3.28 ± 0.4 µg  0.492 µg 
Arsenic  0.34 ± 0.05 mg  0.051 mg 
Cadmium  0.001 ± 0.01 mg  0.15 µg 
Mercury  0.023 ± 0.00 mg  3.45 µg 
Lead   0.001 ± 0.001 mg  0.15 µg 
PCB, polychlorinated biphenyl(s); dl, dioxin like; DDT, dichloro diphenyl trichloroethane(s); WHO TEQ, World Health 
Organisation toxic equivalent   102 
Table 2.5 shows the contribution of two portions of study salmon to the recommended 
intake of EPA plus DHA (11), vitamin D (Reference Nutrient Intake; RNI) and selenium 
(RNI) (18) in the salmon group on a weekly basis. It can be seen two portions of the study 
salmon per week would provide more than the recommended weekly intake of EPA plus 
DHA (3460  mg/week or 494 mg/day), and would also contribute significantly towards 
achieving  the  recommendation  for  vitamin  D  (in  pregnant  and  lactating  women)  and 
selenium. The mean daily intake of vitamin D in women aged 19-64 is below the RNI. 
Mean selenium intake among women 19-64 years old in the UK has been found to cover 
72% of the RNI (which is 60 g/day), and it was shown that 52% of women aged 19-64 
had  selenium  intake  below  the  Lower  Reference  Nutrient  Intake  (LRNI)  which  is  40 
µg/day  (13).  Unfortunately,  the  most  recent  report  of  the  National  Diet  and  Nutrition 
Survey (2008/2009) (13) does not include data on EPA and DHA intake and estimated 
intake figures were taken from previous reports (12, 14, 15). 
Table 2.5 Calculated contribution of two portions of study salmon to LC n-3 PUFA, vitamin D, and 
selenium recommended intakes in the salmon group 























intake per day 
EPA+DHA 
(11)  > 450 mg  > 3150 mg  1730 mg  3460 mg  109% 
< 200 mg but 
probably much 
less than this 
(12, 14, 15) 
Vitamin D
1  10 µg  70 µg  14 µg  28 µg  40%  2.7 µg
 3 
Selenium
3  60 µg  420 µg  43 µg  86 µg  20%  39 µg 
3 
1 Vitamin D Reference Nutrient Intake (RNI) for pregnant and lactating women (18) 
2 Selenium Reference Nutrient Intake (RNI) for 19-50 year old women (18) 
3 According to NDNS 2008/2009 (13) 
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Table 2.6 presents the calculated total intake of selected contaminant compounds from 
consumption of two 150 g portions of the tailored salmon per week. The calculated weekly 
contaminant intake expressed as per kg body weight is much lower than the provisional 
tolerable weekly intake (PTWI) (expressed per kg of body weight per week) established by 
the  Joint  Food  and  Agricultural  Organisation/World  Health  Organisation  Expert 
Committee on Food Additives (204, 205). 
Table 2.6. Weekly intake (crude and per kg of body weight) for selected contaminants from 
consumption of two portions (each 150 g) of tailored salmon per week 
PTWI, provisional tolerable weekly intake; PCB, polychlorinated biphenyl(s); dl, dioxin like; DDT, dichloro diphenyl 
trichloroethane(s); WHO TEQ, World Health Organisation toxic equivalent
 
1 Based on consumption of 2 × 150 g tailored salmon fillets per week 







Intake from study salmon per 
Kg body weight per week
2 
PTWI (per Kg body 
weight per week) 
Sum  of  dioxin 
and dl-PCB  105 pg  1.3-1.75 pg WHO TEQ  14 pg WHO TEQ 
Sum of DDT  0.984 µg  0.012-0.016 µg   
Arsenic  0.102 mg  1.3-1.7 pg  15 µg 
Cadmium  0.3 µg  0.004-0.005 pg  7 µg 
Mercury  6.9 µg  0.09-0.115 pg  5 µg 
Lead   0.3 µg  0.004-0.005 pg  25 µg   104 
 
2.5  Progress of the study and subject follow-up 
Figure 2.2 presents the flow of pregnant women into the two groups. In total 692 
pregnant  women  were  sent  the  initial  information  sheet  about  SIPS  along  with  the 
appointment  letter  for  their  13  week  gestation  ultrasound  scan;  these  women  were 
randomly selected over the 12 month recruiting period. Out of those women, 377 were 
screened  for  eligibility  for  SIPS,  after  signing  the  consent  form  for  initial  screening. 
Subsequently, a total of 315 women were  not screened  for eligibility. The reasons  for 
which they were not screened can be seen on Figure 2.2, with the major reason (n = 241) 
being the lack of interest in the study. 
Out of the women who expressed an interest and were screened (n = 377), 166 were 
eligible and agreed to be randomly assigned to either the control or intervention group, and 
211 women were ineligible. The reasons for which women were not eligible can also be 
seen on the figure, with the main one being the absence of atopy for the mother, father or 
sibling. Out of those subjects who were eligible (44% of the screened), only 123 women 
(74% of the eligible) were randomised at 15 weeks gestation and enrolled onto SIPS at 20 
weeks gestation. The rest of the women, although eligible, were either women who were 
randomised at 15 weeks gestation but not enrolled onto SIPS at 20 weeks (reasons given 
on figure), or were not randomised at all because of mainly not being interested in the 
study any more when contacted at 15 weeks gestation. 
Figure 2.3 presents the progress of the study throughout its different stages. A total 
of 123 women were recruited onto SIPS after signing the SIPS consent form. All 123 
subjects had their 20 week fasting appointment, during which they were randomly assigned 
to the control (n = 61) or the salmon arm of the study (n = 62). This number of subjects 
was slightly greater than the target of recruitment (n = 120). Before delivery, 9 subjects 
withdrew from the salmon group and 7 from the control group. Thus, up to delivery, the 
withdrawal rate was 14.5% for the salmon arm and 11.5% for the control arm, and 13% for 
the total of the subjects. The reasons for subject withdrawal from the study and at which 
time point they withdrew can be seen on Figure 2.3. A total of 111 subjects attended the 34 
week appointment, and 91 subjects attended the 38 week appointment, while 14 subjects 
delivered before the 38 week appointment. Finally, birth samples were collected from 101 
subjects. Between delivery and the 3 month post-partum visit 1 subject withdrew from the 
salmon group and 5 from the control group. A total of 86 3 month visits were completed   105 
and 2 subjects were interviewed on the phone. Infants were followed up at 6 months of age 
for the development of eczema, asthma and allergen sensitisation. A total of 86 6 month 
infant appointments were completed (n = 47 salmon, n = 39 control). A total of 86 mothers 
and 76 fathers were skin prick tested at that appointment.   106 
 
Figure 2.2 Flow of women into SIPS   107 












































Enrolled on SIPS at 34/40 (n = 111) 
i.e. 123 – 12 withdrawn  
55 salmon; 56 control 
Attended 34/40 appointment n = 110 
(111 – 1 very premature delivery) 
 
Withdrew < 34/40 
n = 5 (C), n = 7 (S) 
Hard to bleed n = 1 
Personal reasons n = 5 
Did not like salmon n = 4 
No reason given n = 1 
No longer interested n = 1 
3 Month FFQ possible (n = 101)  
(Completed n = 88) 
47 salmon; 41 control 
Home visits n = 86; FFQ on the phone n = 2  
Enrolled onto SIPS at 20/40 (n = 123) 
62 salmon; 61 control 
Withdrew 34-38/40 
n =2 (c), n = 1 (S) 
No longer interested n = 1 
Personal reasons n = 2 
  Enrolled on SIPS at 38/40 (n = 108) 
i.e. 111 – 3 withdrawn 
54 salmon; 54 control 
Attended 38/40 appointment (n = 91) 
(108 – 4 cancelled: tired/busy/injured; 13 delivered before appointment) 
 
Enrolled on SIPS at delivery (n = 107) 
i.e. 123 – 6 missed; 16 withdrawn 
53 salmon; 54 control 
Birth samples collected (n = 101) [51 salmon; 50 control] 
(107 – 6 missed: 2 team not informed, 4 samples not collected) 
Withdrew 38/40- delivery  
Personal reasons n = 1 (S) 
Withdrew 3/12  
n = 5 (C), n = 1 (S) 
Lost contact n = 2 
Personal reasons n = 2 
No reason given n= 2  
 
n = 15  – did not have  3/12 
appointment,  but  had  not 
officially  withdrawn;  unable 
to make contact. 
Withdrew 3-6/12  
n = 2 (C) 
(186) 6/12 too busy (C) 
(230) 6/12 too busy (C) 
 
6 Month visits possible (n = 99) 
(Completed n = 86)  
47 salmon; 39 control 
Maternal SPT n = 86 (n = 38 (C), n = 48 (S)) 
Paternal SPT = 76 (n = 32 (C), n = 44 (S))   108 
2.6  Subject baseline characteristics 
The baseline characteristics of the subjects are presented on Table 2.7. Age, weight, 
height,  number  of  pregnancies  (gravida),  smoking,  nutritional  supplement  use,  alcohol 
intake, education, and keeping pets in the home did not differ between groups. Also the 
groups  did  not  differ  in  the  frequency  of  conducting  strenuous,  moderate  and  gentle 
physical activity (Figure 2.4- Figure 2.6). However, the groups differed significantly in the 
number of children the women already had. More women in the salmon group had no 
children, and more women in the control group had 1 child (p = 0.013).  
Table 2.8 shows the self reported atopy (any type) in the two groups. It was found that 
paternal self reported atopy was different between the groups with more fathers in the 
salmon  group  reporting  atopy  (p  =  0.015).  However  when  looking  at  different 
manifestations of atopy, the maternal and paternal types did not differ between the groups 
(Figure 2.7). More siblings of the foetus were reported to have asthma in the control group 
compared to the salmon group (p = 0.11) (Figure 2.7); however this may be related to the 
fact that subjects in the control group had more children as mentioned above.    109 
 
Table 2.7 Baseline characteristics of SIPS subjects according to treatment group 
  Control (n = 61)  Salmon (n = 62)  p 
Maternal age (years) (13 week questionnaire)
1  28.4 (4.7)  29.5 (4.3)  0.174 
Maternal height (cm) (13 week questionnaire)
 1  165.6 (6.8)  165.4 (6.2)  0.885 
Maternal weight (kg) (13 week questionnaire)
 1  71.4 (15.4)  67.4 (11.9)  0.117 
Gestation length (days)
 1  279.55 (9.3)  281.8 (7.6)  0.277 
Number of children (13 week questionnaire)
2       
None  26 (42.6%)  38 (61.3%) 
1  23 (37.7%)  9 (14.5%) 
≥ 2  12 (19.7%)  15 (24.2%) 
0.013 
Pregnancies including this (13 week 
questionnaire)
2 
     
1  23 (37.7%)  27 (43.5%)   
≥ 2  38 (62.3%)  35 (56.5%)  0.509 
Maternal smoking (13 week health 
questionnaire)
 2 
     
Never  30 (49.2%)  33 (53.2%)  0.460 
Past  23 (37.7%)  25 (40.3%)   
Current  8 (13.1%)  4 (6.5%)   
Maternal supplement use (20 week FFQ)
 2       
No  15 (24.6%)  14 (22.6%)  0.966 
Folic acid containing   45 (73.8%)  47 (75.8%)   
Non-folic acid containing  1 (1.6%)  1 (1.6%)   
Maternal alcohol intake (20 week health 
questionnaire)
 2 
     
No  46 (78%)  46 (76.7%)  0.866 
Yes (1-7 units/week)  13 (22%)  14 (23.3%)   
Maternal education (20 week questionnaire) 
2       
School  9 (15.5%)  9 (14.5%)  0.513 
Further  24 (41.4%)  20 (32.3%)   
Higher  25 (43.1%)  33 (53.2%)   
Paternal education (20 week questionnaire)
2       
School  17 (29.8%)  16 (25.8%)  0.055 
Further  25 (43.9%)  17 (27.4%)   
Higher  15 (26.3%)  29 (46.8%)   
Cat as a pet (13 week questionnaire)
2       
No  43 (70.5%)  44 (71%)  0.954 
yes  18 (29.5%)  18 (29%)   
Dog as a pet (13 week questionnaire)
2       
No  49 (80.3%)  50 (80.6%)  0.965 
Yes  12 (19.7%)  12 (19.4%)   
Other pet (13 week questionnaire)
2       
No  42 (68.9%)  49 (79%)  0.198 
Yes  19 (31.1%)  13 (21%)   
1 Values are mean (standard deviation). Independent t-test p-values 
2 Number of subjects (within group percentage). χ
2 (chi-square) test p-values   110 
 
 
Figure 2.4 Distribution of frequency of conducting strenuous physical activity in the two treatment 
groups 
χ





Figure 2.5 Distribution of frequency of conducting moderate physical activity in the two treatment 
groups 
χ
2 (chi-square) test p = 0.499   111 
 
 
Figure 2.6 Distribution of frequency of conducting gentle physical activity in the two treatment groups 
χ






Table 2.8 Self reported atopy at the 13 week health screening 
  Control (n = 61)  Salmon (n = 62)  p 
Maternal self reported atopy (any)
 1       
Yes   38 (62.3%)  43 (69.4%)  0.409 
No   23 (37.7%)  19 (30.6%)   
Paternal self reported atopy (any)
 1       
Yes   37 (60.7%)  50 (80.6%)  0.015 
No   24 (39.3%)  12 (19.4%)   
Sibling self reported atopy (any)
 1       
Yes   17 (27.9%)  10 (16.1%)  0.116 
No   44 (72.1%)  52 (83.9%)   
1 Number of subjects (within group percentage). χ
2 (chi-square) test p-values   112 
 
 
Figure 2.7 Distribution of self reported atopy categories in the two treatment groups at the 13 weeks 
heath screening 
*χ
2 (chi-square) test p = 0.011 
 
The two groups did not differ according to maternal and paternal positive skin prick 
testing (SPT) (Table 2.9). The number of subjects with positive SPT to specific allergens 
can be seen on Table 2.10. Finally, Table 2.11 shows how self reported atopy (assessed at 
the beginning of the study) matched with SPT (determined at 6 months postpartum) for the 
mothers and fathers. No statistically significant differences were found between the two 
groups. Within mothers who were skin-prick tested, 44.7% had reported atopy and this was 
confirmed by any positive SPT in the control group, and 52.1% in the salmon group. Also, 
within fathers who were tested, 59.4% had self reported atopy and this was confirmed by 
any positive SPT in the control group, and 68.2% in the salmon group. A small number of 
subjects who reported atopy did not have any positive SPT, and a small number of subjects 
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Table 2.9 Any positive maternal and paternal skin prick tests (SPT) 
 
 
Control  Salmon  p 
Maternal +SPT (any) 
1  (n = 38)  (n = 48)   
Yes   21 (55.3%)  31 (70.5%)  0.380 
No   17 (44.7%)  17 (35.4%)   
Paternal +SPT (any) 
1  ( n = 32)  (n = 44)   
Yes   20 (62.5%)  31 (70.5%)  0.466 
No  12 (37.5%)  13 (29.5%)   
1 Number of subjects (within group percentage). χ
2 (chi-square) test p-values 
 
Table 2.10 Number of subjects sensitised to each allergen assessed by skin prick testing (SPT) 
Skin Prick Test Solution 
Maternal - 
Control  
(n = 38) 
Maternal - 
Salmon  
(n = 48) 
Paternal - 
Control  
(n = 32) 
Paternal - 
Salmon  
(n = 44) 
Dermatophagoides 
pteronyssinus   14  23  13  25 
Felis domesticus (cat)   11  17  6  17 
Canis familiaris (dog)   12  19  11  20 
6 Grass mix   18  26  16  26 
3 Tree mix  6  14  5  16 
Alternaria alternata   2  6  2  8 
Aspergillus fumigatus   4  2  0  5 
Cladosporium herbarum   0  1  1  4 
Penicillum notatum   1  0  0  0 
 
Table 2.11 Maternal and paternal self reported atopy confirmed by skin prick testing (SPT) 
 
 
Control  Salmon  p 
Maternal 
1  (n = 38)  (n = 48)   
Reported atopy confirmed by +SPT   17 (44.7%)  25 (52.1%)  0.433 
No reported atopy confirmed by –SPT   12 (31.6%)  8 (16.7%)   
Reported atopy but no +SPT  5 (13.2%)  9 (18.8%)   
No reported atopy but +SPT  4 (10.5%)  6 (12.5%)   
Paternal 
1  ( n = 32)  (n = 44)   
Reported atopy confirmed by +SPT   19 (59.4%)  30 (68.2%)  0.057 
No reported atopy confirmed by –SPT   9 (28.1%)  3 (6.8%)   
Reported atopy but no +SPT  3 (9.4%)  10 (22.7%)   
No reported atopy but +SPT  1 (3.1%)  1 (2.3%)   
1 Number of subjects (within group percentage out of those skin-prick tested) 
χ
2 (chi-square) test p-values 




















3  Salmon in pregnancy study (SIPS): fish and nutrient 
intake, compliance to the intervention, and dietary 
patterns   115 
3.1  Introduction 
Seafood, especially oily fish, (and also fish oils) are rich sources of the longer-chain n-3 
polyunsaturated  fatty  acids  (LC  n-3  PUFA)  eicosapentaenoic  acid  (EPA,  20:5n-3)  and 
docosahexaenoic acid (DHA, 22:6n-3). In oily fish these fatty acids are found in relatively 
high amounts in the flesh, while in non-oily (white) fish they are found in the flesh but at 
lower  levels  and  they  also  accumulate  in  the  liver.  Examples  of  oily  fish  are  salmon, 
sardines, pilchards, mackerel, herring, trout, and fresh tuna. The average content of EPA 
plus DHA in a portion (140 g) of oily fish is between 1 and 3.5 g, depending mainly upon 
the type of fish (12). Typical LC n-3 PUFA contents of different types of fish and seafood 
see  shown  in  (Table  1.3  transfer).  The  National  Diet  and  Nutrition  Survey  (NDNS) 
(2000/2001) data showed that UK adults have a mean consumption of total fish of 217 
g/week  (about  1.55  portions/week),  of  which  white  fish  (including  fish  products  and 
dishes) was 103 g/week and oily fish (excluding tinned tuna) was 50 g/week (about 0.36 
portion/week) (12). The results of the most recent NDNS (2008/2009) showed that women 
aged 19-64  years (including  non-consumers) consume on average 7 g/day (49 g/week) 
coated and fried white fish, 15 g/day (105 g/week) other white fish, shellfish and tinned 
tuna, and 11 g/day (77 g/week) of oily fish. The same report, showed that amongst female 
consumers of oily fish (29% of women) aged 19-64 years old daily consumption was 39 
g/day (273 g/week or 2 portions/week) (13). This data shows that over 70% of women 
aged 19-64 years do not consume any oily fish, although within the 30% of consumers 
consumption is in accordance with the minimum recommendation. The most recent NDNS 
data (13) did not report on intake of LC n-3 PUFA. However, the previous NDNS results 
(12) showed that mean intake of EPA plus DHA for adults in the UK was 244 mg/day 
from fish and animal sources (12). However, since about 70% of the adult population do 
not eat oily fish, this is an overestimate of true average intake which is likely to be 100 
mg/day (14) or less (15). Also, according to NDNS (2008/2009) 2% of the population aged 
19-64 years is vegetarian (13). However, it has been previously shown that the percentage 
of women in the UK who are vegetarians may be as high as 12% (12). Exclusion of meat 
and fish can result in low intake of EPA and DHA among pregnant vegetarian women. The 
intake  of  DHA  among  pregnant  vegetarian  women  has  been  estimated  around  10-30 
mg/day (16, 17).  
It is currently recommended to the general population to consume a minimum of 450 
mg EPA plus DHA per day (11). Also, it has been recommended that DHA intake should 
be at least 200 mg/day in women of reproductive age (19).The Committee on Medical 
Aspects of Food Policy (COMA) indicates that this intake should be achieved through the   116 
consumption of at least two portions of fish per week, of which one should be oily. This 
recommendation  is  the  same  for  pregnant  women  and  women  of  reproductive  age. 
However,  women  in  these  groups  are  further  advised  not  to  consume  more  than  two 
portions  of  oily  fish  and  tinned  tuna  per  week because  of  potential  for  high  levels  of 
contaminants  (such  as  mercury).  They  are  also  advised  to  avoid  shark,  marlin  and 
swordfish (11). 
The  provision  of  EPA  and  DHA  to the  foetus  is  important  for  foetal  growth  and 
development (11). This relates to specific roles of these fatty acids in brain and visual 
development (206). These fatty acids may also be important for optimal development and 
functioning of the vascular, cardiac, and immune systems. With regard to the latter there is 
some  evidence  that  early  fish  and  LC  n-3  PUFA  exposure  protects  against  immune 
dysfunctions like sensitisation to allergens (atopy) and allergy and asthma in infancy and 
childhood (see section 1.5; (103). These effects have been linked to alterations in the foetal 
or infant immune system (103).  
Oily  fish  are  also  good  sources  of  nutrients  other  than  LC  n-3  PUFA,  including 
vitamin  D  and  selenium.  Early  fish  and  vitamin  D  exposure  improves  bone  health  in 
infancy  and  childhood,  and  it  has  been  suggested  that  vitamin  D  supplementation  in 
pregnant  women  especially  during  winter  months  may  reduce  the  risk  of  osteoporotic 
fracture in the offspring (207, 208). Maternal vitamin D intake during pregnancy has been 
associated with decreased risk of sensitization to food allergens in the offspring (209) and 
evidence  shows  the  importance  of  vitamin  D  in  reducing  risk  of  atopic  disease 
development (210-212). Also, low status of antioxidants such as selenium has been found 
to be associated with increased risk of atopy in neonates (92, 210, 213). 
Thus, a higher consumption of fish especially oily fish in pregnancy appears to be 
linked  to  better  health  outcomes  in  the  offspring  in  infancy  and  childhood,  and  the 
protective effect of oily fish is linked to the nutrients that it contains particularly LC n-3 
PUFA, vitamin D and selenium. Protective effects of the nutrients have been or are being 
examined in intervention studies (22, 92, 183, 209-213). However, there are no published 
intervention trials with fish during pregnancy. Furthermore, there have been no studies so 
far implementing an intervention on a population level which aims to sustainably alter fish 
intake, and thus the factors affecting sustainability of change of fish intake have not been 
examined. The Salmon in Pregnancy Study (SIPS) is the first randomised controlled trial 
with oily fish (in this case farmed salmon) in pregnant women. SIPS specifically focuses 
on pregnant women whose offspring are at high risk of developing atopic disease, with one   117 
aim being to identify whether there is an effect on atopy outcomes in the offspring. As 
described in chapter 2, a total of 123 pregnant women were randomly assigned to either 
consume 2 portions of farmed salmon per week from week 20 of pregnancy until delivery 
or to continue their habitual diet low in oily fish (less or equal to 2 portions per month). 
The aim of the work described  in this chapter is to characterise the habitual diets and 
nutrient intakes of the women enrolled in SIPS, to identify whether diet changes over the 
course of pregnancy in this group, to examine compliance to the SIPS intervention, and to 
identify the effect of the intervention on maternal nutrient intake.  
The primary hypotheses examined by the work described in this chapter are that: 
  the salmon intervention will increase oily fish consumption from a habitually low 
intake (≤ 2 portions per month) to the recommended maximum  level of intake, 
which is 2 portions per week during pregnancy; 
  the  salmon  intervention  will  result  in  increased  maternal  LC  n-3  PUFA  intake 
during pregnancy, and that this intake will be higher than in the control group.  
 
The secondary hypothesis examined by the work described in this chapter are that: 
  the salmon intervention will result in changes in dietary patterns for the salmon 
group, through the replacement of other foods with the study salmon, such as meat 
and other types of fish; 
  the salmon intervention will result in a sustained increase in oily fish intake after 
the end of the intervention (post-partum); 
  the salmon intervention will increase intake of other nutrients provided by the study 
salmon, such as selenium and vitamin D and that intake of these nutrients will be 
higher than in the control group. 
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3.2  Methods 
3.2.1  Study design, subjects, subject characteristics and the 
intervention 
In chapter 2 the study design, the recruiting procedure, the nature of the women recruited 
and their characteristics, and the nature of the intervention were all described in detail. One 
group of pregnant women (n = 61) did not undergo any dietary intervention. A second 
group of pregnant women (n = 62) consumed two portions of farmed salmon per week 
from week 20 of pregnancy until delivery. Full details of the salmon are given in section 
2.4. They provided 1.73 g EPA plus DHA per portion (i.e. 3.46 g per week), 14 µg vitamin 
D per portion (28 µg per week) and 43 µg selenium per portion (86 µg per week). NDNS 
data suggests that average consumption of these nutrients among young adult women is < 
200 mg/day (or < 1.4 g/week) for EPA plus DHA (12), 2.7 µg/day (or 18.9 µg/week) for 
vitamin D and 39 µg/day (or 273 µg/week) for selenium (13). Women completed a food 
frequency questionnaire (FFQ; see below) at weeks 20 and 34 of pregnancy and again at 3 
months post-partum. They completed diaries recording  fish  intake  from week 19/20 of 
pregnancy until delivery.  
 
3.2.2  Assessment of fish, food and nutrient intakes  
3.2.2.1  General considerations 
An important issue with dietary interventions is compliance to the intervention and the 
method by which compliance is measured and controlled. Although weighed food diaries 
are considered to be more accurate when determining nutrient intake for a small number of 
volunteers, compared to FFQ, they cannot reflect a long period of time because of the 
difficulties associated with long-term completion by volunteers. They typically cover a 4 to 
7 day period. On the other hand, a well designed FFQ can reflect the dietary patterns as 
well as the nutrient intake over a longer period of time, especially for large populations 
(103, 214). Although the SIPS sample size was small, because of the primary interest in 
fish  intake  and  the  long  period  of  intervention,  it  seemed  appropriate  to  use  a  FFQ 
especially developed for use in the Southampton population. The FFQ used was developed 
for  use  in  the  Southampton  Women’s  Survey  (SWS);  this  FFQ  included  questions  on 
consumption frequency of different types of fish and reflected diet over the previous three 
months. In addition, in order to assess more closely compliance of both salmon and control 
groups, volunteers completed a specific record of fish consumption, termed a ‘fish diary’. 
The combination of the two methods allows control over compliance, and also provides the   119 
information  required  to  investigate  dietary  patterns  and  nutrient  intake  and  changes  in 
these. The SWS FFQ  has  been  validated for use to assess  nutrient intakes  in pregnant 
women in Southampton (214-217). The SWS is a study of a population sample of non-
pregnant women aged 20 to 34 years in Southampton. Women who subsequently become 
pregnant were followed up. Complete dietary data are available for 12,572 non-pregnant 
women,  2,270  women  in  early  pregnancy  and  2,649  women  in  late  pregnancy  (218). 
Details on the SWS have been published previously (201). Robinson et al. (217) compared 
early pregnancy nutrient intakes assessed by FFQ with those determined from food diaries 
kept over  four  days.  It  was  concluded  that the  FFQ  can  give  meaningful  estimates  of 
nutrient intake in early pregnancy. Godfrey et al. (219) used the same FFQ in early and late 
pregnancy to assess the relationship between maternal nutrient intake and placental and 
foetal  growth.  The  description  of  FFQ  and  fish  diaries  can  be  found  in  the  following 
section of this chapter. 
3.2.2.2  The food frequency questionnaire 
Diet was assessed using a nutritionist-administered (L.-S. Kremmyda and M. Vlachava) 
100-item FFQ covering food intake over the preceding twelve weeks (Appendix H). The 
nutritionists administering the FFQ were blinded to the treatment group of the subjects. 
The FFQ was administered at 20 and 34 weeks gestation, reflecting dietary intake before (8 
to 20 weeks gestation) and during intervention (22 to 34 week gestation). Moreover, the 
FFQ was administered 3 moths after delivery to assess dietary intake after intervention, 
reflecting the first three months post-partum.  
The FFQ reflected intake of various food items including the following categories: 
bread, cereals, different types of fruit, fruit juices, types of vegetables, pasta, rice, potatoes, 
beans/pulses, different types of meat and meat products, fish, eggs, diary products, milk, 
nuts, types of spreading fat and cooking oils, desserts/sweets, savoury snacks, tea/coffee, 
soft  drinks.  Amongst  other  food  items,  the  FFQ  included  questions  of  consumption 
frequency of different types of fish: ‘oily fish’, ‘non-oily fish’ (including tinned tuna), ‘fish 
fingers  and  fish  dishes’,  and  ‘shellfish’.  Also,  volunteers  were  asked  to  think  about 
composite food dishes, including foods they ate out or cooked themselves. The FFQ also 
included questions on nutritional supplement/vitamin/mineral intake and alcohol intake. 
Finally, for the purposes of SIPS, a question on functional food products with added n-3 
and/or n-6 fatty acids, as well as probiotic and prebiotic products, was added at the end of 
the FFQ. Subjects were asked to indicate the brand, quantity and weekly frequency of any 
functional food product they had consumed on a regular weekly basis in the past three   120 
months. Prompt cards with an extensive list of such products in the market were used to 
help the volunteers with answering.  
Subjects were asked to recall their intake during the preceding three months, and to 
ensure standardised responses prompt cards with examples of food items included in each 
food category were used. Categories of consumption frequency were also presented on a 
prompt card and they were: ‘more than once a day’, ‘once a day’, ‘3-6 times per week’, ‘1-
2 times per week’, ‘once a fortnight’, ‘once a month’, ‘once every 2-3 months’, ‘never’. 
Weekly  consumption  frequencies  for selected  food items were calculated. As  for  most 
FFQ, this questionnaire had an ordinal scale of distinct consumption frequency categories, 
rather  than  an  interval  scale  providing  a  ‘true’  measure  (220).  Therefore,  the  above 
frequency categories were transformed to the following weekly frequencies: ‘times per day 
multiplied by seven’, ‘7 times per week’, ‘4.5 times per week’, ‘1.5 times per week’, ‘0.5 
times per week’, ‘0.25 times per week’, ‘0.1 times per week’, ‘0 times per week’. The 
weekly frequencies were used as multiplication factors to calculate nutrients as follows. 
Standard portion sizes were assigned for each food item on the FFQ, derived from a 
published list for the UK (221). The nutrient content of a standard portion of each food was 
multiplied by its reported frequency (translated to a weekly level) to calculated weekly 
nutrient intake. Daily nutrient intake values were calculated after dividing weekly intake 
by seven (8-10). Nutrients from each FFQ food item were added up to obtain total diet 
intake for each nutrient. According to SWS (personal communication with Robinson SM, 
MRC  SWS  nutritionist),  nutrients  declared  to  have  complete  values  and  to  provide  a 
reliable estimate of intake from the total diet are the following: energy, carbohydrates, 
protein, total fat, saturated fat (SFA), monounsaturated fat (MUFA), polyunsaturated fat 
(PUFA),  total  n-3  PUFA,  total  n-6  PUFA,  dietary  fibre,  sodium,  potassium,  calcium, 
magnesium, phosphorus, iron, selenium, zinc, retinol, carotene, thiamin, riboflavin, niacin, 
vitamin B6, vitamin B12, folate, vitamin C, vitamin E, vitamin D. Selenium values are 
complete, however, they were used with caution as selenium content varies widely and 
depends on soil content (222). As a result total dietary selenium intake was treated as a 
rough estimate. 
3.2.2.3  Dietary patterns throughout the study 
In order to determine possible changes occurring in the diets of the pregnant women in 
relation to the intervention and/or to pregnancy, FFQ food items were grouped. All 98 
foods and non-alcoholic drinks of the FFQ were combined to form 48 food groups. Each 
food  group  included  foods  of  similar  nutrient  composition  and  comparable  usage,   121 
according to the food grouping performed by Crozier et al. (218) for the SWS FFQ. For 
instance,  salad,  coleslaw,  tomatoes,  green  peppers  and  watercress  formed  the  ‘salad 
vegetables’ group; white fish, fish fingers and fish dishes, oily fish, and shellfish were 
combined into the ‘total fish and shellfish’ group. Table 3.1 presents the way all food items 
were grouped. Weekly consumption  frequency of these  food groups was calculated by 
summing the weekly consumption frequency of each food item. 
Table 3.1 Food frequency questionnaire food grouping 
Food group created  Foods included in each group 
Rice and pasta  Rice, pasta 
White bread  White bread 
Wholemeal bread  Wholemeal bread 
Quiche and pizza  Quiche and pizza 
Savoury pancakes (including 
Yorkshire pudding)  Yorkshire pudding and savoury pancakes 
Breakfast cereals  ‘Bran’ breakfast cereals, other breakfast cereals 
Cakes and biscuits  Cakes, buns, pastries, biscuits, other biscuits 
Puddings  Fruit based puddings, milk based puddings, other puddings, ice cream 
Cream  Cream 
Full-fat milk (pints)  Full-fat liquid milk 
Reduced-fat milk (pints)  Reduced fat liquid milk 
Yogurt  Yogurt 
Cheese and cottage cheese  Cheese, cottage cheese 
Eggs and egg dishes  Eggs, omelette 
Full-fat spread  Full-fat spread 
Reduced-fat spread  Reduced-fat spread 
Cooking fats and salad oils  Cooking fats and salad oils 
Red meat  Pork, lamb, beef, 
Chicken and turkey  Chicken and turkey 
Liver, liver pate, and kidney  Liver and kidney, pate and liver sausage, faggots and black pudding 
Processed meat  Bacon and gammon, meat pies, sausages, ham and canned meats 
Total fish and shellfish  White fish, fish fingers and fish dishes, oily fish, shellfish 
Salad vegetables  Salad, coleslaw, tomatoes, green peppers and watercress 
Green vegetables  Spinach, Brussels sprouts and broccoli, cabbage and cauliflower, peas, 
courgettes, marrow and leeks 
Root vegetables  Carrots, parsnips, swedes and turnips 
Other vegetables  Sweetcorn, onions, mushrooms 
Tinned vegetables  Tinned vegetables 
Vegetable dishes  Vegetable dishes, vegetarian foods 
Beans and pulses  Beans and pulses   122 
Chips and roast potatoes  Chips and roast potatoes 
Boiled potatoes  Boiled, mashed and jacket potatoes 
Crisps  Crisps and savoury snacks 
Crackers  Crackers and cheese biscuits, wholemeal crackers 
Citrus fruit and fruit juices  Oranges and orange juice, grapefruit and grapefruit juice 
Other fruit  Apples and pears, bananas, peaches, plums, cherries and grapes, 
strawberries and raspberries, melon, pineapple, mango and kiwi 
Other fruit juices  Other fruit juices (not squashes) 
Dried fruit  Dried fruit 
Cooked and tinned fruit  Cooked fruit, tinned fruit 
Nuts  Nuts 
Sugar (teaspoons)  Added sugar 
Sweet spreads and jam  Sweet spreads and jam 
Sweets and chocolate  Chocolate, other sweets and confectionary 
High-energy soft drinks  Blackcurrants and blackcurrant drinks (Ribena), fizzy drinks and squashes, 
cola drinks 
Diet cola  Diet cola drinks 
Tea and coffee  Tea, coffee 
decaffeinated tea and coffee  Decaffeinated tea (including herbal) and decaffeinated coffee 
Hot chocolate drinks  Drinking hot chocolate and milkshakes 
Miscellaneous  Soup, stock cubes and marmite, mayonnaise and salad cream, pickles, 
chutney and ketchup, added bran to foods 
 
Principal component analysis (PCA) was used to assess dietary patterns based on the 
48 food groups formed. PCA is a multivariate statistical method that has been used by a 
number of studies to assess changes or stability of dietary patterns (223). It produces new 
variables that are uncorrelated linear combinations of the dietary variables with maximum 
variance  (224).  The  PCA  was  based  on  the  correlation  matrix  to  adjust  for  unequal 
variances of the original variables. PCA generates coefficients for each of the food groups 
in the analysis, and a dietary pattern score for each individual is calculated by multiplying 
these  coefficients  by  the  individual’s  standardised  reported  consumption  frequencies. 
When  multiplying  the  coefficients  derived  from  PCA  at  one  time  point  by  each 
individual’s standardised reported frequencies of consumption at that time point [reported 
consumption frequency-mean consumption frequency)/standard deviation of consumption 
frequency], the dietary pattern scores produced are termed as ‘natural’ scores (218). On the 
other hand, when dietary pattern scores are calculated using coefficients derived from PCA 
performed on a different time point they are termed as ‘applied’ scores (225). Applied 
scores  have  been  used  by  various  studies  to  examine  the  change  in  individual  pattern 
scores over time. In these studies, scores at follow-up time points are calculated based on 
coefficients  derived  by  PCA  at  baseline  (215,  226).  In  a  follow-up  setting,  when   123 
calculating applied dietary pattern scores, the coefficients for each food group obtained 
from the PCA at baseline are multiplied by the frequencies of consumption at the follow-
up time point standardised to the mean and standard deviation observed at baseline. An 
advantage of applied scores is that the scale of measurement (the dietary pattern) remains 
constant. Applied scores are generally preferred to natural ones (218). The SWS PCA 
revealed a first principal component that was characterized by high intakes of vegetables 
(peppers,  tomatoes,  vegetable  dishes,  courgettes,  green  salad,  onions  and  spinach), 
wholemeal bread, vegetarian food and pasta, and low intakes of full-fat milk, beef, crisps 
and savoury snacks, Yorkshire pudding and savoury pancakes, white bread, sugar, gravy, 
sausages, meat pies and roast potatoes. This first component was termed ‘prudent’ diet 
score in accordance with published data (218, 227). Women with higher ‘prudent’ diet 
scores had diets in accordance with recommendations from the Department of Health (UK) 
(228). 
Using the SIPS FFQ data, PCA was conducted and coefficients derived for the 48 
food groups at each time point at which the FFQ was administered (i.e. 20 and 34 weeks 
gestation, and 3 months post-partum). Further, the SIPS coefficients were correlated with 
the  SWS  ones  (before  pregnancy  coefficients)  (218).  Figure  3.1  shows  that  SIPS 
coefficients (20 week time point) correlated very well with SWS coefficients: Pearson’s 
correlations were 0.853 at 20 weeks gestation, 0.868 at 34 weeks gestation, and 0.635 for 3 
months  postpartum  (all  p<0.01).  On  the  basis  that  the  SIPS  study  was  conducted  in 
Southampton, the SIPS cohort should have similar dietary patterns to the SWS, although 
the  small  sample  size  of  SIPS  is  potentially  a  limitation  in  calculating  food  group 
coefficients  from PCA.  Based on this, the SWS coefficients were applied to the SIPS 
consumption frequency data in order to calculate applied dietary pattern scores for each 
individual  (Southampton  Women’s  Survey/  Salmon  in  Pregnancy  Study  (SWSIPS) 
‘prudent’  score).  SWS  coefficients  for  each  food  group  were  multiplied  by  each 
individual’s  reported  consumption  frequencies  standardised  to  the  mean  and  standard 
deviation observed in SWS (because standardising to the frequencies at each time point 
would  remove  information  about  changes  in  consumption  between  time  points).  The 
applied dietary pattern scores were standardised to the mean and standard deviation of the 
score  [SWSIPS  ‘prudent’  z-score  =  (individual  SWSIPS  ‘prudent’  –  mean  SWSIPS 
‘prudent’)/ standard deviation of SWSIPS ‘prudent’], so that the units of the scores were 
meaningful (standard deviations).   124 
 
 
Figure 3.1 Correlation between SWS and SIPS (at 20 weeks gestation) PCA coefficients 
Pearson’s correlation 0.853, p < 0.01 
 
 
Additional food groups created which were not included in PCA were: total fruit, total 
meat, total vegetables, and total alcohol. These food groups were created in the same way 
as for the 48 food groups for PCA, summing up the consumption frequencies of individual 
FFQ food items or food groups. For example, total fruit was created by the combination of 
all fruit and fruit juice categories from the 48 PCA food groups. Moreover, the following 
categories of fats and oils were formed after combining the different types of fats and oils 
consumed (specific brands and names were recorded on the FFQ): margarine, butter, olive 
oil based spreading fat, vegetable oils, olive oil, animal fat, and salad dressings.  
 
3.2.2.4  Fish diaries 
All volunteers were asked to keep a ‘fish diary’. This was a diary in which they were asked 
to  fill  in  the  quantity,  exact  name,  and  cooking  method  of  any  fish  consumed  during   125 
pregnancy. For those who were in the salmon group, they were also asked to fill in exactly 
when they consumed the study salmon, how much, and how it was cooked. The fish diary 
had the form of a calendar including all days and weeks of pregnancy, between the start of 
the intervention (20 weeks gestation) and delivery. The fish diaries were used as a measure 
of compliance during intervention for both groups, in addition to the FFQ, and to estimate 
fish  consumption  frequencies  and  nutrient  intakes  from  fish.  The  fish  consumed  were 
grouped  into  the  following  fish  categories,  to  match  the  FFQ  fish  categories:  ‘study 
salmon’,  ‘oily  fish’  (including  study  salmon  and  other oily  fish),  ‘non-oily  fish’,  ‘fish 
fingers and fish dishes’, shellfish’, and ‘total fish’. Weekly consumption frequencies were 
multiplied by fish nutrient contents (see below) to calculate weekly nutrient intake, and 
divided by seven to obtain daily nutrient intakes. Mean weekly consumption frequency of 
different fish categories and mean daily nutrient intakes were calculated only for the period 
21 to 38 weeks of pregnancy. Week 39 of gestation to delivery was not included in the 
analysis as the women were very close to delivery and diary keeping was generally poor 
during that period.  
3.2.2.5  Fish nutrient content 
Due to the fact that the study salmon was tailor-made and chemically analysed (see section 
2.4),  the  contents  of  seven  nutrients  of  interest  were  calculated  accurately.  This 
information,  along  with  information  from  other  nutrient  databases (8-10),  was  used  to 
update the  fish  nutrient  content  for  all  of  the  fish  categories  as  SIPS  had  a  particular 
interest in fish consumption. The fish recipes were chosen by the SIPS nutritionists (L-S 
Kremmyda and M Vlachava) to match with the fish habitually consumed by the volunteers 
in the study. This was based on the information given by the fish diaries which included 
the exact type of fish consumed. Table 3.2 provides information on which fish were used 
to create the fish recipes in each fish and seafood category, and Table 3.3 shows content of 
the seven nutrients of interest according to these recipes. The nutrients per portion were 
multiplied, as described above, by the weekly consumption frequency given by the FFQ 
and fish diaries to calculate weekly intake of the eight nutrients of interest from fish. Daily 
intakes were obtained after dividing by seven. These fish recipes were also incorporated 
when calculating total diet nutrient intake.   126 
 
Table 3.2 Fish used to obtain nutrient content of each FFQ fish category 
Fish category  Individual fish in each category 
White fish  Cod, haddock, plaice, tinned tuna in water (drained), tinned tuna in oil (drained) 
Oily fish  Salmon pink/red tinned in brine, mackerel, trout 
Shellfish and seafood  Prawns, mussels, scampi, crab 
Fish fingers and dished  Fish cakes, fish fingers 




Table 3.3 Nutrient content in a standard portion (150 g) of each fish/ seafood category 














White fish  0.642  1.008  111  231  78  1.98  1.245 
Oily fish  2.975  0.595  740  1355  38  13.5  1.48 
Study salmon  3.56  2.31  570  1160  43  14  4.1 
Shellfish and seafood  0.366  0.092  176  122  31  tr.  78.7 
Fish fingers and fish 
dishes  0.25  0.94  45  60  21  tr.  na. 
tr., trace; na., value not available 
 
 
3.2.3  Statistical analysis 
FFQ. Between group (salmon-control) comparisons for not normally distributed data were 
performed using the Mann Whitney test, as a non-parametric 2 independent samples test, 
and the data are described using medians and interquartile ranges: food group consumption 
frequency, meat and fish consumption frequency, nutrients from white, oily, and total fish, 
and  specific  nutrient  intake  from  total  diet.  Between  group  comparisons  for  normally 
distributed data were performed using the  independent samples t-test, and the data are 
described using means and standard deviations (sd): specific nutrient intake from total diet, 
SWSIPS ‘prudent’ diet z-score, changes  in  meat and  fish consumption  frequencies (34 
minus 20 weeks gestation, and 3 months postpartum minus 20 weeks gestation), changes in 
nutrient intake from fish (34 minus 20 weeks gestation). Functional food consumption was 
categorised  in  the  following  consumption  frequencies:  none,  ≥  3  portions/week,  ≤  4 
portions/week,  and  the  Pearson  χ
2  (chi-square)  test  was  used  to  identify  differences 
between  the  groups.  Generalised  linear  modelling  was  used  to  perform  a  3  repeated 
measures analysis of variance (ANOVA). This  was used to examine overtime changes 
during pregnancy (20 and 34 weeks gestation) and 3 months post-partum in relation to the 
intervention: meat and fish consumption frequencies, nutrient intake from total fish.    127 
Fish  diaries.  Between  group  comparisons  for  not  normally  distributed  data  were 
performed using the Mann Whitney test, as a non-parametric 2 independent samples test, 
and  the  data  are  described  using  medians  and  interquartile  ranges:  mean  weekly 
consumption frequency of fish categories, mean daily nutrient intake form white, oily, and 
total fish (period 21 to 38 weeks gestation).  
A p-value of 0.05 was considered statistically significant for all tests. The Statistical 
Package for Social Sciences (SPSS) version 16 was used for all statistical tests. SIPS PCA 
coefficients were calculated using Stata (version 10).    128 
3.3  Results 
 
3.3.1  Food groups consumption frequencies based upon FFQ 
Consumption frequencies of the 48 food groups, according to the SWS categorisation for 
PCA, for all time points of FFQ administration and for both groups, are described in Table 
3.4. Although the volunteers were randomly assigned into the two groups, consumption 
frequencies at baseline (20 week gestation FFQ reflecting the preceding 3 months) differed 
significantly between control and salmon group for the following food groups: whole-meal 
bread, total fish and shellfish, other fruit juices, sweets and chocolate. The salmon group 
had higher intake for all of these food groups, apart from sweets and chocolate for which it 
had a lower intake. Specifically, the salmon group had a median intake of total fish and 
shellfish of 1.75 times per week compared with that of the control group which was 0.75 
times  per  week  at  baseline  (20  weeks  gestation  FFQ)  (p  <  0.001).  The  proportion  of 
women with a baseline intake of 0.5 times of oily fish per week (i.e. volunteers who just 
about fulfilled the criterion of 2 portions per month maximum) was 34% for the salmon 
group and 8% for the control group. These differences between the two groups indicate a 
‘healthier’ dietary pattern for the salmon group compared to control at baseline, although 
volunteers  were  randomly  assigned  to  the  two  groups.  During  intervention  (34  weeks 
gestation FFQ), the salmon group had a significantly higher consumption frequency of 
total  fish  and  shellfish  (2.35  vs.  0.75  times  per  week,  p  <  0.001)  and  a  statistically 
significant lower consumption frequency of red meat than the control group (1.75 vs. 2.5, p 
= 0.022). The result of paired tests (non-parametric Wilcoxon’s Sign Rank test) showed 
that  within  the  salmon  group,  chicken  intake  was  significantly  reduced  from  20  to  34 
weeks gestation (p = 0.018), and so was the intake of non-oily fish (p = 0.014) (data not 
shown on tables). Also, consumption frequencies of chips and roast potatoes, and sugar 
differed between the two groups at 34 weeks of pregnancy (lower in the salmon group). 
After intervention, according to the results of the 3 month post-partum FFQ, the salmon 
group continued to have a significantly higher consumption frequency of total fish and 
shellfish. There were a few other differences between the two groups at that time point. 
Table 3.5 describes the between group comparisons for consumption frequencies of 
additional  food groups. There were  no differences  between the groups  in consumption 
frequencies of total fruit, total vegetables, total meat, and total alcohol at any time point. 
However, total meat consumption decreased significantly from 20 to 34 weeks gestation 
within the salmon group (Wilcoxon’s test, p = 0.048) (data not shown on tables). The same 
table includes information on the different types of spreading fat, cooking fat, and salad   129 
dressings. The only statistically significant differences between the two groups were in 




Table 3.4 Between group comparisons of weekly consumption frequency of food groups in the FFQ 
administered at 20 and 34 weeks gestation, and 3 months after delivery 
Food group  20 weeks gestation  34 weeks gestation  3 months post-partum 
 
Control 
(n = 61) 
Salmon 
(n = 62)  p * 
Control 
(n = 54) 
Salmon 
(n = 55)  p * 
Control 
(n = 41) 
Salmon 
(n = 47)  p * 
Rice and pasta  3 (1.88, 3)  3 (1, 3)  0.533  2 (1, 3)  2 (1, 3)  0.729  3 (1.75, 3)  2 (1.6, 3)  0.371 
White bread  9 (2.25, 14)  3.75 
(0.94, 14) 





3 (0.3, 9)  4.5 (0.69, 























0.25)  0.298  0.1 (0, 0.25)  0.1 (0, 
0.25)  0.287  0.1 (0, 0.25)  0.1 (0, 
0.25)  0.496 
Breakfast 
cereals 
4.5 (0.5, 7)  4.5 (0.88, 
7)  0.212  4.55 (1.5, 7)  7 (1.5, 7)  0.233  6 (1.5, 7)  4.5 (1.5, 







0.331  5.75 (3, 10)  8 (3.50, 
11) 





Puddings  1 (0.5, 2.5)  1.55 (6, 





0.634  1.1 (0.65, 2)  1.25 (0.7, 





0.5)  0.652  0.25 (0, 0.5)  0.25 (0, 
0.5)  0.461  0.25 (0, 0.5)  0.25 (0, 
0.5)  0.790 
Full-fat milk 
(pt/day) 






0.56)  0.580  0.5 (0.2, 1)  0.5 (0.25, 
1)  0.649  0.5 (0.25, 
0.75) 
0.5 (0.25, 






0.758  1.5 (0.5, 4.5)  1.5 (0.25, 
4.5) 








4.6)  0.222  4.5 (1.5, 4.5)  4.5 (1.5, 
4.5)  0.368  4.5 (1.5, 4.5)  4.5 (1.5, 
4.5)  0.740 





1.13)  1.000  0.5 (0.2, 1.5)  0.5 (0.2, 
1)  0.736  0.75 (0.25, 
1.6) 
0.5 (0.25, 
1)  0.218 
Full-fat spread  4.5 (0, 7)  1.5 (0, 
7.38)  0.712  4.5 (0, 7.38)  4.5 (0.25, 
9)  0.701  4.5 (0, 7)  4.5 (0, 7)  0.769 
Reduced-fat 
spread 
0 (0, 5.25)  1.5 (0, 7)  0.108  0 (0, 7)  0 (0, 7)  0.979  0 (0, 4.55)  0 (0, 7)  0.822 
Cooking fats 
and salad oils 
3 (1.5, 4.5)  3.13 (1.5, 
6)  0.234  3 (1.5, 5.06)  4.5 (1.5, 
6)  0.348  3 (1.5, 5)  4.5 (1.85, 
7)  0.143 
Red meat  2.5 (1, 3.5)  2.05 
(0.95, 3.1)  0.354  2.5 (1.75, 
3.53) 
1.75 
(0.95, 3)  0.022 
2.75 (1.7, 






1.5)  0.498  1.5 (1.5, 1.5)  1.5 (0.5, 
1.5)  0.152  1.5 (1, 1.5)  1.5 (5, 
1.5)  0.619 
Liver, liver pate, 
and kidney 







0.877  2.43 (1.18, 
3.64) 
2.5 (1.25, 
5.1)  0.501  3 (2, 4)  2.5 (1.5, 
4)  0.639 
























0.376  3.5 (2.5, 
6.68) 


















4.5)  0.711  1.75 (1.38, 
3) 
1.75 (1.5, 
3)  0.710  3 (1.5, 4.68)  1.7 (1, 3)  0.023 
Other vegetables  3.5 (2, 6.5)  4.5 (2.25, 
6.69)  0.966  3.25 (2.19, 
6.25) 
3.25 (2, 
6.25)  0.956  3.5 (2.38, 
6.38) 
4.5 (2, 







0.192  0.18 (0, 1.5)  0 (0, 0.5)  0.189  0.1 (0, 1)  0 (0, 0.5)  0.136   130 
Food group  20 weeks gestation  34 weeks gestation  3 months post-partum 
 
Control 
(n = 61) 
Salmon 
(n = 62)  p * 
Control 
(n = 54) 
Salmon 
(n = 55)  p * 
Control 
(n = 41) 
Salmon 





0.94)  0.667  0.25 (0, 0.5)  0.25 (0, 
0.5)  0.865  0.1 (0, 1.5)  0.25 (0, 






1.5)  0.910  1 (0.25, 1.5)  1.5 (0.5, 
1.5)  0.641  0.5 (0.5, 1.5)  1.5 (0.5, 
1.5)  0.682 
Chips and roast 
potatoes 
3 (1.50, 6)  3 (1, 4.5)  0.314  3 (1.5, 4.5)  1.5 (1, 
4.5)  0.021  3 (1.5, 4.5)  1.5 (1, 










0.660  9 (4.5, 
14.63) 
4.5 (3, 





4.5)  0.176  1.5 (1.5, 4.5)  1.5 (0.5, 
4.5)  0.158  1.5 (0.5, 4.5)  1.5 (0.5, 





0.75)  0.274  0.1 (0, 0.5)  0.25 (0, 
0.5)  0.692  0.1 (0, 0.25)  0.2 (0, 
1.5)  0.168 





7)  0.047  4.5 (1.5, 5.2)  4.5 (1.5, 
7.1)  0.244  1.5 (0.5, 4.5)  4.5 (0.75, 















0.5 (0, 4.5)  1.5 (0.25, 
7)  0.018  1.5 (1, 4.5)  1.5 (0.1, 
4.5)  0.735  0.5 (0.1, 1.5)  1.5 (0.1, 
4.5)  0.477 
Dried fruit  0.1 (0, 0.5)  0.25 (0, 
0.75)  0.490  0.18 (0, 0.5)  0.1 (0, 
0.5)  0.695  0.25 (0, 1)  0.1 (0, 






0.5)  0.476  0.25 (0, 0.5)  0.25 (0, 
0.5)  0.522  0.25 (0.1, 
0.5) 
0.2 (0, 
0.5)  0.469 
Nuts  0 (0, 0.25)  0.1 (0, 
0.5) 
0.060  0.05 (0, 0.5)  0 (0, 0.5)  0.559  0.25 (0, 1)  0 (0, 0.25)  0.095 






4.5)  0.071  1 (0.25, 1.5)  1.5 (0.25, 
1.5)  0.347  0.25 (0, 1.5)  1.5 (0.5, 
4.5)  0.002 
Sweets and 
chocolate 
5 (2, 9)  3 (1.75, 6)  0.037 
6 (2.75, 
8.63) 
4.75 (2, 7)  0.216  3 (1.5, 7)  3 (1.6, 6)  0.600 
High-energy soft 
drinks 
6 (1.5, 10)  4.5 (0.50, 
9.75)  0.354  7.38 (1.6, 
14.03) 
3 (0.5, 
10.5)  0.058  3 (0.5, 7.38)  3 (0.25, 





1.5)  0.464  0 (0, 0.25)  0.1 (0, 
0.5)  0.209  0 (0, 0.5)  0.25 (0, 
0.5)  0.377 




15.5)  0.508  8.75 (4.5, 
21) 
7 (1.5, 
15.5)  0.187  14 (1.75, 
24.5) 
14 (4.75, 
21.1)  0.763 
decaffeinated 
tea and coffee 






1.5)  0.081  0.25 (0, 1.5)  0.5 (0, 
1.5)  0.635  0.1 (0, 0.5)  0.1 (0, 







0.792  5 (3.25, 8)  5 (2.5, 
8.6) 
0.450  5 (2.3, 7.63)  5 (2.35, 
7.6) 
0.940 
*p-values from non-parametric 2 independent samples test (Mann Whitney)
 
Values are median (interquartile range) 
Number of times per week (apart from milk (pints/day) and sugar (teaspoons/day)) 
Food grouping performed according to principal component analysis (PCA) of the SWS FFQ 
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Table 3.5 Between group comparisons of weekly consumption frequency of additional food groups in 
the FFQ 
Food group  20 weeks gestation  34 weeks gestation  3 months post-partum 
 
Control 
(n = 61) 
Salmon 
(n = 62)  p * 
Control 
(n = 54) 
Salmon 
(n = 55)  p * 
Control 
(n = 41) 
Salmon 
















































9.5)  0.495  7.8 (5.6, 
10.02) 
7 (5.5, 
8.75)  0.355 
Total alcohol  0 (0, 0.33)  0.6 (0, 
0.26)  0.711  0 (0, 0.5)  0 (0, 0.25)  0.898  0.75 
(0.25, 3) 
1.25 (0.1, 
4.5)  0.606 
Margarine**  0 (0, 4.5)  0 (0, 7)  0.810  0.13 (0, 
4.5) 
0 (0, 6)  0.773  0 (0, 4.62)  0 (0, 4.5)  0.653 
Butter  1.5 (0, 7)  1.5 (0, 7)  0.781  4.5 (0, 7)  2 (0, 7)  0.943  1.5 (0, 7)  2.25 (0, 7)  0.906 
Olive oil based 
spreading fat 
0 (0, 0)  0 (0, 0.44)  0.191  0 (0, 0)  0 (0, 0)  0.582  0 (0, 0)  0 (0, 0)  0.038
1 
Vegetable oils  0.5 (0, 1.5)  0.38 (0, 
1.5) 
0.435  0.5 (0, 
1.5) 









4.5)  0.067  0.13 (0, 
3.38)  1.5 (0, 4.5)  0.038 
1.5 (0, 
4.5)  2 (0, 6)  0.244 
Animal fat  0 (0, 0)  0 (0, 0)  0.152  0 (0, 0)  0 (0, 0)  0.322  0 (0, 0)  0 (0, 0)  1.000 
Salad dressing  0 (0, 0)  0 (0, 0)  0.800  0 (0, 0)  0 (0, 0)  0.538  0 (0, 0)  0 (0, 0)  0.344 
Values are median (interquartile range), number of times per week 
*p-values from non-parametric 2 independent samples test (Mann Whitney)
 
1 Higher intake in the salmon group (not evident from median values) 
**Vegetable oil based spreading fat 
 
 
Due to the differences observed at baseline for total fish and shellfish consumption 
between the two groups (median consumption was 0.75 times per week for the control 
group, and 1.75 times per week for the intervention group, p = 0.001) (Table 3.4), the 
different FFQ fish categories were further explored (Table 3.6). At week 20 the salmon 
group was consuming significantly more frequently non-oily fish (medians 0.5 and 0.25 
times per week, for salmon and control groups respectively, p = 0.005), and significantly 
more frequently oily fish (medians 0.25 and 0 times per week, for salmon and control 
groups respectively, p < 0.001). The proportion of women with a baseline intake of 0.5 
times  of  oily  fish  per  week  (i.e.  volunteers  who  just  about  fulfilled  the  criterion  of  2 
portions per month maximum allowed for inclusion into SIPS) was 34% for the salmon 
group and 8% for the control group. The proportion of women with a baseline oily fish 
intake of 0-0.25 times per week was 92% for the control group and 65% for the salmon 
group (χ
2 test  p  =  0.001).  At  34  weeks  gestation  (during  intervention),  there  were  no 
significant differences in white fish intake between the two groups. More importantly, the 
results of the 34 weeks FFQ, showed that all volunteers assigned in the salmon group 
reported having oily fish 1-2 times per week, which was interpreted as 1.5 times per week.   132 
Thus, at 34 weeks gestation the salmon group consumed significantly more frequently oily 
fish than the control group (medians 1.5 and 0 times per week, for salmon and control 
groups respectively, p < 0.001). Finally, at 3 months post-partum, after intervention, the 
salmon group continued to have higher oily and non-oily fish consumption frequencies 
than the control group. Interestingly, at 3 months post-partum 17% of the salmon group 
continued having oily fish more or equal to 1.5 times per week (i.e. ≥ 1-2 times per week) 
compared  to  0%  before  intervention.  Also,  at  3  months  post-intervention  23%  of  the 
salmon group had 0.5 portions of oily fish per week (i.e. twice per month) compared to 
34% before intervention (χ
2 test p = 0.012). This may suggest that for a small number of 
volunteers the intervention had produced a sustainable result, and they continued having 
oily fish twice per week even after the end of the intervention. No differences were seen 
between salmon and control groups at any time point for fish fingers and fish dishes, and 
for shellfish. Figure 3.2 describes the distribution of intake of non-oily fish in the FFQ 
frequency categories, and Figure 3.3 describes the distribution of consumption of oily fish, 
for both study groups and at all time points.    133 
 
Figure 3.2 Distribution of non-oily fish consumption into the FFQ categories at a) 20 weeks gestation, 
b) 34 weeks gestation, c) 3 months post-partum 
a 
b 
c   134 
 
 
Figure 3.3 Distribution of oily fish consumption into FFQ categories at a) 20 weeks gestation, b) 34 
weeks gestation, c) 3 months post-partum 
a 
b 
c   135 
Because of the baseline differences in fish intake between the groups, changes in fish 
consumption frequencies were calculated: 34 minus 20 weeks gestation, 3 months post-
partum minus 20 weeks gestation. The results are shown on Table 3.7. The increase in oily 
fish consumption observed in the salmon group was 1.21 times per week from 20 to 34 
weeks gestation, whereas the oily fish consumption in the control group remained almost 
unchanged (0.04 times per week less). This change can be seen also on Figure 3.4. The 
change in oily fish intake was significantly different between the two groups (p<0.001). 
Also, the increase in total fish consumption in the salmon group (0.85 portions per week 
more)  was  significantly  different  from  the  almost  unchanged  total  fish  consumption 
frequency from the control group (0.05 times per week less) (p < 0.001). Lastly, there were 
no statistically significant differences between the groups in fish categories and total fish 
consumption frequency changes between 3 months post-partum and baseline (20 weeks).  
In  order to  investigate  further  the  red  meat  between  group  differences  seen  at  34 
weeks  gestation  (Table  3.4),  all  FFQ  meat  categories  were  explored.  However,  no 
differences in individual meat categories were seen between the two groups (Table 3.6), 
and the changes of  intake of  individual  meat categories, total red  meat and total  meat 
where not different between the two groups (Table 3.7).  
Finally, Table 3.8 shows that there were no significant differences in consumption 
frequencies of functional food products (including products with added LC n-3 PUFA from 
fish  oil)  between  the  groups.  For  both  groups,  the  majority  of  the  volunteers  did  not 
consume these products on a regular basis. 
 
Figure 3.4 Change in weekly oily fish consumption between 34 and 20 weeks gestation in the two study 
groups 
p < 0.001 (Mann Whitney)   136 
 
Table 3.6 Between group comparisons of weekly consumption frequency of meat and fish categories in 
the FFQ 
Food group  20 weeks gestation  34 weeks gestation  3 months post-partum 
 
Control 
(n = 61) 
Salmon 
(n = 62)  p * 
Control 
(n = 54) 
Salmon 
(n = 55)  p * 
Control 
(n = 41) 
Salmon 









1.5)  0.204  0.25 (0, 
0.5) 
0.5 (0.25, 




0.25 (0, 0.5)  0.25 (0, 0.5)  0.597  0.18 (0, 0.5)  0.1 (0, 0.25)  0.866  0.25 (0, 
0.5) 
0.1 (0, 
0.25)  0.569 
Oily fish  0 (0, 0.25)  0.25 (0, 0.5)  <0.001  0 (0, 0.14)  1.5 (1.5, 1.5)  <0.001  0 (0, 0.25)  0.25 (0, 
0.5)  <0.001 
Shellfish  0 (0, 0.1)  0 (0, 0.1)  0.855  0 (0, 0)  0 (0, 0.1)  0.0760  0 (0, 0.17)  0 (0, 0.1)  0.566 
Pork  0.25 (0, 0.5)  0.17 (0, 0.5)  0.526  0.25 (0.8, 
0.5) 
0.25 (0.1, 
0.5)  0.189  0.25 (0.1, 
0.5) 
0.25 (0, 
0.5)  0.347 





Lamb  0.1 (0, 0.5)  0.17 (0, 0.5)  0.894  0.25 (0, 0.5)  0.1 (0, 0.5)  0.92  1 (0, 0.5)  0.25 (0, 
0.25)  0.812 
Beef  0.5 (0.1, 1.5)  0.37 (0.25, 
1.5)  0.959  0.5 (0.25, 
1.5) 
0.5 (0.1, 
0.50)  0.351  0.5 (0.17, 
1.5) 
0.25 (0.1, 






1.5)  0.315  1.5 (0.5, 1.5)  0.5 (0.25, 
1.5)  0.301  1.5 (0.5, 
1.5) 
0.5 (0.25, 


















1.5)  1.5 (.43, 1.5)  0.467  0.5 (0.25, 
1.5) 
1.5 (0.25, 
1.5)  0.156  1.5 (0, 
1.5) 
1.5 (0.25, 
1.5)  0.806 
*p-values from non-parametric 2 independent samples test (Mann Whitney)
 




Table 3.7 Changes in fish and meat weekly consumption frequencies - between group comparisons 




(n = 54) 
Salmon 
(n = 55)  p * 
Control 
(n = 41) 
Salmon 
(n = 47)  p * 
Non-oily fish  0.02 (±0.96)  -0.25 (±0.7)  0.104  -0.22 (±0.92)  0.01 (±1.26)  0.345 
Fish fingers and fish dishes  0.01 (±0.38)  -0.11 (±0.43)  0.128  0.04 (±0.41)  -0.12 (±0.57)  0.126 
Oily fish  -0.04 (±0.14)  1.21 (±0.26)  <0.001  0.05 (±0.32)  0.21 (±0.78)  0.218 
Shellfish  -0.04 (±0.27)  -0.25 (±0.7)  0.298  -0.01 (±0.19)  0.07 (±0.24)  0.074 
Total fish  -0.05 (±1.07)  0.85 (±0.085)  <0.001  -0.14 (±1.25)  0.17 (±1.63)  0.327 
Pork  0.08 (±0.91)  0 (±0.12)  0.149  0.07 (±0.51)  0.04 (±0.7)  0.847 
Chicken  0.13 (±1.73)  -0.12 (±0.46)  0.094  0.01 (±1.63)  -0.16 (±1.5)  0.612 
Lamb  0.08 (±0.69)  -0.32 (±0.96)  0.320  0.01 (±0.33)  -0.04 (±0.45)  0.619 
Beef  -0.04 (±1.38)  -0.03 (±0.37)  0.673  0.15 (±0.53)  0.03 (±0.84)  0.409 
Total red meat  0.11 (±2.2)  -0.2 (±1.85)  0.424  0.27 (±0.99)  -0.17 (±1.9)  0.195 
Total meat  -0.67 (±4.47)  -0.83 (±3.24)  0.831  -0.01 (±3.37)  -0.63 (±3.37)  0.393 
*p-values from independent samples t-test 
Values are mean (±standard deviation), number of times per week   137 
 
Table 3.8 Between group comparisons of functional food consumption recorded on the FFQ 
Functional 
































≤3 portions/wk  4 (6.6%)  8 (12.9%)  0.478  4 (7.4%)  5 (9.1%)  0.786  3 (7.3)  8 (17%)  0.303 







(93.5%)    50 
(92.6%) 
53 
(96.4%)    41 (100%) 
46 
(97.9%)   
≤3 portions/wk  4 (6.6%)  1 (1.6%)  0.223  3 (5.6%)  2 (3.6%)  0.528  0 (0%)  1 (2.1%)  0.348 















(89.4%)   
≤3 portions/wk  4 (6.6%)  5 (8.1%)  0.668  3 (5.6%)  1 (1.8%)  0.223  1 (2.4%)  3 (6.4%)  0.672 
≥4/portions/wk  2 (3.3%)  4 (6.5%)    0 (0%)  2 (3.6%)    2 (4.9%)  2 (4.3%)   
 















≤3 portions/wk  2 (3.3%)  2 (3.2%)  0.250  1 (1.9%)  0 (0%)  0.437  0 (0%)  0 (0%)  0.376 
≥4/portions/wk  0 (0%)  2 (3.2%)    2 (3.7%)  4 (7.3%)    1 (2.4%)  3 (6.4%)   
 





(96.8%)    54 
(100%) 
53 
(96.4%)   
40 
(97.6%)  47 (100%)   
≤3 portions/wk  2 (3.3%)  1 (1.6%)  0.513  0 (0%)  2 (3.6%)  0.157  0 (0%)  0 (0%)  0.282 
≥4/portions/wk  0 (0%)  1 (1.6%)    0 (0%)  0 (0%)    1 (2.4%)  0 (0%)   
*p-values from Pearson’s χ
2 (chi-square) test 
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3.3.2  Principal component analysis (PCA) 
The PCA results described on Table 3.9 show that the salmon group had a significantly 
higher ‘prudent’ diet z-score than the control group (p = 0.033), indicating a ‘healthier’ 
dietary pattern for the salmon group at baseline. This is in agreement with the food group 
differences  observed  between  the  two  groups  at  20  weeks  gestation  (Table  3.4).  This 
‘healthier’ pattern was also observed at 34 weeks gestation, when the salmon group had 
higher ‘prudent’ diet z-scores that were even more significantly different from the control 
group (p = 0.007). Finally at 3 months post-partum, the mean score for the salmon group 
was not statistically different from that for the control. Moreover, the paired t test showed 
that within the salmon group there was no statistically significant difference between 20 
and 34 weeks gestation, however the ‘prudent’ diet z-score was decreased significantly 
from 20 weeks gestation to 3 months post-partum (p = 0.016). Paired t tests did not reveal 
any difference between time-points within the control group (data not shown on tables). 
 
Table 3.9 Prudent diet z-score calculated after applying the SWS correlation coefficients from the 
principal component analysis (PCA) of the FFQ food categories (Table 3.1)) 
  20 weeks gestation  34 weeks gestation  3 months post-partum 
 
Control 
(n = 61) 
Salmon 
(n = 62)  p * 
Control 
(n = 55) 
Salmon 
(n = 54)  p * 
Control 
(n = 41) 
Salmon 
















(±1.107)  0.141 
*p-values from independent samples t-test (normal distribution) 
**Values are mean (±standard deviation); Units: sd (± sd) 
Z-score= (applied SWSIPS prudent score-prudent score mean)/ prudent score sd 




3.3.3  Nutrient intakes based upon FFQ 
Table 3.10 describes the between group comparisons for total dietary intake of nutrients 
according to the FFQ at each time point of administration. At 20 weeks of pregnancy the 
only differences in nutrient intake between the two groups were the statistically significant 
higher intake of EPA, DHA, and EPA plus DHA in the salmon group (all p < 0.001). At 34 
weeks gestation intakes of EPA, DHA, and EPA plus DHA were significantly higher in the 
salmon group compared to the control group (all p < 0.001). The same pattern was seen at 
3  months  post-partum  (p  =  0.003).  However,  it  must  be  noted  that  these  are  rough 
estimates for the intake from total diet and supplements as they do not belong to the group   139 
of  nutrients  declared  by  SWS  to  be  complete  (personal  communication  with  S.M. 
Robinson). The intake of these LC n-3 PUFA is mainly coming from fish (since none of 
the subjects consumed fish oil containing supplements) and so it is more appropriate to 
look at their intake from fish (Table 3.11-Table 3.13) based upon FFQ calculations (see 
below). Furthermore, although at 20 weeks gestation intake of total n-3 PUFA was not 
different between the two groups, it was significantly higher in the salmon group at 34 
weeks gestation and also at 3 months post-partum.  At 34 weeks gestation, the salmon 
group had a higher daily intake of vitamin B12, selenium, and vitamin D than the control 
group. At 3 months post-partum, the intakes of these nutrients were not different between 
the groups. There were no other significant differences between salmon and control groups 
in intakes of the rest of the macro and micronutrients from total diet at any time point. 
According to the FFQ information, there were no differences between the groups in 
nutritional  supplement  consumption  at  baseline  and  during  the  intervention.  Most 
importantly, none of the subjects consumed fish oil supplements at baseline and during the 
intervention, which was in accordance to the inclusion criteria. In chapter 2, it was shown 
that at baseline (20 weeks FFQ) the majority of the volunteers in both groups (73.8 % 
control  group,  75.8%  salmon  group;  χ
2  (chi-square)  p  =  0.966)  consumed  folic  acid 
containing supplements (Table 2.7). During the intervention (34 weeks FFQ), almost equal 
proportions of subjects either did  not consume  any supplements (40.7% control group, 
47.3%  salmon  group)  or  consumed  folic  acid  containing  supplements  (40.7%  control 
group, 34.5% salmon group), and a lower proportion consumed non-folic acid containing 
supplements (18.5% control group, 18.2% salmon group) (χ
2 (chi-square) p = 0.762). Post-
intervention data (3 month FFQ) showed that there were more women in the salmon group 
consuming  non-folic  acid  containing  supplements  (2.4%  control  group,  19.1%  salmon 
group), whereas the majority in both groups did not consume any supplements (68.3% 
control group, 48.9% salmon group) (χ
2 (chi-square) p = 0.033). 
Table 3.11 - Table 3.13 describe the daily intake of seven nutrients of interest (EPA, 
DHA, total n-3 PUFA, total n-6 PUFA, selenium, vitamins D and E) from non-oily, oily 
(including study salmon), and total fish (shellfish and fish dishes), respectively, for both 
groups at all time points. At 20 weeks gestation, pregnant women in the salmon group had 
a significantly higher intake of all of these nutrients from non-oily, oily, and total fish. At 
34  weeks  gestation,  there  were  no  statistically  significant  differences  between  the  two 
groups in the intake of these seven nutrients from white fish. However, the intakes of all 
seven nutrients of interest from oily fish (including study salmon) and from total fish were 
higher  for  the  salmon  group  compared  with  control  at  34  weeks  (all p  <  0.001).  The   140 
median daily intake of LC n-3 PUFA for the salmon group during intervention (34 weeks 
gestation) was 133.3 mg EPA, 267.2 mg DHA, and 402.6 mg EPA plus DHA, according to 
FFQ fish consumption frequencies. Finally, at 3 months post-partum, the salmon group had 
a higher intake of all of these seven nutrients from non-oily, oily, and total fish. The box-
plots on Figure 3.5 present the daily intake of EPA, DHA, and EPA plus DHA, from total 
fish, at all time points and for both groups. 
Because  the  two  groups  had  a  significantly  different  baseline  intake  of  the  seven 
nutrients of interest from fish, the change in daily intake of these nutrients from total fish 
was calculated (34 weeks gestation minus 20 weeks gestation) (Table 3.14). The mean 
daily intake of EPA plus DHA from total fish increased by 269.3 mg in the salmon group 
and for the control group it decreased by 12.2 mg (p < 0.001). Moreover, the change in 
intakes of EPA, DHA, total n-3 PUFA, total n-6 PUFA, selenium, vitamin D and vitamin E 
from  total  fish  were  significantly  different  between  groups  (all  p  <  0.001,  except  for 
selenium p = 0.011). The changes in intakes of LC n-3 PUFA between 20 and 34 weeks 
gestation are represented on Figure 3.6. 
 
Table 3.10 Between group comparisons of daily intake of selected nutrients from total diet calculated 
from FFQ at 20 weeks, 34 weeks gestation, and 3 months after delivery (reflecting the 3 months 
previous to FFQ administration) 
Nutrients  20 weeks gestation  34 weeks gestation  3 months post-partum 
 
Control 
(n = 61) 
Salmon 
(n = 62)  p 
Control 
(n = 54) 
Salmon 
(n = 55)  p 
Control 
(n = 41) 
Salmon 

















































(±21.3)  0.968  80.3 
(±21.7) 
80.6 
(±19.3)  0.948  74.86 
(±20.22) 
74.77 






(±25.9)  0.905  88.1 
(±23.7) 
90.3 
(±23.6)  0.635  80 
(±25.46) 
83.5 






(±12.2)  0.810  33.9 (±10)  34.9 
(±11.0)  0.604  30.69 
(±11.04) 
31.78 





















(±4.7)  0.994  15.6 
(±4.9) 
15.3 
(±4.7)  0.730  13.92 
(±4.59)  14 (4.6)  0.877 
Total n-3 PUFA (g)
1  1.8 (±0.6)  1.9 (±0.5)  0.900  1.9 (±0.6)  2.5 (±0.5)  <0.001  1.7 (±0.5)  1.9 (±0.6)  0.036 










0.445  12.1 
(±4.2) 
11.9 (±4)  0.822 






(±5.9)  0.730  16.2 
(±4.8) 
17.4 
(±5.4)  0.215  16.5 
(±5.2) 
16.2 






(±804.2)  0.508  3056.6 
(±767.5) 
2989.3 
(±867.6)  0.669  2858.37 
(±708.48) 
2848.4 






(±1050.8)  0.762  3439.1 
(±925.7) 
3529.8 
(±895)  0.604  3257.53 
(±905.84) 
3224 















0.701   141 
Nutrients  20 weeks gestation  34 weeks gestation  3 months post-partum 
 
Control 
(n = 61) 
Salmon 
(n = 62)  p 
Control 
(n = 54) 
Salmon 
(n = 55)  p 
Control 
(n = 41) 
Salmon 






(±101.6)  0.722  341.6 
(±101.9) 
355.2 
(±96.2)  0.475  315 
(±99.5) 
309 






(±469)  0.816  1513.5 
(±428.1) 
1533.7 
(±390.7)  0.797  1374.6 
(±392.5) 
1376.6 






(±5.6)  0.942  12 (±5.4)  12.3 






















(±189.9)  0.915  355.1 
(±167.8) 
327.1 
(±131.9)  0.334  353.7 
(±150.2) 
347.7 






(±1431.9)  0.650  2846.6 
(±1195) 
3008.1 
(±1216)  0.486  3118.5 
(±1342.1) 
2790.2 






(±1.05)  0.789  2.23 
(±1.08) 
2.29 
(±1.05)  0.768  1.97 
(±1.05) 
1.87 




















(±10.8)  26.2 (±9)  0.685  24.8 
(±10.5)  26 (±10.6)  0.554  23.1 (±9)  21.4 






(±2.98)  0.913  3.50 
(±2.72) 
3.74 
(±2.73)  0.649  2.92 
(±2.99) 
2.64 






(±2.46)  0.823  5.91 
(±2.65) 
7.15 

























(±82.3)  0.508  176.5 
(±159.8) 
179.7 
(±106.3)  0.902  125.3 
(±59.5) 
134.2 






(±16.8)  0.244  49.0 
(±17.0) 
58.2 
(±16.7)  0.005  48 (±17.4)  51.1 






(±6.8)  0.934  14.3 
(±6.7)  15 (±7.2)  0.592  11.64 
(±6.77) 
11.21 






























0.590  2.9 (2.02, 
12.37) 
5.75 (5, 




































































1 Nutrient intake only from diet (supplements did not contribute to the intake of these nutrients). Values are 
mean (±standard deviation), p-values from independent t-test (normal distribution) 
2 Nutrient for which supplements contributed to intake (diet plus supplement intake). Values are mean 
(±standard deviation), p-values from independent t-test (normal distribution) 
3 Nutrient for which supplements contributed to intake (diet plus supplement intake). Values are medians 
(interquartile range), p-values from non-parametric 2 independent samples test (Mann Whitney) (not normal 
distribution) 
EPA and DHA: the FFQ cannot provide reliable data on intake from the whole diet (incomplete values) 
Selenium: values completed for all foods in the FFQ- however data are limited as the content of foods varies 
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Table 3.11 Between group comparisons of daily nutrient intake from non-oily (white) fish consumption 
recorded on the FFQ 
Nutrients  20 weeks gestation  34 weeks gestation  3 months post-partum 
 
Control 
(n = 61) 
Salmon 
(n = 62)  p* 
Control 
(n = 54) 
Salmon 
(n = 55)  p* 
Control 
(n = 41) 
Salmon 
(n = 47)  p* 




















Total n-6 PUFA 
(mg) 
36 (36, 72)  72 (36, 




216)  0.204  36 (0, 72)  72 (36, 
216)  0.040 
EPA (mg)  4 (4, 7.9)  7.9 (4, 
23.8)  0.005  4 (1.2, 23.8)  7.9 (4, 
23.8)  0.204  4 (0, 7.9)  7.9 (4, 









49.5)  0.204  8.3 (0, 16.5)  16.5 (8.3, 
































































Table 3.12 Between group comparisons of daily nutrient intake from oily fish* consumption recorded 
on the FFQ 
Nutrients  20 weeks gestation  34 weeks gestation  3 months post-partum 
 
Control 
(n = 61) 
Salmon 
(n = 62)  p* 
Control 
(n = 54) 
Salmon 
(n = 55)  p* 
Control 
(n = 41) 
Salmon 
(n = 47)  p* 
Total n-3 PUFA 
(mg) 
0 (0, 106.3)  106.3 (0, 








212.5)  <0.001 
Total n-6 PUFA 
(mg) 
0 (0, 21.3)  21.3 (0, 
42.5)  <0.001  0 (0, 11.7)  495 (495, 
495)  <0.001  0 (0, 21.3)  21.3 (0, 
42.5)  <0.001 
EPA (mg)  0 (0, 26.4)  26.4 (0, 




<0.001  0 (0, 26.4)  26.4 (0, 
52.9)  <0.001 
DHA (mg)  0 (0, 48.4)  48.4 (0, 




<0.001  0 (0, 48.4)  48.4 (0, 
96.8)  <0.001 
EPA+DHA from 
oily fish (mg) 
0 (0, 74.8)  74.8 (0, 




<0.001  0 (0, 74.8)  74.8 (0, 
149.6)  <0.001 
Selenium (µg)  0 (0, 1.36)  1.36 (0, 





0  (0, 
1.360 
1.36 (0, 
2.71)  <0.001 
Vitamin D (µg)  0 (0, 0.482)  0.482 (0, 
0.964)  <0.001 
0 (0, 




0.964)  <0.001 
Vitamin E (mg)  0 (0, 0.053)  0.053 (0, 










106)  <0.001 
*Including study salmon. When consumption was 2 times/week, it was recorded in the FFQ category ‘1-2 
times/week’ which was interpreted as ‘1.5 times/week’ for nutrient calculations. 
Values are medians (interquartile range); *p-values from non-parametric 2 independent samples test (Mann 
Whitney)  
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Table 3.13 Between group comparisons of daily nutrient intake from total fish* consumption recorded 
on the FFQ 
Nutrients  20 weeks gestation  34 weeks gestation  3 months post-partum 
 
Control 
(n = 61) 
Salmon 
(n = 62)  p-value 
Control 
(n = 54) 
Salmon 
(n = 55)  p-value 
Control 
(n = 41) 
Salmon 
(n = 47)  p-value 












































































(19.4)  0.002 
EPA+DHA from 
















































































*Total fish including non-oily fish, oily fish (and study salmon), fish fingers and fish dishes, shellfish. 




Table 3.14 Changes in daily nutrient intake from total fish* consumption recorded on the FFQ 
Nutrients  Change: 34-20 weeks gestation 
 
Control 
(n = 54) 
Salmon 
(n = 55)  p** 
Total n-3 PUFA (mg)  -16.5 (±120.6)  611.8 (±110.6)  <0.001 
Total n-6 PUFA (mg)  0.2 (±145.0)  420.0 (±119.8)  <0.001 
EPA (mg)  -4.8 (±25.4)  86.5 (±26.7)  <0.001 
DHA (mg)  -7.5 (±47.7)  182.8 (±49.0)  <0.001 
EPA+DHA(mg)  -12.2 (±72.8)  269.3 (±75.6)  <0.001 
Selenium (µg)  -0.182 (±10.923)  4.534 (±7.861)  0.011 
Vitamin D (µg)  -0.069 (±0.437)  2.365 (±0.488)  <0.001 
Vitamin E (mg)  -0.010 (±0.185)  0.772 (±0.123)  <0.001 
*Total fish including non-oily fish, oily fish (and study salmon), fish fingers and fish dishes, shellfish. 
Values are mean (±standard deviation), nutrient units/day; **p-values from independent samples t-test 
   144 
 
Figure 3.5 Box-plots presenting daily intake of total fish a) EPA, b) DHA and c) EPA plus DHA, at all time points (FFQ) 
All p ≤ 0.002 between groups (Mann Whitney) 
 
Figure 3.6 Box-plots presenting the change in intake of a) EPA, b) DHA, c) EPA plus DHA, from total fish, between 34 and 20 weeks gestation (FFQ) 
All p < 0.001 between groups (independent samples t-test)
a  b  c 
a  b  c   145 
3.3.4  Information from fish diaries 
Table 3.15 describes the mean weekly consumption frequency of study salmon and fish 
categories  consumed  by  both  groups  during  intervention  (21  to  38  weeks  gestation), 
according to the fish diaries. It must be mentioned that the majority, but not all subjects, 
returned the completed fish diaries, and so this data represents only a subset of the study 
groups  (control  group  n  =  47;  salmon  group  n  =  49).  The  median  of  the  weekly 
consumption frequency of study salmon in the salmon group was 1.94 portions (Figure 3.7 
and Figure 3.8), whereas the median of the weekly oily fish consumption frequency from 
the control group was 0 portions (p < 0.001). The salmon group consumed fewer portions 
of white fish per week (0.17) compared to control group (0.33) (p = 0.036). Also, the 
salmon  group  consumed  fewer  portions  of  fish  fingers  and  fish  dishes.  Total  fish 
consumption frequency was 2.11 portions per week for the salmon group and 0.47 portions 
per week for the control group (p < 0.001). Figure 3.9 represents the compliance of the 
salmon group to consuming two portions of study salmon weekly. The fish diaries showed 
that, 79.6% of the volunteers in the salmon group were having 2 (or more) portions of 
study salmon per week for 81.25% of the weeks during intervention (data presented cover 
the period between 21 to 38 weeks gestation). Also, 24.5% of the volunteers in the salmon 
group had 2 or more portions of study salmon per week, every single week during 21 to 38 
weeks  gestation.  This  data  shows  that  the  salmon  group  complied  very  well  with 
consuming the salmon as requested (2 portions per week). Figure 3.10 shows the weekly 
consumption of oily, non-oily, and total fish during every week of pregnancy.  
Table 3.16 - Table 3.18 describe the daily intakes of the seven nutrients of interest 
from  non-oily,  oily  (including  study  salmon),  and  total  fish,  for  both  groups  during 
intervention according to the fish diaries. The salmon group had a lower daily intake for all 
seven  nutrients of  interest coming  from white  fish compared to control group (all p  = 
0.036). Oily fish and total fish provided significantly more nutrients to the salmon group 
compared to control (all p < 0.001). The median daily intake of the fatty acids of interest 
from total fish was 162 mg EPA, 325.8 mg DHA, and 490.9 mg EPA plus DHA for the 
salmon group, and 10 mg EPA, 16.2 mg DHA and 24.4 mg EPA plus DHA for the control 
group, during  intervention (all p < 0.001) (data represent the period between 21 to 38 
weeks gestation). This data can be seen on Figure 3.11. Figure 3.12 shows the daily intake 
of EPA plus DHA from total fish, for both groups and during every week of pregnancy.   146 
 
Table 3.15 Between group comparisons of mean weekly consumption frequencies of fish categories 
recorded in the fish diaries (data on 21-38 weeks gestation) 
Fish Categories  21 to 38 weeks gestation 
  Control (n = 47)  Salmon ( n= 49)  p* 
Study salmon  0 (0, 0)  1.94 (1.83, 2.00)  <0.001 
White fish  0.33 (0.06, 0.56)  0.17 (0.06, 0.33)  0.036 
Oily fish
1  0 (0, 0.07)  1.94 (1.87, 2.00)  <0.001 
Fish fingers and fish dishes  0 (0, 0.11)  0 (0, 0)  0.002 
Shellfish  0 (0, 0)  0 (0, 0)  .507 
Total fish
2  0.47 (0.17, 0.8)  2.11 (2, 2.35)  <0.001 
1Including study salmon 
2Total fish including non-oily fish, oily fish (and study salmon), fish fingers and fish dishes, shellfish. 
Values are medians (interquartile range) of number of portions/week; *p-values from non-parametric 2 
independent samples test (Mann Whitney) (not normal distribution). 
 
 
Table 3.16 Between group comparisons of mean daily nutrient intake from non-oily (white) fish 
consumption recorded in the fish diaries 
Nutrients  21 to 38 weeks gestation 
  Control (n = 47)  Salmon ( n= 49)  p* 
EPA (mg)  5.2 (0.9, 8.7)  2.6 (0.9, 5.2)  0.036 
DHA (mg)  11.0 (1.8, 18.3)  5.5 (1.8, 11)  0.036 
Total n-3 PUFA (mg)  30.6 (5.1, 51)  15.3 (5.1, 30.6)  0.036 
Total n-6 PUFA (mg)  48 (8, 80)  24 (8, 48)  0.036 
Selenium (µg)  3.71 (0.62, 6.19)  1.86 (0.62, 3.7)  0.036 
Vitamin D (µg)  0.094 (0.016, 0.157)  0.047 (0.016, 0.094)  0.036 
Vitamin E (mg)  0.056 (0, 0.01)  0.03 (0.01, 0.059)  0.036 
Values are medians (interquartile range) of nutrient units/day; *p-values from non-parametric 2 
independent samples test (Mann Whitney) 
 
 
Table 3.17 Between group comparisons of mean daily nutrient intake from oily fish* 
consumption recorded in the fish diaries 
Nutrients  21 to 38 weeks gestation 
  Control (n = 47)  Salmon ( n= 49)  p** 
EPA (mg)  0 (0, 7.6)  158.3 (152.7, 164.2) 
<0.001 
DHA (mg)  0 (0, 14)  322.2 (310.6, 333)  <0.001 
Total n-3 PUFA (mg)  0 (0, 30.7)  988.9 (950.1, 1017.1)  <0.001 
Total n-6 PUFA (mg)  0 (0, 6.1)  641.7 (608.5, 660)  <0.001 
Selenium (µg)  0 (0, 0.392)  11.94 (11.49, 12.29)  <0.001 
Vitamin D (µg)  0 (0, 0.139)  3.89 (3.74, 4)  <0.001 
Vitamin E (mg)  0 (0, 0.015)  1.14 (1.08, 1.17)  <0.001 
*Oily fish includes study salmon 
Values are medians (interquartile range) of nutrient units/day; **p-values from non-parametric 2 
independent samples test (Mann Whitney)   147 
 
Table 3.18 Between group comparisons of mean daily nutrient intake from total fish* consumption 
(fish diaries) 
Nutrients  21 to 38 weeks gestation 
  Control (n = 47)  Salmon ( n= 49)  p** 
EPA (mg)  10 (4.5, 18.3)  162 (156.4, 167.1) 
<0.001 
DHA (mg)  16.2 (7.6, 37.2)  325.8 (317.9, 339.2)  <0.001 
Total n-3 PUFA (mg)  43.4 (23.2, 98.8)  996.3 (974.4, 1035.3)  <0.001 
Total n-6 PUFA (mg)  60.3 (16.4, 106.9)  660 (641.7, 691.4)  <0.001 
Total fish EPA+DHA (mg)  24.4 (12.7, 56.7)  490.9 (474.6, 506.2)  <0.001 
Selenium (µg)  4.33 (1.51, 6.96)  13.49 (12.27, 15.73)  <0.001 
Vitamin D (µg)  0.123 (0.047, 0.311)  3.9 (3.8, 4.1)  <0.001 
Vitamin E (mg)  0.069 (0.023, 0.130)  1.158 (1.13, 1.194)  <0.001 
*Total fish includes non-oily fish, oily fish (and study salmon), fish fingers and fish dishes, shellfish. Values 
are medians (interquartile range) of nutrient units/day; **p-values from non-parametric 2 independent 




Figure 3.7 Weekly consumption of study salmon in the salmon group for every week of pregnancy 
 
 
Figure 3.8 Mean weekly consumption of study salmon during the period 21-38 weeks gestation 
p < 0.001 between groups (Mann Whitney)   148 
 
Figure 3.9 Salmon group compliance to consuming ≥ 2 portions of study salmon per week 
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Figure 3.10 Weekly consumption of a) oily, b) non-oily, and c) total fish, for every week of pregnancy 
 
Figure 3.11 Mean daily intake of a) EPA, b) DHA, c) EPA plus DHA, from total fish, during the period 21-38 weeks gestation 
All p < 0.001 between groups (Mann Whitney) 
a  b  c 
a  b  c   150 
 
Figure 3.12 Daily intake of EPA plus DHA from total fish, for every week of pregnancy   151 
3.4  Discussion  
SIPS is the first dietary intervention with fish in pregnant women. The primary reason for 
FFQ administration was to determine fish and fish nutrient intake before and during the 
study,  so  as  to  examine  the  hypotheses  that  the  salmon  intervention  will  result  in  a) 
increased  intake  of  oily  fish,  b)  increased  intake  of  specific  nutrients  (LC  n-3  PUFA, 
vitamin D, Se), c) an improved dietary pattern, and d) a sustained change in diet beyond 
the end of pregnancy. The data obtained allows each of these hypotheses to be accepted. 
According  to  the  FFQ  at  34  weeks  gestation  all  subjects  (100%)  assigned  in  the 
salmon group reported having oily  fish 1-2 times per week. This result  shows that all 
volunteers in the salmon group may have complied with consuming 2 portions of salmon 
per  week,  which  falls  into  the  FFQ  category  1-2  times  per  week.  Also,  at  34  weeks 
gestation the salmon group consumed statistically significant more frequently oily fish than 
the control group (medians 1.5 and 0 times per week, for salmon and control respectively, 
p  <  0.001).  In  accordance  with  this,  the  fish  diary  results  showed  that  the  median 
consumption  frequency of  study salmon  from the salmon group was 1.94 portions per 
week. It has to be pointed out here that a limitation of the FFQ, as with most FFQ, is that it 
had an ordinal scale of distinct consumption frequency categories, rather than an interval 
scale providing a ‘true’ measure (220). The fish diaries were important in determining a 
more precise consumption frequency. Also, the use of fish diaries as a compliance measure 
was essential and can be considered as a strength of SIPS. The fish diaries showed that, 
79.6% of the volunteers in the salmon group were having 2 or more portions of study 
salmon per week for the 81.25% of intervention period (data presented cover the period 
between 21 to 38 weeks gestation). 
Also, according to the fish diaries, the salmon group consumed fewer non-oily fish 
and  fish  fingers-fish  dishes,  but  had  a  higher  overall  total  fish  consumption  during 
pregnancy. This does not totally agree with the FFQ results which showed that during 
intervention (34 weeks) the two groups did not differ in non-oily fish and fish fingers/ fish 
dishes consumption frequencies. The difference in the two methods of assessing fish intake 
may be again attributed to the limitation of the FFQ to identify small differences because 
of the distinct consumption frequency categories. 
However, at the same time, the use of this specific FFQ in the current study was a 
strength  as  it  has  been  validated  for  use  in  pregnant  women  in  Southampton (219),  it 
reflected a long term period (presiding 3 months), and it included distinct fish categories.   152 
Although FFQ are designed for larger populations, they have the advantage of being cheap 
to administer and also of having the ability to summarise data over a long period of time 
and so to describe habitual diet (229). Epidemiological studies investigating the effect of 
maternal fish intake during pregnancy on atopic outcomes in the offspring have also used 
FFQ as a method for determining intake of different types of fish (154-159). These studies 
are reviewed in section 1.5 and summarised on Table 1.5 (103). Prospective, open-ended 
dietary  methods  such  as  food  diaries  are  demanding  to  fill  in.  Food  diaries,  when 
completed by motivated volunteers may provide a good source of information. However, 
in the general population, food diaries are poorly kept (12). In SIPS, the combination of the 
FFQ with the fish diary is considered as a strength.  
Also  it  is  worth  mentioning  that  FFQ  may  be  limited  in  determining  nutrients 
accurately  enough to investigate  nutrient-disease associations (230, 231). However, the 
FFQ used in this study has been validated for calculating nutrients. Crozier et al. (214) 
compared the SWS FFQ dietary pattern data with a 4 day prospective food diary, and 
concluded  that  FFQ  data  provide  useful  information  on  dietary  patterns  in  large 
populations. According to a sub-analysis of the SWS cohort (219), median maternal intake 
of  energy  during  early  pregnancy  was  2329  Kcal/day  and  during  late  pregnancy  2314 
Kcal/day. Median intake of total fat was 91.2 g/day during early pregnancy and 93.2 g/day 
during late pregnancy. These figures, as well as those for the rest of the nutrients presented 
by Godfrey et al. (219), are very close to the ones calculated here for the SIPS volunteers, 
showing that the FFQ was a reliable tool to estimate nutrient intake although the study 
group had a small size. Also, these similarities along with the fact that (as discussed in the 
methods of this chapter) SIPS correlation coefficients from PCA correlated very well with 
the SWS coefficients shows that, apart from the SIPS subjects having a low intake of oily 
fish and being atopic, they are very similar to the average Southampton population and 
representative of that.  
The FFQ data at 34 weeks gestation showed that, during intervention, the intake of 
EPA, DHA, and EPA plus DHA from oily fish (including study salmon) and from total 
fish was higher for the salmon group compared to control (all p < 0.001). The median daily 
intake of LC n-3 PUFA from total fish for the salmon group during intervention was 133.3 
mg EPA, 267.2 mg DHA, and 402.6 mg EPA plus DHA, whereas for the control group it 
was 11.9 mg EPA, 19.7 mg DHA, and 30.1 mg EPA plus DHA, according to FFQ fish 
consumption frequencies at 34 weeks. On the other hand, the results from fish diaries gave 
slightly  higher  values  of  intake  for  the  salmon  group  and  lower  for  the  control. 
Specifically, the median daily intake of the fatty acids of interest from total fish was 162   153 
mg EPA, 325.8 mg DHA, and 490.9 mg EPA plus DHA for the salmon group, and 10 mg 
EPA, 16.2 mg DHA and 24.4 mg EPA plus DHA for the control group, during intervention 
(all p < 0.001). This intake covers the recommendation for minimum intake of EPA plus 
DHA during pregnancy (108% of 450 mg/day). Also, DHA intake in the salmon group 
covered more than the minimum recommended intake for DHA (200 mg/day) (19). 
This  difference  in  intakes  calculated  by  the  two  different  methods  of  fish  intake 
assessment is associated with the FFQ limitation in calculating nutrients because of its 
distinct consumption frequency categories. Consumption of salmon twice per week was 
recorded as consumption 1-2 times per week, and was interpreted as 1.5 times per week for 
calculations. Also, a limitation of this specific FFQ is that it has not been validated to 
calculate total diet EPA and DHA. However, the main sources of EPA and DHA are fish 
and  fish  oil  supplements  or  functional  foods.  The  FFQ  indicated  that  no  subject  was 
consuming  fish oil  containing  supplements during pregnancy.  Also, only  a  minority of 
subjects consumed fish oil containing functional foods and this did not differ significantly 
between the two groups. When calculating ‘total diet’ EPA and DHA intake (Table 3.10), 
fish  oil  contained  in  functional  products  was  taken  into  account  and  no  substantial 
differences  with EPA and DHA  intake  from total  fish were observed. Thus,  it can  be 
suggested that intake of EPA and DHA from total fish would be a very good estimate of 
total  intake  of  these  LC  n-3  PUFA  from  the  whole  diet.  The  use  of  FFQ  to  assess 
micronutrient  intake  and  especially  LC  n-3  PUFA  has  been  validated  in  studies  on 
pregnant (232, 233) and  non-pregnant subjects (234, 235) and  has also  been reviewed 
(236). These studies support that the intake of EPA and DHA can be adequately estimated 
by FFQ.  
An advantage of the fish diaries as opposed to the FFQ, is that they provided exact 
information  of  the  quantity  and  types  of  fish  consumed,  and  therefore  consumption 
frequencies were not distinct categories but a ‘true’ measure. Also, volunteers filled in the 
diaries on a daily bases and so the recall bias associated with the FFQ was minimised. 
However, a disadvantage of the fish diaries is that they have not been validated. Also, fish 
diaries may have been subject to over or under reporting, as with any other dietary record 
method, especially when filled in for such a long period of time (12). Finally, the fish 
diaries were filled in only by a subset of subjects and not by the whole study group. 
The use of a FFQ allowed the investigation of other changes that may have occurred 
in the dietary pattern of the subjects associated with the intervention. However, a too long 
FFQ may be a limitation especially when conducting larger studies. Crozier et al. (237)   154 
showed that a 20-item FFQ based on the foods that characterise the SWS ‘prudent’ diet 
pattern  can  be  used  as  an  alternative  tool  to  summarise  the  diets  of  young  women  in 
Southampton. Also, the 20-item ‘prudent’ diet score was correlated with red blood cell 
folate similarly to the 100-item SWS FFQ score. The use of a shorter FFQ may be helpful 
when there is interest in only one aspect of the diet, such as vitamin D and calcium or fat 
(237), or fish intake and LC n-3 PUFA. Generally, a shorter FFQ, especially designed to 
determine consumption of food rich in the nutrients that are of interest can be less time 
consuming and equally efficient.  
There  have  been  no  studies  of  fish  intervention  during  pregnancy.  However  the 
current study may be compared to other studies which investigated the effect of increased 
fish  consumption  on  different  health  outcomes  and  in  different  populations  (238-241). 
Unlike  the  current  study,  these  studies  used  food  diaries  as  a  method  for  measuring 
compliance and dietary intake. Specifically, the study of Pot et al. (241, 242) investigated 
the effects of increased fish consumption on colorectal cancer markers. The intervention 
period was 6 months, and volunteers were randomly allocated to receive dietary advice 
plus either two portions per  week of oily  fish (salmon) (n=82), or non-oily  fish (cod) 
(n=78), or just dietary advice (n=82). According to the article, salmon and cod provided 
1.4 and 0.09 g of LC n-3 PUFA per day, respectively. Volunteer compliance was checked 
by  food  diaries  and  by  regular  phone  calls  every  2-4  weeks.  Before  the  start  of  the 
intervention  fish  consumption  was  on  average  1.5  times  per  week.  Fish  consumption 
increased by 1.4 times per week for the salmon group and 1.3 times per week for the cod 
group. The study of Din et al. (238) examined the effect of increased oily fish on platelet-
monocyte aggregation. Fourteen volunteers were asked to consume 500 g of mackerel per 
week for 4 weeks (providing the equivalent of approximately 1 g of EPA plus DHA per 
day). The control arm did not receive a dietary intervention. Subjects were asked to keep a 
3-day weighed food diary at baseline, during intervention, and after intervention. The study 
of Vidgren et al. (243) included dietary fish and fish oil intervention in a university setting. 
Subjects were asked to consume 5 portions of fish per week and diet was assessed with a 
4-day record at baseline and three 4-day records during intervention. Also, the records of 
the University restaurant were used to identify types of fish consumed. In the dietary fish 
group intake of EPA was 380 mg/day and of DHA 670 mg/day.  
Borland et al. (215) reported a median intake of total fish and shellfish of 1.5 times 
per week and 1.8 times per week for two measures made two years apart in young women 
in Southampton. The more recently published SWS data (218) reported a median intake of 
total  fish  and  shellfish  of  1.8  and  1.9  times  per  week  for  early  and  late  pregnancy   155 
respectively. These figures represent median intakes in the general Southampton female 
population which is very close to the consumption of total fish and shellfish of the salmon 
group at baseline (before intervention 1.75 times/week). However, the control group had a 
much lower level of consumption (0.75 times/week). Subjects were recruited in SIPS on 
the basis of low self reported oily fish intake. 
The baseline difference in intakes of fish and nutrients from fish between the two 
SIPS groups, despite the fact that subjects were randomly assigned to the two arms, is a 
limitation of the current study. The proportion of women with a baseline intake of 0.5 
times  of  oily  fish  per  week  (i.e.  volunteers  who  just  about  fulfilled  the  criterion  of  2 
portions per  month  maximum) was 34%  for the salmon group and 8%  for the control 
group. However, the increase in oily fish consumption observed in the salmon group was 
1.21 times per week from 20 to 34 weeks gestation, whereas the oily fish consumption in 
the control group remained almost unchanged (decreased by 0.04 times per week) (p < 
0.001). Also, the mean daily intake of EPA plus DHA from total fish was increased by 
269.3 mg for the salmon group and for the control group it remained almost unchanged 
(slight decreased by 12.2 mg) between before and during intervention (p < 0.001).  
A strength of the current study is that it explored the intake of different types of fats 
and oils. The reason why this was explored was because of the particular interest of the 
study in the effect of dietary intake of LC n-3 PUFA on maternal fatty acid status and 
immunity. It was essential to make sure that the two groups were not different in terms of 
intake of different sources of fat, and thus other fatty acids apart from the ones coming 
from the study salmon. Moreover, it was important to investigate the intake of functional 
foods with added LC n-3 PUFA, as well as the intake of prebiotic and probiotic products 
which  have  been  associated  with  effects  on the  immune  system (244).  There  were  no 
differences in intake of these products between the groups. 
An issue of interest, which was not primarily targeted by the intervention (at least 
initially), was its impact on the intake of nutrients other than the LC n-3 PUFA. According 
to the nutrient content of salmon, such nutrients of interest would be vitamin D, vitamin E, 
selenium, total n-3 PUFA, total n-6 PUFA. It was shown from both the fish diaries and the 
FFQ, that the salmon group had a higher intake of vitamin D, selenium, and total n-3 
PUFA from oily fish and total fish at 34 weeks gestation compared to the control group. 
More importantly, this increased intake form fish was reflected in an increased intake of 
these nutrients from total diet (estimated by FFQ). Total diet selenium intake was 58.2 
µg/day for the salmon group (97% of Reference Nutrient Intake (RNI; 60 µg/day)) and 49   156 
µg/day for the control group (82% RNI) (p = 0.005) (18). The contribution of study salmon 
to total diet  intake of selenium was 20% which  is quite  substantial. The  intake of the 
control group was very close to the average intake that has been recently reported by the 
National Diet and Nutrition Survey (NDNS) in the UK (39 µg/day) (13). It has to be noted 
that total diet selenium intake should be treated as a rough estimate, since the content of 
selenium in foods depends on soil content and data are not completely reliable (222). Total 
diet vitamin D intake was 5.75 µg/day for the salmon group (57% RNI; RNI for pregnant 
women is 10 µg/day) and 2.9 µg/day for the control group (29% RNI) (p < 0.001) (18). It is 
worth noting that the study salmon contributed to 68% of the total vitamin D intake in the 
salmon group. Total diet vitamin D intake in the control group was comparable to that 
reported by NDNS (2.7 µg/day) (13). As mentioned in the introduction, early fish and 
vitamin D exposure improves bone health in infancy and childhood (207, 208). Maternal 
vitamin D intake during pregnancy has been associated with decreased risk of sensitization 
to food allergens in the offspring (209) and evidence shows the importance of vitamin D 
and  selenium  in  reducing  risk  of  atopic  disease  development  (92,  210-213).  Also, 
according to the 34 week FFQ data, total diet vitamin B12 intake was also higher in the 
salmon group compared to the control group (p = 0.009). Din et al. who conducted an 
intervention  with  mackerel,  showed  with  dietary  records  that  the  mackerel  group  had 
higher intakes of iodine, selenium, vitamin B12, and vitamin D during intervention (238). 
The study of Vidgren  et al. (243) showed that consumption of 5  fish  meals per week 
increased  vitamin  D  intake  (9  µg/day)  according  to three  4-day  dietary  records  (243). 
These results are in agreement with the results of SIPS reported here, although nutrient 
intake  was  measured  by  FFQ.  The  study  of  Pot  et  al.  (241,  242),  mentioned  earlier, 
involved  intervention  in  non-pregnant women with oily  fish (salmon), or non-oily  fish 
(cod), or just dietary advice. It was shown that serum selenium and vitamin D were not 
significantly increased in the fish consumption groups compared to control (241). This 
may be due to the content of selenium and vitamin D in the fish provided by that study, or 
also by the intake of these nutrients from other sources and sun exposure. In SIPS, it would 
be expected that the blood levels of selenium and vitamin D would be higher in the salmon 
group compared to the control group based on the fact that intake was significantly and 
substantially higher. Finally, vitamin E and total n-6 PUFA intake from oily and total fish 
at 34 weeks gestation were significantly  higher  for the salmon group compared to the 
control group (reflected by FFQ and fish diaries). However, the contribution of fish to the 
intake of these nutrients from total diet was small and it did not result in a significant 
increase in the intake of these nutrients (vitamin E and total n-6 PUFA) from total diet 
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An interesting question to be addressed, through the dietary information available in 
SIPS, was whether the salmon intervention resulted in changes of dietary patterns during 
the  intervention.  During  the  intervention,  according  to  the  findings  of  the  34  weeks 
gestation FFQ, the salmon group had a statistically significant lower intake of red meat 
compared  to  the  control  group.  Also,  within  the  salmon  group,  chicken  intake  was 
significantly reduced from 20 to 34 weeks gestation, and so was the intake of non-oily fish. 
Also, fish diaries showed lower intake of non-oily fish and fish dishes in the salmon group 
compared to the control group during intervention. Total meat consumption was decreased 
significantly from 20 to 34 weeks gestation within the salmon group. As a result of the 
above,  it can  be speculated that increased salmon consumption was  compensated  by  a 
decreased  consumption  of  other  fish  (non-oily  fish  and  fish  dishes  according  to  fish 
diaries) and also by a decrease in red meat, chicken, and total meat intake. In contrast to 
our findings, the fish intervention of Pot et al. (241, 242) found that dietary habits other 
than fish consumption did not change in any of the intervention groups and specifically 
that  meat  consumption  remained  constant.  It  is  difficult  to  explain  how  fish  could  be 
incorporated into the diet of the subjects in the study of Pot et al., without a reduction in 
intake of some other component such as red meat or chicken. This may be related to the 
use of food diaries that do not reflect long periods of time and such a change in dietary 
patterns cannot be observed. 
The PCA results described showed that the salmon group had a statistically significant 
higher ‘prudent’ diet z-score than the control group, indicating a ‘healthier’ dietary pattern 
for the salmon group, at baseline and at 34 weeks gestation. The higher ‘prudent’ diet 
scores in the salmon group, reflecting ‘healthier’ dietary patterns, are in accordance with 
the higher fish consumption both at baseline and at 34 weeks. The higher scores might be a 
true reflection of the group’s diet, however it could be attributed to misreporting from the 
volunteers of the salmon group as their answers might have been affected by the fact that 
they were ‘chosen’ to take part in the study, and allocated to the salmon group. On the 
other hand, it may be considered that volunteers in the salmon group made an effort to eat 
more healthily as they were aware of the fact that they were taking part in a nutrition 
intervention, and they belonged to the salmon group. Many volunteers reported verbally 
during  appointments  that  they  were  trying  to  combine  salmon  with  ‘healthier’  dietary 
choices, such as cooking it with vegetables, and generally taking care of their diet in total, 
as they realised that this would be good for themselves and the baby. At 3 months post-
partum,  the  mean  ‘prudent’  diet  z-score  did  not  differ  significantly  between  the  two 
groups. The lower ‘prudent’ diet scores for the salmon group after intervention may be   158 
associated with them not taking such care of their diet at the same level as they did during 
pregnancy, or it may be as a result of more realistic reporting compared to before and 
during intervention. 
The information from the 3 month post-partum FFQ was used to investigate whether 
the intervention had an impact on fish consumption habits after its end. The salmon group 
had a higher oily and non-oily fish consumption after intervention than the control group. 
Interestingly, at 3 months post-partum 17% of the salmon group continued having oily fish 
more or equal to 1.5 times per week (i.e. ≥ 1-2 times per week) compared to 0% before 
intervention.  However,  there  were  no  statistically  significant  differences  between  the 
groups in fish categories and total fish consumption frequency changes between 3 months 
post-partum and baseline (20 weeks). This may suggest that, although the study salmon 
provision during pregnancy increased oily fish intake during intervention (because of the 
salmon consumed), there was a sustained effect beyond the intervention period for only for 
a small number of volunteers. However, for the majority of the volunteers this increase was 
not sustained after the end of the intervention, as volunteers returned to their habitually low 
intake of oily fish (65% at 20 weeks gestation and 60% at 3 months post-partum had oily 
fish 0-0.25 times per week). Similarly, the fish intervention study of Din et al. showed that 
the nutrient  intake differences observed during the study (higher iodine, selenium, vitamin 
B12, vitamin D) due to the intervention were not sustained after the end of the intervention 
(238). Borland et al. (215) examined the stability of dietary patterns in young women over 
a 2-year period. The study was performed on a subgroup of the SWS and it was concluded 
that dietary patterns were reasonably stable. This may explain the difficulty in changing 
dietary patterns and why high oily fish intake was not sustained after the end of SIPS 
intervention for the majority of the subjects in the salmon group. 
A typical nutrition supplement containing fish oil for pregnant women contains 60 mg 
EPA, 300 mg DHA, 30 µg selenium, and 10 µg vitamin D in a daily dose. According to the 
findings of the fish diaries, consumption of two portions of study salmon per week (oily 
fish data  including  study  salmon) provided 158.3  mg EPA, 322.2  mg DHA, 11.94 µg 
selenium,  and  3.89  µg  vitamin  D  per  day.  This  would  mean  that  consumption  of  two 
portions of oily fish per week would cover approximately 40% of the amount of vitamin D 
and selenium, 260% of the amount of EPA, 106% of the DHA, and 133% of total EPA 
plus  DHA  provided  from  a  pregnancy  supplement.  This  is  the  first  study  in  pregnant 
women  to  provide  this  information,  supporting  the  importance  of  oily  fish  during 
pregnancy  as  they  can  be  an  excellent  source  of  a  combination  of  nutrients.  This,  in 
relation to the fact that increased oily fish consumption resulted in lower meat intake, can   159 
provide strong evidence in order to support public health messages and interventions that 
target increased consumption of oily fish (at least two portions) instead of the use of fish 
oil supplements during pregnancy. Of course all considerations about limiting contaminant 
intake during pregnancy should be taken into account when choosing the source of fish. 
 
3.5  Summary and conclusions 
In conclusion, SIPS successfully increased oily fish intake in the salmon group to the target 
of 2 portions of study salmon per week. This was reflected by FFQ (all volunteers reported 
intake  1-2  times  per  week  during  intervention  at  34  weeks  gestation)  and  fish  diaries 
(median  intake of study salmon  was 1.94 portions per week). Both dietary assessment 
methods reported a median oily fish intake of the control group of 0 portions per week. 
According to FFQ, median daily intake of EPA plus DHA was 403 mg for the salmon 
group and 30 mg for the control group (p < 0.001). The fish diary results showed similar 
levels of intake (490 mg for the salmon group and 24 mg for the control group) (p < 
0.001). Moreover, it was shown that increased salmon consumption increased total diet 
intake of selenium, vitamin D, and total n-3 PUFA. Consumption of two portions of oily 
fish per week would provide more than the minimum recommended intake of DHA and of 
EPA plus DHA, 60% of the recommended intake of vitamin D, 20% of the recommended 
intake of selenium. Furthermore, consumption of two portions of oily fish per week would 
cover approximately 40% of the amount of vitamin D and selenium, 260% of the amount 
of EPA, 106% of the DHA, and 133% of total EPA plus DHA provided  by a typical 
pregnancy supplement. Increased salmon consumption was compensated by a decreased 
consumption of other fish (non-oily fish and fish dishes) and also by a decrease in red 
meat,  chicken,  and  total  meat  intake.  These  results  further  support  the  public  health 
messages  and  interventions  that  aim  to  increase  oily  fish  consumption  to  at  least  two 
portions of oily fish per week during pregnancy. Finally, the SIPS intervention resulted in a 
sustained increased oily fish consumption after the end of the intervention only for a small 
number of volunteers in the salmon group. The majority of volunteers returned to their 
habitually low intake of oily fish. Factors associated with long-term sustainable increase of 
oily fish consumption by women of reproductive age but also for the general population 
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4.1  Introduction 
Apart from being important as energy sources to the body, fatty acids are associated with 
structural  and  metabolic  functions  which  primarily  involve  polyunsaturated  fatty  acids 
(PUFA) (245). The human body does not have the ability to synthesise the simplest PUFA 
with double bonds three (n-3 PUFA) or six (n-6 PUFA) carbon atoms from the methyl 
terminus  of  the  hydrocarbon  chain  (see  section  1.1).  These  fatty  acids  -  linoleic  acid 
(18:2n-6) and α-linolenic acid (18:3n-3) - must be obtained from the diet and thus they are 
termed essential fatty acids. Their metabolic derivatives arachidonic acid (ARA; 20:4n-6), 
eicosapentaenoic  acid  (EPA;  20:5n-3),  and  docosahexaenoic  acid  (DHA;  22:6n-3)  are 
functionally very important. These fatty acids may be termed long chain (LC) n-3 and n-6 
PUFA, and they are conditionally essential. Fatty acids are required by the developing 
foetus  in  order  to  maintain  fluidity  and  structure  of  membranes,  as  well  as  to  act  as 
precursors of eicosanoids (prostaglandins, leukotrienes, thromboxanes) (245). LC PUFA 
(especially DHA and ARA) are important for foetal growth and development (246, 246-
248) and they  influence   length of gestation (249). Perhaps  most importantly, DHA  is 
accumulated in high concentration in the membranes of cells of the nervous and visual 
system (i.e. in foetal brain and in foetal retina) during pregnancy, and this accumulation is 
very important for visual and cognitive development both before and after birth (250). 
High amounts of DHA are incorporated into membranes in the brain and retina especially 
during the last trimester of pregnancy when foetal nervous system growth is very rapid 
(248). Total foetal DHA accretion in utero is approximately 10 g and it takes place mainly 
in the last 10 weeks of pregnancy, and it has been estimated that foetal accrual of DHA 
occurs at a rate of about 200 mg/day in late pregnancy, and such accrual continues after 
birth (Figure 4.1) (245). Most of the DHA is stored in foetal adipose tissue in utero (50 
times more than in foetal brain) in order to be released after birth and utilised for growth 
(245). Obviously fatty acids including ARA and DHA are provided to the foetus from the 
mother via the placenta. There is a specific mechanism of uptake of these LC PUFA across 
the placenta (245). It is known that preterm birth, which curtails maternal supply of DHA 
to the foetus, is associated with sub-optimal neural and visual development (251), which 
can be improved by providing exogenous DHA (252-254). LC n-3 PUFA have also been 
shown to influence immune function (7, 38, 94) and it is now considered that supply of 
EPA  and  DHA  to  the  foetus  might  be  important  in  promoting  appropriate  immune 
development (47, 87, 88, 93). However this has been little studied in intervention studies, 
and those studies that have been conducted have been in the context of influencing immune 
development in a way that would reduce risk of allergy in the infant (22, 178, 182, 183,   162 
186,  188).  Thus,  studies  have  demonstrated  that  maternal  fish  intake  or  fish  oil 
supplementation during pregnancy has a protective effect against allergy, asthma and atopy 
in the offspring (see section 1.5, (103)).  
 
Figure 4.1 Docosahexaenoic acid (DHA) oxidation in the mother and accretion in the foetal brain, 
adipose tissue, lean tissues, and placenta 
Figure taken from Haggarty (245). The DHA content of the foetal lean tissue and organs was assumed to be 
the same as the placenta. The rate of accretion in the brain and placenta is very small relative to other 
components. The right y axis shows the reported daily dietary intake of DHA in different groups. 
Fatty acids of chain length of about 8 carbons or more, including LC n-3 and n-6 
PUFA, are insoluble in plasma as they are highly hydrophobic. In order to allow their 
transport in the bloodstream they are esterified to form more complex lipid forms including 
triglycerides (TAG), phospholipids, and cholesteryl esters (CE) and these are assembled 
along with proteins into large, soluble structures termed lipoproteins. In TAG, three fatty 
acids are bound, each by an ester bond, to the glycerol backbone. One fatty acid bound by 
an ester bond to the fourth ring of cholesterol forms CE. In phospholipids two fatty acids 
are bound, each by an ester bond, to the sn-1 and sn-2 positions of the glycerol backbone; 
the sn-3 position is bound to a polar head group. Thus most non-cellular fatty acid in the 
bloodstream  is  within  lipoproteins  in  the  form  of  TAG,  phospholipids  and  CE;  the 
principal phospholipid in human plasma is phosphatidylcholine (PC). TAG, PC and CE 
represent transport pools of fatty acids typically carrying fatty acids from the gut or liver to 
peripheral tissues and back. PC is also a major component of cell membranes along with 
other phospholipids. The fatty acid composition of plasma PC is similar to that of cell 
membrane PC. Thus the fatty acid composition of plasma PC can also be taken to reflect 
that of a functional fatty acid pool, i.e. cell membrane phospholipids, although this is of   163 
course only an approximation. Fatty acids are also present in plasma in non-esterified form 
(termed  non-esterified  fatty  acids  (NEFA))  bound  non-covalently  to  albumin.  The 
composition of fasting plasma NEFA reflects adipose tissue fatty acids (245, 255) released 
during hydrolysis of TAG in adipose tissue.  
During  pregnancy  there  are  two  principal  metabolic  stages.  During  the  first  two 
trimesters foetal growth is limited and the mother accumulates nutrients and energy in her 
body  stores. The  last trimester  is characterised  by a catabolic phase whereby  maternal 
adipose  tissue  lipolysis  releases  fatty  acids  to  the  maternal  circulation  which  will  be 
transferred  to  the  foetus  through  the  placenta  (256).  Maternal  NEFA  released  from 
lipolysis are mainly re-esterified into TAG in the liver, and these are released into the 
circulation in the form of very low density lipoprotein (VLDL). There is an increase in 
plasma  TAG  concentration  during  late  gestation  and  this  is  termed  hyperlipidemia  of 
pregnancy  (256).  Also,  during  late  pregnancy  levels  of  TAG  increase  in  low  density 
lipoproteins  (LDL)  and  high  density  lipoproteins  (HDL)  probably  associated  with 
increased  activity  of  the  cholesteryl  ester  transfer  protein  (CETP)  (257).  This  enzyme 
controls  TAG  and  CE  exchange  between  VLDL,  LDL,  and  HDL.  Maternal 
hypertriglyceridemia is considered to be beneficial for the foetus, as it may enhance the 
availability of  important fatty acids  from the  mother. During  late pregnancy,  intestinal 
absorption of TAG is very efficient and TAG are carried in the form of chylomicrons in 
maternal plasma (255).  
The function of the placenta and many physiological and metabolic adaptations taking 
place during pregnancy play a fundamental role in optimising the transport of fatty acids to 
the foetus (245). Complex mechanisms are involved in placental fatty acid transport (247). 
Lipoproteins  can  be  taken-up  by  the  placenta  by  lipoprotein  receptors  existing  on  the 
placenta.  Also,  because  of  the  expression  of  lipoprotein  lipases  (LPL)  on  placenta, 
maternal TAG can by hydrolysed and the NEFA released can by taken up by the placenta, 
which can  be re-esterified  and stored and then  hydrolysed and released  into the  foetal 
bloodstream (256). Transport of LC PUFA to the placenta is mainly done by uptake of 
maternal TAG intact in plasma lipoproteins (see Figure 4.2 taken from Herrera (258)). This 
is greater than uptake of NEFA from placenta.   164 
 
Figure 4.2 Lipid metabolism during pregnancy and placental lipid transfer 
Figure taken from Herrera (258). LPL, lipoprotein lipase(s); HDL, high density lipoprotein(s); VLDL, very 
low density lipoprotein(s); LDL, low density lipoprotein(s); TG, triglyceride(s); EC, esterified cholesterol; 
EFA, essential fatty acid(s); LC-PUFA, long-chain polyunsaturated fatty acid(s); CETP, cholesteryl ester 
transfer protein(s) 
However, maternal plasma NEFA are also a source of LC PUFA for the foetus (257). 
Thus,  fatty  acids  to  be  transported  by  the  placenta  are  derived  mainly  from  TAG  in 
chylomicrons  or  VLDL,  from  which  they  are  released  by  TAG  hydrolase/LPL  before 
entering the placenta. The placenta uptake of circulating TAG is concentration gradient 
dependent. Also, as mentioned above, maternal NEFA bound to albumin or lipoproteins 
bound  to  apoprotein  receptors  are  sources  of  fatty  acids  for  the  placenta  (248).  The 
demands  for  cholesterol  by  the  foetus  are  relatively  high,  especially  during  the  last 
trimester of gestation. In the early stages of gestation, maternal cholesterol substantially 
contributes to foetal cholesterol, whereas later on the foetus seems to have the ability to 
synthesise  cholesterol  especially  in  liver  and  brain  (256).  The  presence  of  lipoprotein 
receptors in placenta, enables the placenta to take up fatty acids in the form of CE from 
maternal lipoproteins, but the maternal contribution to the foetal plasma cholesterol pool 
seems to be very small (259). Fatty acids present in phospholipids (e.g. PC) in lipoproteins 
may also be hydrolysed, taken up and resynthesised as TAG or PC in placenta (248). 
The presence of membrane fatty acid binding protein in human placenta results in 
preferential transfer of certain fatty acids to the foetus. There is preferential transfer of LC 
PUFA, mainly DHA, as opposed to the essential fatty acid precursors (247, 248). Because 
the placenta lacks Δ6- and Δ5-desaturase activity for the conversion of essential fatty acids 
(linoleic and α-linolenic) to LC PUFA and foetal enzyme activity in utero is very low, the   165 
foetus depends on placental LC PUFA transfer (245, 248). Accretion of LC PUFA in utero 
results in higher concentration of DHA and ARA in the foetal adipose tissue compared to 
maternal (Figure 4.3) (245).  
 
Figure 4.3 Arachidonic acid (AA) and docosahexaenoic acid (DHA) as a proportion of total fatty acids 
in the mother and foetus  
Figure taken from Haggarty (245). Data are shown for the diet of pregnant mothers, the adipose tissue, 
maternal and cord blood plasma phospholipids (PL), triglyceride (TG), cholesteryl ester (CE) and NEFA, the 
placental microvillous and basal membranes, and adipose tissue and brain at birth. 
De  Vriese  et  al.  (260)  showed  that  maternal  and  cord  plasma  at  delivery  had  a 
different CE and PC fatty acid profile, with umbilical  cord plasma exhibiting a higher 
concentration of ARA and DHA, indicating a preferential supply to the foetus with the LC 
PUFA needed for development. In the study of Berghaus et al. (261) higher proportions of 
DHA  and  ARA  were  found  in  cord  plasma  in  almost  all  lipid  fractions  compared  to 
maternal plasma, indicating the selective mobilisation through placenta and accretion of 
these from the mother to the foetus. Burdge et al. (262) showed enrichment of 18:3n-3 in 
plasma  TAG  and  of  DHA  in  plasma  PC  in  pregnant  women,  which  reflects  hepatic 
regulation of n-3 PUFA metabolism during pregnancy and may act to enhance the delivery 
of DHA to the placenta. Min et al. (263) showed that pregnancy  is  associated with a 
decline  in  percentage  levels  of  ARA  and  DHA  in  maternal  plasma  TAG,  which  may 
indicate the selective transfer of these fatty acids to the foetus. 
Houwelingen et al. (264) found that maternal plasma PC fatty acids expressed as a 
percentage  (i.e.  each  fatty  acid  as  a  percentage  of  total  fatty  acids)  were  highly 
significantly correlated with foetal plasma PC fatty acids. Vlaardingerbroek & Hornstra 
(265)  concluded  that  maternal  fatty  acid  percentages  at  delivery  in  red  blood  cell  and   166 
plasma PC were highly correlated with neonatal fatty acid percentages at birth. Also, De 
Vriese et al. (266) showed that  maternal plasma PC EPA and  DHA percentages  were 
positively associated with intake of these fatty acids during pregnancy. Also, EPA and total 
n-6 PUFA levels in cord plasma PC were positively correlated with maternal dietary intake 
of these fatty acids during pregnancy. Similarly, another study showed that maternal intake 
of EPA plus DHA during pregnancy (determined by FFQ) correlated significantly with 
maternal and cord LC n-3 PUFA blood levels. Also, maternal LC n-3 PUFA levels were 
associated with cord blood levels (267). Placenta fatty acid content might reflect the ability 
to supply fatty acids to the foetus, and its analysis may be a good indicator of placenta fatty 
acid transfer (247, 248). The placenta lacks the enzymes Δ5- and Δ6-desaturase needed for 
conversion of essential fatty acids to ARA, EPA and DHA. Also, the foetus has limited 
capacity to synthesise these fatty acids because of limited desaturase activity (245, 248). 
This results in the foetus being dependent on maternal supply of these fatty acids (247, 
248), and thus, maternal dietary intake of LC PUFA is related to the availability of these 
fatty acids to the foetus (245). Studies in healthy non-pregnant volunteers have shown that 
plasma concentrations of EPA and DHA can be useful biomarkers for the assessment of 
habitual dietary intake of these fatty acids (268, 269). 
The results of the most recent NDNS (2008/2009) showed that women aged 19-64 
years (including non-consumers) consume on average 7 g/day (49 g/week) coated and fried 
white fish, 15 g/day (105 g/week) other white fish, shellfish and tinned tuna, and 11 g/day 
(77 g/week) of oily fish. The same report, showed that amongst female consumers of oily 
fish (29% of women) aged 19-64 years daily consumption was 39 g/day (273 g/week or 2 
portions/week) (13). The most recent NDNS data (13) did not report on intake of LC n-3 
PUFA. However, the previous NDNS results (12) showed that mean intake of EPA plus 
DHA for adults in the UK was 244 mg/day, from fish and animal sources (12). However, 
since about 70% of the adult population do not eat oily fish, this is an overestimate of true 
average intakes which are likely to be 100 mg/day (14) or less (15). Also, according to 
NDNS (2008/2009) 2% of the population aged 19-64 years are vegetarian (13). However, 
it has been previously shown that the percentage of women in the UK who are vegetarians 
is higher than this (around 11-12%) (12). Exclusion of meat and fish can result in low 
intake  of  EPA  and  DHA  among  pregnant  vegetarian  women.  The  intake  of  DHA  in 
vegetarian pregnant women has been estimated around 10-30 mg/day (16, 17). 
There are no published intervention trials with fish during pregnancy. The Salmon in 
Pregnancy Study (SIPS) is the first randomised controlled trial with oily fish (in this case 
farmed salmon) in pregnant women. SIPS specifically focuses on pregnant women whose   167 
offspring are at high risk of developing atopic  disease, with one aim  being to identify 
whether there is an effect on atopy outcomes in the offspring. As described in Chapter 2, a 
total of 123 pregnant women were randomly assigned to either consume 2 portions of 
farmed salmon per week from week 20 of pregnancy until delivery or to continue their 
habitual diet low in oily fish (less or equal to 2 portions per month). The aim of the work 
described in this chapter is to investigate the effect of the intervention on the fatty acid 
status of the women enrolled in SIPS during pregnancy and on that of their placenta and 
umbilical  cord  tissue  at  delivery.  It  is  considered  that  the  fatty  acid  composition  of 
maternal plasma and of placenta will determine the provision of fatty acids to the foetus 
affecting  its  fatty  acid  status  and  consequently  its  developing  immune  system  in  a 
protective way though the provision of LC n-3 PUFA (and other key nutrients) from the 
study salmon. 
The primary hypotheses examined by the work described in this chapter are that: 
  increasing habitually low intake of oily fish (≤ 2 portions per month) to 2 portions 
per week during pregnancy, will increase maternal plasma lipid levels of EPA and 
DHA, and that these levels will be higher than in the control group; 
  the salmon intervention will increase maternal peripheral blood mononuclear cell 
(PBMC) levels of EPA and DHA, and that these levels will be higher than in the 
control group; 
  the salmon intervention will result in higher placenta and umbilical cord tissue EPA 
and DHA levels in the salmon group compared to the control group.    168 
4.2  Study design, materials and methods 
 
4.2.1  Study design, subjects, subject characteristics and the 
intervention 
In chapter 2 the study design, the recruiting procedure, the nature of the women recruited 
and their characteristics, and the nature of the intervention were all described in detail. One 
group of pregnant women (n = 61) did not undergo any dietary intervention and maintained 
their habitual diet which was low in oily fish. A second group of pregnant women (n = 62) 
consumed  two  portions  of  farmed  salmon  per  week  from  week  20  of  pregnancy  until 
delivery, which corresponds to the recommended oily fish intake for pregnant women in 
the UK (1-2 portions per week) (11). Full details of the salmon are given in section 2.4: 
salmon provided 1.73 g EPA plus DHA per portion (i.e. 3.46 g per week or 494 mg/day), 
which would result in intake higher than the UK minimum recommendation of 450 mg/day 
(11). Also, it has been recommended that DHA intake should be at least 200 mg/day in 
women of reproductive age (19). Subjects were seen in the fasting state at 20, 32-34 and 38 
weeks gestation and blood was drawn to enable fatty acid analysis of plasma and PBMC 
and  measurement  of  immunological  markers  (next  chapter).  At  delivery,  placenta  and 
umbilical cord tissue samples were collected and analysed for fatty acid status.  
 
4.2.2  Maternal blood collection 
Plastic  6  mL  lithium  heparin  (LH)  vacutainer  blood  bottles  were  obtained  from  NHS 
stores, Southampton General Hospital. Maternal blood collection was performed  by an 
adequately  trained  nurse  or  member  of  the  SIPS  team.  At  20,  32-34,  and  38  weeks 
gestation, blood was collected in three 6 mL LH bottles and stored at room temperature for 
further processing within 8 hours of collection.  
4.2.3  Preparation of peripheral blood plasma and mononuclear cells 
 
4.2.3.1  Materials 
Histopaque (density 1.077 g/L, containing polysucrose 5.7 g/dL, and sodium diatrizoate 
9.0 g/dL), L-glutamine (200 mM), antibiotics (penicillin, streptomycin), and crystal violet 
were  purchased  from  Sigma-Aldrich.  RPMI  culture  medium  (without  L-glutamine  and 
antibiotics) was purchased from PAA Laboratories. Acetic acid was purchased from Fisher 
Scientific. Phosphate buffered saline (PBS) tablets were purchased from Oxoid.   169 
White cell counting fluid was made as follows: 100 mL PBS, 2 mL acetic acid, 
approximately 5 g crystal violet. The solution was millipore filtered before use. 
4.2.3.2  Procedures 
Heparinised whole blood was layered onto Histopaque (ratio of blood to Histopaque: 2:1) 
and centrifuged for 15 min at 800 × g (2000 rpm, R = 18 cm) at room temperature. Plasma 
was collected from the top layer and frozen at -80˚C for later fatty acid analysis and to be 
used for culturing PBMC (see chapter 4).  
PBMC were collected from the interphase and washed once for 10 min at 450 × g 
(1500  rpm,  R  =  18  cm)  with  RPMI  medium  containing  0.75  mmol/L  glutamine  and 
antibiotics (penicillin and streptomycin). After being resuspended in 1 mL RPMI medium, 
the cells were counted with a  haemocytometer using white cell  counting  fluid (crystal 
violet). After counting total PBMC number, 2 × 10
6 cells were removed and frozen at -
80˚C for fatty acid analysis. The remaining PBMC were prepared for culturing (chapter 4).  
4.2.4  Preparation and storage of placenta and umbilical cord tissues 
4.2.4.1  Materials  
Phosphate-buffered saline (PBS) tablets were purchased from Oxoid.  
4.2.4.2  Procedures 
Instructions about how to collect the placenta and umbilical cord were given to midwives 
in  the  Princess  Anne  Hospital  and  other  local  birth  centres,  in  the  form  of  verbal 
information and laminated cards. The whole placenta and umbilical cord were collected by 
the midwife after delivery and stored at 4˚C.  
Within  48  hours  of  collection,  a  cross-sectional  placental  sample  of  full  depth, 
including both amniotic membrane and decidua (approximate size 1 cm × 1 cm × full 
depth of placenta) was taken from a position where the placenta was the thickest and close 
to umbilical cord. A 2-3 mm transverse section of the initial placental sample obtained, 
including amniotic membrane and decidua, was washed in PBS, blotted dry and stored at -
80˚C for fatty acid analysis. 
A 2-3 mm transverse section of umbilical cord from a position close to the placenta 
was taken, wrapped in aluminium foil and stored in liquid nitrogen for fatty acid analysis.   170 
4.2.5  Fatty acid analysis of plasma, peripheral blood mononuclear 
cells, and placenta and cord tissue by gas chromatography  
4.2.5.1  Materials 
Sodium  chloride  (NaCl),  butylated  hydroxytoluene  (BHT),  potassium  bicarbonate 
(KHCO3), potassium carbonate (K2CO3), heneicosanoic acid, cholesteryl heptadecanoate, 
tripentadecanoin,  and  menhaden  oil  standard  fatty  acid  methyl  ester  mix  were  all 
purchased  from  Sigma.  Dipentadecanoyl  PC  was  purchased  from  Avanti  Polar  Lipids. 
Chloroform, methanol, glacial acetic acid, hexane, ethyl acetate, toluene, sulphuric acid 
(H2SO4) were purchased from Fisher Scientific. Aminopropylsilica solid phase extraction 
(SPE) cartridges (NH2) were purchased from Varian. Institute of Human Nutrition (IHN) 
oil  standard  mix  was  an  ‘in  house’  preparation  using  Sigma  and  Nuchek  fatty  acid 
standards (see Appendix M for details of the FAME included in the IHN standard mix). 
4.2.5.2  Procedure 
Quantitative analysis of fatty acids was performed for plasma samples, and thus a known 
volume of plasma was used for analysis (0.5 mL). Moreover, internal standards of known 
concentration  and  volume  (Table  4.1)  were  added  to  plasma  samples  prior  to  lipid 
extraction. The plasma with added internal standards was reconstituted with 0.9% NaCl to 
a final volume 0.8 mL. 






















(PC)  15:0  Dipentadecanoyl 
PC  1 mg/mL  100 µL  100 µg 
Non-esterified fatty 
acids (NEFA)  21:0  Heneicosanoic 
acid  0.5 mg/mL  25 µL  12.5 µg 
Cholesteryl esters (CE)  17:0  Cholesteryl 
heptadecanoate  3 mg/mL  50µL  150 µL 
Triglycerides (TAG)  15:0  Tripentadecanoin  1 mg/mL  50µL  50 µg 
 
The whole amount of PBMC stored for fatty acid analysis (approximately 2 × 10
6 
cells) was reconstituted with 0.9% NaCl to a final volume of 0.8 mL. Placenta and cord 
tissue sections (obtained as described above) were mixed with 0.8 mL of ice cold 0.9% 
NaCl and homogenised using an Ultraturrax. Internal standards were not added to PBMC 
or tissues, as these were not analysed quantitatively.    171 
Total  lipid was extracted from  samples with chloroform:methanol (2:1;  vol/vol) 
containing butylated hydroxytoluene as antioxidant. After adding NaCl (1M), the sample 
was centrifuged and the lower non-aqueous phase was collected. The sample was dried 
under gas nitrogen at 40
ºC. 
Separation  of  lipid  classes  was  performed  for  plasma  samples  by  solid  phase 
extraction  (SPE).  An  aminopropylsilica  SPE  cartridge  was  placed  on  the  SPE  tank 
connected to a vacuum pump. The total lipid extract was dissolved in chloroform before 
applying the sample to the column. The sample was allowed to drip through under gravity 
and the remaining liquid was collected under vacuum. The column was washed twice with 
chloroform  under  vacuum.  The  washes  contained  TAG  and  CE  and  were  dried  under 
nitrogen  gas  at  40
ºC.  PC  was  eluted  by  chloroform:methanol  (60:40;  vol/vol)  under 
vacuum until dry. The washes containing PC were dried under nitrogen gas at 40
ºC. NEFA 
were  eluted  by  chloroform:methanol:glacial  acetic  acid  (100:2:2;  vol/vol/vol)  under 
vacuum  until  dry.  The  fractions  were  dried  under  nitrogen  gas  at  40
ºC.  A  new 
aminopropylsilica SPE cartridge was placed on the SPE tank, and the cartridge was washed 
four times with  hexane. The TAG and CE fraction collected  initially was dissolved  in 
hexane and was applied to the new column. The sample was allowed to drip through under 
gravity  and  the  remaining  liquid  was  collected  under  vacuum.  The  column  was  then 
washed twice with hexane under vacuum. The washes containing CE were dried under 
nitrogen  gas  at  40
ºC.  TAG  were  eluted  by  hexane:chloroform:ethyl  acetate  (100:5:5; 
vol/vol/vol) under vacuum and the fraction was dried under nitrogen gas at 40
ºC. 
The purified lipid classes of plasma or the total lipid extract of PBMC or tissues 
were  diluted  with  toluene.  Fatty  acid  methyl  esters  (FAME)  were  formed  by  adding 
methanol containing 2% (v/v) H2SO4 to the purified lipid classes (for plasma samples) or 
to the total lipid extract (for PBMC and tissues). The sample was incubated at 50˚C for 2 
hours. Neutralising solution (0.25M KHCO3, 0.5M K2CO3) and hexane were added to the 
sample.  The  sample  was  centrifuged  and  the  upper  phase  containing  the  FAME  was 
collected and then dried under nitrogen gas at 40
ºC. The sample was diluted with hexane 
and was transferred to a gas chromatography (GC) vial.  
The fatty acid composition of each sample was determined by GC in a Hewlett-
Packard  6890  gas  chromatograph  fitted  with  an  autosampler.  A  30  m  BPX-70  SGE 
capillary  column  was  used.  Helium  was  used  as  the  carrier  gas.  The  exact  running 
conditions and details of the GC program are described in Appendix N. The detector was a 
flame ionisation detector (FID). A series of standards run previously (Institute of Human   172 
Nutrition  mix  (IHN),  Menhaden  oil)  (Figure  4.4  and  Figure  4.5)  was  used  to  identify 
individual  peaks  of  FAME.  Figure  4.6-Figure  4.12  show  the  chromatogram  for  each 
plasma lipid fraction (PC, TAG, CE, NEFA), PBMC, and placenta and cord tissues. The 
software used to analyse the chromatograms was Agilent ChemStation. 
 
 





Figure 4.5 Typical GC profile of the Institute of Human Nutrition (IHN) standard mix 
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Figure 4.8 Typical GC profile for plasma CE 
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Figure 4.9 Typical GC profile for plasma NEFA 
 
 
Figure 4.10 Typical GC profile for PBMC total lipids 
 
 
Figure 4.11 Typical GC profile for placenta tissue total lipids   175 
 
Figure 4.12 Typical GC profile for cord tissue total lipids 
 
4.2.5.3  Fatty acid identification and quantification principles 
Qualitative analysis: Each sample run on the GC results in a chromatogram where fatty 
acids (actually FAME) appear as individual peaks as shown in Figure 4.6 to Figure 4.12. 
Each peak is characteristic and unique for each fatty acid and it appears according to the 
order that each of the FAME is detected by the FID of the GC. The time that each peak of 
fatty acid appears on the chromatogram is equal to the time that each fatty acid is retained 
inside the column of the GC until it gets carried by helium to the detector, it is called 
‘retention time’ and it is characteristic for each fatty acid. Typically, FAME with shorter 
chains and fewer or no double bonds have a shorter retention time than fatty acids with 
longer  hydrocarbon  chains  and  more  double  bonds,  and  thus  they  appear  first  on  a 
chromatogram. This is attributed to the physical properties of the fatty acids according to 
their structure. The identification of the specific fatty acid is done by comparison of the 
retention times of FAME within a known standard mix of fatty acids (IHN and Menhaden 
oil) with those of FAME in the sample. After the identification of the fatty acid, the area 
under each peak is calculated and the proportion of each peak area to the sum of all peak 
areas identified is calculated. This proportion represents the percentage of the fatty acid in 
the total fatty acids in the sample analysed: total lipids (for PBMC and tissues) or each 
lipid class (PC, TAG, CE, NEFA for plasma). 
Quantitative analysis: Internal standards added to the sample at the beginning of the lipid 
extraction (see Table 4.1 for plasma internal standards) allow for determination of absolute 
concentrations of each fatty acid in the chromatogram. The area under the internal standard 
peak  refers  to  the  known  amount  of  standard  fatty  acid  added  to  the  sample.  This   176 
information along with the known initial amount of sample used in analysis allows for 
calculations of the absolute concentration of each fatty acid in the sample. 
4.2.6  Statistical analysis 
All  data  from  fatty  acid  analysis  presented  here  were  normally  distributed  and  thus 
parametric statistical tests were used. The independent samples t-test was used for between 
group comparisons at each of the three time points of measurement (20, 34, 38 weeks 
gestation) and for placenta and cord tissue. The 3-repeated measures analysis of variance 
(ANOVA) was used as generalised linear modelling to examine overtime changes during 
pregnancy in relation to the intervention. The 3-repeated measures ANOVA was also used 
to produce p for trend over time within each group. Pearson’s correlation coefficient (r) 
was used to correlate maternal PC and PBMC fatty acid composition. A p-value of 0.05 
was considered statistically significant for all tests.   177 
4.3  Results 
4.3.1  Fatty acid composition of lipid classes in maternal plasma 
during pregnancy 
4.3.1.1  Fatty acid composition of plasma phospholipids (PC) 
Table  4.2  describes  the  maternal  plasma  PC  fatty  acid  composition  expressed  as 
percentages (%) of each fatty acid, for the two groups during pregnancy (20, 34, and 38 
weeks gestation). Repeated measures ANOVA identified significant effects of time on the 
percentages of a number of fatty acids and significant effects of group (i.e. salmon vs. 
control) on the percentages of trans oleic acid (18:1n-9), α-linolenic acid (18:3n-3), EPA, 
DPA, DHA, total n-3 PUFA, dihomo-γ-linolenic acid (DGLA; 20:3n-6), ARA and total n-
6 PUFA. There were significant time x group interactions for EPA, DHA, total n-3 PUFA, 
DGLA, ARA and total n-6 PUFA. These were explored further by pair-wise comparisons 
between groups at each time point. At 20 weeks gestation (baseline, before intervention) 
the  two  groups  differed  significantly  in  LC  n-3  PUFA  content: the  salmon  group  had 
significantly  higher  percentages  of  EPA,  DHA,  and  total  n-3  PUFA  compared  to  the 
control group. Also, the salmon group had lower ARA percentages at baseline compared to 
the control group. At 34 and 38 weeks gestation (during intervention) the salmon group 
continued to exhibit significantly higher percentages of EPA, DHA and total n-3 PUFA 
(and also DPA), and lower percentages of ARA (and also DGLA and total n-6 PUFA). The 
percentages of EPA, DHA, and total n-3 PUFA decreased during pregnancy in the control 
group (p for trend = 0.029, 0.008, 0.002), whereas they increased in the salmon group (all p 
for trend < 0.001) (Figure 4.13). The changes in % EPA and DHA in plasma PC were 
significantly different between groups (p < 0.001 for both) (Table 4.3). Also, plasma PC % 
ARA decreased significantly in both groups (both p for trend < 0.001), but the decrease 
was greater in the salmon group (Table 4.3). The decrease in total % n-6 PUFA was greater 
in the salmon group compared to the control group. 
Table 4.4 describes the absolute concentrations (µg/mL plasma) of plasma PC fatty 
acids for both groups during pregnancy. Repeated measures ANOVA identified significant 
effects of time on the concentrations of all fatty acids detected in PC and in total plasma 
PC  fatty  acid.  There  were  significant  effects  of  group  (i.e.  salmon  vs.  control)  on the 
concentrations of EPA, DPA, DHA, and total n-3 PUFA, but not on any other fatty acid. 
There were significant time x group interactions for EPA and DGLA only. These were 
explored further by pair-wise comparisons between groups at each time point. There were 
no significant differences in plasma PC fatty acid concentrations between the two groups at 
baseline (20 weeks). At 34 and 38 weeks gestation, the salmon group had higher absolute   178 
concentrations of EPA, DPA, DHA, and total n-3 PUFA, and a lower concentration of 
ARA  compared  to  the  control  group.  Total  n-6  PUFA  concentration  was  significantly 
lower in the salmon group compared to the control group at 34 weeks. The concentrations 
of all fatty acids increased from week 20 to week 34 in both groups and then declined at 
week 38 (Table 4.4). The changes in EPA concentration in plasma PC from week 20 to 
week 34 were significantly different between groups (p = 0.002 for both) (Table 4.5). 
There were  no significant differences  in changes  in  concentrations of other fatty acids 
between the groups (Table 4.5). Finally, Table 4.4 includes the ratios of fatty acids of 
interest in the plasma PC fraction. ARA/EPA, ARA/DHA, ARA/(EPA+DHA), and n-6 
PUFA/n-3 PUFA were affected by time and group and there was a significant time x group 
interaction. All four ratios were significantly lower in the salmon group compared to the 
control  group  at  baseline,  and  at  34  and  38  weeks  gestation.  The  ARA/DHA  and 
ARA/(DHA+EPA)  ratios  remained  almost  unchanged  in  the  control  group  but  they 
decreased significantly in the salmon group (p for trend < 0.001 for both ratios).  
 
Figure 4.13 Maternal plasma PC EPA (A) and DHA (B) expressed as percentage of total fatty acids 
during pregnancy in both groups 
p < 0.05; for exact values see text and Table 4.2 
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Table 4.2 Maternal plasma phospholipid (PC) fatty acid content (%) during pregnancy 




(n = 61) 
Salmon 
(n = 62)  p
* 
Control 
(n = 55) 
Salmon 
(n = 56)  p
* 
Control 
(n = 41) 
Salmon 
(n = 47)  p
*  Group  Time 
Time × 
group 
14:0  0.40 (±0.12  0.40 (±0.11)  0.738  0.40 (±0.09)  0.40 (±0.09)  0.669  0.39 (±0.11)  0.40 (±0.10)  0.595  0.555  0.590  0.939 
16:0  33.01 (±1.74)  32.84 (±1.40)  0.572  34.11 (±1.08)  34.18 (±1.71)  0.794  34.47 (±0.85)  34.30 (±0.98)  0.393  0.640  <0.001  0.637 
18:0   10.83 (±0.99)  10.67 (±1.02)  0.379  9.75 (±0.79)  9.69 (±0.80)  0.670  9.83 (±0.86)  9.72 (±0.81)  0.551  0.728  <0.001  0.697 
20:0   0.10 (±0.10)  0.10 (±0.03)  0.698  0.09 (±0.08)  0.11 (±0.11)  0.414  0.05 (±0.02)  0.05 (±0.03)  0.664  0.934  <0.001  0.569 
SFA  44.33 (±2.02)  44.01 (±1.68)  0.342  44.36 (±0.73)  44.39 (±1.46)  0.894  44.74 (±0.71)  44.48 (±0.70)  0.087  0.431  0.078  0.613 
16:1n-7  0.86 (±0.30)  0.78 (±0.21)  0.099  0.86 (±0.21)  0.82 (±0.24)  0.301  0.86 (±0.24)  0.83 (±0.27)  0.558  0.300  0.097  0.248 
18:1n-9   11.21 (±1.54)  11.12 (±1.41)  0.737  11.93 (±1.24)  11.69 (±1.33)  0.317  12.07 (±1.18)  12.00 (±1.22)  0.777  0.530  <0.001  0.636 
18:1n-9 Trans  1.48 (±0.24)  1.46 (±0.24)  0.676  1.40 (±0.17)  1.31 (±0.16)  0.005  1.45 (±0.18)  1.35 (±0.17)  0.008  0.010  <0.001  0.651 
20:1n-9   0.21 (±0.09)  0.22 (±0.15)  0.537  0.20 (±0.04)  0.21 (±0.08)  0.348  0.16 (±0.03)  0.16 (±0.03)  0.520  0.688  <0.001  0.734 
MUFA  13.76 (1.75)  13.59 (1.59)  0.570  14.39 (±1.34)  14.02 (±1.45)  0.168  14.55 (±1.27)  14.34 (±1.36)  0.459  0.273  <0.001  0.792 
18:3n-3   0.32 (±0.11)  0.35 (±0.12)  0.138  0.37 (±0.11)  0.43 (±0.15)  0.020  0.37 (±0.12)  0.43 (±0.16)  0.041  0.038  <0.001  0.217 
20:5n-3 (EPA)   0.62 (±0.27)  0.74 (±0.33)  0.028  0.46 (±0.19)  0.89 (±0.42)  <0.001  0.42 (±0.18)  0.89 (±0.39)  <0.001  <0.001  0.758  <0.001 
22:5n-3 (DPA)   0.67 (±0.18)  0.72 (±0.17)  0.189  0.58 (±0.13)  0.70 (±0.17)  <0.001  0.53 (±0.14)  0.62 (±0.14)  0.003  0.002  <0.001  0.063 
22:6n-3 (DHA)   4.19 (±0.71)  4.71 (±0.98)  0.001  3.99 (±0.66)  5.12 (±1.14)  <0.001  3.71 (±0.67)  5.02 (±0.89)  <0.001  <0.001  0.003  <0.001 
Total n-3  5.79 (±0.96)  6.51 (±1.21)  <0.001  5.41 (±0.83)  7.14 (±1.55)  <0.001  5.03 (±0.90)  6.97 (±1.25)  <0.001  <0.001  0.005  <0.001 
18:2n-6   21.45 (±2.51)  22.06 (±2.45)  0.175  22.24 (±2.20)  22.68 (±2.31)  0.315  22.68 (±2.40)  22.74 (±2.22)  0.903  0.666  <0.001  0.877 
18:3n-6   0.10 (±0.08)  0.11 (±0.15)  0.899  0.10 (±0.10)  0.10 (±0.12)  0.790  0.06 (±0.02)  0.05 (±0.02)  0.402  0.790  0.003  0.117 
20:2n-6   0.49 (±0.15)  0.49 (±0.11)  0.965  0.45 (±0.09)  0.47 (±0.09)  0.173  0.39 (±0.08)  0.41 (±0.08)  0.359  0.650  <0.001  0.098 
20:3n-6  4.39 (±0.71)  4.20 (±0.77)  0.149  4.35 (±0.72)  3.70 (±0.57)  <0.001  4.17 (±0.62)  3.65 (±0.57)  <0.001  <0.001  <0.001  0.011 
20:4n-6 (ARA)  9.67 (±1.48)  9.03 (±1.77)  0.032  8.70 (±1.34)  7.49 (±1.37)  <0.001  8.38 (±1.23)  7.36 (±1.30)  <0.001  0.002  <0.001  0.008 
Total n-6  36.11 (±2.30)  35.89 (±2.09)  0.576  35.84 (±1.53)  34.45 (±1.70)  <0.001  35.68 (±1.74)  34.22 (±1.90)  <0.001  <0.001  <0.001  0.048 
PUFA  41.91 (±2.37)  42.40 (±1.93)  0.210  41.25 (±1.56)  41.59 (±1.77)  0.287  40.71 (±1.45)  41.19 (±1.51)  0.142  0.153  <0.001  0.858 
*p-values from independent samples t-test 
Values are mean (± standard deviation) percentage levels (%) of total fatty acids in PC 
 
Table 4.3 Changes of percentage phospholipid levels (% PC fatty acids) for selected fatty acids of interest 
Fatty Acids  34-20 week change  38-20 week change 
 
Control 
(n = 55) 
Salmon 
(n = 56)  p
* 
Control 
(n = 41) 
Salmon 
(n = 47)  p
* 
20:5n-3 (EPA)  -0.16 (±0.30)  0.15 (±0.45)  <0.001  -0.17 (±0.16)  0.13 (±0.40)  <0.001 
22:6n-3 (DHA)   -0.17 (±0.50)  0.38 (±0.93)  <0.001  -0.41 (±0.49)  0.13 (±0.69)  <0.001 
20:4n-6 (ARA)   -1.09 (±0.94)  -1.54 (±1.36)  0.043  -1.30 (±0.81)  -1.86 (±1.08)  0.008 
*p-values from independent samples t-test 
Values are mean (± standard deviation) of changes in percentage levels (%)   180 
 
Table 4.4 Absolute concentration of maternal plasma phospholipid (PC) fatty acids during pregnancy 




(n = 61) 
Salmon 
(n = 62)  p
* 
Control 
(n = 55) 
Salmon 
(n = 56)  p
* 
Control 
(n = 41) 
Salmon 
(n = 47)  p
*  Group  Time 
Time × 
group 
14:0   10.9 (±5.8)  10.2 (±5.1)  0.465  13.8 (±5.1)  13.1 (±5.1)  0.464  8.0 (±3.0)  8.2 (±2.9)  0.754  0.921  <0.001  0.507 
16:0   829.1 (±340.8)  813.9 (±331.6)  0.804  1163.7 (±287.9)  1092.8 (±271.9)  0.187  701.0 (±134.5)  702.0 (±162.4)  0.973  0.935  <0.001  0.263 
18:0   271.3 (±111.9)  264.1 (±109.4)  0.718  331.3 (±81.3)  310.3 (±81.2)  0.177  199.8 (±42.1)  197.9 (±43.1)  0.838  0.990  <0.001  0.218 
20:0   5.3 (±4.9)  4.6 (±3.2)  0.347  3.1 (±2.2)  3.6 (±4.8)  0.538  1.1 (±0.4)  1.1 (±0.5)  0.801  0.467  <0.001  0.250 
SFA  1116.73 (±455.46)  1092.80 (±441.61)  0.770  1511.89 (±367.89)  1419.69 (±351.04)  0.182  909.82 (±174.49)  909.25 (±204.19)  0.989  0.946  <0.001  0.257 
16:1n-7   22.0 (±13.2)  19.3 (±9.4)  0.196  30.0 (±11.9)  26.7 (±12.5)  0.160  17.8 (±6.7)  17.2 (±7.0)  0.688  0.463  <0.001  0.671 
18:1n-9   288.2 (±127.2)  279.2 (±121.9)  0.693  408.1 (±105.4)  376.0 (±112.8)  0.126  246.4 (±57.7)  247.5 (±70.8)  0.939  0.672  <0.001  0.193 
18:1n-9 Trans  38.5 (±16.5)  36.7 (±15.4)  0.524  47.4 (±11.5)  42.2 (±11.9)  0.023  29.3 (±6.0)  27.4 (±6.3)  0.145  0.189  <0.001  0.270 
20:1n-9   5.9 (±4.0)  5.5 (±3.0)  0.599  6.7 (±2.0)  6.9 (±4.2)  0.754  3.3 (±0.6)  3.2 (±0.9)  0.779  0.922  <0.001  0.874 
MUFA  354.60 (±155.86)  340.73 (±146.30)  0.615  492.17 (±125.55)  451.85 (±134.89)  0.108  296.78 (±67.55)  295.28 (±81.68)  0.926  0.584  <0.001  0.231 
18:3n-3   6.3 (±6.5)  6.9 (±6.4)  0.635  12.9 (±5.5)  14.0 (±6.1)  0.309  7.6 (±2.9)  9.0 (±4.4)  0.098  0.099  <0.001  0.865 
20:5n-3 (EPA)  16.3 (±12.7)  18.7 (±13.8)  0.312  16.1 (±9.2)  29.4 (±16.7)  <0.001  8.6 (±4.2)  18.4 (±10.2)  <0.001  <0.001  <0.001  0.008 
22:5n-3 (DPA)  18.0 (±10.9)  18.1 (±10.0)  0.930  20.0 (±7.1)  23.0 (±8.5)  0.046  10.9 (±4.0)  12.7 (±3.9)  0.037  0.033  <0.001  0.398 
22:6n-3 (DHA)  104.3 (±50.1)  115.2 (±57.9)  0.271  134.6 (±36.3)  167.0 (±60.6)  0.001  75.1 (±18.6)  102.1 (±26.1)  <0.001  <0.001  <0.001  0.398 
Total n-3  144.9 (±76.24)  158.97 (±82.37)  0.332  183.61 (±52.66)  233.36 (±82.81)  <0.001  102.20 (±26.73)  142.15 (±39.71)  <0.001  <0.001  <0.001  0.279 
18:2n-6   539.8 (±222.0)  541.6 (±217.3)  0.965  763.8 (±206.9)  723.8 (±177.8)  0.280  460.0 (±95.8)  462.4 (±102.3)  0.913  0.948  <0.001  0.212 
18:3n-6   2.8 (±2.2)  2.2 (±1.7)  0.085  3.4 (±4.0)  3.4 (±5.7)  0.980  1.2 (±0.6)  1.1 (±0.6)  0.482  0.982  0.001  0.272 
20:2n-6   13.2 (±7.6)  12.3 (±5.4)  0.449  15.4 (±5.2)  15.4 (±5.5)  0.968  8.0 (±2.2)  8.3 (±2.3)  0.524  0.959  <0.001  0.844 
20:3n-6   112.3 (±50.0)  105.3 (±50.0)  0.438  147.8 (±43.5)  119.2 (±39.3)  <0.001  85.1 (±22.5)  75.5 (±24.3)  0.061  0.055  <0.001  0.028 
20:4n-6 (ARA)  241.3 (±107.0)  223.1 (±106.0)  0.350  292.1 (±76.8)  242.2 (±75.5)  0.001  170.0 (±40.9)  150.4 (±41.2)  0.029  0.138  <0.001  0.072 
Total n-6  909.40 (±368.5)  884.40 (±356.54)  0.705  1222.48 (±303.17)  1103.98 (±269.97)  0.033  724.22 (±136.88)  697.61 (±152.66)  0.397  0.418  <0.001  0.129 
PUFA  1054.30 (±439.32)  1043.37 (±430.40)  0.890  1406.09 (±347.19)  1337.34 (±335.02)  0.293  826.42 (±153.62)  839.76 (±181.21)  0.714  0.772  <0.001  0.329 
Total fatty acids  2525.63 (±1037.77)  2476.9 (±1006.53)  0.794  3410.16 (±826.58)  3208.89 (±802.16)  0.198  2033.02 (±387.39)  2044.29 (±459.63)  0.903  0.999  <0.001  0.278 
ARA/DHA  2.43 (±0.51)  2.01 (±0.41)  <0.001  2.20 (±0.37)  1.52 (±0.36)  <0.001  2.30 (±0.38)  1.50 (±0.35)  <0.001  <0.001  <0.001  <0.001 
ARA/EPA  18.21 (±7.10)  14.41 (±5.30)  0.001  21.29 (±8.50)  10.57 (±5.69)  <0.001  23.59 (±10.12)  9.89 (±4.61)  <0.001  <0.001  0.366  <0.001 
ARA/(DHA+EPA)  2.13 (±0.48)  1.74 (±0.36)  <0.001  1.98 (±0.33)  1.31 (±0.34)  <0.001  2.07 (±0.36)  1.29 (±0.33)  <0.001  <0.001  <0.001  <0.001 
n-6/n-3  6.85 (±1.54)  6.03 (±1.45)  0.003  6.79 (±1.13)  5.09 (±1.56)  <0.001  7.36 (±1.57)  5.11 (±1.21)  <0.001  <0.001  <0.001  0.001 
*p-values from independent samples t-test 
Values are mean (± standard deviation) absolute concentrations (µg fatty acid/mL plasma) in PC   181 
 
Table 4.5 Changes in phospholipid (PC) fatty acid absolute concentration for selected fatty acids of interest 
Fatty Acids  34-20 week change  38-20 week change 
 
Control 
(n = 55) 
Salmon 
(n = 56)  p
* 
Control 
(n = 41) 
Salmon 
(n = 47)  p
* 
20:5n-3 (EPA)  -0.33 (±14.85)  10.27 (±19.77)  0.002  -5.64 (±9.45)  -1.34 (±15.98)  0.136 
22:6n-3 (DHA)  30.50 (±57.85)  47.78 (±72.56)  0.170  -20.69 (±43.40)  -19.80 (±50.12)  0.930 
20:4n-6 (ARA)  49.31 (±127.14)  12.52 (±120.92)  0.123  -55.70 (±90.59)  -82.06 (±86.83)  0.170 
*p-values from independent samples t-test 
Values are mean (± standard deviation) of changes in absolute concentration (µg/mL) 
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4.3.1.2  Fatty acid composition of plasma triglycerides (TAG) 
Table  4.6  describes  the  maternal  plasma  TAG  fatty  acid  composition  expressed  as 
percentages (%) of each fatty acid, for the two groups during pregnancy (20, 34, and 38 
weeks gestation). Repeated measures ANOVA identified significant effects of time and 
group on the percentages of a number of fatty acids. There were significant time x group 
interactions for EPA, DPA, DHA, and total n-3 PUFA. These were explored further by 
pair-wise comparisons between groups at each time point. At 20 weeks gestation (baseline, 
before intervention) the two groups differed significantly in LC n-3 PUFA content: the 
salmon group had significantly  higher percentages of EPA, DHA, and total n-3 PUFA 
compared to the control group. At 34 and 38 weeks gestation (during intervention) the 
salmon group continued to exhibit significantly higher percentages of EPA, DHA and total 
n-3 PUFA (and also DPA). The percentages of EPA, DHA, and total n-3 PUFA decreased 
during pregnancy in the control group (p for trend < 0.001, 0.001, 0.041), whereas the 
percentage did not change for EPA (p for trend = 0.281) and they increased significantly 
for  DHA  and  total  n-3  PUFA  in  the  salmon  group  (p  for  trend  <  0.001,  0.007).  The 
changes in % EPA and DHA in plasma TAG were significantly different between groups 
(p < 0.001 for both) (Table 4.7). Also, plasma TAG % ARA decreased significantly in both 
groups (both p for trend < 0.001), with little difference between them (Table 4.7).  
Table 4.8 describes the absolute concentration (µg/mL plasma) of plasma TAG fatty 
acids for both groups during pregnancy. Repeated measures ANOVA identified significant 
effects of time on the concentrations of all fatty acids (except ARA and DGLA) detected in 
TAG and  in total plasma TAG  fatty acid. There were significant effects of group (i.e. 
salmon vs. control) on the concentrations of EPA, DPA, DHA, and total n-3 PUFA, but not 
on most other fatty acids. There were significant time x group interactions for stearic acid 
(18:0),  EPA,  DHA,  and  total  n-3  PUFA.  These  were  explored  further  by  pair-wise 
comparisons between groups at each time point. The concentration of ARA in plasma TAG 
was significantly lower in the salmon group at baseline. At 34 and 38 weeks gestation, the 
salmon group had higher absolute concentrations of EPA and DHA, and at 34 weeks lower 
concentrations of linoleic acid (18:3n-6), γ-linolenic acid (GLA;18:3n-6), DGLA, ARA 
and  total  n-6  PUFA  compared  to the  control  group.  The  concentrations  of  n-3  PUFA 
increased from week 20 to week 34 and from week 34 to week 38 in both groups (Table 
4.8), but the increases were greater in the salmon group. The increases in EPA and DHA 
concentration in plasma TAG from week 20 to week 34 and from week 20 to week 38 
were significantly different between groups (p < 0.002 for all) (Table 4.9). There were no 
significant differences in changes in concentration of ARA in plasma TAG between the   183 
groups (Table 4.9). Finally, Table 4.8 includes the ratios of fatty acids of interest in the 
plasma  TAG  fraction.  ARA/EPA,  ARA/DHA,  ARA/(EPA+DHA),  and  n-6  PUFA/n-3 
PUFA  were  affected  by  time  and  group,  but  there  was  a  significant  time  x  group 
interaction only for ARA/EPA. All four ratios were significantly lower in the salmon group 
compared to the control group at baseline, and at 34 and 38 weeks gestation and all four 
ratios declined to a greater extent in the salmon group.  
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Table 4.6 Maternal plasma triglyceride (TAG) fatty acid content (%) during pregnancy 




(n = 61) 
Salmon 
(n = 62)  p
* 
Control 
(n = 55) 
Salmon 
(n = 56)  p
* 
Control 
(n = 41) 
Salmon 
(n = 47)  p
*  Group  Time 
Time × 
group 
14:0   2.23 (±0.84)  2.30 (±0.79)  0.892  2.27 (±0.63)  2.32 (±0.63)  0.687  2.27 (±0.67)  2.32 (±0.74)  0.720  0.907  0.915  0.698 
16:0   28.38 (±3.22)  28.25 (±3.60)  0.837  31.01 (±2.54)  31.15 (±2.97)  0.792  32.11 (±2.83)  32.14 (±4.67)  0.965  0.742  <0.001  0.917 
18:0  2.54 (±0.50)  2.79 (±0.68)  0.022  2.84 (±0.46)  2.95 (±0.59)  0.263  2.80 (±0.59)  3.16 (±0.82)  0.020  0.001  <0.001  0.262 
20:0  0.05 (±0.03)  0.05 (±0.03)  0.595  0.15 (±0.31)  0.24 (±0.49)  0.223  0.05 (±0.03)  0.06 (±0.04)  0.033  0.231  0.002  0.334 
SFA  33.29 (±4.01)  33.39 (±4.44)  0.890  36.27 (±3.07)  36.67 (±3.76)  0.546  37.22 (±3.53)  37.69 (±5.43)  0.635  0.475  <0.001  0.985 
16:1n-7   4.08 (±1.35)  3.64 (±1.11)  0.055  3.91 (±0.99)  3.66 (±1.02)  0.195  3.99 (±1.13)  3.67 (±1.19)  0.206  0.116  0.433  0.498 
18:1n-9   38.55 (±3.36)  38.40 (±3.12)  0.800  38.59 (±3.08)  37.35 (±2.91)  0.033  38.11 (±3.83)  36.13 (±4.24)  0.025  0.037  0.003  0.118 
18:1n-9 Trans   2.64 (±0.46)  2.54 (±0.44)  0.217  2.60 (±0.38)  2.37 (±0.36)  0.002  2.49 (±0.40)  2.14 (±0.41)  <0.001  <0.001  <0.001  0.191 
20:1n-9   0.46 (±0.11)  0.44 (±0.09)  0.372  0.52 (±0.10)  0.50 (±0.09)  0.232  0.45 (±0.11)  0.39 (±0.10)  0.014  0.010  <0.001  0.486 
MUFA  45.73 (±3.51)  45.02 (±3.09)  0.245  45.62 (±3.07)  43.88 (±2.99)  0.003  45.04 (±3.54)  42.34 (±4.09)  0.001  0.001  0.001  0.109 
18:3n-3   1.15 (±0.39)  1.25 (±0.38)  0.176  1.04 (±0.47)  1.13 (±0.57)  0.397  1.15 (±0.44)  1.48 (±0.69)  0.010  0.033  0.034  0.117 
20:5n-3 (EPA)   0.20 (±0.09)  0.24 (±0.15)  0.045  0.14 (±0.06)  0.28 (±0.15)  <0.001  0.11 (±0.06)  0.29 (±0.17)  <0.001  <0.001  0.172  <0.001 
22:5n-3 (DPA)   0.19 (±0.07)  0.20 (±0.07)  0.542  0.17 (±0.06)  0.23 (±0.10)  <0.001  0.16 (±0.09)  0.25 (±0.14)  0.001  <0.001  0.452  0.005 
22:6n-3 (DHA)   0.78 (±0.24)  0.93 (±0.41)  0.017  0.67 (±0.22)  1.27 (±0.68)  <0.001  0.65 (±0.28)  1.50 (±0.81)  <0.001  <0.001  0.009  <0.001 
Total n-3  2.32 (±0.59)  2.62 (±0.78)  0.019  2.01 (±0.54)  2.92 (±1.27)  <0.001  2.07 (±0.73)  3.52 (±1.61)  <0.001  <0.001  0.073  0.002 
18:2n-6   15.93 (±3.71)  16.44 (±3.39)  0.435  14.13 (±2.72)  14.66 (±2.93)  0.330  13.90 (±2.52)  14.59 (±3.17)  0.265  0.408  <0.001  0.810 
18:3n-6   0.27 (±0.13)  0.25 (±0.13)  0.303  0.15 (±0.06)  0.14 (±0.05)  0.339  0.17 (±0.10)  0.20 (±0.13)  0.216  0.921  <0.001  0.094 
20:2n-6   0.25 (±0.10)  0.25 (±0.06)  0.807  0.25 (±0.07)  0.25 (±0.07)  0.828  0.23 (±0.07)  0.22 (±0.05)  0.411  0.369  0.001  0.898 
20:3n-6   0.40 (±0.12)  0.38 (±0.09)  0.355  0.32 (±0.09)  0.29 (±0.06)  0.074  0.28 (±0.10)  0.28 (±0.16)  0.831  0.271  <0.001  0.226 
20:4n-6 (ARA)   1.81 (±0.58)  1.65 (±0.52)  0.110  1.24 (±0.40)  1.19 (±0.33)  0.414  1.09 (±0.34)  1.16 (±0.47)  0.480  0.644  <0.001  0.164 
Total n-6  18.66 (±4.12)  18.96 (±3.62)  0.672  16.09 (±2.87)  16.53 (±3.05)  0.442  15.67 (±2.74)  16.45 (±3.54)  0.255  0.515  <0.001  0.642 
PUFA  20.98 (±4.34)  21.58 (±4.06)  0.436  18.11 (±3.11)  19.45 (±3.67)  0.042  17.74 (±3.15)  19.97 (±4.45)  0.009  0.039  <0.001  0.165 
*p-values from independent samples t-test  
Values are mean (± standard deviation) percentage levels (%) of total fatty acids in triglycerides 
 
Table 4.7 Changes of percentage triglyceride levels (%TAG) for selected fatty acids of interest 
Fatty Acids  34-20 week change  38-20 week change 
 
Control 
(n = 55) 
Salmon 
(n = 56)  p
 * 
Control 
(n = 41) 
Salmon 
(n = 47)  p
 * 
20:5n-3 (EPA)   -0.06 (±0.10)  0.03 (±0.16)  <0.001  -0.07 (±0.07)  0.02 (±0.14)  <0.001 
22:6n-3 (DHA)   -0.12 (±0.19)  0.31 (±0.50)  <0.001  -0.12 (±0.23)  0.50 (±0.68)  <0.001 
20:4n-6 (ARA)   -0.57 (±0.46)  -0.49 (±0.43)  0.389  -0.73 (±0.51)  -0.54 (±0.46)  0.079 
*p-values from independent samples t-test 
Values are mean (± standard deviation) of changes in percentage levels (%)   185 
 
Table 4.8 Absolute concentration of maternal plasma triglyceride (TAG) fatty acids during pregnancy 




(n = 61) 
Salmon 
(n = 62)  p
 * 
Control 
(n = 55) 
Salmon 
(n = 56)  p
 * 
Control 
(n = 41) 
Salmon 
(n = 47)  p
 *  Group  Time 
Time × 
group 
14:0  25.4 (±15.3)  22.0 (±14.3)  0.219  39.8 (±20.8)  33.5 (±15.7)  0.074  38.2 (±18.6)  40.5 (±28.1)  0.664  0.610  <0.001  0.228 
16:0   307.1 (±160.0)  273.2 (±158.5)  0.244  548.4 (±270.6)  447.7 (±177.8)  0.023  530.8 (±219.9)  564.3 (±318.8)  0.573  0.709  <0.001  0.109 
18:0   26.9 (±13.1)  26.2 (±15.1)  0.801  49.6 (±21.7)  41.6 (±15.3)  0.026  47.1 (±22.8)  56.6 (±39.4)  0.176  0.643  <0.001  0.038 
20:0   0.5 (±0.3)  0.4 (±0.2)  0.221  2.1 (±4.1)  3.2 (±6.8)  0.324  0.9 (±0.8)  1.3 (±1.3)  0.103  0.314  0.002  0.449 
SFA  359.80 (±185.85)  321.84 (±186.12)  0.264  640.05 (±308.94)  525.93 (±205.47)  0.025  616.91 (±257.63)  662.65 (±380.72)  0.517  0.758  <0.001  0.094 
16:1n-7  45.7 (±33.3)  35.6 (±20.7)  0.047  70.2 (±44.6)  52.8 (±26.0)  0.014  66.3 (±33.2)  65.6 (±43.0)  0.934  0.273  <0.001  0.415 
18:1n-9  404.7 (±172.5)  360.3 (±170.5)  0.157  670.0 (±268.0)  531.7 (±195.0)  0.003  610.6 (±227.1)  621.6 (±304.9)  0.850  0.293  <0.001  0.058 
18:1n-9 Trans  28.0 (±13.8)  23.7 (±10.8)  0.055  45.2 (±20.0)  33.6 (±12.2)  <0.001  40.0 (±16.3)  36.0 (±17.2)  0.273  0.021  <0.001  0.189 
20:1n-9  4.8 (±2.2)  4.2 (±2.1)  0.080  9.0 (±3.6)  7.0 (±2.6)  0.001  7.3 (±3.6)  6.4 (±2.6)  0.180  0.017  <0.001  0.174 
MUFA  483.26 (±215.17)  423.72 (±200.26)  0.118  794.37 (±328.74)  625.10 (±227.81)  0.002  724.16 (±269.29)  729.65 (±357.22)  0.936  0.241  <0.001  0.074 
18:3n-3  12.0 (±6.0)  11.6 (±6.1)  0.707  18.4 (±11.0)  16.2 (±10.2)  0.278  19.9 (±13.6)  27.4 (±25.1)  0.094  0.286  <0.001  0.076 
20:5n-3 (EPA)  2.1 (±1.4)  2.1 (±1.3)  0.713  2.2 (±1.0)  3.8 (±2.0)  <0.001  2.1 (±1.8)  4.8 (±4.3)  <0.001  <0.001  <0.001  0.004 
22:5n-3 (DPA)  2.0 (±1.3)  1.8 (±1.1)  0.408  2.8 (±1.5)  3.2 (±1.7)  0.214  2.9 (±2.5)  4.8 (±4.7)  0.027  0.011  <0.001  0.052 
22:6n-3 (DHA)  8.1 (±4.2)  8.4 (±4.7)  0.728  11.1 (±4.5)  17.8 (±11.0)  <0.001  11.9 (±8.7)  27.9 (±27.7)  0.001  <0.001  <0.001  0.004 
Total n-3  24.20 (±11.18)  23.98 (±11.62)  0.916  34.52 (±14.91)  40.96 (±22.73)  0.082  36.91 (±24.97)  64.85 (±59.49)  0.006  0.002  <0.001  0.020 
18:2n-6  163.5 (±70.8)  149.4 (±65.7)  0.255  243.8 (±102.5)  206.4 (±79.0)  0.034  229.8 (±117.0)  256.0 (±153.1)  0.375  0.727  <0.001  0.073 
18:3n-6  2.8 (±1.7)  2.3 (±1.6)  0.081  2.5 (±1.4)  1.9 (±0.9)  0.011  3.1 (±3.3)  3.9 (±3.9)  0.320  0.980  0.001  0.155 
20:2n-6  2.6 (±1.7)  2.2 (±1.1)  0.124  4.4 (±2.1)  3.6 (±1.6)  0.039  4.0 (±2.6)  3.8 (±2.3)  0.790  0.163  <0.001  0.375 
20:3n-6  4.2 (±2.2)  3.6 (±1.9)  0.106  5.4 (±2.2)  4.1 (±1.7)  0.001  4.8 (±3.6)  5.5 (±5.5)  0.514  0.495  0.011  0.109 
20:4n-6 (ARA)  18.2 (±7.4)  14.8 (±6.9)  0.012  20.2 (±6.9)  16.3 (±5.9)  0.002  18.5 (±11.6)  20.5 (±15.7)  0.486  0.407  0.064  0.100 
Total n-6  191.33 (±79.90)  172.28 (±74.10)  0.176  276.26 (±110.58)  232.34 (±85.73)  0.022  260.21 (±135.15)  289.79 (±176.13)  0.385  0.675  <0.001  0.071 
PUFA  215.52 (±88.53)  196.26 (±84.17)  0.222  310.78 (±122.73)  273.30 (±100.73)  0.083  297.12 (±156.50)  354.64 (±227.79)  0.177  0.807  <0.001  0.052 
Total fatty acids  1058.58 (±466.10)  941.82 (±454.04)  0.165  1745.20 (±733.43)  1424.33 (±504.63)  0.009  1638.19 (±658.13)  1746.93 (±915.27)  0.529  0.562  <0.001  0.060 
ARA/DHA  2.41 (±0.73)  1.94 (±0.62)  <0.001  1.92 (±0.51)  1.10 (±0.47)  <0.001  1.76 (±0.55)  0.95 (±0.48)  <0.001  <0.001  <0.001  0.096 
ARA/EPA  10.50 (±4.05)  8.15 (±3.16)  0.001  10.11 (±3.79)  5.14 (±2.45)  <0.001  10.87 (±4.55)  5.66 (±4.06)  <0.001  <0.001  0.001  0.027 
ARA/(DHA+EPA)  1.93 (±0.56)  1.54 (±0.48)  <0.001  1.60 (±0.41)  0.90 (±0.38)  <0.001  1.50 (±0.47)  0.81 (±0.42)  <0.001  <0.001  <0.001  0.069 
n-6/n-3  8.43 (±2.47)  7.62 (±1.81)  0.042  8.45 (±2.33)  6.62 (±2.97)  0.001  8.01 (±2.87)  5.71 (±2.39)  <0.001  <0.001  <0.001  0.134 
*p-Values from independent samples t-test 
Values are mean (± standard deviation) absolute concentrations (µg fatty acid/mL plasma) in TAG   186 
 
Table 4.9 Changes in triglyceride (TAG) fatty acid absolute concentration for selected fatty acids of interest 
Fatty Acids  34-20 week change  38-20 week change 
 
Control 
(n = 55) 
Salmon 
(n = 56)  p
 * 
Control 
(n = 41) 
Salmon 
(n = 47)  p
 * 
20:5n-3 (EPA)  0.07 (±1.60)  1.64 (±2.21)  <0.001  0.26 (±1.88)  2.54 (±4.11)  0.002 
22:6n-3 (DHA)  2.78 (±5.19)  9.21 (±9.94)  <0.001  4.23 (±7.63)  18.93 (±26.38)  0.001 
20:4n-6 (ARA)  1.68 (±8.63)  1.43 (±7.15)  0.867  0.69 (±10.10)  5.63 (±14.72)  0.074 
*p-Values from independent samples t-test  
Values are mean (± standard deviation) of changes in absolute concentration (µg/mL)   187 
 
4.3.1.3  Fatty acid composition of plasma cholesteryl esters (CE) 
Table  4.10  describes  the  maternal  plasma  CE  fatty  acid  composition  expressed  as 
percentages (%) of each fatty acid, for the two groups during pregnancy (20, 34, and 38 
weeks gestation). Repeated measures ANOVA identified a significant effect of time on 
percentages of most fatty acids and a significant effect of group on the percentages of EPA, 
DHA, total n-3 PUFA, DGLA and ARA. There were significant time x group interactions 
for  EPA,  DHA,  and  total  n-3  PUFA.  These  were  explored  further  by  pair-wise 
comparisons between groups at each time point. At 20 weeks gestation the salmon group 
had significantly lower percentages of DGLA and ARA compared to the control group. At 
34 and 38 weeks gestation (during intervention) the salmon group exhibited significantly 
higher percentages of EPA, DHA and total n-3 PUFA and significantly lower percentages 
of DGLA and ARA. The percentages of EPA and DHA decreased during pregnancy in the 
control  group  (p  for  trend  <  0.001,  0.039),  whereas  the  percentage  of  EPA  increased 
significantly (p for trend = 0.030) and that of DHA did not change in the salmon group (p 
for trend = 0.220). The changes in % EPA and DHA in plasma CE were significantly 
different between groups (Table 4.11). Also, plasma CE % ARA decreased significantly in 
both groups (both p for trend < 0.001), with little difference between them (Table 4.11).  
Table 4.12 describes the absolute concentration (µg/mL plasma) of plasma CE fatty 
acids for both groups during pregnancy. Repeated measures ANOVA identified significant 
effects of time on the concentrations of almost all fatty acids detected in CE and in total 
plasma CE fatty acid. There were significant effects of group (i.e. salmon vs. control) on 
the  concentrations  of  EPA,  DHA,  total  n-3  PUFA,  DGLA  and  ARA.  There  were 
significant time x group  interactions  for EPA, DPA, DHA, total  n-3 PUFA and  ARA. 
These were explored further by pair-wise comparisons between groups at each time point. 
The concentration of DGLA in plasma CE was significantly lower in the salmon group at 
baseline.  At  34  and  38  weeks  gestation,  the  salmon  group  had  higher  absolute 
concentrations of EPA and DHA, and lower concentrations of DGLA and ARA compared 
to control group. The concentration of EPA decreased and that of DHA increased over 
time  in  the  control  group  (p  for  trend  =  0.262,  <  0.001).  In  the  salmon  group  the 
concentrations of both EPA and DHA increased (both p for trend < 0.001). The changes in 
EPA concentration in plasma CE from week 20 to week 34, and in both EPA and DHA 
from week 20 to week 38 were significantly different between groups (p < 0.015 for all) 
(Table 4.13). Finally, Table 4.12 includes the ratios of fatty acids of interest in the plasma   188 
CE fraction. ARA/EPA, ARA/DHA, ARA/(EPA+DHA), and n-6 PUFA/n-3 PUFA were 
affected by time and group, and there were significant time x group interactions for all four 
ratios. These ratios changed little in the control group but decreased significantly over time 
in the salmon group (all ratios p for trend < 0.001 for the salmon group).  
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Table 4.10 Maternal plasma cholesteryl ester (CE) fatty acid content (%) during pregnancy 




(n = 61) 
Salmon 
(n = 62)  p
 * 
Control 
(n = 55) 
Salmon 
(n = 56)  p
 * 
Control 
(n = 41) 
Salmon 
(n = 47)  p
 *  Group  Time 
Time × 
group 
14:0   0.80 (±0.21)  0.83 (±0.20)  0.374  0.74 (±0.19)  0.76 (±0.20)  0.624  0.94 (±0.45)  1.19 (±0.68)  0.057  0.074  <0.001  0.085 
16:0   12.17 (±0.76)  11.93 (±0.76)  0.091  12.20 (±0.71)  12.11 (±0.90)  0.538  14.39 (±5.52)  16.05 (±6.29)  0.196  0.221  <0.001  0.160 
18:0   0.75 (±0.26)  0.78 (±0.41)  0.618  0.62 (±0.33)  0.59 (±0.28)  0.656  0.85 (±0.61)  1.07 (±0.77)  0.145  0.260  <0.001  0.166 
20:0  0.14 (±0.07)  0.15 (±0.07)  0.514  0.77 (±0.28)  0.84 (±0.36)  0.317  0.03 (±0.03)  0.04 (±0.04)  0.052  0.136  <0.001  0.360 
SFA  13.86 (±0.90)  13.70 (±1.05)  0.360  14.34 (±1.02)  14.30 (±1.25)  0.852  16.21 (±6.50)  18.34 (±7.65)  0.166  0.159  <0.001  0.155 
16:1n-7   3.15 (±1.28)  3.18 (±1.35)  0.876  4.01 (±1.41)  3.57 (±1.43)  0.109  4.12 (±1.18)  4.05 (±1.57)  0.829  0.651  <0.001  0.207 
18:1n-9  20.74 (±2.48)  20.80 (±2.01)  0.873  21.09 (±2.23)  21.68 (±1.77)  0.568  23.72 (±4.00)  24.98 (±5.86)  0.250  0.344  <0.001  0.263 
18:1n-9 Trans   1.44 (±0.25)  1.42 (±0.23)  0.653  0.98 (±0.19)  0.98 (±0.21)  0.859  1.25 (±0.34)  1.25 (±0.31)  0.958  0.962  <0.001  0.759 
20:1n-9   0.18 (±0.12)  0.17 (±0.14)  0.633  0.11 (±0.07)  0.10 (±0.07)  0.642  0.10 (±0.11)  0.14 (±0.14)  0.193  0.512  <0.001  0.411 
MUFA  25.51 (3.30)  25.58 (3.03)  0.901  26.99 (3.12)  26.33 (2.57)  0.231  29.19 (4.56)  30.42 (6.99)  0.339  0.557  <0.001  0.273 
18:3n-3  0.82 (±0.24)  0.89 (±0.24)  0.126  0.44 (±0.40)  0.44 (±0.43)  0.993  0.93 (±0.25)  1.09 (±0.29)  0.010  0.148  <0.001  0.194 
20:5n-3 (EPA)  0.53 (±0.25)  0.61 (±0.26)  0.067  0.42 (±0.15)  0.72 (±0.28)  <0.001  0.38 (±0.19)  0.68 (±0.32)  <0.001  <0.001  0.153  0.001 
22:5n-3 (DPA)   0.24 (±0.18)  0.20 (±0.15)  0.249  0.14 (±0.06)  0.14 (±0.07)  0.928  0.06 (±0.05)  0.09 (±0.08)  0.011  0.713  <0.001  0.267 
22:6n-3 (DHA)   0.68 (±0.15)  0.73 (±0.24)  0.158  0.60 (±0.13)  0.76 (±0.19)  <0.001  0.61 (±0.19)  0.84 (±0.22)  <0.001  <0.001  0.346  0.040 
Total n-3  2.26 (±0.57)  2.43 (±0.54)  0.093  1.60 (±0.46)  2.07 (±0.59)  <0.001  1.98 (±0.48)  2.70 (±0.57)  <0.001  <0.001  <0.001  0.007 
18:2n-6   49.71 (±4.23)  50.35 (±3.88)  0.387  49.40 (±4.11)  50.64 (±3.54)  0.095  45.64 (±9.26)  42.48 (±12.65)  0.190  0.395  <0.001  0.137 
18:3n-6   0.70 (±0.24)  0.63 (±0.26)  0.128  0.46 (±0.40)  0.45 (±0.38)  0.877  0.58 (±0.24)  0.52 (±0.30)  0.285  0.405  <0.001  0.714 
20:2n-6   0.12 (±0.13)  0.10 (±0.08)  0.166  0.07 (±0.03)  0.08 (±0.06)  0.929  0.07 (±0.06)  0.19 (±0.75)  0.306  0.405  0.406  0.285 
20:3n-6  1.03 (±0.18)  0.94 (±0.19)  0.009  0.93 (±0.18)  0.81 (±0.25)  0.003  0.86 (±0.21)  0.73 (±0.26)  0.013  0.001  <0.001  0.869 
20:4n-6 (ARA)   6.81 (±1.24)  6.27 (±1.42)  0.029  6.19 (±1.15)  5.33 (±1.10)  <0.001  5.48 (±1.81)  4.63 (±1.55)  0.020  0.013  <0.001  0.196 
Total n-6  58.37 (±3.79)  58.29 (±3.53)  0.905  57.07 (±3.49)  57.31 (±3.06)  0.703  52.62 (±10.63)  48.54 (±13.61)  0.124  0.122  <0.001  0.152 
PUFA  60.63 (±3.70)  60.72 (±3.40)  0.888  58.67 (±3.51)  59.37 (±3.08)  0.270  54.60 (±10.64)  51.24 (±13.53)  0.203  0.274  <0.001  0.182 
*p-values from independent samples t-test  
Values are mean (± standard deviation) percentage levels (%) of total fatty acids in CE 
 
Table 4.11 Changes of percentage cholesteryl ester levels (%CE) for selected fatty acids of interest 
Fatty Acids  34-20 week change  38-20 week change 
 
Control 
(n = 55) 
Salmon 
(n = 56)  p
 * 
Control 
(n = 41) 
Salmon 
(n = 47)  p
 * 
20:5n-3 (EPA)  -0.11 (±0.24)  0.11 (±0.30)  <0.001  -0.11 (±0.18)  0.04 (±0.35)  0.014 
22:6n-3 (DHA)   -0.07 (±0.17)  0.01 (±0.25)  0.040  -0.06 (±0.20)  0.07 (±0.26)  0.013 
20:4n-6 (ARA)   -0.60 (±0.77)  -1.00 (±0.77)  0.009  -0.1.26 (±1.46)  -1.74 (±1.67)  0.158 
*p-values from independent samples t-test  
Values are mean (± standard deviation) of changes in percentage levels (%)   190 
 
Table 4.12 Absolute concentration of maternal plasma cholesteryl ester (CE) fatty acids during pregnancy 




(n = 61) 
Salmon 
(n = 62)  p
 * 
Control 
(n = 55) 
Salmon 
(n = 56)  p
 * 
Control 
(n = 41) 
Salmon 
(n = 47)  p
 *  Group  Time 
Time × 
group 
14:0  17.8 (±6.1)  18.0 (±6.6)  0.822  19.9 (±7.0)  18.6 (±6.8)  0.302  37.4 (±37.4)  51.4 (±57.1)  0.183  0.219  <0.001  0.157 
16:0   268.3 (±55.6)  258.2 (±66.6)  0.364  321.9 (±62.0)  295.7 (±72.0)  0.045  557.1 (±511.1)  672.1 (±627.9)  0.353  0.449  <0.001  0.273 
18:0   16.4 (±6.1)  16.4 (±6.8)  0.937  16.0 (±8.7)  14.4 (±7.3)  0.325  35.6 (±44.2)  49.5 (±61.0)  0.231  0.282  <0.001  0.190 
20:0   3.0 (±1.7)  3.1 (±1.7)  0.724  11.8 (±11.5)  11.7 (±11.7)  0.956  1.1 (±1.3)  1.8 (±2.0)  0.060  0.743  <0.001  0.787 
SFA  305.57 (±63.43)  295.65 (±74.82)  0.434  369.57 (±74.17)  340.42 (±85.43)  0.060  631.18 (±591.80)  774.85 (±742.96)  0.323  0.410  <0.001  0.251 
16:1n-7   71.0 (±35.6)  70.1 (±39.0)  0.896  106.4 (±43.3)  88.5 (±48.6)  0.046  140.6 (±70.1)  144.7 (±90.9)  0.816  0.758  <0.001  0.204 
18:1n-9   459.2 (±113.6)  452.7 (±130.9)  0.772  576.9 (±128.8)  537.3 (±153.2)  0.147  854.2 (±549.4)  966.5 (±730.5)  0.423  0.570  <0.001  0.354 
18:1n-9 Trans  31.6 (±7.7)  30.1 (±6.7)  0.258  25.2 (±5.1)  23.8 (±6.2)  0.202  46.0 (±35.0)  48.3 (±35.8)  0.767  0.925  <0.001  0.623 
20:1n-9   3.9 (±2.5)  3.4 (±2.1)  0.267  2.8 (±2.0)  2.6 (±2.0)  0.537  4.8 (±7.9)  6.6 (±8.9)  0.325  0.488  0.004  0.281 
MUFA  565.76 (±146.57)  556.43 (±166.19)  0.744  711.20 (±161.65)  652.18 (±191.50)  0.085  1045.63 (±650.33)  1166.07 (±849.93)  0.462  0.655  <0.001  0.318 
18:3n-3   18.4 (±7.7)  19.3 (±7.7)  0.496  21.3 (±9.5)  20.1 (±10.2)  0.537  32.1 (±16.7)  40.9 (±30.4)  0.104  0.159  <0.001  0.101 
20:5n-3 (EPA)  11.8 (±6.6)  13.4 (±6.9)  0.207  11.8 (±7.0)  17.3 (±7.3)  <0.001  12.1 (±5.5)  21.8 (±10.5)  <0.001  <0.001  <0.001  0.003 
22:5n-3 (DPA)  5.0 (±3.8)  4.1 (±2.8)  0.107  3.7 (±1.3)  3.4 (±1.8)  0.315  2.3 (±2.9)  4.0 (±4.7)  0.042  0.473  0.010  0.040 
22:6n-3 (DHA)  15.0 (±4.6)  15.6 (±5.6)  0.560  15.9 (±4.4)  18.4 (±5.9)  0.016  20.3 (±9.4)  30.6 (±19.9)  0.003  0.001  <0.001  0.017 
Total n-3  50.27 (17.57)  52.37 (16.90)  0.505  52.69 (17.70)  58.85 (18.49)  0.078  66.71 (29.81)  97.30 (58.26)  0.003  0.002  <0.001  0.016 
18:2n-6   1097.7 (±254.0)  1086.9 (±274.8)  0.822  1318.6 (±324.0)  1238.5 (±315.6)  0.194  1439.1 (±302.8)  1375.3 (±473.9)  0.461  0.410  <0.001  0.226 
18:3n-6   15.6 (±6.2)  13.8 (±7.5)  0.167  12.3 (±10.7)  10.4 (±9.7)  0.338  18.5 (±7.9)  16.0 (±6.5)  0.113  0.186  <0.001  0.501 
20:2n-6   2.6 (±2.7)  1.9 (±1.4)  0.066  1.9 (±0.9)  1.7 (±1.2)  0.326  2.9 (±4.0)  6.9 (±23.5)  0.285  0.391  0.125  0.251 
20:3n-6   22.7 (±5.9)  20.3 (±6.5)  0.038  24.5 (±6.5)  19.7 (±7.7)  0.001  27.2 (±7.3)  23.3 (±8.4)  0.021  0.005  <0.001  0.152 
20:4n-6 (ARA)  150.0 (±40.3 )  135.9 (±46.0)  0.076  163.1 (±40.7)  128.9 (±36.6)  <0.001  167.1 (±50.1)  145.7 (±47.5)  0.044  0.025  0.001  0.002 
Total n-6  1288.64 (±286.88)  1258.89 (±315.18)  0.589  1520.43 (±355.07)  1399.21 (±342.53)  0.073  1654.79 (±328.36)  1567.20 (±521.71)  0.357  0.275  <0.001  0.136 
PUFA  1338.91 (±297.73)  1311.26 (±325.54)  0.627  1573.11 (±366.73)  1458.06 (±353.67)  0.098  1721.50 (±344.90)  1664.50 (±561.95)  0.575  0.410  <0.001  0.188 
Total fatty acids  2210.25 (±468.50)  2163.34 (±539.04)  0.611  2653.88 (±565.57)  2450.65 (±604.94)  0.073  3398.31 (±1439.15)  3605.42 (±1982.54)  0.581  0.925  <0.001  0. 304 
ARA/DHA  10.33 (±2.21)  9.15 (±2.61)  0.008  10.48 (±1.92)  7.42 (±2.11)  <0.001  9.50 (±3.41)  5.89 (±2.44)  <0.001  <0.001  <0.001  0.002 
ARA/EPA  15.04 (±6.77)  11.66 (±4.35)  0.001  15.97 (±5.76)  8.76 (±4.05)  <0.001  16.33 (±7.48)  7.60 (±3.04)  <0.001  <0.001  0.013  0.001 
ARA/(DHA+EPA)  5.96 (±1.51)  4.99 (±1.47)  <0.001  6.17 (±1.37)  3.91 (±1.22)  <0.001  5.83 (±2.05)  3.21 (±1.20)  <0.001  <0.001  <0.001  <0.001 
n-6/n-3  27.25 (±6.92)  25.20 (±6.15)  0.088  30.41 (±7.69)  25.38 (±8.24)  0.001  28.21 (±9.30)  18.87 (±6.70)  <0.001  <0.001  <0.001  0.012 
*p-values from independent samples t-test  
Values are mean (± standard deviation) absolute concentrations (µg fatty acid/mL plasma) in CE   191 
 
Table 4.13 Changes in cholesteryl ester (CE) fatty acid absolute concentration for selected fatty acids of interest 
Fatty Acids  34-20 week change  38-20 week change 
 
Control 
(n = 55) 
Salmon 
(n = 56)  p
 * 
Control 
(n = 41) 
Salmon 
(n = 47)  p
 * 
20:5n-3 (EPA)  -0.13 (±7.34)  3.56 (±8.09)  0.015  1.5 (±4.4)  7.5 (±8.5)  <0.001 
22:6n-3 (DHA)  1.00 (±4.85)  2.39 (±6.45)  0.209  6.04 (±9.18)  14.11 (±18.16)  0.012 
20:4n-6 (ARA)  13.11 (±37.20)  -9.09 (±38.14)  0.003  23.06 (±47.18)  6.18 (±28.77)  0.043 
*p-values from independent samples t-test 
Values are mean (± standard deviation) of changes in absolute concentration (µg/mL)   192 
4.3.1.4  Fatty acid composition of plasma non-esterified fatty acids (NEFA) 
Table  4.14  describes  the  maternal  plasma  NEFA  fatty  acid  composition  expressed  as 
percentages (%) of each fatty acid, for the two groups during pregnancy (20, 34, and 38 
weeks gestation). Repeated measures ANOVA identified a significant effect of time on 
percentages of many fatty acids and a significant effect of group on the percentages of 
several fatty acids but particularly EPA, DPA, DHA, and total n-3 PUFA. There were 
significant time x group interactions for EPA, total n-3 PUFA, and ARA. At 20 weeks 
gestation the salmon group had a significantly higher percentages of DHA and total n-3 
PUFA in plasma NEFA compared to the control group. At 34 and 38 weeks gestation the 
salmon group exhibited significantly higher percentages of EPA, DPA, DHA and total n-3 
PUFA. The percentage of EPA decreased and that of DHA increased during pregnancy in 
the control group (p for trend = 0.042, < 0.001), whereas they both increased in the salmon 
group (p  for trend  =  0.018,  <  0.001).  The  changes  in  %  EPA  in  plasma  NEFA  were 
significantly different between groups (Table 4.15). Also, plasma NEFA % ARA increased 
significantly in both groups (p for trend < 0.001 for the control, and 0.014 for the salmon 
group), but the increase was significantly greater in the control group (Table 4.15).  
Table 4.6 describes the absolute concentration (µg/mL plasma) of plasma NEFA fatty 
acids for both groups during pregnancy. Repeated measures ANOVA identified significant 
effects of time on the concentrations of all fatty acids detected in NEFA and in total plasma 
NEFA. There were significant effects of group on the concentrations of EPA, DHA, and 
total n-3 PUFA. There was a significant time x group interaction only for EPA. There were 
no significant differences in concentrations of individual NEFA at baseline. At 34 and 38 
weeks gestation the salmon group had a higher absolute concentration of EPA, and at 38 
weeks of DHA and total n-3 PUFA. The concentrations of EPA and DHA increased over 
time in both groups (all p for trend < 0.001 for both groups), but the increase was greater in 
the salmon group. The change in EPA and DHA concentrations in plasma NEFA from 
week 20 to week 38 were significantly different between groups (p = 0.001 and 0.048, 
respectively) (Table 4.17). Furthermore the increase in ARA from week 20 to week 38 was 
smaller in the salmon group (Table 4.17). Table 4.16 includes the ratios of fatty acids of 
interest in the plasma NEFA fraction. ARA/EPA, ARA/(EPA+DHA), and n-6 PUFA/n-3 
PUFA were affected by time, ARA/EPA, ARA/DHA and n-6 PUFA/n-3 PUFA by group, 
and there was a significant time x group interaction for ARA/EPA.    193 
Table 4.14 Maternal plasma non-esterified fatty acid (NEFA) content (%) during pregnancy 




(n = 61) 
Salmon 
(n = 62)  p
 * 
Control 
(n = 55) 
Salmon 
(n = 56)  p
 * 
Control 
(n = 41) 
Salmon 
(n = 47)  p
 *  Group  Time 
Time × 
group 
14:0   1.23 (±0.40)  1.39 (±0.41)  0.035  1.30 (±0.32)  1.26 (±0.30)  0.439  1.44 (±0.37)  1.43 (±0.38)  0.906  0.542  0.003  0.059 
16:0   24.12 (±3.38)  25.02 (±2.06)  0.078  26.34 (±1.82)  26.26 (±1.76)  0.822  25.82 (±1.84)  25.78 (±2.09)  0.928  0.171  <0.001  0.061 
18:0   14.59 (±3.02)  15.73 (±2.88)  0.036  13.71 (±2.53)  14.93 (±3.60)  0.043  12.57 (±2.24)  13.56 (±2.91)  0.082  0.043  <0.001  0.967 
20:0  0.98 (±0.47)  1.12 (±0.47)  0.110  0.40 (±0.35)  0.56 (±0.59)  0.082  1.49 (±0.34)  1.66 (±0.38)  0.031  0.032  <0.001  0.783 
SFA  40.93 (±6.04)  43.26 (±4.02)  0.013  41.75 (±3.18)  43.00 (±4.11)  0.077  41.32 (±3.04)  42.42 (±3.84)  0.142  0.018  0.693  0.332 
16:1n-7   2.74 (±0.95)  2.62 (±0.81)  0.451  2.93 (±0.82)  2.59 (±0.69)  0.019  3.21 (±0.95)  2.73 (±0.93)  0.018  0.087  0.013  0.064 
18:1n-9   31.81 (±4.96)  31.08 (±4.05)  0.376  31.62 (±3.60)  29.62 (±4.56)  0.012  32.39 (±3.55)  30.27 (±4.21)  0.013  0.035  0.486  0.178 
18:1n-9 Trans  3.08 (±3.21)  2.40 (±0.83)  0.108  2.18 (±0.34)  2.01 (±0.44)  0.031  2.41 (±0.48)  2.33 (±0.58)  0.483  0.040  0.020  0.102 
20:1n-9  1.56 (±3.32)  0.99 (±0.82)  0.192  0.39 (±0.07)  0.38 (±0.10)  0.648  0.59 (±0.20)  0.75 (±0.44)  0.036  0.116  0.003  0.051 
MUFA  39.19 (±6.40)  37.09 (±4.63)  0.040  37.11 (±4.33)  43.60 (±5.32)  0.008  38.60 (±4.27)  36.08 (±5.02)  0.013  0.006  0.003  0.980 
20:5n-3 (EPA)  0.29 (±0.20)  0.33 (±0.17)  0.188  0.22 (±0.10)  0.41 (±0.19)  <0.001  0.22 (±0.09)  0.44 (±0.27)  <0.001  <0.001  0.802  0.002 
22:5n-3 (DPA)   0.38 (±0.22)  0.41 (±0.17)  0.425  0.43 (±0.14)  0.54 (±0.19)  0.001  0.42 (±0.13)  0.54 (±0.18)  0.001  0.001  <0.001  0.269 
22:6n-3 (DHA)   1.89 (±1.28)  2.45 (±1.34)  0.021  3.08 (±0.90)  4.12 (±1.21)  <0.001  2.85 (±0.85)  4.29 (±1.42)  <0.001  <0.001  <0.001  0.113 
Total n-3  2.83 (±1.26)  3.40 (±1.25)  0.014  4.64 (±1.14)  6.01 (±1.50)  <0.001  3.48 (±1.02)  5.26 (±1.81)  <0.001  <0.001  <0.001  0.033 
18:2n-6   11.97 (±2.24)  12.58 (±1.81)  0.102  12.72 (±2.07)  12.68 (±1.59)  0.920  12.71 (±1.74)  12.43 (±1.35)  0.400  0.784  0.051  0.005 
18:3n-6   0.57 (±0.76)  0.48 (±0.49)  0.425  0.06 (±0.22)  0.19 (±1.23)  0.411  0.11 (±0.05)  0.08 (±0.08)  0.083  0.690  <0.001  0.102 
20:3n-6   0.43 (±0.17)  0.45 (±0.17)  0.612  0.48 (±0.12)  0.47 (±0.18)  0.703  0.48 (±0.18)  0.45 (±0.13)  0.519  0.705  0.140  0.147 
20:4n-6 (ARA)   2.52 (±0.94)  2.70 (±1.03)  0.315  3.22 (±0.89)  3.01 (±0.85)  0.210  3.31 (±0.95)  3.27 (±0.88)  0.849  0.620  <0.001  0.004 
Total n-6  17.05 (±7.26)  16.25 (±2.10)  0.410  16.49 (±2.12)  16.39 (±2.13)  0.802  16.60 (±2.03)  16.24 (±1.34)  0.321  0.260  0.430  0.623 
PUFA  19.88 (±7.18)  19.65 (±2.72)  0.817  21.14 (±2.75)  22.40 (±2.74)  0.017  20.08 (±2.56)  21.50 (±2.59)  0.012  0.178  0.023  0.331 
*p-Values from independent samples t-test  
Values are mean (± standard deviation) percentage levels (%) of total fatty acids in NEFA 
 
Table 4.15 Changes of percentage non-esterified fatty acid levels (%NEFA) for selected fatty acids of interest 
Fatty Acids  34-20 week change  38-20 week change 
 
Control 
(n = 55) 
Salmon 
(n = 56)  p
 * 
Control 
(n = 41) 
Salmon 
(n = 47)  p
 * 
20:5n-3 (EPA)   -0.07 (±0.21)  0.07 (±0.20)  <0.001  -0.06 (±0.20)  0.09 (±0.25)  0.004 
22:6n-3 (DHA)   1.17 (±1.27)  1.61 (±1.46)  0.101  1.07 (±1.25)  1.72 (±1.95)  0.072 
20:4n-6 (ARA)   0.70 (±1.13)  0.22 (±0.93)  0.018  0.96 (±1.02)  0.43 (±1.13)  0.025 
*p-values from independent samples t-test  
Values are mean (± standard deviation) of changes in percentage levels (%)   194 
 
Table 4.16 Absolute concentration of maternal plasma non-esterified fatty acids (NEFA) during pregnancy 




(n = 61) 
Salmon 
(n = 62)  p
 * 
Control 
(n = 55) 
Salmon 
(n = 56)  p
 * 
Control 
(n = 41) 
Salmon 
(n = 47)  p
 *  Group  Time 
Time × 
group 
14:0   0.53 (±0.57)  0.65 (±0.69)  0.296  0.97 (±0.71)  0.82 (±0.63)  0.260  2.03 (±0.98)  1.80 (±0.94)  0.258  0.331  <0.001  0.226 
16:0   10.52 (±10.35)  11.82 (±11.87)  0.525  18.91 (±10.68)  17.19 (±12.95)  0.451  35.39 (±11.81)  31.82 (±11.93)  0.162  0.269  <0.001  0.307 
18:0   6.61 (±7.53)  7.58 (±7.98)  0.493  9.55 (±5.04)  9.70 (±9.86)  0.923  16.60 (±3.62)  15.72 (±3.64)  0.259  0.505  <0.001  0.501 
20:0   0.43 (±0.45)  0.53 (±0.67)  0.326  0.29 (±0.39)  0.39 (±0.61)  0.292  2.01 (±0.71)  2.03 (±0.89)  0.915  0.503  <0.001  0.943 
SFA  18.10 (±18.64)  20.58 (±20.94)  0.492  29.72 (±16.27)  28.11 (±22.99)  0.672  56.03 (±16.28)  51.36 (±16.74)  0.189  0.974  <0.001  0.350 
16:1n-7  1.22 (±1.23)  1.29 (±1.51)  0.761  2.20 (±1.78)  1.70 (±1.29)  0.097  4.54 (±2.34)  3.60 (±2.23)  0.055  0.078  <0.001  0.098 
18:1n-9  13.89 (±13.17)  14.99 (±15.58)  0.678  22.83 (±13.61)  19.37 (±13.95)  0.191  44.85 (±16.65)  38.85 (±18.47)  0.114  0.138  <0.001  0.239 
18:1n-9 Trans  1.31 (±1.55)  1.15 (±1.24)  0.518  1.56 (±0.95)  1.33 (±1.00)  0.213  3.32 (±1.29)  2.99 (±1.65)  0.303  0.084  <0.001  0.992 
20:1n-9  0.65 (±1.23)  0.46 (±0.50)  0.270  0.27 (±0.14)  0.27 (±0.26)  0.964  0.81 (±0.37)  0.92 (±0.74)  0.399  0.256  <0.001  0.068 
MUFA  17.07 (±15.80)  17.89 (±18.64)  0.795  26.86 (±16.30)  22.67 (±16.33)  0.181  53.53 (±20.07)  46.36 (±22.33)  0.118  0.587  <0.001  0.399 
20:5n-3 (EPA)  0.12 (±0.12)  0.15 (±0.12)  0.186  0.15 (±0.10)  0.24 (±0.19)  0.003  0.28 (±0.11)  0.48 (±0.23)  <0.001  <0.001  <0.001  0.002 
22:5n-3 (DPA)  0.16 (±0.19)  0.19 (±0.21)  0.476  0.30 (±0.16)  0.34 (±0.30)  0.324  0.55 (±0.17)  0.61 (±0.18)  0.108  0.104  <0.001  0.686 
22:6n-3 (DHA)  0.86 (±1.16)  1.14 (±1.31)  0.222  2.08 (±1.08)  2.67 (±2.15)  0.072  3.69 (±0.98)  4.88 (±1.45)  <0.001  <0.001  <0.001  0.094 
Total n-3  1.25 (±1.40)  1.58 (±1.65)  0.240  3.18 (±1.64)  3.85 (±2.93)  0.142  4.52 (±1.17)  5.97 (±1.77)  <0.001  <0.001  <0.001  0.124 
18:2n-6  5.10 (±4.55)  5.91 (±6.06)  0.410  9.18 (±5.64)  8.38 (±6.15)  0.479  17.46 (±6.24)  15.53 (±6.56)  0.164  0.284  <0.001  0.174 
18:3n-6  0.26 (±0.37)  0.25 (±0.34)  0.906  0.05 (±0.20)  0.08 (±0.45)  0.582  0.14 (±0.09)  0.11 (±0.11)  0.109  0.623  <0.001  0.253 
20:3n-6  0.17 (±0.13)  0.19 (±0.16)  0.473  0.34 (±0.19)  0.32 (±0.37)  0.746  0.63 (±0.24)  0.54 (±0.20)  0.061  0.063  <0.001  0.118 
20:4n-6 (ARA)  1.05 (±1.02)  1.16 (±1.04)  0.562  2.17 (±1.10)  1.99 (±1.99)  0.562  4.27 (±0.97)  3.79 (±1.11)  0.034  0.135  <0.001  0.077 
Total n-6  6.59 (±5.84)  7.52 (±7.43)  0.451  11.75 (±6.73)  10.80 (±8.19)  0.507  22.50 (±6.76)  19.97 (±7.40)  0.099  0.211  <0.001  0.162 
PUFA  7.85 (±7.14)  9.10 (±8.99)  0.399  14.93 (±8.24)  14.65 (±10.96)  0.879  27.02 (±7.39)  25.94 (±8.44)  0.527  0.796  <0.001  0.408 
Total fatty acids  43.01 (±40.82)  47.57 (±48.11)  0.576  71.51 (±39.93)  65.43 (±48.31)  0.473  136.58 (±41.98)  123.66 (±46.35)  0.176  0.251  <0.001  0.350 
ARA/DHA  1.71 (±3.55)  1.10 (±0.76)  0.213  1.07 (±0.15)  0.75 (±0.17)  <0.001  1.18 (±0.19)  0.79 (±0.17)  <0.001  0.041  0.133  0.573 
ARA/EPA  7.32 (±2.44)  7.31 (±2.76)  0.988  14.76 (±6.02)  8.11 (±4.59)  <0.001  17.07 (±6.99)  9.13 (±4.36)  <0.001  <0.001  <0.001  <0.001 
ARA/(DHA+EPA)  1.90 (±2.20)  1.59 (±2.01)  0.430  1.00 (±0.16)  0.69 (±0.18)  <0.001  1.10 (±0.18)  0.72 (±0.16)  <0.001  0.164  0.001  0.384 
n-6/n-3  6.75 (±3.45)  5.49 (±2.46)  0.022  3.71 (±0.84)  2.89 (±0.86)  <0.001  5.15 (±1.55)  3.44 (±1.26)  <0.001  <0.001  <0.001  0.326 
*p-values from independent samples t-test  
Values are mean (± standard deviation) absolute concentrations (µg fatty acid/mL plasma) in NEFA   195 
 
Table 4.17 Changes in non-esterified fatty acid (NEFA) absolute concentration for selected fatty acids of interest 
Fatty Acids  34-20 week change  38-20 week change 
 
Control 
(n = 55) 
Salmon 
(n = 56)  p
 * 
Control 
(n = 41) 
Salmon 
(n = 47)  p
 * 
20:5n-3 (EPA)  0.03 (±0.16)  0.09 (±0.24)  0.113  0.17 (±0.15)  0.33 (±0.28)  0.001 
22:6n-3 (DHA)  1.28 (±1.58)  1.56 (±2.82)  0.524  2.88 (±1.44)  3.69 (±2.19)  0.048 
20:4n-6 (ARA)  1.18 (±1.55)  0.87 (±2.45)  0.436  3.29 (±1.41)  2.59 (±1.67)  0.041 
*p-values from independent samples t-test  
Values are mean (± standard deviation) of changes in absolute concentration (µg/mL)   196 
4.3.1.5  Total plasma lipids and total plasma ARA, EPA, DPA and DHA 
Figure 4.14 describes the total plasma PC, TAG, CE and NEFA concentrations (g/mL) 
across pregnancy in the control group (values can be seen on Table 4.4, Table 4.8, Table 
4.12, and Table 4.16). As it can be seen from the graph, higher absolute concentrations 
were observed for PC and CE, and then TAG. NEFA concentration was the lowest and on 
the graph is represented with a different scale from the other fractions. It was shown that 
total fatty acid concentrations in each lipid fraction changed significantly during pregnancy 
(all p for trend < 0.001). Total PC concentration increased (by 40%) from week 20 to week 
34 gestation and then it decreased at 38 weeks (by 25% compared to 20 weeks). Total 
plasma TAG concentration increased from 20 to 34 weeks (by 70%) and remained stable 
thereafter. Interestingly, total plasma CE concentration increased progressively throughout 
pregnancy (by 54% at 38 weeks compared to 20 weeks), resulting in higher concentrations 
than  any  other  fraction  at  38  weeks.  Total  plasma  NEFA  concentration  increased 
remarkably during pregnancy (by 220% at 38 weeks compared to 20 weeks). These data 
show that pregnancy is associated with increase of total blood lipid concentrations and that 
significant changes occur between mid to late pregnancy. 
 
Figure 4.14 Total plasma PC, TAG, CE, and NEFA concentrations (g/mL) across pregnancy in the 
control group 




Table  4.18  describes  the  maternal  total  plasma  EPA,  DHA,  DPA  and  ARA 
concentration during pregnancy calculated by summing the concentrations of each of these 
fatty acids of interest across the four plasma lipid fractions (i.e. TAG + PC + CE + NEFA). 
Repeated  measures  ANOVA  showed  significant  effects  of  time  on  the  total  plasma 
concentration of all four fatty acids and significant group effects on the concentrations of 
EPA, DHA and DPA. There were significant time x group interactions for EPA and ARA. 
These were further explored by pair-wise comparisons between groups at each time point. 
There were no significant differences between the two groups at 20 weeks gestation. At 34 
and  38  weeks  gestation,  the  salmon  group  had  lower  total  plasma  ARA  concentration 
compared to the control group. At 34 and 38 weeks gestation, the salmon group had higher 
total  plasma  EPA  and  DHA  concentrations.  Total  plasma  DPA  concentration  was 
significantly higher in the salmon group at 38 weeks. Total plasma EPA decreased over 
time during pregnancy in the control group (p for trend = 0.030), whereas it increased in 
the salmon group (p for trend = 0.001). Total plasma ARA decreased during pregnancy in 
both groups (both p for trend < 0.001), but the decrease was greater in the salmon group. 
Total plasma DHA increased and then decreased during pregnancy in both groups (both p 
for trend < 0.001). Total plasma DPA decreased during pregnancy in the control (p for 
trend < 0.001). 
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Table 4.18 Maternal total plasma concentrations (g/mL) of fatty acids of interest during pregnancy 




(n = 61) 
Salmon 
(n = 62)  p
 * 
Control 
(n = 55) 
Salmon 
(n = 56)  p
 * 
Control 
(n = 41) 
Salmon 
(n = 47)  p
 *  Group  Time 
Time × 
group 
Total EPA  30.4 (±19.9)  34.6 (±21.0)  0.265  30.3 (±14.9)  50.3 (±24.2)  <0.001  23.1 (±9.9)  45.6 (±22.6)  <0.001  <0.001  0.001  0.003 
Total DHA  129.3 (±55.7)  141.5 (±63.9)  0.273  163 (±41.9)  205.9 (±71.9)  <0.001  110.9 (±31.3)  165.9 (±68.1)  <0.001  <0.001  <0.001  0.201 
Total DPA  25.1 (±12.4)  24.4 (±11.2)  0.728  26.8 (±8.5)  29.8 (±9.8)  0.083  16.6 (±7.9)  22.2 (±11.9)  0.013  0.029  <0.001  0.l74 
Total ARA  412.1 (±141.7)  376.5 (±144.3)  0.180  477.6 (±111.5)  390.3 (±109.1)  <0.001  359.8 (±84.6)  320.8 (±94.0)  0.048  0.080  <0.001  0.014 
*p-values from independent samples t-test  
Values are mean (± standard deviation) absolute concentrations (µg fatty acid/mL plasma) of each fatty acid concentration in all lipid fractions (PC+TAG+CE+NEFA) 
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4.3.2  Fatty acid composition of maternal peripheral blood 
mononuclear cells (PBMC) during pregnancy 
Table 4.19 describes the maternal PBMC fatty acid composition expressed as percentages 
(%)  of  each  fatty  acid,  for  the  two  groups  during  pregnancy  (20,  34,  and  38  weeks 
gestation).  Repeated  measures  ANOVA  identified  a  significant  effect  of  time  on 
percentages of many fatty acids and a significant effect of group on the percentages of 
EPA, DHA, total n-3 PUFA, linoleic acid (18:2n-6) and ARA. There were significant time 
x group interactions for oleic acid (18:1n-9), EPA, DPA, DHA, total n-3 PUFA, and totals 
n-6 PUFA. At 20 weeks gestation the salmon group had a significantly higher percentage 
of  linoleic  acid  in  PBMC  lipids  compared  to the  control  group.  At  34  and  38  weeks 
gestation the salmon group exhibited significantly higher percentages of EPA, DPA, DHA 
and total n-3 PUFA in PBMC. The percentages of EPA, DPA and DHA decreased during 
pregnancy  in  the  control  group  (all  p  for  trend  ≤  0.001),  while  these  decreases  were 
prevented in the salmon group for EPA and DPA (p for trend = 0.598, 0.051), whereas 
percentage DHA increased in the salmon group (p for trend = 0.005) (Figure 4.15). The 
changes in % EPA, DPA and DHA in PBMC were significantly different between groups 
(Table 4.20). Also, PBMC % ARA decreased significantly in both groups (p for trend = 
0.005 for control, and < 0.001 for salmon group), and the decrease tended to be greater in 
the salmon group but not significantly so (Table 4.20).  
 
Figure 4.15 Maternal PBMC EPA (A) and DHA (B) percentages during pregnancy for both groups 
p < 0.05; for exact values see text and Table 4.19   200 
Figure 4.16 shows the correlation between maternal plasma PC and PBMC fatty acid 
composition (both expressed as percentages of total fatty acids). Data from all time points 
during pregnancy in both groups showed that maternal plasma PC EPA, DHA, DPA, and 
ARA percentage levels correlated significantly with maternal PBMC EPA, DHA, DPA and 
ARA percentage levels (Figure 4.16, all p < 0.001). Data from individual time points in 
both groups during pregnancy also showed significant correlations. Figure 4.17 presents 
data from 38 weeks gestation in both groups, showing significant correlations between 
maternal plasma PC and PBMC content for EPA and DHA (all p < 0.001). These data 
show that plasma PC can be used to indicate the fatty acid composition in cells. 
 
Figure 4.16 Correlation between maternal plasma PC (%) and PBMC content of EPA (A), DHA (B), 
DPA (C), ARA (D) for all time points in both groups   201 
 
Figure 4.17 Correlation between maternal plasma PC (%) and PBMC content of EPA (A), DHA (B) at 
38 weeks gestation in both groups 
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Table 4.19 Maternal peripheral blood mononuclear cell (PBMC) fatty acid composition (%) during pregnancy- between group comparisons 




(n = 57) 
Salmon 
(n = 61)  p
 * 
Control 
(n = 53) 
Salmon 
(n = 55)  p
 * 
Control 
(n = 41) 
Salmon 
(n = 47)  p
 *  Group  Time 
Time × 
group 
14:0  1.05 (±0.69)  0.94 (±0.77)  0.399  1.29 (±0.73)  1.31 (±0.84)  0.883  0.98 (±0.89)  1.20 (±1.33)  0.371  0.682  0.082  0.371 
16:0   20.78 (±2.30)  20.15 (±3.30)  0.233  21.89 (±1.71)  21.97 (±1.32)  0.793  23.23 (±2.41)  23.01 (±2.04)  0.634  0.800  <0.001  0.462 
18:0   21.61 (±5.03)  21.27 (±4.73)  0.707  19.46 (±3.66)  19.97 (±4.00)  0.494  19.04 (±2.86)  18.47 (±2.51)  0.329  0.402  <0.001  0.430 
20:0   0.58 (±0.44)  0.57 (±0.39)  0.933  0.68 (±0.22)  0.70 (±0.26)  0.638  0.46 (±0.16)  0.51 (±0.20)  0.270  0.928  0.001  0.684 
SFA  44.02 (±5.43)  42.93 (±5.18)  0.262  43.32 (±3.47)  43.94 (±4.65)  0.429  43.71 (±3.85)  43.18 (±3.50)  0.505  0.458  0.946  0.095 
16:1n-7   0.85 (±0.56)  0.76 (±0.38)  0.311  0.92 (±0.41)  0.79 (±0.28)  0.044  0.93 (±0.45)  0.92 (±0.48)  0.971  0.606  0.083  0.783 
18:1n-9   17.30 (±2.64)  17.74 (±2.39)  0.341  18.82 (±1.96)  18.29 (±1.81)  0.150  20.17 (±2.08)  19.61 (±2.00)  0.200  0.894  <0.001  0.016 
18:1n-9 Trans  1.90 (±1.13)  1.64 (±0.64)  0.132  2.13 (±0.40)  1.88 (±0.31)  0.001  1.58 (±0.26)  1.48 (±0.23)  0.066  0.007  <0.001  0.411 
20:1n-9   0.75 (±0.30)  0.71 (±0.31)  0.532  1.38 (±0.59)  1.21 (±0.47)  0.099  71 (±0.18)  0.70 (±0.27)  0.898  0.108  <0.001  0.241 
MUFA  20.79 (±2.74)  20.85 (±2.84)  0.901  23.25 (±1.96)  22.17 (±1.95)  0.005  23.38 (±2.45)  22.71 (±2.32)  0.191  0.367  <0.001  0.040 
20:5n-3 (EPA)  0.63 (±0.53)  0.58 (±0.48)  0.563  0.34 (±0.19)  0.55 (±0.21)  <0.001  0.27 (±0.09)  0.55 (±0.22)  <0.001  0.001  0.001  0.017 
22:5n-3 (DPA)  1.70 (±0.48)  1.67 (±0.48)  0.742  1.36 (±0.30)  1.56 (±0.37)  0.003  1.31 (±0.29)  1.48 (±0.29)  0.007  0.084  <0.001  0.034 
22:6n-3 (DHA)  2.38 (±0.60)  2.55 (±0.52)  0.118  2.13 (±0.52)  2.79 (±0.81)  <0.001  1.95 (±0.35)  2.70 (±0.54)  <0.001  <0.001  0.002  <0.001 
Total n-3  4.72 (±1.36)  4.80 (v1.13)  0.731  3.83 (±0.86)  4.91 (v1.25)  <0.001  3.53 (±0.53)  4.73 (±0.88)  <0.001  <0.001  <0.001  <0.001 
18:2n-6   9.71 (±3.29)  10.96 (±3.42)  0.045  10.43 (±2.50)  10.86 (±2.62)  0.376  10.17 (±2.45)  10.94 (±2.10)  0.115  0.013  0.776  0.148 
20:2n-6   0.60 (±0.37)  0.51 (±0.22)  0.114  0.49 (±0.17)  0.50 (±0.16)  0.734  0.52 (±0.27)  0.52 (±0.34)  0.999  0.077  0.105  0.107 
20:3n-6   2.03 (±0.58)  2.01 (±0.45)  0.870  1.72 (±0.33)  1.62 (±0.33)  0.136  2.12 (±1.19)  2.20 (±1.67)  0.790  0.639  0.003  0.615 
20:4n-6 (ARA)  18.13 (±2.52)  17.93 (±3.00)  0.695  16.71 (±3.14)  15.64 (±3.29)  0.089  16.58 (±2.93)  15.71 (±2.25)  0.121  0.041  <0.001  0.589 
Total n-6  30.47 (±3.76)  31.42 (±3.45)  0.156  29.34 (±3.38)  28.63 (±3.90)  0.317  29.38 (±2.69)  29.37 (±2.57)  0.983  0.942  <0.001  0.027 
PUFA  35.19 (±4.05)  36.22 (±3.46)  0.140  33.17 (±3.83)  33.54 (±4.56)  0.651  32.91 (±2.91)  34.11 (±2.97)  0.061  0.173  <0.001  0.220 
ARA/DHA  7.94 (±1.73)  7.35 (±1.90)  0.080  8.07 (±1.55)  5.93 (±1.72)  <0.001  8.65 (±1.60)  6.00 (±1.16)  <0.001  <0.001  0.008  <0.001 
ARA/EPA  53.16 (±52.62)  43.45 (±22.33)  0.190  57.22 (±21.52)  32.69 (±14.80)  <0.001  69.88 (±30.61)  32.34 (±12.39)  <0.001  <0.001  0.214  0.035 
ARA/(DHA+EPA)  6.50 (±1.69)  6.11 (±1.72)  0.210  6.98 (±1.32)  4.98 (±1.50)  <0.001  7.57 (±1.51)  5.00 (±1.03)  <0.001  <0.001  0.070  <0.001 
n-6/n-3  6.91 (±1.80)  6.84 (±1.48)  0.821  7.92 (±1.35)  6.17 (±1.57)  <0.001  8.48 (±1.22)  6.40 (±1.24)  <0.001  <0.001  0.001  <0.001 
*p-values from independent samples t-test 
Values are mean (± standard deviation) percentage levels (%) of total fatty acids in PBMC   203 
 
Table 4.20 Peripheral blood mononuclear cell (PBMC) fatty acid changes 
Fatty Acids  34-20 week change  38-20 week change 
 
Control 
(n = 53) 
Salmon 
(n = 55)  p
 * 
Control 
(n = 41) 
Salmon 
(n = 47)  p
 * 
20:5n-3 (EPA)  -0.31 (±0.57)  -0.02 (±0.49)  0.006  -0.37 (±0.59)  -0.06 (±0.55)  0.012 
22:6n-3 (DHA)  -0.25 (±0.75)  0.27 (±0.68)  <0.001  -0.41 (±0.55)  0.07 (±0.62)  <0.001 
20:4n-6 (ARA)  -1.07 (±3.01)  -2.05 (±3.25)  0.113  -1.61 (±3.36)  -1.89 (±3.01)  0.680 
22:5n-3 (DPA)  -0.34 (±0.56)  -0.07 (±0.51)  0.014  -0.40 (±0.56)  -0.17 (±0.51)  0.048 
*p-Values from independent samples t-test 
Values are mean (± standard deviation) of changes in percentage levels (%)   204 
4.3.3  Fatty acid composition of placenta and umbilical cord  
Table 4.21 shows the fatty acid composition of placenta and umbilical cord tissues in both 
groups, expressed as percentage (%) of each fatty acid. The salmon group had significantly 
higher percentages of α-linolenic acid (18:3n-3), EPA, DPA, DHA, DPA, and total n-3 
PUFA compared to the control group and significantly lower percentages of ARA and total 
n-6  PUFA.  Finally,  the  fatty  acid  ratios  calculated  were  all  significantly  lower  in  the 
salmon group compared to the control group (all p < 0.001). 
The  percentages  of  DPA,  DHA  and  total  n-3  PUFA  were  significantly  higher  in 
umbilical cord tissue of the salmon group compared to the control group. The percentage 
of  ARA  in  cord  tissue  lipids  did  not  differ  between  the  groups.  All  fatty  acid  ratios 
calculated were significantly lower in the salmon group compared to control group (all p < 
0.001, apart from ARA/EPA for which p = 0.022). 
Table 4.21 Placenta and cord tissue fatty acid composition expressed as percentage levels (%) 
Fatty Acids  Placenta tissue  Cord tissue 
 
Control 
(n = 45) 
Salmon 
(n = 47)  p
 * 
Control 
(n = 41) 
Salmon 
(n = 45)  p
 * 
14:0   0.42 (±0.09)  0.45 (±0.15)  0.286  1.45 (±0.34)  1.45 (±0.46)  0.964 
16:0 (%)  25.25 (±0.96)  25.40 (±0.89)  0.458  26.88 (±1.98)  27.47 (±2.59)  0.247 
18:0 (%)  12.21 (±0.77)  12.06 (±0.96)  0.416  16.55 (±1.60)  16.28 (±1.78)  0.465 
20:0 (%)  0.11 (±0.02)  0.11 (±0.03)  0.315  0.40 (±0.17)  0.43 (±0.19)  0.505 
24:0 (%)  -  -    4.45 (±0.88)  4.34 (±0.75)  0.565 
SFA  38.00 (±0.67)  38.03 (±0.90)  0.868  49.73 (±1.97)  49.98 (±2.30)  0.600 
16:1n-7 (%)  0.84 (±0.20)  0.83 (±0.19)  0.701  1.90 (±0.36)  1.84 (±0.59)  0.574 
18:1n-9 (%)  11.14 (±0.94)  11.19 (±0.94)  0.787  18.26 (±2.03)  17.14 (±1.94)  0.011 
18:1n-9 Trans (%)  1.78 (±0.19)  1.70 (±0.15)  0.026  3.89 (±0.68)  3.56 (±0.51)  0.013 
20:1n-9 (%)  0.23 (±0.03)  0.24 (±0.04)  0.228  0.95 (±0.32)  0.86 (±0.22)  0.128 
MUFA  13.99 (±1.16)  13.96 (±1.06)  0.885  25.00 (±2.92)  23.40 (±2.75)  0.011 
18:3n-3  0.11 (±0.03)  0.13 (±0.04)  0.009  -  -   
20:5n-3 (EPA) (%)  0.18 (±0.05)  0.33 (±0.13)  <0.001  0.31 (±0.26)  0.43 (±0.56)  0.192 
22:5n-3 (DPA) (%)  0.95 (±0.17)  1.11 (±0.20)  <0.001  0.57 (±0.24)  0.71 (±0.29)  0.017 
22:6n-3 (DHA)  4.92 (±0.79)  5.93 (±0.94)  <0.001  3.65 (±0.86)  4.30 (±0.88)  0.001 
Total n-3  6.15 (0.77)  7.50 (0.97)  <0.001  4.53 (1.07)  5.44 (1.22)  <0.001 
18:2n-6 (%)  11.22 (±1.43)  11.75 (±1.59)  0.095  4.48 (±1.38)  5.06 (±1.54)  0.073 
18:3n-6  0.13 (±0.03)  0.13 (±0.03)  0.298  0.21 (±0.11)  0.26 (±0.36)  0.383 
20:2n-6 (%)  0.42 (±0.05)  0.44 (±0.06)  0.033  0.41 (±0.11)  0.52 (±0.26)  0.010 
20:3n-6 (%)  6.19 (±0.91)  5.88 (±0.96)  0.114  2.41 (±0.43)  2.57 (±0.49)  0.116 
20:4n-6 (ARA) (%)  23.89 (±1.38)  22.32 (±2.11)  <0.001  12.07 (±2.30)  11.74 (±1.72)  0.450 
Total n-6  41.85 (±1.32)  40.51 (±1.50)  <0.001  19.58 (±3.13)  20.15 (±2.76)  0.372 
22:2n-9 (%)  -  -    1.16 (±0.36)  1.03 (±0.32)  0.071 
PUFA  48.01 (±1.34)  48.01 (±1.59)  0.985  25.27 (±3.79)  26.62 (±3.45)  0.088 
ARA/DHA  4.97 (±0.81)  3.85 (±0.68)  <0.001  3.38 (±0.46)  2.79 (±0.41)  <0.001 
ARA/EPA  148.08 (56.23)  80.94 (±38.73)  <0.001  54.04 (±29.86)  40.72 (±23.08)  0.022 
ARA/(DHA+EPA)  4.79 (±0.76)  3.64 (±0.64)  <0.001  3.12 (±0.48)  2.55 (±0.44)  <0.001 
n-6/n-3  6.92 (±1.00)  5.50 (±0.81)  <0.001  4.46 (±0.76)  3.82 (±0.68)  <0.001 
*p-values from independent samples t-test 
Values are mean (± standard deviation) percentage levels (%) of total fatty acids in placenta and cord tissues   205 
4.3.4  Summary of the data 
Table 4.22 summarises the findings of this study with regard to lipid concentrations and 
the  fatty  acids  of  principal  interest  (ARA,  EPA,  DPA,  DHA).  Pregnancy  resulted  in 
increased total plasma fatty acid concentrations in all lipid fractions (especially for CE and 
NEFA) apart from the PC fraction for which total plasma fatty acids increased initially 
(between 20 to 34 weeks) and then decreased (at 38 weeks). These data show that the 
pregnancy associated hyperlipidemia occurred and that it was not affected by the salmon 
intervention. Total plasma ARA, EPA, DPA and DHA concentrations decreased during 
pregnancy. The salmon intervention reversed the change in LC n-3 PUFA, resulting in 
increased total plasma EPA, DPA and DHA concentrations. However, for ARA the salmon 
intervention resulted in a further decrease in total plasma concentration. ARA decreased in 
plasma PC, TAG (%), and PBMC, whereas it increased in plasma CE (µg/mL) and NEFA 
during pregnancy. The salmon intervention resulted in further decrease of ARA in plasma 
PC  (%)  and  CE,  and  in  PBMC.  Also,  salmon  decreased  ARA  in  placental  tissue. 
Pregnancy resulted in decreased EPA in plasma PC, TAG (%) and CE (%), and PBMC, 
whereas  NEFA  EPA  (µg/mL)  increased  during  pregnancy.  The  salmon  intervention 
resulted  in  increased  percentage  levels  and  concentrations  of  EPA  in  all  plasma  lipid 
fractions,  and  in  PBMC  and  placenta  tissue.  Pregnancy  resulted  in  decreased  DPA  in 
maternal plasma PC and CE, and PBMC, whereas it resulted in increased DPA in plasma 
NEFA and TAG (µg/mL). The effect of the salmon intervention was to increase DPA in all 
plasma lipid fractions and PBMC during pregnancy, and in placenta and cord tissues at 
delivery. Pregnancy decreased DHA in plasma PC and in PBMC, whereas it increased 
DHA  in  plasma  TAG  (µg/mL),  CE  (µg/mL),  and  NEFA.  The  effect  of  the  salmon 
intervention on DHA was to reverse the pregnancy-associated decrease in plasma PC and 
PMBC, resulting in increased levels, and it further increased DHA in plasma TAG, CE, 
and  NEFA.  The  salmon  intervention  also  resulted  in  higher  DHA  status  in  cord  and 
placenta tissue at delivery.  
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Table 4.22 The effect of pregnancy and the effect of the salmon intervention on maternal total lipid 
concentrations and the fatty acids of principal interest 
  Effect of pregnancy  Effect of salmon 
Total plasma PC (g/mL)  ↑ then ↓  ↔ 
Total plasma TAG (g/mL)  ↑  ↔ 
Total plasma CE (g/mL)  ↑  ↔ 
Total plasma NEFA (g/mL)  ↑  ↔ 
Total plasma ARA (g/mL)  ↓  ↓ 
Total plasma EPA (g/mL)  ↓  ↑ 
Total plasma DPA (g/mL)  ↓  ↑ 
Total plasma DHA (g/mL)  ↑ then ↓  ↑ 
ARA in: 
Plasma PC (g/mL) 
Plasma PC (%) 
Plasma TAG (g/mL) 
Plasma TAG (%) 
Plasma CE (g/mL) 
Plasma CE (%) 
Plasma NEFA (g/mL) 
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4.4  Discussion 
 
4.4.1  Discussion of the current findings 
This is the first study to report the effect of increased salmon consumption in pregnant 
women upon plasma and cell fatty acid concentrations. Changes in fatty acid compositions 
of maternal lipid pools might be of importance to the woman’s own health but will be 
especially important in terms of the ability of the woman to provide key fatty acids to her 
developing foetus. The main findings of the work presented in this chapter were: 
The hypotheses being examined in this chapter are that: 
  increasing habitually low intake of oily fish (≤ 2 portions per month) to 2 portions 
per week during pregnancy, will increase maternal plasma lipid levels of EPA and 
DHA, and that these levels will be higher than in the control group; 
  the salmon intervention will increase maternal peripheral blood mononuclear cell 
(PBMC) levels of EPA and DHA, and that these levels will be higher than in the 
control group; 
  the salmon intervention will result in higher placenta and umbilical cord tissue EPA 
and DHA levels compared to the control group.  
It is evident from the data presented that all three hypotheses can be accepted. 
At  baseline  (20  weeks  gestation),  the  salmon  group  had  significantly  higher 
percentages of EPA, DHA, and total n-3 PUFA, and a lower percentage of ARA in plasma 
PC and in the other plasma lipid fractions, compared to the control group. Oily fish and 
fish oil supplements are the major dietary sources of LC n-3 PUFA that these have a major 
influence on the LC n-3 PUFA status in plasma, cells and tissues. In the current study, 
subjects were not consuming fish oil supplements (see chapter 3). This baseline difference 
in  fatty  acid  status  between  the  groups  probably  reflects  a  baseline  difference  in  fish 
consumption. Specifically, as discussed in chapter 3, it was found that the salmon group 
consumed significantly more frequently total fish and shellfish, oily fish, and non-oily fish 
at 20 weeks gestation, although the subjects were randomly assigned to the study groups. 
This information was obtained from the FFQ which reflected dietary intake in the past 
three months. Plasma lipid fatty acids reflect fairly short-term changes in the diet since 
they are associated, mainly, with continuous lipoprotein synthesis from the liver. However, 
cell  fatty  acid  composition  (especially  red  blood  cells  but  also  mononuclear  cells)  is 
affected in the long-term because of the long period of life of the cells (red blood cells   208 
have a half life of about 4 months). There were no baseline differences in the PBMC fatty 
acid composition between the groups which may reflect that the salmon group consumed 
more fish closer to the start of the intervention (20 weeks) rather than habitually for a 
longer period. The baseline differences between the two groups may be considered as a 
limitation of the current study. For this reason between group comparisons of the change in 
the fatty acid content between time points (34 minus 20 weeks, and 38 minus 20 weeks), 
along with the 3 repeated measures ANOVA, were conducted. 
Although  baseline differences were observed  for percentage  levels of certain  fatty 
acids,  there  were  no  baseline  differences  when  plasma  fatty  acids  were  expressed  as 
absolute concentrations (µg/mL plasma). Also, the effects of pregnancy and of the salmon 
intervention on maternal plasma fatty acid status did not always give the same result when 
comparing  the  two  different  types  of  expression  for  the  same  fatty  acid.  These  two 
different ways of expressing fatty acid content is an important point to be considered when 
interpreting the data. Percentages reflect the level of each fatty acid relative to the rest of 
the fatty acids in the lipid fraction studied. This means that a significant increase in the 
percentage of one fatty acid will be compensated by a decrease in the percentage  of at 
least one other fatty acid. On the other hand, the absolute concentration of each fatty acid is 
not relative to the concentration of the rest of the fatty acids, and thus a change in the 
concentration of one fatty acid is not necessarily followed by a change in that of others. 
What is more, it is possible that the absolute concentration of a fatty acid increases but its 
relative percentage remains  constant or decreases, and  vice  versa. For example,  it was 
observed  that  plasma  CE  DHA  concentration  increases  whereas  percentage  DHA  in 
plasma CE remains unchanged during pregnancy in the control group. Also, plasma TAG 
DHA concentration increased but TAG DHA percentage decreased during pregnancy in 
the control group. The inclusion of both expressions of fatty acid status in the current study 
is a strength of the current study as there is no indication for any expression being more 
advantageous than the other. The combination of the two expressions gives a better picture 
of the changes that occur. Also, it has to be pointed out here, that the current analysis does 
not take into account the pregnancy-associated plasma volume expansion. 
The calculation of absolute fatty acid concentrations as performed here, allows for 
total fatty acid absolute concentrations in each lipid class to be determined. It was observed 
that  pregnancy  resulted  in  increased  total  plasma  concentrations  of  all  lipid  fractions 
(especially for CE and NEFA), apart from the PC fraction which increased in concentration 
initially (between 20 to 34 weeks) and then decreased (at 38 weeks). The hyperlipidemia of 
pregnancy has been well established in literature (245, 255) and was seen in both groups in   209 
the  current  study  without  being  affected  by  the  salmon  intervention.  The  increased 
concentration  of  lipids  in  maternal  plasma  during  pregnancy,  especially  of  NEFA  and 
TAG, are important for ensuring supply of fatty acids to the foetus. The increased lipid 
concentration  in  maternal  plasma  results  in  the  required  concentration  gradient  at  the 
materno-foetal interface to allow for fatty acids to be transported via the placenta. 
Apart  from  the  changes  observed  in  total  fatty  acid  concentration  in  each  lipid 
fraction, there were also changes in specific fatty acids associated with pregnancy which 
were  observed  in  the  control  group.  In  total  plasma,  ARA,  EPA,  DPA  and  DHA 
concentrations decreased during pregnancy. More specifically, changes were also observed 
with each lipid fraction. ARA, EPA, DPA and DHA concentrations decreased in plasma 
PC whereas they increased in plasma NEFA, and either increased or remained stable in CE 
and  TAG.  On  the  other  hand,  ARA,  EPA,  DPA,  and  DHA  expressed  as  percentages 
decreased in all lipid fractions apart from the NEFA fraction where they increased. These 
results suggest that the mother is progressively depleted in these fatty acids (especially 
DHA and ARA) during pregnancy as they are transported to the foetus to be used for foetal 
growth,  visual  and  neuronal  development  (245,  251).  The  decrease  in  EPA  is  also 
associated to the fact that it is metabolised to DPA and eventually to DHA which is highly 
demanded by the foetus (47, 245, 251). The current findings agree with existing literature 
that  the  concentrations  of  ARA  and  DHA  increase  during  pregnancy  but  that  their 
percentages  in  various  plasma  lipids  decrease  (260,  265,  270,  271).  The  pregnancy 
associated LC n-3 PUFA and ARA depletion observed in the control group must also be 
related to its very low intake of fish and thus of EPA and DHA. Low intake of these LC n-
3 PUFA results in remarkable depletion of these fatty acids during pregnancy and may lead 
to alterations in the function of the maternal immune system (7, 47, 121). 
The  current  study  showed  for  the  first  time  that  consumption  of  two  portions  of 
salmon  per  week  from  week  20  of  pregnancy  until  delivery  reversed  the  pregnancy 
associated decrease in plasma EPA, DPA and DHA, resulting in an increase of these fatty 
acids in all plasma lipid fractions. The increase of EPA percentages was more pronounced 
in  the  plasma  PC  and  NEFA  fractions  (increase  by  20%  and  27%  respectively).  The 
increase  in  EPA  concentration  was  more  substantial  in  the  TAG  and  NEFA  fractions 
(120% and 220% respectively). The increase of DHA percentage was greater in the TAG 
fraction (by 54%). The increase in DHA concentration was greater for the TAG and CE 
fractions (by 225% and 90% respectively). In contrast, the salmon intervention enhanced 
the pregnancy associated ARA decrease in maternal plasma lipids. The ratios of fatty acids 
of  interest (ARA/EPA, ARA/DHA, ARA/(EPA+DHA), and  n-6/n-3) were  lower in the   210 
salmon group compared to control at 34 and at 38 weeks gestation for all plasma lipid 
fractions.  As  a  generality,  the  fatty  acid  ratios  decreased  in  the  salmon  group  during 
pregnancy, whereas they increased or remained stable in the control group. The data show 
that increased maternal intake of EPA and DHA through consumption of two portions of 
salmon per week increased their status in LC n-3 PUFA which was compensated by a 
lower status of ARA. The lower ARA/DHA ratio in the salmon group may have an impact 
on the relative transfer of these fatty acids to the foetus via fatty acid transport proteins on 
the placenta for which these fatty acids may compete (258). Also, fatty acid content in 
maternal plasma may affect the expression of such placental transport proteins and thus the 
transfer of fatty acids to the foetus (189). It can be speculated that the increased maternal 
status in EPA and DHA may have resulted in higher provision of these fatty acids to the 
foetus  which  may  have  beneficial  implications  for  the  foetal  growth,  visual  and  brain 
development, and also immune system development. In addition to that, the reversal of the 
decrease in LC n-3 PUFA may be associated to benefits for the mother herself and for her 
immune  system.  The  increased  provision  of  LC  n-3  PUFA  to  the  foetus  is  further 
supported by the fact that consumption of two portions of salmon per week resulted in 
higher LC n-3 PUFA content in placenta and umbilical cord tissue. 
A novel finding of the current study is that pregnancy had an effect on the fatty acid 
composition  of  immune  cells.  Maternal  PBMC  EPA,  DPA,  DHA  and  ARA  content 
decreased during pregnancy. This decrease agrees with the finding that the content of these 
fatty acids in plasma PC also decreased. Plasma PC fatty acid content is an indication of 
the cell membrane fatty acid composition and for this reason it is termed as the ‘functional 
pool’. This was verified by our findings which showed that maternal plasma PC fatty acid 
correlated very well and significantly with maternal PBMC fatty acid composition. The 
pregnancy-associated decrease in PBMC LC n-3 PUFA and ARA indicates that immune 
cells give up these fatty acids in order for them to be transferred to the foetus through the 
placenta. The current data support that these fatty acids essential for foetal growth and 
development are mobilised from the maternal cells to plasma lipoprotein CE and TAG 
fractions, and eventually plasma NEFA, that play a key role in transporting fatty acids to 
the  foetus.  Whether  the  change  in  fatty  acid  composition  of  PBMC  is  important  in 
influencing (or regulating) pregnancy-associated changes in immune function is not clear, 
but this is an intriguing possibility since EPA, DHA and ARA all play a role in immune 
cell function.  
It was shown that consumption of two portions of salmon per week not only prevented 
the pregnancy associated decrease in PBMC EPA and DHA status, but it also resulted in an   211 
increase of PBMC DHA. Moreover, the salmon intervention resulted in further decrease of 
maternal PBMC ARA content during pregnancy. The decrease of maternal immune cell 
content in EPA and DHA during pregnancy, and its reversal by the salmon intervention 
may  have  an  impact  on  the  function  of  the  immune  cells,  including  cytokine  and 
eicosanoid production, which will be further investigated in chapter 5. 
A limitation of the current study may be that for PBMC, placenta and cord tissue total 
lipid fatty acid composition was analysed without separating in lipid fractions. This might 
not have had much impact on the PBMC results as the majority of the cell fatty acids are in 
the cell membrane phospholipids. However, for placenta and cord tissue there might have 
been more specific changes within the different lipid fractions.  
Consumption on two portions of salmon per week during pregnancy resulted in higher 
EPA, DPA, and DHA content in maternal plasma NEFA. This is of great importance as the 
plasma NEFA fraction is an indication of the fatty acids released by hydrolysis of TAG in 
adipose tissue. Thus, a higher content of LC n-3 PUFA in plasma NEFA reflects a higher 
adipose tissue storage of these fatty acids which was achieved by the salmon intervention. 
This is of high importance not only for foetal supply with LC n-3 PUFA during pregnancy 
but also for infant supply through breast milk after birth. It has been well established that 
fatty acids in breast milk originate from maternal adipose tissue fatty acids stored during 
pregnancy (160, 272). A higher supply of these fatty acids to the infant during the critical 
window of the initial post-partum period is also vital for its growth and potentially for its 
immune system modulation.  
 
4.4.2  Comparison with the findings of other studies 
4.4.2.1  Fatty acid changes during pregnancy  
Otto et al. (271) investigated maternal and neonatal fatty acid status in plasma PC in an 
international study including England. It was found that maternal plasma PC total fatty 
acid concentration was 1521.97 µg/mL, that of ARA was 136.21 µg/mL, EPA was 8.39 
µg/mL, and DHA was 69.68 µg/mL, during early pregnancy (about 14 weeks gestation). 
Similar  concentrations  were  also  reported  by  Houwelingen  et  al.  (264).  These 
concentrations are lower than the concentrations observed in the current study. Maternal 
plasma was also collected at 22 and 34 weeks gestation in the study of Otto et al. (271). It 
was  shown  that  the  total  fatty  acid  concentration  as  well  as  that  of  all  fatty  acids 
individually  increased  during  pregnancy.  The  current  study  is  in  agreement  with  these   212 
earlier  observations,  since  in  all  four  plasma  lipid  fractions  all  (or  most)  fatty  acid 
concentrations increased over the course of pregnancy. Otto et al. (271) also showed that, 
when expressed as percentages, almost all PUFA decreased during pregnancy. This was 
also observed in the control group in the current study.  
Another study (265) compared fatty acids in red blood cell PC during pregnancy (16, 
22, 32 weeks) and at delivery in mothers and their neonates with fatty acids in plasma PC. 
At  22  weeks  gestation  total  fatty  acid  concentration  in  maternal  plasma  PC  was  1652 
µg/mL, and at 32 weeks it was 1760 µg/mL (again higher than seen in the current study). 
Absolute concentrations of DHA, total n-3 LC PUFA, and ARA in maternal plasma PC 
increased  during  pregnancy.  The  observations  of  the  current  study  agree  with  these 
findings. In the same study (265) percentage levels of ARA, EPA, and DHA in maternal 
plasma PC were 8.6%, 0.4% and 3.9% respectively. Percentage levels of ARA, EPA, DPA, 
and  DHA  decreased  during  pregnancy,  although  they  remained  stable  after  32  weeks 
gestation.  The  current  study,  where  percentages  of  ARA,  EPA  and  DHA  in  maternal 
plasma PC at week 20 of pregnancy were approximately 9%, 0.6% and 4.5% generally 
agree with these earlier values.  
Al et al. (270) studied the relationship between maternal and neonatal plasma PC fatty 
acid status. Maternal plasma PC levels were reported every 4 weeks in the period between 
10 to 40 weeks gestation. Mean total plasma PC fatty acid concentration increased by 51% 
between 10 to 40 weeks gestation (1238.11 µg/mL and 1867.84 µg/mL respectively) in 
maternal plasma PC. Also, the absolute concentrations of individual fatty acids increased 
during pregnancy, with the greatest  increases observed  for DHA and  AA. The  current 
study found an increase of 40% in total plasma PC from week 20 to week 34 of gestation, 
and  that  the  absolute  concentrations  of  individual  fatty  acids  increased  over  this  time 
period. Al et al. (270) showed that when maternal plasma PC fatty acids were expressed as 
percentages, a different pattern was observed. Total n-3 PUFA, total n-6 PUFA and ARA 
percentages all decreased from 10 to 40 weeks gestation, while percentage DHA increased 
between 10 to 18 weeks and declined thereafter. In the current study percentage of total n-3 
PUFA, ARA, EPA, DPA, and DHA decreased in all lipid fractions apart from the NEFA 
fraction where they increased during pregnancy in the control group. 
The study of De Vriese et al. (260) investigated the fatty acid composition of maternal 
plasma CE and PC during pregnancy and at delivery. Maternal plasma was collected at all 
three trimesters of pregnancy. In the plasma PC fraction, ARA levels were 8.8%, EPA 
levels were 0.7% and DHA levels were 5.1% at the second trimester of pregnancy, similar   213 
to values observed  in the current study.  When  comparing  levels at  first trimester with 
levels at delivery, plasma PC ARA, EPA and DHA dropped significantly (260). In the 
current study significant decreases in percentages of ARA, EPA and DHA in plasma PC 
were observed  in the control group. De Vriese et al. (260) showed that at the second 
trimester, mean  maternal plasma CE percentages of  ARA, EPA and DHA were 6.4%, 
0.6%, and 0.8% respectively. In comparison, in the current study the values were about 
6.5%, 0.55% and 0.7%. During pregnancy percentages of  ARA, EPA and total PUFA 
decreased in the CE fraction (260), effects that were also seen in the current study.  
Berghaus et al. (261) compared the fatty acid composition of all plasma lipid classes 
in maternal and cord blood at delivery. In the maternal plasma TAG fraction, percentages 
of ARA, EPA and DHA were 0.75%, 0.06%, and 0.32%, respectively. In the current study 
values  for  these  fatty  acids  at  week  38  of  pregnancy  were  1.1%,  0.1%  and  0.65%, 
respectively. In the PC fraction, ARA, EPA and DHA were 7.7%, 0.35%, and 2.9% (261) 
compared with 8.4%, 0.42% and 3.7% at 38 weeks in the current study. In the CE fraction, 
ARA, EPA and DHA were 5.7%, 0.33%, 0.52% (261). In the current study at 38 weeks 
these values were 5.5%, 0.38% and 0.61% in the control group. Thus, in general the fatty 
acid percentages seen in maternal plasma lipids at 38 weeks gestation in the current study 
are in agreement with the data of Berghaus et al. (261) Berghaus et al. (261) reported that 
in the plasma NEFA percentages of  ARA, EPA and DHA of 0.74%, 0%, and 0.18%, 
respectively. In the current study the percentages of these fatty acids in maternal plasma 
NEFA were higher than these.  
Thus, comparing the data from the current study with existing data in the literature 
indicates that the fatty acid concentrations and proportions seen in maternal plasma lipids 
at different stages of pregnancy in the control group in the current study are in general 
agreement with existing data for these fatty acids. As a general rule, the concentrations of 
fatty acids in maternal plasma increase, whereas the proportions of LC n-3 PUFA and 
ARA in maternal plasma decrease during pregnancy. The agreement between fatty acid 
levels in the current study, which was conducted on a UK population of low intake of oily 
fish,  with  studies  from  other  North  Western  European  countries  (Germany,  the 
Netherlands,  Belgium)  may  imply  similar  dietary  patterns  in  these  ‘western-type’ 
environments and may also be associated to the similarity of the ethnic groups.  
4.4.2.2  Fatty acid composition of placenta 
The placenta will have been built up using those fatty acids available from the maternal 
bloodstream  and  thus  some  relationship  or  similarity  between  placental  and  maternal   214 
plasma fatty acid compositions might be expected. Furthermore, placenta fatty acid content 
might reflect the nutrient supply to the foetus, and its analysis may be a good indicator of 
placental fatty acid transfer (247, 248). The study of Klinger et al. (247) investigated the 
fatty acid content of placenta tissue lipid fractions in Germany. In placenta PC, ARA, EPA 
and DHA comprised 24.9%, 0.11%, and 4.72% of fatty acids; in placenta TAG, ARA, 
EPA and DHA were 15.2%, 0.27% and 4.5%; in placenta CE, ARA, EPA and DHA were 
10.6%, 0.45%, and 2.1%; in placenta NEFA, ARA, EPA and DHA were 21.3%, 0.41%, 
and 4.0%. Similar percentages of these fatty acids in total placenta lipids (as studied here) 
were reported for UK subjects (16). In the current study percentages of ARA, EPA and 
DHA in total placental lipids in the control group were 23.9%, 0.18% and 4.9%, in good 
agreement  with  the  earlier  studies  in  Germany  and  UK.  Placental  PC  from  a  Spanish 
population had higher proportions of EPA (0.40%) and DHA (5.63%) and a slightly lower 
proportion of ARA (22.6%). These differences might reflect differences in maternal diet 
including differences in fish intake (273).  
4.4.2.3  Maternal fish and n-3 PUFA intake and maternal plasma lipid fatty 
acid composition 
Zhang et al. (274) investigated maternal dietary intake of EPA and DHA and levels of 
these  fatty acids  in plasma PC of pregnant women and their  neonates  from river/lake, 
coastal, and inland regions of China. Dietary intake was assessed using a validated semi-
quantitative FFQ which included 156 foods which was administered at 28 and 35 weeks 
gestation.  Median  daily  intake  of  EPA  in  the  three  regions  was  22.4,  28.6,  3.1  mg 
respectively, and that of DHA was 51.7, 54.7, 33.3 mg, showing that the river/lake and 
coastal regions had higher intake of these fatty acids, probably from fish and other seafood. 
The median maternal plasma PC levels of DHA and EPA were higher in the river/lake and 
coastal regions compared to the  inland region.  Also, neonates  in the  inland group had 
higher levels of ARA and lower levels of EPA and DHA in their plasma PC compared to 
those in the lake/river and coastal regions. It was concluded that there is a close association 
between dietary intake of EPA and DHA and the corresponding levels of these fatty acids 
in  maternal plasma PC, and that  maternal plasma EPA and DHA were also positively 
associated with the corresponding levels in cord plasma PC.  
4.4.2.4  Fish oil supplementation studies in pregnant and non-pregnant 
subjects 
The study of Damsgaard et al. (275) investigated the effects of fish oil and high or low 
linoleic  acid  intake  on  fatty  composition  of  human  PBMC.  Although  this  study  was 
conducted on  healthy  men  and  not on  pregnant  women,  it  provides  information  about   215 
levels of fatty acids in PBMC. Baseline PBMC percentages of ARA, EPA and DHA were 
about 22-23%, 0.4-0.5%, and 2.7-2.9%, respectively. In the current study percentages of 
these fatty acids in PBMC at week 20 of gestation were 18%, 0.6% and 2.4%, respectively. 
Thus the percentages of EPA and DHA are comparable to those reported by Damsgaard et 
al. (275) but the percentage of ARA is lower in the current study. This may be difference 
due  to  sex,  to  pregnancy  or  to  diet.  Damsgaard  et  al.  (275)  found  that  fish  oil 
supplementation resulted in higher levels of EPA and DHA, and lower levels of ARA in 
PBMC, as seen in the current study in the salmon group.  
Hawkes et al. (276) conducted a trial with DHA-rich tuna oil in healthy mothers from 
day 3 post-partum. Women were asked to consume daily either placebo, 300 mg DHA plus 
70 mg EPA, or 600 mg DHA plus 140 mg EPA. After 4 weeks of supplementation, DHA 
concentrations in maternal plasma, PBMC, breast milk and breast milk cell PC increased in 
a  linear  manner  in  response  to  dietary  DHA.  In  PBMC  PC  in  the  placebo  group, 
percentages of ARA, EPA and DHA were 23%, 0.43%, and 2.1%; again EPA and DHA 
were very similar to these values in the current study but ARA was lower. In the high DHA 
intake group, percentages of PBMC PC EPA (0.56%) and DHA (3.3%) were significantly 
higher than those of the placebo group. In the current study PBMC EPA at week 34 of 
gestation was 0.55% while DHA was 2.7%.  
In the study of Dunstan et al. (180) pregnant women were supplemented with fish oil 
(4 g/day of fish oil providing 2.2 g/day DHA plus 1.1 g/day EPA) or olive oil as placebo (4 
g/day)  between  week  20  gestation  to  delivery.  At  30  and  37  weeks  gestation,  fish  oil 
supplementation  significantly  increased  maternal  erythrocyte  PC  EPA  and  DHA 
percentages and significantly decreased the percentages of all n-6 PUFA including ARA 
compared to baseline. The current study did not examine erythrocyte lipids. 
In the European multi-center study of Krauss-Etschmann et al. (184), pregnant women 
received a supplement providing 0.5 g/day DHA plus 0.15 g/day EPA or placebo from 
week 22 of gestation to delivery. Maternal plasma PC DHA levels increased from 5.75% at 
20 weeks to 7.49% at 30 weeks and 7.26% at delivery in the fish oil group. Maternal 
plasma PC EPA  levels  increased  from 0.18% at 20 weeks, to 0.53% at 30 weeks and 
0.37% at delivery in the fish oil group. In the current study salmon increased plasma PC 
EPA and DHA compared with baseline and compared with control, although the increases 
seen were not as great as those of Krauss-Etschmann et al. (184). Krauss-Etschmann et al. 
(184) showed that the intervention also increased DHA levels in cord plasma PC. Cord 
plasma EPA could not be evaluated as it was below the detection limit. In the same study,   216 
Larque et al. (189) showed that fish oil supplementation increased the levels of DHA in 
placenta PC, whereas ARA levels remained unchanged. In the current study placenta DHA 
(and EPA) increased, but ARA declined. Also, it was shown that mRNA expression of 
some fatty acid transport proteins on placenta was correlated with DHA in maternal plasma 
and  placenta  PC  as  well  as  with  DHA  in  cord  plasma  PC.  Also,  placental  mRNA 
expression of membrane lipid carriers was correlated with placenta TAG EPA and DHA 
and placenta NEFA EPA levels.  
4.4.2.5  Increased fish consumption interventions in non-pregnant subjects 
In the study of Vidgren et al. (243) healthy men where asked to consume five portions of 
fish per week, or received DHA supplementation (algae or fish derived), or continued their 
habitual diet for 14 weeks. The subjects kept 4-day food records four times during the 
study to estimate nutrient intake. It was estimated that in the fish group average intake of 
EPA  was  380  mg/day  and  that  of  DHA  was  670  mg/day.  Increased  fish  consumption 
resulted in higher levels of EPA and DHA in plasma lipid pools (PC, TAG, CE) and also in 
erythrocyte membranes and platelets.  
Pot et al. (241) studied the effects of increased fish consumption on colorectal cancer 
markers. The intervention period was 6 months, and subjects were randomly allocated to 
receive dietary advice plus either two portions per week of oily fish (salmon) (n=82), or 
non-oily fish (cod) (n = 78), or just dietary advice (n = 82). Serum CE EPA plus DHA 
increased significantly in the salmon group, whereas in the cod and dietary advice group 
these did not change. In the salmon group, EPA plus DHA content in serum CE increased 
from 2.85% at baseline to 3.59% at the end of the intervention, which means that baseline 
levels of very LC n-3 PUFA increased by about 25%. In the current study, the salmon 
group EPA plus DHA content in plasma CE was 1.35% (lower than what was reported by 
Pot  et  al.)  and  at the  end  of  the  intervention  it  increased  to  1.52%.  This  indicates  an 
increase of 12.5% from the baseline value which is lower than the increase observed in the 
study of Pot et al. (241). The lower levels of CE very LC n-3 PUFA and the lower increase 
of these levels observed in the current study may be attributed to the maternal supply of 
these fatty acids to the foetus (whereas Pot et al. studied non-pregnant subjects). More 
importantly, although both Pot et al. and the current study supplied two portions of salmon 
per week, the salmon provided in the study of Pot et al. had a much higher content of EPA 
plus DHA resulting in intake of about 1.4 g EPA+DHA/day which is three times higher 
than the intake of these fatty acids from the current study salmon (about 490 mg/day).   217 
Din et al. (238) examined the effect of increased oily fish intake on platelet-monocyte 
aggregation. Subjects were asked to consume 500 g of mackerel per week for 4 weeks 
(providing the equivalent of approximately 1 g of EPA plus DHA per day) or to continue 
their habitual diet. The dietary intervention with fish resulted in higher percentages of EPA 
and DHA and lower percentage of ARA in plasma PC at 4 weeks compared to baseline.  
The fish intervention studies of Vidgren et al. (243), Pot et al. (241), and Din et al. 
(238), although not conducted on pregnant women, show a higher level of EPA and DHA 
in fish consuming subjects and a lower level of ARA compared to control subjects. The 
current study adds to this body of literature as it is a novel study of fish intervention on 
pregnant women, and showing that increased oily fish consumption can increase status of 
LC n-3 PUFA even during pregnancy when the maternal LC n-3 PUFA stores are normally 
depleted in the benefit of the foetus.  
4.5  Summary and conclusions 
The available literature indicates that the percentages of EPA and DHA in maternal plasma 
lipids decline during pregnancy. This was also observed in the control group in the current 
study and it is probably associated with the conversion of EPA to DHA, and the further 
preferential  transfer  of  DHA  into  the  placenta  which  potentially  leads  to  increased 
provision of DHA to the foetus essential for its development. SIPS is the first randomised 
controlled trial with fish during pregnancy. The data presented in this chapter show that 
consumption of two portions of salmon per week between week 20 gestation and delivery 
not only prevented the pregnancy associated decrease in percentages of EPA and DHA in 
maternal plasma lipids (and in PBMC), but also resulted in increased levels of these LC n-
3 PUFA in all plasma lipid classes and in PBMC, compared to a habitually low intake of 
oily fish. On the other hand, during normal pregnancy maternal absolute concentrations of 
fatty  acids  in  plasma  increase  and  this  is  the  characteristic  gestational  hyperlipidemia 
which enables the transfer of fatty acids through the placenta to the foetus. This increase 
was observed in the current study in both of the experimental groups. However, in the 
salmon  group  absolute  concentrations  of  EPA  and  DHA  in  maternal  plasma  lipids 
increased more compared to the control group, resulting in higher absolute concentrations 
of these fatty acids in the salmon group in all lipid classes. Further, it was shown that the 
salmon  intervention  resulted  in  lower  levels  of  ARA  in  maternal  plasma  compared  to 
control. Thus, consumption of two portions of salmon per week  from  mid-gestation to 
delivery, which provided at least 403 mg/day EPA plus DHA according to FFQ (or 490 
mg/day according to fish diaries – see chapter 3), increased maternal plasma EPA and   218 
DHA  levels  which  could  be  of  significant  importance  since  the  mother  is  not  totally 
depleted and the foetus is potentially provided with greater amounts of these fatty acids. 
This is further supported by the observations on maternal PBMC and on placenta and cord 
tissues at birth. This study found, for the first time, that pregnancy is associated with a 
decline  of  EPA  and  DHA  in  maternal  PBMC.  The  salmon  intervention  resulted  in 
prevention of this decline for both EPA and DHA, and it further increased the levels of 
DHA during pregnancy, resulting in higher levels of both EPA and DHA in the salmon 
group than in the control group at the end of pregnancy. This is of great importance since 
the functionality of these cells, such as eicosanoid and cytokine production, can be affected 
by an altered fatty acid composition. Finally, placenta and cord tissue had higher levels of 
LC n-3 PUFA in the salmon group compared to control. The implications of these results 
are that increased EPA and DHA concentrations in maternal plasma may facilitate better 
transfer of key fatty acids to the foetus, and that increased EPA and DHA concentrations in 
maternal  plasma  and  cells  may  modulate  the  immune  system  of  the  mother  during 
pregnancy.  These  effects  either  alone  or  together  may  influence  the  developing  foetal 
immune system in a way that may reduce the risk of developing atopy.  
In  summary,  pregnancy  is  associated  with  changes  in  the  concentrations  of  blood 
lipids and in the fatty acid components of these lipids. Provision of oily fish to pregnant 
women prevents the decline in LC n-3 PUFA seen in plasma lipids and immune cells with 
pregnancy and results in increased amounts of these fatty acids in plasmas lipids and in 
immune cells. This may influence of health of the mother and the growth, development and 
health of the foetus and newborn infant. If pregnant women with low habitual intake of fish 
consume two portions of salmon per week they will significantly increase their status of 
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5.1  Introduction 
During pregnancy complex immunological changes occur in order to suppress maternal 
cell-mediated  responses  to  foetal  and  paternal  antigens  which  allows  the  normal 
progression  of  pregnancy  (64).  The  immunologic  balance  is  shifted  towards  humoral 
immunity,  and  specifically  towards  type  2  helper  T-cell  (Th2)  responses.  This  shift 
happens first in the materno-fetal interface (decidua) and later on in systemic circulation 
(64, 65). According to Wegmann’s hypothesis (277), foetal survival depends on a bias of 
maternal immune responses towards Th2 immune responses and the inhibition of cytotoxic 
type 1 helper T-cell (Th1) responses. This has been well demonstrated in mouse models. In 
humans, pregnancy leads to worsening of clinical symptoms of Th2 dominated diseases 
(systemic lupus erythematosis) and regression of Th1 diseases (rheumatoid arthritis) (278), 
consistent with the switch away from Th1-type responses and towards Th2-type responses. 
Recent studies have challenged the Th2 bias hypothesis of pregnancy (279) suggesting 
that,  although  the  bias  has  been  observed,  it  is  not  clear  whether  it  is  essential  for 
successful  pregnancy  or  whether  it  is  secondary  to  hormonal  (progesterone,  relaxin, 
placental growth factor) changes (280). However, in pregnancy-related complications such 
as recurrent miscarriage and pre-eclampsia, the Th2 bias is not present or it is reversed 
resulting in Th1 dominance (65). The predominant immune interactions in the decidua are 
between the placenta trophoblast and maternal natural killer (NK) cells rather than T-cells. 
Thus,  it  has  been  proposed  that  innate,  and  not  adaptive,  immunity  controls 
immunoregulation and type 2 cytokines in normal pregnancy through a shift towards ‘type 
2 NK cells’ (281). Also, the dysregulation of NK cells in peripheral blood and endometrial 
layers has been associated with reproductive immunopathology and recurrent spontaneous 
abortions (RSA) (282). 
The presence of immunoglobulins (Ig) and cytokines in the amniotic fluid is highly 
important for the developing foetal immune system. It has been shown that amniotic fluid 
contains IgE which correlates with  maternal  circulating IgE  levels.  Amniotic  fluid IgE 
might bind to CD23
+ cells within the lymphoid follicles of the foetal gastrointestinal tract 
affecting the developing immune system (68). It has been suggested that cytokines present 
in amniotic fluid (such as IL-16) can be swallowed by the foetus and attract immune cells 
(CD4
+)  to the  foetal  gut.  Such  observations  may  signify  pathways  by  which  maternal 
cytokines can affect early immune development (283).  
Maternal immune responses during pregnancy have been shown to closely correlate 
with  cytokine  production  and  IgE  concentration  at  birth  (284,  285).  Healthy  neonates   221 
appear to have Th2 polarised allergen-specific responses as a consequence of the maternal 
Th2  polarisation  during  pregnancy,  and  diminished  capacity  for  production  of  Th1 
responses.  This  is  balanced  by  rapid  postnatal  maturation  of  Th1  responses  and 
downregulation of Th2 responses, which continues during the first two years of life with 
appropriate antigen exposure (66). However, this is not the case for the offspring of atopic 
mothers. Atopy is characterised by polarisation towards Th2 responses to antigens. This 
has led to the idea that pregnancy may exacerbate the Th2 biased phenotype of allergic and 
atopic women (286). It has  been shown that allergic women have  increased peripheral 
blood allergen-specific Th2 responses during pregnancy compared to non-allergic pregnant 
women. It was suggested that the peripheral responses in women with allergic disease may 
also  alter  the  cytokine  milieu  in  the  materno-foetal  interface,  contributing  to  altered 
immune responses of the offspring (287). There is strong evidence that the development of 
atopy in the offspring is strongly influenced by maternal atopy (288), and that maternal 
atopy has a greater impact compared to paternal (289, 290). 
Prescott et al. (291) showed that both atopic and non-atopic infants had a diminished 
capacity for production of Th1 (IFN-γ) responses. However, it was shown that neonates 
who subsequently developed atopy initially had reduced capacity of Th2 responses as well. 
Soon after birth non-atopic infants selectively downregulated their Th2 polarised allergen 
specific responses. In contrast, atopic infants failed to do, continuing to upregulate Th2 
immunity  after  birth  which  was  believed  to  contribute  to  the  development  of  atopy. 
Moreover, it has been shown that Th1 responses at birth of infants who go on to develop 
atopy are  lower than those of non-atopic children. This  ‘immaturity’ of Th1  immunity 
continues to be evident later on in the first years of infancy (2 years old) for atopic infants 
versus non atopic (292). Prescott et al. (291) showed that skewed cord blood mononuclear 
cell  Th2  cytokine  responses  (IL-4,  IL-5,  IL-6,  IL-9,  IL-3)  to  common  environmental 
allergens  are  present  in  all  newborns  irrespective  of  their  atopy  heritability  and  are 
dominated by high level IL-10 (regulatory cytokine) production. It was suggested that the 
redirection of neonate’s immune responses towards the Th1 cytokine phenotype soon after 
birth,  may  be  more  important  that  the  initial  Th2-skewed  immunity  in  explaining  the 
development of atopic disease.  
Although  elevated  cord  blood  IgE  is  associated  with  the  development  of  atopy, 
asthma, and elevated IgE in childhood, it is thought that cord blood IgE is less valuable 
than family history in predicting allergy, and it does not have the value of screening test 
(293).  Atopic  disease  includes  allergy,  hay-fever,  allergic  rhinitis,  eczema  and  asthma 
which are IgE mediated (atopy). Similar responses but which are non-IgE mediated are   222 
termed non-atopic. During allergic sensitisation, environmental antigen (allergen) exposure 
leads to IgE produced by B-cells which binds to specific receptors on the surfaces of mast 
cells and basophils. Re-exposure to the same allergen will interact with the bound IgE 
resulting in histamine and Th2 cytokine (IL-4, IL-5, IL-13) production (42). Especially in 
early  infancy,  IgE  mediated  food  allergy  and  atopic  dermatitis  can  be  related  to  the 
development of future atopic asthma (294).  
Although  more  than  half  of  the  individuals  with  childhood  asthma  enter  clinical 
remission by puberty, about half of them develop asthma symptoms again during early 
adulthood. Thus young adults with childhood asthma that has remitted, continue to be in 
high risk of future relapse. The mechanism of relapsing asthma in early adulthood remains 
unclear (295). The occurrence of new-onset asthma during adulthood is common, but there 
is insufficient understanding of its determinants. A study has recently shown that atopy 
explains only a small proportion of new-onset asthma (296). Another study showed the 
importance of exposure to substances in the workplace on new-onset adulthood asthma 
(297). Another study showed that adult-onset asthma is associated with lifestyle factors 
such as smoking and  increased weight gain. Neither pre-existing atopy  nor new atopy 
measured by skin prick testing was associated with adult-onset asthma (298). 
Epidemiological  data  show  that  the  incidence  of  childhood  atopic  disease  has 
increased  dramatically  over  the  past  three  to  four  decades  especially  in  westernised 
environments (73, 74, 77). This has coincided  with, or followed  behind, a decrease  in 
infectious  diseases  (77).  These  observations  contributed  to the  development  of  the  so-
called  hygiene  hypothesis,  which  was  initially  based  upon  findings  of  epidemiological 
studies which showed that natural microbial exposure may be protective towards atopy 
development (75-77). The role of adaptive immune responses in this concept has been 
highlighted by the capacity of microbial antigens to enhance Th1 (IFN-γ) and T-regulatory 
responses,  resulting  in  a  shift  away  from  Th2  responses.  However  the  contribution  of 
decreased microbial antigen exposure in westernised countries to the increasing rates of 
allergic disease is not clear. It has been suggested that allergic disease may result from an 
inappropriate balance  between T-regulatory and  Th2 cells. This  imbalance could result 
from either a deficiency in suppressive activity of T-regulatory cells or strong activation 
which overcomes regulation (299). 
Both  adaptive  and  innate  immunity  are  needed  when  fighting  against  infectious 
microorganisms in humans. These two types of immunity, although involving different 
types  of  immune  cells  and  acting  with  different  antigenic  specificity,  interact  and   223 
communicate affecting one another through cytokine production and antigen presentation. 
The role of innate immunity in explaining the impact of decreased microbial exposure on 
susceptibility to develop atopic disorders is also important. Pattern recognition receptors, 
such as CD14 and toll-like receptors (TLR) on monocytes, detect in a non-specific way 
antigenic molecules on the surface of gram-positive (peptidoglycans, lipoteichoic acid) and 
gram-negative  (e.g.  lipopolysaccharide  (LPS)  recognised  by  TLR-4).  This  recognition 
leads  to  cytokine  production  and  though  complex  pathways  activates  and  enhances 
adaptive immune responses, which may influence the shift away from the Th2 phenotype 
(see section 1.2 for details on the immune system). Genetic polymorphisms of TLR and 
CD14 receptor genes have been associated with the pathogenesis of asthma, although this 
evidence is not clear (300). 
Complex  multifactorial  genetic  and  environmental  interactions  determine  the 
development of atopic disease. Recently Martino & Prescott (301) reviewed the evidence 
that  immune  development  is  under  epigenetic  regulation,  including  Th1/Th2  cell 
differentiation, T-regulatory cell differentiation, and Th17 development. It is believed that 
gene-environment  interactions  are  mediated  through  epigenetic  mechanisms.  There  is 
evidence that early environmental exposures are important in activating or silencing genes 
by altering DNA and histone methylation, histone acetylation, and chromatin structure. As 
a result, phenotype and disease susceptibility are altered. The evidence suggests that atopy 
prone  individuals  have  very  early  developmental  differences  in  innate  immune  gene 
expression. Several new studies indicate that in utero microbial and dietary exposures can 
modify  allergic  disease  expression  through  epigenetic  mechanisms.  Candidate 
environmental  factors  in  the  allergy  epidemic  include  a  reduction  in  microbial  signals 
promoting  Th1/T-regulatory  responses  (hygiene  hypothesis)  (75-77),  dietary  changes, 
smoking, pollutants (302, 303) and toxins (304). For example, dietary folate as a methyl 
donor may have the capacity to alter methylation patterns in utero. A study in mice showed 
that  folate  supplementation  during  pregnancy,  resulted  in  altered  methylation  and 
adversely effected airway and allergic response development (305). One study in humans, 
has shown that folate supplements in pregnancy are associated with increased childhood 
wheezing (306).  
The  role  of  early  dietary  exposures  and  feeding  practices  in  pathogenesis  and 
prevention of allergic disease has been recently reviewed by Jennings & Prescott (307). 
Food allergen avoidance in allergic disease prevention has been unsuccessful and it is no 
longer  recommended  unless  allergy  is  confirmed.  A  study  of  maternal  egg  avoidance 
during  pregnancy  showed  that  rigorous  dietary  egg  exclusion  did  not  eliminate  trans-  224 
placental  and  breast  milk  ovalbumin  passage  (308).  Dietary  factors  that  the  foetus  is 
exposed to in utero or at early postnatal stages have shown immunomodulatory effects. 
These  include  folate,  long  chain  n-3  polyunsaturated  fatty  acids  (LC  n-3  PUFA), 
oligosaccharides,  probiotics,  vitamin  D,  retinoic  acid,  vitamin  E  (309),  and  other 
antioxidants such as selenium. The decreased intake of antioxidant vitamins and selenium 
(13) are important dietary changes and may be associated with the increased rates of atopy. 
It has been shown that early childhood wheezing is associated with reduced neonatal and 
foetal selenium status (92, 213). Also, low maternal vitamin E intake during pregnancy 
was associated with increased risk of wheezing at 2 years of age (213). The effects of 
antioxidant intake on allergic disease have been recently reviewed by Allan et al. (310). A 
small number of cohort studies reported potential beneficial associations between maternal 
intake of antioxidants during pregnancy and childhood asthma. However, there  is  very 
limited data on childhood atopic dermatitis and atopic rhinitis. The literature available is 
too  limited  to  draw  firm  conclusions  on  the  effect of  antioxidants  on  atopy.  Maternal 
vitamin D intake during pregnancy has been associated with decreased risk of sensitization 
to food allergens in the offspring at five years old in a prospective cohort study in Finland 
(209).  Other  studies  also  support  the  importance  of  vitamin  D  in  atopic  disease 
development (210-212). 
Most  importantly  in  the  context of  this  thesis,  decreased  intake  of  LC  n-3  PUFA 
accompanying  increased  intake  of  n-6  PUFA  is  a  major  dietary  change  which  has 
happened in the last 30-40 years, and may be associated with the increase in childhood 
atopic disease. The major dietary n-6 PUFA is linoleic acid (18:2n-6) and it can be further 
metabolised  to  arachidonic  acid  (ARA;  20:4n-6).  On  the  other  hand,  α-linolenic  acid 
(18:3n-3) is the precursor of the LC n-3 PUFA, eicosapentaenoic acid (EPA; 20:5n-3), and 
docosahexaenoic acid (DHA; 22:6n-3) which are found in oily fish such as salmon and in 
fish oils. LC PUFA have immunomodulatory properties which differ between the n-3 and 
n-6  family and  are  mainly  associated with the  lipid  mediators produced by these  fatty 
acids. 
Arachidonic  acid  is  the  principal  substrate  of  cyclooxygenase  (COX)  and 
lipoxygenase  (LOX)  enzymes  giving  rise  to  2-series  prostaglandins  (PG)  and 
thromboxanes  (TX)  or  5-hydroxy-eicosatetraenoic  acids  (5-HETE)  and  4-series 
leukotrienes (LT). These mediators, specifically PGE and 4-series LT (LTB4), have been 
shown to be important in inflammation and immunity (see section 1.4 for details). For 
example PGE2 induces fever, pain and production of inflammatory cytokines. PGE2 also 
influences cell-mediated immunity through inhibition of T-cell proliferation, inhibition of   225 
production of Th1 type responses (IL-2, IFN-γ), promotion of Th2 type responses, and 
induction of IgE production by B-cells (103). Consumption of fish oil results in increased 
amounts of EPA and DHA in inflammatory cells, partly in the expense of arachidonic acid 
(106, 311). Changes in the fatty acid composition of immune cells can effect membrane 
structure, function, fluidity, and that of lipid rafts. As has been reviewed (38, 94, 312), 
altered fatty acid composition of cell membranes can also alter receptor expression, signal 
transduction  pathways,  transcription  factor  activation,  and  patterns  of  gene  expression. 
Most importantly LC n-3 PUFA can alter the production of lipid mediators. The decrease 
in  arachidonic  acid  results  in  lower  production  of  eicosanoids  derived  by  this  (PGE2, 
LTB4) (313, 314). EPA antagonises ARA and becomes a substrate for COX and LOX 
enzymes giving rise to 3-series PG, TX and 5-series LT and 5-HETE. These EPA-derived 
eicosanoids are less potent mediators than those derived from arachidonic acid. Moreover, 
EPA  and  DHA  give  rise  to  potent  anti-inflammatory  mediators  termed  resolvins, 
docosatrienes, and protectins. The EPA and DHA mediators produced are the main reason 
why LC n-3 PUFA in fish oil have been characterised as anti-inflammatory. Through their 
above actions (membrane fluidity, cell signalling and mediator production), EPA and DHA 
also influence innate immune processes such as phagocytosis and cytokine production by 
monocytes  and  macrophages,  and  influence  adaptive  immunity  altering  cytokine 
production  and  proliferation  of  T-cells  (see  section  1.4  for  details).  Both  in  vitro  and 
animal  feeding  studies  showed  that  LC  n-3  PUFA  inhibit  T-cell  proliferation  and 
production  of  IL-2  and  IFN-γ  (126,  128,  311,  314).  However,  the  results  of  human 
supplementation studies indicate that, although high levels of fish oil supplementation may 
inhibit T-cell responses (113), lower doses do not exhibit significant effects (105, 132). 
The evidence that fish oil supplementation may affect T-cell function independently of 
eicosanoid production is conflicting and further studies in humans are needed in order to be 
able to draw clear conclusions.  
It  has  been  shown  that  LC  n-3  PUFA  status  in  maternal  blood,  breast  milk  and 
umbilical  cord  blood  is  lower  in  mothers  of  atopic  children  (83-86,  92).  Prescott  & 
Dunstan (93) have reviewed the effects of dietary LC PUFA on early immune development 
and their potential role in immune disease development or prevention. The potential effects 
of LC PUFA may be of great importance during early life. Potential pathways through 
which LC PUFA could influence immune programming include effects on: local tissue 
factors  (production  of  lipid-derived  inflammatory  mediators, oxidative  stress),  neonatal 
antigen presenting cell function, T-regulatory cell function, T-cell function, B-cell function 
(antibody production), end-organ factors (affecting clinical phenotype).    226 
Epidemiological studies  looking at the effect of  maternal  fish consumption during 
pregnancy and fish consumption during infancy/childhood suggest that fish consumption 
may play a protective role against atopic disease development in the children. However 
little  is known about the effect of  fish consumption on  immune  functions. It has  been 
shown  that  fish  oil  supplementation  during  pregnancy  and  lactation  resulted  in  higher 
provision of LC n-3 PUFA to the offspring and so in a higher LC n-3 PUFA status in the 
offspring (22, 177-188). Early fish oil provision was associated with immunologic changes 
in cord blood which may be consistent with decreased risk of atopy in the offspring and 
such  changes  may  persist.  These  studies  suggested  clinical  effects  of  early  fish  oil 
provision  including  reduced  sensitization  to  common  food  allergens  and  reduced 
prevalence and severity of atopic dermatitis in the first year of life, again with a possible 
persistence until adolescence with a reduction in eczema, hay fever, and asthma. Also, 
studies of  fish oil  supplementation during  infancy or childhood have  shown protective 
effects, although the evidence is inconsistent.  
There are no published intervention trials with fish during pregnancy. The Salmon in 
Pregnancy Study (SIPS) is the first randomised controlled trial with oily fish (in this case 
farmed salmon) in pregnant women. SIPS specifically focuses on pregnant women whose 
offspring are at risk of developing atopic disease, with one aim being to identify whether 
there is an effect on atopy outcomes in the offspring. As described in Chapter 2, a total of 
123 pregnant women were randomly assigned to either consume 2 portions of  farmed 
salmon per week from week 20 of pregnancy until delivery or to continue their habitual 
diet low in oily fish (less or equal to 2 portions per month). The aim of the work described 
in this chapter is to investigate the effect of the intervention on the immune system of the 
women enrolled in SIPS during pregnancy. It is considered that maternal immune system 
changes during pregnancy will influence the developing immune system of the foetus so 
affecting  its  maturation  and  polarisation  in  a  way  that  would  decrease  the  risk  of 
developing atopy. The primary hypotheses examined in this chapter are that: 
  increasing habitually low intake of oily fish (≤ 2 portions per month) to 2 portions 
per week during pregnancy, will result in altered maternal immune cell phenotypes 
during pregnancy; 
  the salmon intervention will result in altered maternal innate and adaptive immune 
responses,  measured  as  Th1,  Th2,  and  regulatory  cytokine  expression  by 
mononuclear cells cultured with various stimulants; 
  the salmon intervention will result in lower production of PGE2 by mononuclear 
cells cultured with various stimulants.   227 
 
5.2  Study design, materials and methods 
5.2.1  Study design, subjects, subject characteristics and the 
intervention 
In  chapter  2  the  study  design,  the  recruiting  procedure,  the  nature  of  the  women 
recruited and their characteristics, and the nature of the intervention were all described in 
detail. One group of pregnant women (n = 61) did not undergo any dietary intervention and 
maintained their habitual diet which was low in oily fish. A second group of pregnant 
women (n = 62) consumed two portions of farmed salmon per week from week 20 of 
pregnancy  until  delivery,  which  corresponds  to  the  recommended  oily  fish  intake  for 
pregnant women in the UK (1-2 portions per week) (11). Full details of the salmon are 
given in section 2.4: salmon provided 1.73 g EPA plus DHA per portion (i.e. 3.46 g per 
week  or  494  mg/day),  which  would  result  in  intake  higher  than  the  UK  minimum 
recommendation of 450 mg/day (11). Also, it has been recommended that DHA intake 
should be at least 200 mg/day in women of reproductive age (19). Subjects were seen in 
the fasting state at 20, 32-34 and 38 weeks gestation and blood was drawn to enable fatty 
acid  analysis  of  plasma  and  PBMC  (chapter  4)  and  measurement  of  immunological 
markers, which is the focus of this chapter. 
 
5.2.2  Maternal blood collection 
Plastic 2 mL ethylenediaminetetraacetic acid (EDTA) vacutainer blood bottles and 
plastic  6  mL  lithium  heparin  (LH)  vacutainer  blood  bottles  were  obtained  from  NHS 
Stores, Southampton General Hospital. Maternal blood collection was performed by an 
adequately  trained  nurse  or  member  of  the  SIPS  team.  At  20,  32-34,  and  38  weeks 
gestation, blood was collected into one 2 mL EDTA bottle and into three 6 mL LH bottles 
and stored at room temperature for further analysis. The blood collected in EDTA was 
used to enumerate the total number of leukocytes and the types of leukocytes. The blood 
collected  in  LH  was  used  to  assess  immune  cell  subsets  and  for  the  preparation  of 
peripheral  blood  mononuclear  cells  (PBMC)  for  future  culturing;  this  preparation  was 
performed within 8 hours of collection.   228 
 
5.2.3  Analysis of total blood leukocytes 
 
Blood  was  sent  to  Chemical  Pathology,  SUHT  for  the  assessment  of  total 
leukocytes, neutrophils, lymphocytes, monocytes, eosinophils, and basophils. The analysis 
was performed using a Sysmex XE-2100 flow cytometer for haematology analysis.  
 
5.2.4  Analysis of blood immune cell subsets 
5.2.4.1  Materials 
Mouse  anti-human  fluorochrome-conjugated  antibodies  were  purchased  from 
Serotec.  Mouse  PE-labelled  anti-human  CD127  was  purchased  from  IOTest-Beckman 
Coulter.  FACS  lysing  solution,  cell  wash,  and  cell  fix  were  purchased  from  BD 
Biosciences. 
5.2.4.2  Procedure 
Flow cytometry was used to measure the presence of markers on the surface of 
leukocytes. Heparinised whole blood (100 µL) was incubated with fluorochrome-labelled 
monoclonal antibodies (Table 5.1) for 30 min at 4˚C in the dark to identify different cell 
subsets. After this incubation, erythrocytes were lysed for 10 min using 2 mL 10% FACS 
lysing solution in deionised distilled water. After centrifugation (7 min, 200 × g), lysed 
erythrocytes were discarded and leukocytes were washed with 2 mL cell wash (7 min, 200 
× g), and then fixed with 200 µL 10% cell fix solution in deionised distilled water. Fixed 
leukocytes were analysed by a flow cytometer (FACSCalibur, Becton Dickinson, Oxford, 
UK) equipped with a 488 nm argon blue laser. Lymphocytes were identified based on 
characteristic properties of the cells with regard to forward scatter (FSC) and side scatter 
(SSC). FSC and SSC were set to a linear scale, and 10
4 cells were acquired for all analyses, 
except of the enumeration of T regulatory cells, where 10
5 cells were collected. CaliBRITE 
3 beads (Becton Dickinson) were employed for calibration of instrument settings and the 
same voltage settings were used for each sample. Compensation for spectral fluorochrome 
overlap was performed. In all experiments, gates were set so that isotype control staining 
consistently  yielded  <  1%  positive  cells.  Data  were  analysed  using  CELLQuest  Pro 
software (Becton Dickinson). Figure 5.1, Figure 5.2, and Figure 5.3 show typical profiles 
for each stain set. Such profiles can be used to identify the percentage of a specific cell   229 
population with a pool of cells. These profiles also generate another parameter, median 
fluorescence intensity (MFI), which is an indication of how dense the marker is on the 
surface of the cells  identified;  MFI  is related to the  level of expression of the  marker 
protein  on  the  cell  surface.  MFI  was  determined  for  the  expression  of  CD127  on  T-
regulatory cells (Figure 5.3).  
 
Table 5.1. Labelled monoclonal antibodies (“stains”) used to identify different cell subsets 
Stain  Cell type identified  Phenotype of cell type 
identified 
Volume of 
stain used (µl) 
Negative stain  Control (No stain)    - 
Anti-CD3-FITC/Anti-CD4-PE  T helper/inducer cells  CD3
+CD4
+  10 
Anti-CD3-FITC/Anti-CD8-PE   Cytotoxic/suppressor T 
cells  CD3
+CD8
+  10 
Anti-CD3-FITC/Anti-CD16-
PE   Natural Killer (NK) cells  CD3
-CD16
+  10 
Anti-CD3-FITC/Anti-CD19-
PE  B-cells  CD3
-CD19
+  10 
Anti-CD14-FITC + Anti-
CD282-PE  TLR-2 bearing monocytes  CD14
+TLR-2
+  10+10 
Anti-CD4-FITC + Anti-CD25-
PE-Cy5 + Anti-CD127-RPE   T-regulatory cells  CD4
+CD25
+CD127
low  10+5+20 
Anti CD4-FITC + Anti-CD25-
PE-Cy5 + IgG1-RPE  T-regulatory cells control    10+5+10 
IgG1-FITC + IgG1-PE + 
IgG1-RPE-Cy5  Triple isotype control    10+10+10 
FITC, Fluorescein isothiocyanate isomer 1 (liquid); PE, Phycoerythrin (lyophilised)   230 
 
 
Figure 5.1 Typical flow cytometry profiles of total leukocytes, lymphocytes, and lymphocyte subsets: 
helper T-cells, cytotoxic T-cells, natural killer (NK) cells, and B-cells 
Figures show: gated lymphocytes (A), control (no stain) (B), helper T-cells (CD3
+/CD4
+) (C), cytotoxic T-
cells (CD3
+/CD8
+) (D), natural killer (NK) cells (CD3
-/CD16
+) (E) and B-lymphocytes (CD3
-/CD19
+) (F) 
Figures B-F are based on the lymphocyte gate of figure A.   231 
 
 













Gate M1 (low CD127) has been drawn on the CD4
+/CD25
+ cells of gate R5 
Mean fluorescence intensity was determined for the CD127 receptor   232 
5.2.5  Preparation of peripheral blood plasma and mononuclear cells 
for culturing 
 
5.2.5.1  Materials 
Histopaque  (density  1.077  g/L,  containing  polysucrose  5.7  g/dL,  and  sodium 
diatrizoate 9.0 g/dL), L-glutamine (200 mM), antibiotics (penicillin, streptomycin), and 
crystal violet were purchased from Sigma-Aldrich. Phosphate-buffered saline (PBS) tablets 
were purchased  from Oxoid. RPMI  medium (without L-glutamine and antibiotics) and 
heat-inactivated foetal bovine serum (HI-FBS) were purchased from PAA Laboratories. 
Dimethyl  sulphoxide  (DMSO)  and  acetic  acid  were  purchased  from  Fisher  Scientific. 
Saline  (0.9%  sodium  chloride)  was  purchased  from  SUHT  Pharmacy,  Southampton 
General Hospital.  
White cell counting fluid was made as follows: 100 mL PBS, 2 mL acetic acid, 
approximately 5 g crystal violet. The solution was millipore filtered before use. 
5.2.5.2  Procedures 
Heparinised  whole  blood  was  layered  onto  Histopaque  (ratio  of  blood  to 
Histopaque: 2:1) and centrifuged for 15 min at 800 × g (2000 rpm, R = 18 cm) at room 
temperature. Plasma was collected from the top layer and frozen at -80˚C to be used for 
culturing maternal PBMC and for fatty acid analysis (see chapter 4).  
PBMC were collected from the interphase and washed once for 10 min at 450 × g 
(1500  rpm,  R  =  18  cm)  with  RPMI  medium  containing  0.75  mmol/L  glutamine  and 
antibiotics (penicillin and streptomycin). After being resuspended in 1 mL RPMI medium, 
the cells were counted with a  haemocytometer using white cell  counting  fluid (crystal 
violet). After counting total PBMC number, 2 × 10
6 cells were removed and frozen at -
80˚C for fatty acid analysis (see chapter 4). 
The remaining PBMC were washed once (10 min, 450 × g) with RPMI medium 
containing 2% HI-FBS. The PBMC were resuspended in RPMI medium containing 2% 
HI-FBS and were cryopreserved with 15% DMSO  in HI-FBS (freezing  medium). The 
freezing  medium  was  added  to  the  resuspended  PBMC  drop-wise  on  ice  (ratio  of 
resuspended cells in RPMI medium containing 2% HI-FBS to freezing medium: 1:1). The 
PBMC concentrations were adjusted to 12-20 × 10
6 cells/mL/cryovial
 and were frozen at -
80˚C in a Nalgene Cryo 1˚C freezing container (filled with 250 mL isopropanol). After at   233 
least 4 hours of freezing, cryovials containing the PBMC were stored in liquid nitrogen for 
later thawing and culturing. 
5.2.6  Resuscitation and culture of cryopreserved mononuclear cells 
 
5.2.6.1  Materials 
L-glutamine  (200  mM),  antibiotics  (penicillin,  streptomycin),  trypan  blue  and 
phytohaemaglutinin (PHA; HA16) were purchased from Sigma-Aldrich. RPMI medium 
(without L-glutamine and antibiotics) was purchased from PAA Laboratories. Ultra-pure 
LPS (Escherichia coli K12 strain), bacterial peptidoglycan (Staphylococcus aureus) and 
polyinosine-polycytidylic  acid  (poly(I:C))  were  purchased  from  InvivoGen.  LoTox 
Dermatophagoides  pteronyssinus  allergen  1  (Der  p  1)  was  purchased  from  Indoor 
Biotechnologies.  Low-endotoxin  ovalbumin  (Ova)  was  purchased  from  Profos  AG 
(Germany).  Salmon  parvalbumin  (Sal  s1)  was  a  kind  gift  of  John  Doe  (University  of 
Bergen, Norway).   
5.2.6.2  Procedures 
Cryopreserved PBMC were thawed rapidly in a 37C water bath and resuspended 
with 15 mL ice cold RPMI (containing 0.75 mmol/L glutamine and antibiotics (penicillin 
and streptomycin)) added dropwise on ice. After centrifugation, cells were resuspended in 
1 mL PRMI. Cells were stained with trypan blue and counted using a haemocytometer. 
Cell viability was assessed and was routinely greater than 80-90%.  
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All cultures were plated in duplicate in 96-well, round-bottom plates (2 x 10
6/mL) 
in  200L  of  RPMI  plus  10%  autologous  plasma  and  incubated  at  37
oC  in  a  5%  CO2 
atmosphere for the times indicated below.  The stimuli used were: Der p 1, Sal s1, Ova, 
PHA, TLR-2 ligand (peptidoglycan (PGN)), TLR-3 ligand (synthetic double stranded RNA 
Poly I:C), TLR-4 ligand (LPS). Controls wells were left unstimulated. Table 5.2 describes 
the type, concentration, and amount of each stimulus used. The incubation period for TLR 
ligands was 24 hours, whereas for allergens and mitogen it was 48 hours. After incubation, 
the plate was centrifuged and the supernatants were collected and frozen at -20C for later 
analysis of cytokines and PGE2. 
Table 5.2 Stimuli used for culturing of maternal peripheral blood mononuclear cells 
Stimulant  Type  Final 
concentration  Volume/well  Amount/well  Culture 
duration 
Der p 1  Allergen  10 µg/mL  10 µL  100 ng  48 h 
Sal s1  Allergen  200 µg/mL  10 µL  2000 ng  48 h 
Ova  Allergen  15 µg/mL  10 µL  150 ng  48 h 
PHA  Mitogen  7.5 µg/mL  10 µL  75 ng  48 h 
PGN  TLR-2 ligand  10 µg/mL  10 µL  100 ng  24 h 
Poly I:C  TLR-3 ligand  100 µg/mL  10 µL  1000 ng  24 h 
LPS  TLR-4 ligand  10 ng/mL  10 µL  0.1 ng  24 h 
 
5.2.7  Measurement of cytokine concentrations in mononuclear cell 
culture supernatant by cytometric bead array (CBA) and flow 
cytometry 
5.2.7.1  Principle 
The  cytometric  bead  array  (CBA)  employs  a  series  of  particles  with  discrete 
fluorescence intensities to simultaneously detect multiple soluble analytes. The CBA is 
combined with flow cytometry to create a multiplexed assay. Six bead populations with 
distinct fluorescence intensities have been coated with capture antibodies specific for each 
of the Th1 and Th2 cytokines. The six bead populations are mixed together to form the 
CBA that is resolved in a red channel (FL3) of a fluorescence-activated cell sorter (FACS). 
The CBA capture bead mixture is in suspension to allow for the detection of multiple 
analytes in a small volume of sample. The cytokine capture beads are mixed with the PE-
conjugated  detection  antibodies  and  then  incubated  with  recombinant  standards  or  test 
samples  to  form  sandwich  complexes.  Acquisition  of  data  is  done  using  the  flow 
cytometer.   235 
5.2.7.2  Materials 
Human Th1/Th2 cytometric bead array kit purchased from Becton Dickinson Biosciences 
included human interleukin (IL)-2, IL-4, IL-5, IL-10, tumour necrosis factor (TNF-α), and 
interferon-γ  (IFN-γ)  capture  beads,  human  Th1/Th2  PE  detection  reagent,  lyophilised 
human Th1/Th2 cytokine standards (all contained in one vial), cytometer setup beads, PE 
positive control detector, FITC positive control detector, wash buffer, assay diluent.  
5.2.7.3  Procedure 
The BD CBA protocol was followed. The lyophilised cytokine standard, containing 
all  six  human  Th1/Th2  cytokines,  was  reconstituted  in  assay  diluent  and  allowed  to 
equilibrate for 15 minutes. A serial dilution of the top standard was performed using assay 
diluent to achieve final concentrations of: 5000 (top standard), 2500 (1:2), 1250 (1:4), 625 
(1:8),  312.5 (1:16),  156 (1.32),  80 (1:64),  40 (1:128),  and  20  (1:256)  pg/mL  for  each 
cytokine in the standard. All capture bead populations were pooled together into a ‘mixed 
capture beads’ tube before analysis. Per test conducted (standard, negative control, and 
samples) 4.5 µL from each capture bead were used. Each assay tube was added with: 25 
µL ‘mixed capture beads’, 25 µL human PE detection reagent, 25 µL standard dilutions to 
the standard assay tubes, 25 µL assay diluent to the negative control assay tube, and 25 µL 
PBMC culture supernatant to the test assay tubes. The human Th1/Th2 cytokine detection 
reagent that was used included PE-conjugated anti-human IL-2, IL-4, IL-5, IL-10, TNF-α, 
and  IFN-γ  antibodies.  The  tubes  were  incubated  in  the  dark  for  3  hours  at  room 
temperature. After incubation, 1 mL of wash buffer was added to each tube and the tubes 
were centrifuged (200 × g, 5 min). After discarding the supernatant, the bead pellet was 
resuspended with 300 µL of wash buffer. The samples were analysed using Fluorescence-
Activated  Cell  Sorter  (FACSCalibur,  Becton  Dickinson,  Oxford,  UK)  The  number  of 
events counted was set at 1800 of gated events (i.e. 300 events per capture bead). The 
cytometer and instrument settings setup were performed according to the instructions of 
BD CBA protocol. Compensation for spectral fluorochrome overlap was performed. The 
BD CellQuest software was used for data acquisition and formatting. The sample results 
were generated in graphical and tabular format using the Becton Dickinson CBA analysis 
software. The limits of detection (LOD) for IL-2, IL-4, IL-5, IL-10, TNF-α, and IFN-γ 
were 2.6, 2.6, 2.4, 2.8, 2.8, 7.1 pg/mL, respectively. Values below level of detection were 
set at ½ LOD for all cytokines Figure 5.4 shows typical acquisition template example with 
the six distinct bead populations in the negative control standard and Figure 5.5 that of a 
culture supernatant  from PBMC stimulated with PHA. The populations of the specific 
capture beads, having discrete fluorescence intensity characteristics, can be seen on the   236 
figures and are distributed from brightest to dimmest as follows: IL-2, IL-4, IL-5, IL-10, 
TNF-α, and IFN-γ.  
 
Figure 5.4 Cytometric bead array acquisition template for negative control standard (0 pg/mL)   237 
 
 
Figure 5.5 Cytometric bead array acquisition template for culture supernatant from PHA stimulated 
PBMC (48 hours)   238 
5.2.8  Measurement of prostaglandin E2 concentration in mononuclear 
cell culture supernatant by enzyme-linked immunosorbent assay 
5.2.8.1  Principle 
This enzyme-linked immonosorbent assay (ELISA) is based on the forward sequential 
competitive  binding  technique  in  which  prostaglandin  E2  (PGE2)  present  in  a  sample 
competes  with  horseradish  peroxidase  (HRP)-labelled  PGE2  for  a  limited  number  of 
binding  sites  on  a  mouse  monoclonal  antibody  which  is  bound  to  goat  anti-mouse 
polyclonal  antibodies  covering  the  bottom  of  the  ELISA  plate.  PGE2  in  the  sample  is 
allowed  to  bind  with  the  mouse  antibody  in  the  first  incubation.  During  the  second 
incubation, HRP-labelled PGE2 binds to the remaining antibody sites. Following a wash to 
remove unbound  materials, a  substrate solution  is added to the wells to determine the 
bound enzyme activity. The colour development is stopped and the absorbance is read at 
450 nm. The colour is inversely proportional to the concentration of PGE2 in the sample.  
5.2.8.2  Materials 
PGE2 ELISA  kit  purchased  from  R&D  Systems  included:  goat-antimouse  96  well 
microplate, HRP-PGE2 conjugate, PGE2 standard, primary antibody (monoclonal antibody 
to PGE2 ), calibrator diluent, wash buffer, colour reagent A and B, stop solution 
5.2.8.3  Procedure 
The procedure followed was according to the manufacturer’s protocol. A 1:3, 1:10, or 
1:100 dilution of initial culture supernatant was performed as needed in order to be able to 
detect PGE2 within the  limit of detection. All reagents, working standards, and  buffers 
were prepared according to the protocol. The lyophilised PGE2 standard was reconstituted 
with 1 mL distilled water to produce a stock of 25,000 pg/mL. This was left for 15 minutes 
to stabilise. A serial dilution of the stock standard was performed using calibrator diluent 
to achieve final concentrations of: 2500, 1250, 625, 313, 156, 78, 39 pg/mL. Calibrator 
diluent was used as negative control (0 pg/mL). 200 µL of calibrator diluent was added to 
the  non-specific  binding  (NSB)  wells.  150  µL  of  calibrator  diluent  was  added  to  the 
negative control well. 150 µL of standard, control or sample was added to the remaining 
wells, and 50 µL of the primary antibody solution was added to each well, turning their 
colour to blue, apart from the NSB wells. The plate was then covered and incubated for 1 
hour at room temperature on horizontal orbital microplate shaker. Without washing the 
plate, after incubation, 50 µL of HRP-PGE2 conjugate was added to each well. All wells 
turned to violet colour apart from the NSB. The plate was again incubated for 2 hours at   239 
room temperature on the shaker. The plates were then aspirated, washed, and blot-dried 
four times with wash buffer. 200 µL of substrate solution (colour reagents A and B mixture 
15  minutes  before  use  according  to  protocol)  was  added  to  each  well.  The  plate  was 
incubated for 30 minutes at room temperature in the dark. Finally, 100 µL stop solution 
was  added  to  each  well.  The  optical  density  was  measured  immediately  after  using  a 
microplate reader (Thermo Labsystems) set at 450 nm. Wavelength correction was set to 
550 nm. The software used for plate reading was Ascent (Thermo Labsystems, version 
2.6).  The  NSB  optical  density  was  subtracted  from  that  of  the  standards,  control  and 
samples.  A  standard  curve  was  created  for  the  optical  density  and  PGE2  standard 
concentration. PGE2 concentration corresponding to the absorbance of each sample was 
calculated from the standard curve. The concentration was multiplied by the dilution factor 
of the samples. 
5.2.9  Statistical analysis 
Data  on  immune  cell  phenotypes  were  normally  distributed  and  thus  parametric 
statistical tests were used. The 3-repeated measures analysis of variance (ANOVA) was 
used as generalised linear modelling to examine overtime changes during pregnancy in 
relation to the intervention for all immune markers. The independent samples t-test was 
used for between group comparisons at each of the three time points of measurement (20, 
34, 38 weeks gestation). Data on cytokine and PGE2 expression from cultured PBMC were 
not normally distributed and the non-parametric 2 independent samples Mann Whitney test 
was used to compare the two groups at each of the three time points of measurement. The 2 
related samples non-parametric Wilcoxon signed rank test was used to compare changes 
between  time  points  within  the  groups  for  not  normally  distributed  data.  Pearson’s 
correlation was used for bivariate correlations. The level of statistical significance was set 
for all tests at p-value ≤ 0.05.   240 
5.3  Results 
5.3.1  Maternal leukocytes during pregnancy 
Table 5.3 describes the maternal leukocyte counts (cells x 10
3/µL whole blood) during 
pregnancy  in  both groups. Repeated measures  ANOVA  identified significant effects of 
time  on  the  numbers  of  total  leukocytes,  neutrophils,  lymphocytes,  monocytes,  and 
eosinophils.  There  were  no  significant  effects  of  group  or  group  x  time  interactions. 
Eosinophils did  not change  significantly over time  in the control group (p for trend = 
0.602) but they decreased significantly in the salmon group (p for trend = 0.011). At 20 
weeks gestation the  salmon group had a  lower  number of  leukocytes compared to the 
control group.  
5.3.2  Maternal mononuclear cell phenotypes during pregnancy 
Table 5.4 describes the maternal mononuclear cell phenotypes during pregnancy in 
both groups expressed as percentage of total lymphocytes, apart from TLR-2
+ monocytes 
which  are  expressed  as  percentage  of  total  monocytes.  Repeated  measures  ANOVA 
identified significant effects of time on the percentages of B cells (p < 0.001) and of group 
(i.e. salmon vs. control) on the percentage of TLR-2
+ monocytes (p = 0.026). There was a 
significant time x group interaction for the percentage of NK cells (p = 0.039). During 
pregnancy  the  percentage  of  NK  cells  in  the  total  lymphocyte  population  changed 
differently in the two groups; it remained stable in the control group (p for trend = 0.425), 
whereas in the salmon group it decreased significantly (p for trend = 0.002) 
The between group comparisons did not reveal differences between the groups at any 
time point, apart from the significantly  higher percentage of TLR-2
+  monocytes  in the 
salmon group compared to the control group at 20 weeks gestation (p = 0.026).  
Table 5.5 presents the maternal mononuclear cell subsets expressed as percentage of 
total leukocytes in both study groups. Repeated measures ANOVA identified significant 
effects  of  time  on  the  percentages  of  helper  T-cells,  T-regulatory  cells  and  TLR-2
+ 
monocytes and of group (i.e. salmon vs. control) on the percentage of TLR-2
+ monocytes. 
There  was  a  significant  time  x  group  interaction  for  the percentage  of  helper  T-cells. 
During  pregnancy  the  percentage  of  helper  T-cells,  T-regulatory  cells  and  TLR-2
+ 
monocytes  increased  progressively  with  no  significant  differences  between  groups, 
although  there  was  a  tendency  for  a  greater  increase  in  the  salmon  group.  The  mean 
increase  of  percentage  helper  T-cells  was  greater  in  the  salmon  group  (2.56,  ±  2.4) 
compared to the control group (0.95, ± 2.2) (p = 0.007; independent-samples t-test). The   241 
salmon group had a higher percentage of TLR-2
+ monocytes in total leukocytes at 20 and 
at 34 weeks gestation (p < 0.001 and p = 0.024 respectively). The MFI of CD127 receptor 
on T-regulatory cells increased during pregnancy (p = 0.037) (Figure 5.6). 
Table 5.6 describes the maternal mononuclear cell subset numbers (cells x 10
3/µL 
whole blood) during pregnancy. These were calculated based on information from Table 
5.3  - Table  5.5.  Repeated  measures  ANOVA  identified  significant time  effects  on  the 
numbers of helper T-cells, cytotoxic T-cells, T-regulatory cells, and TLR-2
+ monocytes. 
There  were  no  significant  differences  between  the  two  groups,  apart  from  the  higher 
number of TLR-2
+ monocytes in the salmon group at 20 weeks gestation.  
 
Figure 5.6 Median fluorescence intensity (MFI) of CD127 receptor on T regulatory cells during 
pregnancy   242 
Table 5.3 Maternal leukocyte counts (cells x 10
3/µL whole blood) during pregnancy 




n = 56 
Salmon 
n = 54  p
* 
Control 
n = 52 
Salmon 
n = 50  p
* 
Control 
n = 37 
Salmon 
n = 44  p
*  Group  Time 
Time × 
group 
Neutrophils  6.91 (± 1.8)  6.12 (± 1.6)  0.015  7.11 (± 1.8)  6.62 (± 1.6)  0.150  6.72 (± 1.8)  6.14 (± 1.5)  0.119  0.511  0.004  0.839 
Lymphocytes  1.59 (± 0.4)  1.49 (± 0.4)  0.165  1.69 (± 0.4)  1.73 (± 0.4)  0.609  1.83 (± 0.4)  1.82 (± 0.5)  0.857  0.829  <0.001  0.104 
Monocytes  0.49 (± 0.1)  0.52 (± 0.1)  0.208  0.61 (± 0.1)  0.64 (± 0.2)  0.348  0.63 (± 0.2)  0.63 (± 0.2)  0.987  0.433  <0.001  0.354 
Eosinophils  0.16 (± 0.3)  0.17 (± 0.1)  0.890  0.16 (± 0.3)  0.13 (± 0.1)  0.401  0.18 (± 0.3)  0.12 (± 0.1)  0.298  0.535  0.01  0.096 
Basophils  0 (± 0)  0 (± 0)  0.430  0 (± 0)  0 (± 0)  0.676  0.02 (± 0)  0.04 (± 0)  0.072  0.260  0.784  0.057 
Total leukocytes  9.16 (± 1.9)  8.32 (± 1.8)  0.022  9.57 (± 2.1)  9.12 (± 2.0)  0.270  9.37 (± 2.1)  8.72 (± 1.8)  0.136  0.567  <0.001  0.669 
Values are mean (± standard deviation) 
*p-values from independent samples t-test 
 
 
Table 5.4 Maternal mononuclear cell phenotypes during pregnancy expressed as percentage of the gated cell population 




n = 45 
Salmon 
n = 48  p
* 
Control 
n = 52 
Salmon 
n = 54  p
* 
Control 
n = 41 
Salmon 
n = 47  p

























69.80 (± 19.42)  77.31 (± 12.44)  0.026  73.45 (± 19.35)  76.24 (± 16.09)  0.423  73.98 (± 20.01)  71.78 (± 16.18)  0.570  0.039  0.822  0.428 
Values are mean (± standard deviation) percentage of the gated cell population. The cells gated were the lymphocyte population for all cells apart from TLR-2
+ monocytes for which the 
gated cells were the monocyte population 
*p-values from independent samples t-test  243 
 
Table 5.5 Maternal mononuclear cell phenotypes during pregnancy expressed as percentage of the total leukocyte population 




n = 45 
Salmon 
n = 48  p
* 
Control 
n = 52 
Salmon 
n = 54  p
* 
Control 
n = 41 
Salmon 
n = 47  p











3.17 (± 1.12)  3.36 (± 1.67)  0.510  3.76 (± 1.86)  4.57 (± 5.79)  0.331  3.74 (± 1.43)  4.11 (± 1.67)  0.275  0.196  0.264  0.335 
NK cells (CD3
-CD16
+)  0.84 (± 0.53)  1.05 (± 0.52)  0.068  0.91 (± 0.58)  0.94 (± 0.54)  0.791  1.01 (± 0.59)  0.96 (± 0.55)  0.711  0.918  0.906  0.120 
B-cells (CD3
-CD19










 low)  0.67 (± 0.72)  0.82 (± 0.69)  0.338  1.05 (± 0.62)  1.04 (± 0.61)  0.922  1.16 (± 0.73)  1.20 (± 0.69)  0.824  0.997  <0.001  0.765 
Values are mean (± standard deviation) percentage of the total leukocyte population 
*p-values from independent samples t-test 
 
Table 5.6 Maternal mononuclear cell subset numbers (cells x 10
3/µL blood) during pregnancy 




n = 44 
Salmon 
n = 40  p
* 
Control 
n = 49 
Salmon 
n = 49  p
* 
Control 
n = 37 
Salmon 
n = 44  p












0.380 (±0.1)  0.337 (±0.1)  0.137  0.442 (±0.2)  0.424 (±0.1)  0.616  0.429 (±0.2)  0.448 (±0.2)  0.606  0.899  <0.001  0.079 
NK cells (CD3
-CD16
+)  0.095 (±0.1)  0.104 (±0.1)  0.502  0.106 (±0.1)  0.109 (±0.1)  0.782  0.113 (±0.1)  0.106 (±0.1)  0.647  0.799  0.130  0.384 
B-cells (CD3
-CD19











0.336 (±0.1)  0.426 (±0.1)  0.003  0.456 (±0.1)  0.489 (±0.2)  0.315  0.466 (±0.2)  0.457 (±0.2)  0.823  0.018  <0.001  0.117 
Values are mean (± standard deviation) number of cells x 10
3/µL blood 
*p-values from independent samples t-test   244 
5.3.3  Production of cytokines by maternal mononuclear cells cultured 
with various stimulants 
Concentrations of a range of cytokines (regulatory (IL-10), Th1 (IFN-γ, TNF-α, IL-2), 
Th2 (IL-4, IL-5)) in the culture medium of maternal peripheral blood mononuclear cells 
(PBMC)  stimulated  with  allergens  (Der  p  1,  ovalbumin,  salmon  paralbumin),  mitogen 
(PHA), and TLR (-2, -3, -4) ligands are presented in Table 5.7-Table 5.10. 
IL-10.  Production  of  IL-10  in  response  to  the  allergen  Der  p  1  was  low  and  the 
concentrations measured were very similar to those seen for unstimulated cells (data not 
shown). Exposure to the TLR-3 ligand Poly I:C also resulted in low concentrations of IL-
10, which were lower than observed for unstimulated cells (Table 5.7). The TLR-2 ligand 
PGN, the TLR-4 ligand LPS and the mitogen PHA all greatly increased IL-10 production 
(Table 5.7). Spontaneous production of IL-10 and production  in response to and PHA 
decreased over time in both groups. IL-10 production in response to ovalbumin and to 
salmon paralbumin decreased in the control group (both p for trend < 0.001) and remained 
stable in the salmon group (p for trend = 0.201, 0.132). There were no other differences in 
IL-10 production between groups (Table 5.7).  
IFN-. Unstimulated PBMC produced very little IFN-γ, although the production that 
was seen was higher at week 20 of pregnancy, such that there was a significant decrease in 
concentration  over  time  (Table  5.8).  IFN-  concentration  following  exposure  to  the 
allergens  was  low  and  not  different  from  that  seen  with  unstimulated  cells  (data  not 
shown). PGN, Poly I:C, LPS and especially PHA induced IFN- production (Table 5.8). 
IFN- concentration decreased significantly with time for all stimulants with no differences 
between salmon and control groups (Table 5.8).  
TNF-α. Unstimulated PBMC produced TNF-α in readily detectable amounts (Table 
5.9). TNF- concentration following exposure to the allergens was low and not different 
from that seen with unstimulated cells (data not shown). PGN, LPS and PHA induced 
TNF-α  production,  while  Poly  I:C  appeared  to  suppress  it  (Table  5.9).  TNF-α 
concentration following exposure to TLR-3 and -4 ligands did not change over the course 
of  pregnancy  and  was  not  different  between  groups  (Table  5.9).  However,  TNF- 
production in response to TLR-2 ligand did not change in the control group (p for trend = 
0.400) but it decreased and then it increased in the salmon group during pregnancy (p for 
trend = 0.042). Finally, TNF-α concentration following PHA stimulation decreased over   245 
the course of pregnancy (p = 0.004), although there were no differences between salmon 
and control groups (Table 5.9).  
IL-2, IL-4 and IL-5. IL-2, IL-4, IL-5 concentrations were below the limit if detection 
in the supernatants of unstimulated PBMC and PBMC stimulated with TLR ligands or with 
allergens. PHA induced a rise in IL-2, IL-4 and IL-5 concentrations. These decreased over 
time (p < 0.001 for all three; Table 5.10) with no difference between groups.  
The  ratio  of  concentrations  of  IFN-γ  to  IL-4  in  supernatants  of  cultures  of  PHA 
stimulated maternal PBMC was used as a surrogate marker of the Th1 to Th2 ratio and so 
of the relative activities of Th1 and Th2 cells. This ratio favoured IFN- at all time points 
in both groups and declined over the course of pregnancy, although that was not significant 
by ANOVA (Table 5.10). However the 2 related samples non-parametric Wilcoxon signed 
ranks test showed that for both control and salmon groups, the ratio was significantly lower 
at 34 weeks compared to 20 weeks (p = 0.011 for the control group and p = 0.036 for the 
salmon group) and at 38 weeks compared to 20 weeks (p = 0.047 for the control group and 
p  =  0.011  for  the  salmon  group).  The  IFN-γ/IL-10  ratio,  which  represents  the  Th1/T-
regulatory  responses  ratio  decreased  significantly  over  time  (p  =  0.001)  but  was  not 
different between groups. This ratio favoured IFN-γ at 20 weeks gestation and IL-10 at 34 
and 38 weeks gestation (Table 5.10). 
5.3.4  Cytokine production in relation to skin prick testing 
As presented in chapter 2, subjects were skin prick tested with various allergens. It 
was found that subjects with positive SPT to Der p 1 had higher IL-10 (median 55 vs. 45 
pg/mL) and TNF-α (median 11.7 vs. 9.9 pg/mL) production in response to this allergen 
compared to those with negative SPT, but this was not significant (p = 0.290 and 0.488, 
Mann  Whitney  test  for  all  time  points  and  groups  combined).  The  same  pattern  was 
observed when data were explored for each time point separately (groups combined), for 
each  group  separately  (time  points  combined),  and  for  each  time  point  and  group 
separately (between group comparisons, i.e. salmon vs. control were not significant). The 
only significant difference found was within subjects with positive SPT to Der p 1, where 
the salmon group had significantly lower production of IL-10 to Der p 1 compared to 
control (medians 37 vs. 72 pg/mL, p = 0.012, all time points combined). There were no 
other allergens used for both ex vivo cytokine production and SPT.  
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Table 5.7 Interleukin-10 concentration (pg/mL) in supernatants of cultured PBMC collected at different times during pregnancy and stimulated with various TLR ligands, 
allergens and mitogens for 24 or 48 hours 




n = 40 
Salmon 
n = 48  p
* 
Control 
n = 42 
Salmon 
n = 49  p
* 
Control 
n = 35 
Salmon 
n = 41  p




1  139.9 (70.7, 261.9)  120.1 (39.6, 188.5)  0.085  78.9 (21.5, 169.1)  54.1 (15.5, 106.7)  0.083  68.8 (37.2, 94.4)  71.1 (26.8, 114.5)  0.799  0.401  <0.001  0.223 
PGN
 1  439.5 (290.7, 606.6)  409.8 (144.6, 614.1)  0.472  364.6 (218.1, 598.9)  437.5 (207.7, 616.4)  0.656  357.0 (216.4, 504.7)  394.4 (255.4, 577.0)  0.750  0.640  0.406  0.616 
Poly I:C
 1  50.8 (16.1, 119.7)  36.4 (7.5, 91.2)  0.313  30.4 (8.4, 82.3)  18.2 (11.9, 53.2)  0.746  28.3 (11.1, 70.1)  20.3 (8.8, 41.8)  0.273  0.793  0.550  0.404 
LPS
 1  951.6 (532.5, 1295.0)  860.1 (348.7, 1351.8)  0.586  717.8 (441.5, 1410.3)  815.0 (419.6, 1072.8)  0.971  698.3 (434.7, 1262.2)  940.8 (493.7, 1333.8)  0.527  0.682  0.767  0.776 
48h control 
2  89.1 (50.8, 181.1)  71.8 (22.8, 131.5)  0.123  57.1 (23.5, 133.5)  46.8 (21.9, 82.9)  0.324  49.3 (21.9, 121.2)  57.4 (27.8, 99.6)  0.938  0.110  0.007  0.384 
Ova 
2  114.4 (70.6, 186.7)  74.6 (36.1, 130.2)  0.016  67.5 (36.2, 121.5)  58.0 (30.7, 100.0)  0.415  52.2 (29.3, 105.7)  70.0 (36.2, 121.4)  0.479  0.692  0.004  0.051 
Sal s1
 2  130.9 (86.3, 188.5)  90.3 (54.3, 149.3)  0.054  80.3 (50.3, 135.5)  72.6 (47.2, 115.8)  0.628  73.3 (46.0, 109.7)  80.4 (38.8, 163.5)  0.923  0.663  0.010  0.029 
PHA
 2  180.9 (91.8, 295.4)  128.9 (86.4, 203.0)  0.127  93.2 (34.5, 160.9)  61.9 (31.5, 97.7)  0.077  73.2 (32.8, 143.7)  78.0 (39.8, 117.5)  0.988  0.051  <0.001  0.497 
Values are median (interquartile range) 
The limit of detection (LOD) was 2.8 pg/mL. When the value was below the LOD this was set at LOD/2 i.e. 1.4 pg/mL 
*p-values from non-parametric 2 independent samples test (Mann Whitney) 
124 hour mononuclear cell cultures 
248 hour mononuclear cell cultures 
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Table 5.8 Interferon-γ concentration (pg/mL) in supernatants of cultured PBMC collected at different times during pregnancy and stimulated with various TLR ligands and 
mitogens for 24 or 48 hours 




n = 40 
Salmon 
n = 48  p
* 
Control 
n = 42 
Salmon 
n = 49  p
* 
Control 
n = 35 
Salmon 
n = 41  p
*  Group  Time 
Time × 
group 
24 h control 
1  3.6 (3.6, 12.5)  3.6 (3.6, 8.8)  0.205  3.6 (3.6, 3.6)  3.6 (3.6, 3.6)  0.245  3.6 (3.6, 3.6)  3.6 (3.6, 3.6)  0.516  0.298  0.029  0.464 
PGN
 1  13.6 (3.6, 29.4)  11.6 (3.6, 39.3)  0.865  3.6 (3.6, 15.9)  3.6 (3.6, 11.8)  0.756  3.6 (3.6, 10.5)  3.6 (3.6, 12.3)  0.838  0.934  0.037  0.172 
Poly I:C
 1  40.2 (14.8, 274.0)  50.2 (15.3, 148.5)  0.877  10.2 (3.6, 43.9)  16.0 (3.6, 56.2)  0.454  6.9 (3.6, 41.4)  18.5 (3.6, 62.3)  0.067  0.271  0.004  0.244 
LPS
 1  35.9 (15.1, 91.8)  36.5 (10.9, 102.0)  0.800  14.6 (3.6, 42.0)  18.6 (8.2, 40.0)  0.546  12.3 (3.6, 30.5)  12.9 (3.6, 35.9)  0.441  0.950  0.004  0..785 
48 h control 
2  8.0 (3.6, 53.2)  3.6 (3.6, 28.5)  0.275  3.6 (3.6, 12.7)  3.6 (3.6, 8.8)  0.675  3.6 (3.6, 5.7)  3.6 (3.6, 3.6)  0.345  0.224  <0.001  0.499 
PHA
 2  299.2 (90.1, 1011.4)  159.0 (57.5, 1078.1)  0.669  31.9 (6.3, 
170.8) 
16.6 (3.6, 168.0)  0.386  36.3 (9.7, 201.6)  24.6 (3.6, 163.2)  0.599  0.957  <0.001  0.835 
Values are median (interquartile range). 
The limit of detection (LOD) was 7.1 pg/mL. When the value was below the LOD this was set at LOD/2 i.e. 3.6 (3.55) pg/mL 
*p-values from non-parametric 2 independent samples test (Mann Whitney) 
124 hour mononuclear cell cultures 
248 hour mononuclear cell cultures   248 
Table 5.9 Tumour necrosis factor-α concentration (pg/mL) in supernatants of cultured PBMC collected at different times during pregnancy and stimulated with various TLR 
ligands and mitogens for 24 or 48 hours 




n = 40 
Salmon 
n = 48  p
* 
Control 
n = 42 
Salmon 
n = 49  p
* 
Control 
n = 35 
Salmon 
n = 41  p




1  145.9 (21.7, 274.9)  48.0 (17.3, 166.3)  0.104  63.0 (6.9, 135.9)  19.6 (1.4, 61.6)  0.054  21.2 (5.2, 86.5)  18.0 (5.0, 40.0)  0.633  0.923  0.271  0.108 
PGN
 1  847.2 (402.4, 1430.9)  722.7 (286.5, 1091.4)  0.090  766.6 (400.0, 1439.6)  784.4 (365.2, 1418.8)  0.676  752.8 (377.8, 1368.3)  677.5 (288.8, 1671.2)  0.977  0.367  0.149  0.029 
Poly I:C
 1  20.0 (5.4, 60.3)  13.7 (7.4, 58.9)  0.785  10.5 (1.4, 59.0)  7.1 (3.1, 28.3)  0.342  7.0 (3.6, 25.7)  9.2 (1.4, 16.5)  0.790  0.313  0.129  0.537 
LPS
 1  643.3 (286.4, 1625.9)  590.5 (224.8, 874.6)  0.283  577.8 (298.6, 825.2)  423.7 (229.0, 930.1)  0.554  465.7 (299.3, 999.4)  540.0 (262.1, 1053.0)  0.590  0.788  0.347  0.193 
48h control 
2  26.3 (8.0, 139.3)  25.8 (3.9, 68.9)  0.243  17.0 (1.4, 106.1)  8.2 (1.4, 55.7)  0.428  8.5 (1.4, 42.4)  7.8 (4.0, 20.5)  0.710  0.214  0.541  0.064 
PHA 
 2  109.7 (30.3, 204.4)  58.3 (24.1, 208.4)  0.325  24.1 (5.0, 82.2)  11.4 (4.5, 83.4)  0.414  21.7 (6.6, 106.3)  16.8 (8.1, 44.6)  0.810  0.956  0.004  0.747 
Values are median (interquartile range) 
The limit of detection (LOD) was 2.8 pg/mL. When the value was below the LOD this was set at LOD/2 i.e. 1.4 pg/mL 
*p-values from non-parametric 2 independent samples test (Mann Whitney) 
124 hour mononuclear cell cultures 
248 hour mononuclear cell cultures 
 
Table 5.10 Interleukin-2, 4 and 5 concentrations (pg/mL) in supernatants of cultured PBMC collected at different times during pregnancy and stimulated with a mitogen (PHA) 
for 48 hours 




n = 40 
Salmon 
n = 48  p
* 
Control 
n = 42 
Salmon 
n = 49  p
* 
Control 
n = 35 
Salmon 
n = 41  p
 *  Group  Time 
Time × 
group 
IL-2  25.7 (9.3, 37.3)  18.9 (5.6, 49.7)  0.970  6.2 (2.8, 13.6)  5.7 (1.3, 12.5)  0.475  9.7 (3.2, 19.4)  8.7 (2.9, 18.8)  0.810  0.617  <0.001  0.667 
IL-4  5.1 (1.3, 17.0)  5.5 (1.3, 20.5)  0.691  1.3 (1.3, 3.6)  1.3 (1.3, 2.9)  0.579  1.3 (1.3, 4.1)  1.3 (1.3, 4.9)  0.874  0.776  <0.001  0.990 
IL-5  6.7 (1.2, 28.5)  7 (2.6, 25.6)  0.619  1.2 (1.2, 5.8)  1.2 (1.2, 4.8)  0.806  1.2 (1.2, 7.4)  1.2 (1.2, 7.8)  0.468  0.654  <0.001  0.556 
IFN-IL-4  40.7 (13.6, 125.5)  43.6 (8.9, 94.8)  0.615  14.6 (3.4, 47.9)  11.2 (2.7, 50.8)  0.363  12.3 (6.4, 37.2)  8.5 (2.7, 48.4)  0.398  0.528  0.324  0.502 
IFN-IL-10  2.2 (0.3, 5.2)  2.1 (0.4, 6.5)  0.828  0.5 (0.1, 1.8)  0.4 (0.1, 3.5)  0.940  0.5 (0.2, 1.7)  0.6 (0.1, 2.1)  0.743  0.226  0.001  0.223 
Values are median (interquartile range) 
*p-values from non-parametric 2 independent samples test (Mann Whitney)   249 
5.3.5  Production of prostaglandin E2 by maternal mononuclear cells 
cultured with various stimulants 
Unstimulated PBMC produced significant amounts of PGE2 and this declined over the 
course  of  pregnancy  (Table  5.11).  At  34  weeks  gestation  PGE2  production  from 
unstimulated PBMC was significantly lower in the salmon group compared to the control 
group  (p  =  0.023).  Exposure  to  LPS  increased  PGE2  production  (Table  5.11).  PGE2 
production  in response to PHA decreased over time  but was not significantly different 
between groups (Table 5.11). PGE2 production in response to LPS correlated significantly 
and positively with arachidonic acid content of PBMC (data for both groups and all time 
points combined) (Figure 5.7). Similarly, significant positive correlations were observed 
for PGE2 production from LPS stimulated PBMC and PBMC arachidonic acid content at 
20 weeks of pregnancy for both groups combined (Pearson’s r = 0.237, p = 0.024), and at 
20 weeks for the salmon group (Pearson’s r = 0.372, p = 0.011). Also, PGE2 production 
from  PHA  stimulated  PBMC  correlated  negatively  with  PBMC  EPA  content  for  both 
groups and all time points combined (Pearson’s r = -0.144, p= 0.022), and at 38 weeks for 
both  groups  combined  (Pearson’s  r=  -0.313,  p  =  0.006).  PGE2  production  from 
unstimulated PBMC correlated negatively with PBMC EPA content at 34 weeks gestation 
for the salmon group (Pearson’s r= -0.347, p = 0.015). Lastly, spontaneous production of 
PGE2  correlated  negatively  with  PBMC  DHA  content  at  34  weeks  for  both  groups 
combined (Pearson’s r = -0.215, p = 0.038). 
 
Figure 5.7 Correlation between maternal PBMC arachidonic acid content and PGE2 production from 
lipopolysaccharide (LPS; TLR-4 ligand) stimulated PMBC in both groups 
All time points during pregnancy included   250 
Table 5.11 Prostaglandin E2 concentration (pg/mL) in supernatants of cultured PBMC collected at different times during pregnancy and stimulated  with TLR-4 ligand (LPS) 
and a mitogen (PHA) 




n = 45 
Salmon 
n = 49  p
* 
Control 
n = 46 
Salmon 
n = 49  p
* 
Control 
n = 39 
Salmon 
n = 42  p










3550.8)  0.204  0.249  0.001  0.486 
LPS




0.098  8604.8 (4897, 
13823.7) 
6286 (3542.5, 14069)  0.394  0.809  0.224  0.754 
PHA 
2  3783 (1741-8955.6)  2595 (1138, 7298)  0.178  2356 (1138, 4808)  2136 (299, 5170)  0.326  2977 (1749, 6272)  2311.1 (1335.5, 
4463.3)  0.203  0.200  0.037  0.644 
Values are median (interquartile range) 
*p-values from non-parametric 2 independent samples test (Mann Whitney) 
124 hour mononuclear cell cultures 
248 hour mononuclear cell cultures 
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5.3.6  Summary of the results 
Table 5.12 summarises the findings of this chapter and differentiates between the effect of 
pregnancy and the effect of the salmon intervention. Pregnancy had a significant effect on 
the number of leukocytes and their subsets. Neutrophil numbers initially increased and 
then  decreased,  and  lymphocytes,  monocytes,  and  total  leukocytes  increased  during 
pregnancy  in  both  groups,  without  any  effect  of  the  salmon  intervention.  Eosinophil 
numbers did not change during pregnancy but they decreased significantly in the salmon 
group. During the course of pregnancy, B-cells decreased whereas TLR-2
+ monocytes, T-
regulatory  cells,  and  cytotoxic  T-cells  (only  cell  number)  increased.  The  salmon 
intervention had no effect on these. Although NK cells were not affected by pregnancy, the 
salmon intervention resulted in a decrease in their percentage (% lymphocytes). Helper T-
cells increased as a result of pregnancy and this increase was further augmented by the 
salmon intervention (% leukocytes). PBMC production of cytokines (IL-10, IFN-γ, TNF-α, 
IL-4,  IL-2,  IL-5)  in  response  to  a  mitogen  (PHA)  declined  with  the  progression  of 
pregnancy. The salmon intervention did not affect this decline. However, IL-10 production 
decreased  during  pregnancy  also  in  response  to  allergens  (ovalbumin  and  salmon 
paralbumin) and the salmon intervention prevented this decrease. Also, TNF-α production 
in response to TLR-2 ligand was not affected during the course of pregnancy in the control 
group, whereas it increased and then decreased in the salmon group. IFN-γ production in 
response to TLR ligands declined during pregnancy and was not affected by the salmon 
intervention.  Finally,  PGE2  production  by  unstimulated  and  mitogen  stimulated  cells 
declined over the course of pregnancy. The salmon intervention resulted in greater decline 
of PGE2 production from unstimulated cells (34 weeks gestation).   252 
 
Table 5.12 The effects of pregnancy and of salmon intervention on immune markers 
 
  Effect of pregnancy  Effect of salmon 
Neutrophils (cells/µL blood)  ↑ then ↓  ↔ 
Lymphocytes (cells/µL blood)  ↑  ↔ 
Monocytes (cells/µL blood)  ↑  ↔ 
Eosinophils (cells/µL blood)  ↔  ↓ 
Total leukocytes (cells/µL blood)  ↑  ↔ 
B-cells (%Lymphocytes)  ↓  ↔ 
NK cells (%Lympholytes)  ↔  ↓ 
Helper T-cells 
% Leukocytes 




















Cell count (cells/µL blood) 









PBMC IL-10 response to: 














PBMC IFN-γ response to: 
























↑ then ↓ 
↔ 
PBMC IL-2 response to mitogen (PHA)  ↓  ↔ 
PBMC IL-4 response to mitogen (PHA)  ↓  ↔ 
PBMC IL-5 response to mitogen (PHA)  ↓  ↔ 
IFN-γ/IL-4 to mitogen (PHA)  ↓  ↔ 
IFN-γ/IL-10 to mitogen (PHA)  ↓  ↔ 
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5.4  Discussion  
Pregnancy  is  known  to  be  associated  with  changes  in  maternal  immune  function, 
believed to be  important to prevent rejection of the  foetus which  could  be  seen  as an 
allograft (i.e. transplant) that would normally elicit an immune response resulting in its 
rejection. Thus the immune changes that occur allow a successful pregnancy to ensue. At 
birth several aspects of the foetal immune response are like those in the mother. Some 
foetal immune responses indicate a predisposition to atopy. Fatty acid-derived mediators 
might play a role in the immune changes that occur during pregnancy and in setting up the 
foetal immune system. In chapter 4 it was shown that increased intake of salmon during 
pregnancy results in higher n-3 PUFA status in maternal plasma and immune cells. Thus it 
was thought that salmon intake in pregnancy could influence maternal immunity (studied 
here) that could impact on development of the foetal immune system and predisposition to 
atopy.  The  studies  described  in  this  chapter  set  out  to  address  the  hypotheses  that 
increasing habitually low intake of oily fish (≤ 2 portions per month) to 2 portions per 
week  during  pregnancy  will  result  in  altered  maternal  immune  cell  phenotypes  during 
pregnancy, in altered maternal innate and adaptive immune responses, measured as Th1, 
Th2,  and  regulatory  cytokine  expression  by  mononuclear  cells  cultured  with  various 
stimulants, and in lower production of PGE2 by mononuclear cells cultured with various 
stimulants. The results obtained indicate that, while there were some effects of salmon 
intake on certain immune parameters, these hypotheses cannot be accepted (i.e. increased 
salmon intake during pregnancy had only a limited impact on maternal immunity, at least 
as  measured  here).  Furthermore  the  data  obtained  show  that  the  effect  of  progression 
through pregnancy on immune function is of a much greater magnitude than the effect of 
salmon: a number of immune measures were significantly affected by progression through 
pregnancy.   
5.4.1  Maternal whole blood immune cell subsets during pregnancy 
and the effect of increased salmon consumption 
The immune cell subset analysis showed that the percentage of B-cells in lymphocytes 
decreased during pregnancy, whereas the percentage of helper T-cells in total leukocytes 
(and their total number in the bloodstream) increased during pregnancy. These findings are 
supported  by  other  studies  and  are  consistent  with  the  immune  shifts  observed  during 
normal  pregnancy  (64,  65).  The  study  of  Kuhnert  et  al.  (315)  examined  changes  in 
lymphocyte subsets during  normal pregnancy  and compared these with data from non-
pregnant control women. The percentage of B-cells decreased but not-significantly during 
pregnancy;  the  percentage  of  cytotoxic  T-cells  did  not  change  during  pregnancy;  the   254 
percentage of helper T-cells increased but not significantly during pregnancy (315). The 
study of Mahmoud et al. (316) showed that helper T-cells (expressed as a percentage of 
total lymphocytes) were higher in pregnant (44.3%) as opposed to non-pregnant (41.7%) 
women, whereas the percentage of B-cells was lower in pregnancy (12% versus 13.9%). 
Madmoud et al. (317) showed that the percentage of B-cells was lower and of helper T-
cells  higher  in  pregnant  than  non-pregnant  women.  The  findings  of  the  current  study, 
showing changes  in percentages of B-cells and  helper T-cells (and their number)  from 
week 20 of pregnancy are in agreement with these comparisons of pregnant versus non-
pregnant women. Also, in the current study it was shown that the number of cytotoxic T-
cells in blood increased during pregnancy (but not their percentage). Other studies have 
shown a lower number of these cells in pregnant compared to non-pregnant women (316). 
The percentage of T-regulatory cells in total leukocytes (and their number in blood) 
increased  during  pregnancy.  Also,  T-regulatory  cell  mean  fluorescence  intensity  (MFI) 
increased  during  pregnancy  which  indicates  that  not  only  the  number  of  these  cells 
increased  but also the  level of expression of the cell surface  marker  CD127  increased 
suggesting  increased  activation.  This  finding  is  in  accordance  with  previous  literature 
findings  on  T-regulatory  cell  pool  expansion  (i.e.  increase  in  number)  during  normal 
pregnancy. Zhao et al. (318) showed that foetal alloantigen is responsible for the increase 
of T-regulatory cells during pregnancy, and the expansion of the T-regulatory population is 
an  important maternal  immune response. Taams et al. (319) reported that T-regulatory 
cells (CD4
+CD25
+) play a key role in the suppression and regulation of immune responses, 
by  affecting  T-cell  responses,  antibody  production,  cytokine  secretion,  and  antigen-
presenting cells. It has been suggested that the expansion in the T-regulatory cell pool 
observed  during  pregnancy  is  important  for  prevention  of  “transplant”  (i.e.  foetal) 
rejection. Tilburgs et al. (320) showed that there is a preferential recruitment of foetus-
specific T-regulatory cells from maternal peripheral blood to the materno-foetal interface 
in the decidua, where they may contribute to local regulation of foetus-specific responses. 
It should be mentioned that there was a limitation in the method used to identify T-




low cells as T-regulatory cells: this is an antibody 
to the FOXP3 transcription factor expressed by these cells (321). This was not possible in 
the  current  study  since  the  flow  cytometer  used  can  detect  only  three  antibody  stains 
simultaneously; using anti-FOXP3 would require detection of four “stains”. Despite this 
limitation, it seems likely that the cells identified as being positive for CD4, positive for   255 
CD25 and expressing a low level of CD127 (the α chain of IL-7 receptor) are T regulatory 
cells.  
The percentage of TLR2
+  monocytes  in total  leukocytes, as well as their  number, 
increased  during  pregnancy.  This  indicates  an  upregulation  of  innate  immunity  during 
pregnancy which is in agreement with current literature that the innate immune system is 
important  during  pregnancy  (322-324).  During  pregnancy  the  maternal  innate  immune 
system responds to the ‘semi-allograft’ foetus in part by an upregultion of innate immunity. 
It has been suggested that trophoblast cells regulate this change through an activation via 
TLR  (323).  The  current  findings  of  an  increased  percentage  and  number  of  TLR2
+ 
monocytes are consistent with this idea.  
In the current study the increase in helper T-cells (as a % of leukocytes) was greater in 
the salmon group compared to the control group. To my knowledge, there is no literature 
on fish or fish oil intake and maternal immune cell subsets in pregnancy with which to 
compare this finding. Since an increase in helper T-cells as a % of leukocytes is normally 
seen  during  pregnancy,  this  finding  may  indicate  better  progression  to  successful 
pregnancy with increased salmon intake.  
Also it was found that the percentage of lymphocytes as NK cells (% lymphocytes) 
decreased in the salmon group but not in the control group. Kuhnert et al. (315) showed 
that percentage of NK cells did not change over pregnancy but was lower compared to 
non-pregnant women. In contrast Mahmoud et al. (316) found no differences between NK 
cell levels in pregnant and non pregnant women. The regulation of NK cells in peripheral 
blood and endometrial layers has been associated with reproductive immunopathology and 
recurrent  spontaneous  abortions  (RSA).  Different  subsets  of  NK  cells  with  various 
functional roles can interact with trophoblasts. An increase in number and/or activity of 
NK cells and their subsets (CD56
+/CD16
+) has been observed in women with RSA (282). 
This would suggest that a suppression in NK cell numbers and activity would promote 
successful pregnancy. Thus this effect of salmon may be an important and beneficial one. 
However,  what  happens  in  the  maternal  periphery  may  not  necessarily  reflect  what 
happens in the materno-foetal interface. The only study available with which to compare 
these findings with NK cells in the salmon group is that of Krauss-Etschmann et al. (72) 
which  showed  that  fish  oil  supplementation  during  pregnancy  was  associated  with 
decreased frequencies of NK cells and CCR3
+CD8
+
 T-cells in cord blood. However, that 
study did not investigate the effect of fish oil intervention on maternal immune cell subsets   256 
during  pregnancy.  There  are  no  previous  studies  on  fish  oil  supplementation  or  fish 
consumption during pregnancy that have reported results on maternal immune cell subsets.  
One limitation to the current study is that intracellular markers that would characterise 
the functional properties of immune cell subsets and differentiate them into Th1 or Th2 
phenotypes were not investigated. However, the current study did examine production of 
Th1 and Th2-type cytokines by unstimulated and stimulated mononuclear cells, a measure 
that does provide insight into the functional phenotype of the cells present. This work is 
discussed  in  the  next  section.  Also,  it  has  to  be  noted  that  distinguishing  between 
immunological changes that occur locally in the uterus and systemically in the maternal 
circulation is important (322). Whether the salmon intervention affected frequencies and/or 
functionality of immune cell subsets in the materno-foetal interface is unknown and was 
not investigated here.    257 
5.4.2  Maternal innate and adaptive immune responses during 
pregnancy 
A strength of the current study is the use of different (ex vivo) stimulants in order to 
investigate  different  aspects of  the  immune  system  including  both  innate  and  adaptive 
immunity. The use of allergens as stimulants was important in order to investigate adaptive 
immune  responses  of  T-cells  already  sensitised  specifically  to  these  allergens.  These 
responses would follow the mechanism of antigen presentation by antigen presenting cells 
(APC). Only T-cells which have previously encountered these specific allergens and have 
been activated and developed immunologic memory would respond in culture. The number 
of  T-cells  specifically  sensitised  to  each  allergen  would  be  low  and  so  longer  culture 
periods were required for such responses to be seen. In fact there was a very poor cytokine 
response to any of the three allergens used. However, subjects already sensitised to specific 
allergens were expected to have higher responses. Indeed, subjects with positive SPT to a 
specific allergen (Der p 1) tended to have higher ex-vivo cytokine production (IL-10, TNF-
α) to this allergen compared to those with negative SPT, although this was not significant. 
Another stimulant which also activates adaptive immune responses is the T-cell mitogen 
PHA. In contrast to the allergens, the mitogen activates T-cells non-specifically via the 
CD3 receptor present on their surface. This means that all T-cells respond to the mitogen in 
a  non-specific  way  and  bypassing  the  need  for  antigen  presentation.  The  response  to 
mitogen can be used as a positive control since all T-cells are expected to respond non-
specifically. Indeed there was a strong cytokine response to PHA. Innate immune system 
responses  were  investigated  stimulating  TLR-2,-3  and  -4  with  specific  ligands.  TLR 
ligands stimulate mainly monocytes which express the different TLR on their surface. TLR 
stimulation  is  non-antigen  specific, TLR  being responsible  for recognition of  so-called 
pathogen  associated  molecular  patterns  (PAMP).  This  means  that  TLR  on  monocytes 
recognise  a  general  feature  of  pathogen  structure  and  respond  to  this  with  cytokine 
production (and phagocytosis if the intact pathogen is present). Cytokines were measured 
using a flow cytometry based assay termed cytometric bead array, which measures a range 
of cytokines characteristic for different responses: Th1 (IL-2, TNF-α, IFN-γ), Th2 (IL-4, 
IL-2) and regulatory (IL-10).  
IL-2, IL-4, and IL-5 were only produced in cultures stimulated with PHA; these are 
prototypical T-cell cytokines and so this observation is consistent with production by T-
cells in response to the T-cell mitogen. IFN- γ was strongly produced in response to PHA 
and  weakly  in  response  to the  TLR  ligands.  IFN-γ  is  a  prototypical  T-cell  (Th1  cell) 
cytokine  so high production  in response to PHA  accords with this. IFN-γ  can also  be   258 
produced by monocytes and this explains the weak production when TLR ligands were 
used. IL-10 and TNF-α were produced in response to PHA and especially the TLR-2 and 
TLR-4 ligands. Both these cytokines can be produced by T-cells and by monocytes, so this 
observation  is  in  accordance  with  this.  Interestingly,  the  TLR-3  ligand  decreased 
production of both IL-10 and TNF-α.  
The production of all cytokines determined (IL-10, TNF-α, IFN-γ, IL-2, IL-4, IL-5) by 
maternal PBMC stimulated with PHA decreased during the course of pregnancy, as did the 
production of IL-10 in response to allergens. These observations suggest T cell reactivity 
decreases as pregnancy proceeds. Furthermore, the production of IFN-γ by TLR (-2, -3, -4) 
ligand stimulated PBMC decreased during pregnancy. The ratio of prototypical Th1 to Th2 
cytokines (IFN-γ/IL-4) produced in response to PHA and the ratio of Th1 to T-regulatory 
cytokines  (IFN-γ/IL-10)  both  decreased  significantly  during  pregnancy.  These  changes 
signify a polarisation of the helper T-cells towards the Th2 and T-regulatory phenotype 
during pregnancy which is in agreement with current literature (277, 278).  
Ho  et  al.  (325)  found  that  the  proportion  of  IL-4  secreting  cells  exceeded  IFN-γ 
secreting cells in peripheral blood and in decidua of normal pregnancies (early stages of 
pregnancy, 6-10 weeks). In the study of Langer-Gould et al. (326) CD4
+ and CD8
+ T-cell 
subgroups  were  identified  and  analysed  for  simultaneous  expression  of  IFN-γ  and 
CD45RA, IL-2 and CD45RA, TNF and CD45RA, IL-4, or IL-10. They showed that IFN-γ 
producing CD8
+ T-cells decreased during the course of pregnancy. The findings of the 
current study are consistent with these earlier studies. The findings of the current study 
also partly agree with those of Breckler et al. (287) who investigated the allergen-specific 
production of IL-10, IL-13, and IFN-γ by PBMC at 20, 30 and 36 weeks gestation and 6 
weeks postpartum in allergic and non-allergic pregnant women. For both allergic and non-
allergic women, IFN-γ production by stimulated maternal PBMC (house dust mite (HDM), 
cat hair allergen, and PHA) was lower during pregnancy compared to postpartum. This 
agrees with the reported Th1 response suppression that has been seen in pregnancy (277, 
278)  and  confirmed  in  the  current  study.  However  Breckler  et  al.  (287)  reported  that 
(regulatory) IL-10 responses to stimulants did not change during pregnancy and were not 
different from postpartum levels in either allergic or non-allergic women. This contrasts 
with the decrease in IL-10 production found in the current study. Finally, Breckler et al. 
(287) showed that Th2 IL-13 response to HDM significantly decreased during pregnancy 
and were lower in pregnancy compared to postpartum in non-allergic women. This finding 
agrees with the current finding of decreased Th2 responses (IL-4, IL-5) over pregnancy. 
However,  Breckler  et  al.  (287)  showed  that  for  allergic  mothers  IL-13  production  in   259 
response to HDM did not change during pregnancy and did not differ from postpartum 
levels. Allergic women were found to have higher IL-13 responses to HDM compared to 
non-allergic women both during pregnancy and postpartum. These results show that for 
both allergic and non-allergic women, although the regulatory responses (IL-10) did not 
change  during  pregnancy,  Th1  responses  (IFN-γ)  were  suppressed  compared  to 
postpartum. Non-allergic women downregulated Th2 responses (IL-13) during pregnancy, 
while allergic women failed to do so and continued to exhibit high Th2 responses. The 
authors suggested that these peripheral responses in allergic women may also skew the 
cytokine milieu at the maternal-fetal interface towards the Th2 phenotype, contributing to 
increased risk of atopy in the offspring of allergic mothers. This partly agrees with my 
findings that Th1, Th2, and T-regulatory responses to PHA decreased during pregnancy in 
both groups.  
According to several studies (287, 327, 328) atopy status of the mother may affect 
maternal cytokine responses during pregnancy which may further affect the materno-foetal 
interface milieu away from Th1 and towards Th2 responses predisposing the foetus to a 
higher risk of developing atopy. The SIPS did not differentiate between atopic and non-
atopic  mothers,  but  observed  a  decreased  maternal  Th2  response.  Although  cytokine 
expression  from  PBMC  reflects  what  happens  in  maternal  periphery  and  not  in  the 
materno-foetal interface, it can speculated that reduced Th2 responses may also be present 
in decidua. This would result in the foetuses being in low risk of having enhanced Th2 
responses at birth and thus lower risk of atopy development. A study (329) investigated 
maternal unstimulated PBMC cytokine secretion in normal and pre-eclamptic pregnancies. 
It was found that PBMC from healthy pregnant women secreted higher levels of IL-18 and 
lower levels of IL-12 compared to those from non-pregnant women. Also the ratio IL-
18/IL-12 was significantly higher in healthy pregnant women than non-pregnant women. 
The Th1/Th2 ratio in PBMC was determined by flow cytometry. It was found that the 
Th1/Th2 ratio negatively correlated with IL-18/IL-12. It was suggested that elevated IL-18 
and decreased IL-12 secretion by maternal PBMC may be involved in the Th2 dominance 
during  normal  pregnancy.  The  Th2  dominance  was  also observed  in  the  current  study 
(although both Th1 and Th2 responses were suppressed) since the Th1/Th2 ratio at 34 and 
38 weeks gestation was significantly lower than at 20 weeks.  
In the study of Ho et al. (325) after culturing decidual mononuclear cells and maternal 
PBMC it was found that IL-10 was expressed and exceeded IFN-γ secretion, whereas IL-4 
and IL-5 levels were lower than IFN-γ during pregnancy. These findings are in accordance 
with the current findings on cytokine production from maternal PBMC.    260 
As mentioned in the introduction, the paradox that embryos are not rejected by the 
maternal immune system despite the presence of paternal MHC histocompatibility antigens 
has been explained in mice by a Th2 switch at the level of materno-foetal interface. In 
humans, some hormones enhanced during pregnancy can affect the development of Th1 
and Th2 responses. It was found that progesterone promotes the production of Th2-type 
cytokines (IL-4 and IL-5), whereas relaxin promotes the production of Th1-type cytokines 
(IFN-γ) by PBMC (280). 
There were no major or consistent statistically significant differences between the two 
groups  in  terms  of  cytokine  production.  IL-10  production  from  salmon  paralbumin 
stimulated PBMC decreased significantly in the control group whereas it remained stable 
in the salmon group. The same pattern was observed for IL-10 production in response to 
ovalbumin. The former observation may be related to the increased salmon consumption of 
the intervention group which increased exposure of the subjects to salmon antigens. The 
levels of this regulatory cytokine (IL-10) may be pivotal for the regulation of the immune 
system of the foetus with increased exposure to salmon antigen through the materno-fetal 
unit, and may result in better tolerance of the offspring to salmon antigen (i.e. reduced 
likelihood of mounting an active immune response). Although the study of Breckler et al. 
(287)  did  not  show  any  difference  between  during  and  after  pregnancy  for  IL-10 
production, other studies have shown that this cytokine is essential in regulating immune 
responses in pregnancy and that it is higher in the plasma of pregnant compared to non-
pregnant  women  (330). The  only  study  showing  that  fish  oil  supplementation  affected 
maternal T-cell responses is the study of Krauss-Etschmann et al. (183). It was shown that 
fish oil supplementation during pregnancy was associated with lower mRNA expression of 
IL-1 and IFN-γ in maternal blood at delivery. In contrast, mRNA levels of the regulatory 
cytokine transforming growth factor-β (TGF-β) were higher in maternal blood at delivery 
and  maternal  m-RNA  levels  of  IL-13  and  IL-4  did  not  differ  between  the  groups  at 
delivery. Thus, it appeared that fish oil supplementation during pregnancy downregulates 
Th1  responses  in  the  mother  (183).  This  agrees  with  the  current  observation  that  the 
maternal  immune  system  was  suppressed  and  polarised  towards  Th2/T-regulatory 
responses during pregnancy  in  both groups. Warstedt et al. (188) conducted a  fish oil 
supplementation  trial  during  pregnancy  and  lactation.  No  differences  in  secretion  of 
chemokines and cytokines (IL-1β, TNF, IL-6, IL-10, IL-12, IFN-γ) were observed in the 
mothers with fish oil supplementation which agrees with the findings of the current study. 
In the current study, TNF-α production in response to TLR-2 ligand was not affected in the 
control group, but it increased and then decreased in the salmon group. This may indicates   261 
a greater upregulation of innate immunity in the salmon group during pregnancy. Since 
innate immune system is important during pregnancy (322-324) this may indicate a better 
progression to successful pregnancy in the salmon group. 
Although results of the current study indicate that maternal immune responses during 
pregnancy  were  suppressed and polarised towards the Th2/T-regulatory phenotype, the 
hypothesis that increased oily fish intake will alter cytokine expression by maternal PBMC 
during pregnancy was not supported.  
Both in vitro and animal feeding studies showed that LC n-3 PUFA inhibit T-cell 
proliferation  and  production  of  IL-2  and  IFN-γ  (126,  128).  The  results  of  human 
supplementation studies indicate that high levels of fish oil supplementation may inhibit T-
cell responses, although lower doses do not exhibit significant effects (105, 132). In fact, 
one  study  showed  that  fish  oil  supplementation  increased  IFN-γ  production  and 
lymphocyte  proliferation  in  response  to  concanavalin-A  (112).  Although  fish  oil 
supplementation  did  not  have  an  effect  on  IL-4  production,  it  was  shown  that  EPA 
concentration in plasma phospholipids were positively correlated with the production of 
both IL-4 and IFN-γ by stimulated PBMC (112). The same study showed that TNF-α and 
IL-6 production by mononuclear cells was inhibited after fish oil supplementation (331). A 
study in healthy men showed that fish oil supplementation reduced IL-6 production from 
LPS-stimulated whole blood cultures compared to control (olive oil) (332). These studies, 
although not conducted on pregnant women, show an effect of increased EPA and DHA 
intake on T-cell function which was not observed in the current study. 
Studies  of  maternal  fish  oil  supplementation  during  pregnancy  or  lactation  have 
shown effects on immune markers (including cytokine production in cord blood) in the 
offspring consistent with decreased risk of developing atopy (22, 178, 183, 185). Also, it 
has been shown that fish oil supplementation during pregnancy resulted in decreased risk 
of  developing  clinical  signs  of  atopy  in  the  offspring (186,  187).  Moreover,  there  are 
various studies of fish oil supplementation in infancy or childhood showing that fish oil 
supplementation in early life may affect immune function in a protective way (196, 197, 
199), although the evidence is inconsistent (103). 
According to the above (22, 178, 183, 185-188, 196, 197, 199), although studies of 
maternal  fish  oil  supplementation  have  not  reported  major  changes  on  maternal  T-cell 
function (apart from the study of Krauss-Etschmann et al.), they showed that early fish oil 
provision is associated with T-cell function changes in cord blood which may be consistent   262 
with decreased risk of developing atopy. Thus, our finding that maternal T-cell responses 
were  not  altered  by  the  salmon  intervention  cannot  exclude  the  possibility  that  the 
intervention might have affected foetal T-cell responses and subsequently immune system 
changes  in  the  offspring.  Also,  the  evidence  available  suggests  that  maternal  fish  oil 
supplementation may have a protective effect against the development of atopy clinical 
outcomes in the offspring early in life with a possible persistence until adolescence (103). 
It  may  be  proposed  that  immune  function  changes  observed  in  the  offspring  are  not 
associated  with  immune  function  changes  in  the  maternal  blood  periphery  but  in  the 
decidua. Also, production of lipid mediators, such as eicosanoids (as discussed below), and 
the increased provision of LC n-3 PUFA from the study salmon through the placenta to the 
foetus may be more important in programming the immune system of the offspring.    263 
5.4.3  Maternal prostaglandin E2 production from mononuclear cells 
during pregnancy 
PGE2  production  from  unstimulated  and  PHA-stimulated  PBMC  decreased  during 
pregnancy.  This  effect  was  related  to  the  changes  in  PBMC  fatty  acid  compositions 
presented in chapter 4. PBMC ARA decreased in both the salmon and control groups (p for 
time < 0.001). ARA from the cell membrane lipids is converted by COX to PGE2. Thus the 
effect of pregnancy on PGE2 production may simply relate to reduced ARA availability. In 
agreement with this, it was shown that PBMC ARA content correlated significantly and 
positively with PGE2 production, whereas there was a significant and negative correlation 
between PBMC EPA and DHA, and PGE2 production. Why PGE2 production in response 
to LPS was not affected by pregnancy is not clear. To my knowledge there are no previous 
studies that have looked at PGE2 production from cultured PBMC during pregnancy. The 
pregnancy associated reduction in PGE2 production by unstimulated PBMC occurred more 
quickly  in  the  salmon  group,  probably  associated  with  the  lower  PBMC  ARA  levels 
observed  in  the  salmon  group  compared  to the control  group.  Increased  production  of 
PGE2 by decidual macrophages has been shown to regulate labour initiation at term (333). 
A  study  showed  that  incubation  of  decidual  cells  with  DHA  in  culture  reduced  PGE2 
production,  suggesting  a  mechanism  though  which  fish  oil  may  be  protective  against 
preterm  birth.  In  the  current  study  decidual  production  of  PGE2  was  not  measured, 
although it could be anticipated that it would be lower in the salmon group in relation to 
the observed lower ARA placenta content. Lower PGE2 production in the placenta could 
potentially explain the slightly longer, but not significant, gestational length in the salmon 
group (chapter 2), however further investigation is needed to confirm this. One limitation 
in further interpreting these results is that other lipid mediators such as PGE3, LTB4, LTB5, 
resolvins, and protectins were not measured. The determination of other mediators would 
help in showing that higher EPA and DHA content in PBMC, due to salmon intake, leads 
to the production of less potent mediators.  
In accordance to the current findings, a randomised controlled trial of various doses of 
EPA showed that EPA was incorporated in a linear dose-response fashion into plasma and 
mononuclear  cell  phospholipids.  It  was  shown  that  increased  EPA  incorporation  into 
PBMC  was  associated  with  decreased  production  of  PGE2  in  response  to  LPS  (313). 
Another  study  showed  that  fish  oil  supplementation  decreased  PGE2  production  by 
stimulated PBMC (112). Warstedt et al. (188) conducted a fish oil supplementation trial 
during pregnancy (from week 25) and lactation. They showed that plasma phospholipid 
EPA and DHA increased in the fish-oil-treated women during pregnancy. LPS-induced   264 
PGE2 secretion from whole blood cultures was decreased in the majority of women in the 
fish oil group (between baseline at 25 weeks gestation and 1 week postpartum). However, 
the  mean  decrease  in  the  fish  oil  group  was  not  significant.  In  contrast,  the  PGE2 
production in the control group increased significantly (between 25 weeks gestation and 1 
week  postpartum).  The  non-significant  decrease  of  PGE2  secretion  in  the  intervention 
group was probably due to the observation of higher secretion at baseline from the mothers 
that were randomized to the fish oil group compared to those allocated in the placebo 
group. Most importantly, the change in PGE2 production differed significantly between the 
two  groups.  Also,  the  decrease  in  PGE2  secretion  in  the  fish  oil  group  was  more 
pronounced among non-atopic women (but not significant). No differences in secretion of 
LTB4 were observed in the mothers with fish oil supplementation (188). These results party 
agree with our findings supporting the idea that increased intake of EPA and DHA from 
fish  may  result  in  lower  PGE2  production  in  the  maternal  periphery  but  also  in  the 
materno-foetal  interface  resulting  in  a  less  inflammatory  environment  for  the  foetus, 
independently of cytokine production, and thus reduction of the risk of developing atopy in 
the offspring. The study of Prescott & Dunstan (182) showed that fish oil supplementation 
during pregnancy resulted in lower LTB4 production and higher LTB5 production by cord 
blood neutrophils. Cord neutrophil LTB4 production was inversely related to LC n-3 PUFA 
status. It could be speculated that also in the current study, increased provision of EPA and 
DHA to the foetus will result in decreased production of ARA derived lipid mediators and 
increased production of the  less potent EPA and DHA derived  lipid  mediators (PGE3, 
LTB5) from the offspring’s immune cells. This may affect the offspring’s T-cell function 
and polarisation and it may also predispose to a less inflammatory environment during 
early  life,  contributing  to  lower  risk  of  developing  atopy  in  the  offspring  related  to 
increased maternal oily fish intake during pregnancy. 
5.5  Summary and conclusions 
The hypotheses that salmon intervention will result in altered immune cell phenotypes and 
different maternal innate and adaptive immune responses were not supported. However, a 
number of changes occurring in both groups consistent with the current literature on the 
immunology of pregnancy were observed. The percentage of B-cells decreased and that of 
T-helper  cells  (and  their  number)  increased  during  pregnancy.  The  expansion  of  T-
regulatory cells which plays  a key role  in successful pregnancy was also observed. In 
addition,  both  adaptive  and  innate  immune  responses  of  mononuclear  cells  were 
suppressed for all cytokines during pregnancy. Maternal immune responses were polarised 
towards the  Th2  and  T-regulatory  responses.  Interestingly,  maternal  regulatory  (IL-10)   265 
response  to  salmon  paralbumin  and  ovalbumin  remained  stable  for  the  salmon  group, 
whereas  it  decreased  for  the  control  group.  This  may  have  been  associated  with  the 
increased exposure to salmon in the intervention group. Immune effects at the materno-
foetal interface which may have an important role in immune system development of the 
foetus were not investigated, and the possibility that the salmon intervention may have 
resulted  in  local  immune alterations cannot be excluded. The  salmon  intervention  may 
have resulted  in programming of the  immune system of the  foetus and the developing 
offspring, mediated, not through changes in maternal immune cell phenotype and function, 
but  through  the  provision  of  higher  amounts  of  LC  n-3  PUFA  and  lipid  mediator 
alterations in the decidua. Production of PGE2 by maternal mononuclear cells decreased 
during pregnancy in both groups probably associated with the decreased ARA content of 
those cells, since there was a significant negative correlation between PBMC ARA content 
and PGE2 production. However, at 34 weeks gestation PGE2 expression by unstimulated 
mononuclear cells was lower in the salmon group. This may be accompanied by increased 
eicosanoid  and  lipid  mediators  from  EPA  and  DHA  which  have  less  inflammatory 
potency. This may potentially affect the offspring’s T-cell function and polarisation and it 
may also predispose to a less inflammatory environment during early life, contributing to 
lower risk of developing atopy  in the offspring related to increased  maternal oily  fish 
intake during pregnancy. 




















6  Final Discussion   267 
Epidemiological data show that the incidence of childhood atopic disease (allergy, hay-
fever, atopic dermatitis, atopic asthma) has increased dramatically over the past three to 
four decades especially in westernised environments (73, 74, 77). This has coincided with, 
or followed behind, a decrease in infectious diseases which has lead to the idea of the so-
called  hygiene  hypothesis  (75-77).  Other  candidate  environmental  factors  in  the  atopy 
epidemic include dietary changes, smoking, and pollutants (302-304). Decreased intake of 
long chain (LC) n-3 polyunsaturated fatty acids (PUFA) (eicosapentaenoic acid (EPA); 
20:3n-3, and docosahexaenoic acid (DHA); 22:6n-3) accompanying increased intake of n-6 
PUFA is a major dietary change which has happened in the last 30-40 years, and may be 
associated with the increase in childhood atopic disease. The decreased intake of vitamin D 
and  of  antioxidant  vitamins  and  minerals  such  as  selenium  (13)  are  important  dietary 
changes and may also be associated with the increased rates of atopy. Exposure of the 
foetus or the newborn infant to LC n-3 PUFA, vitamin D, and selenium has been shown to 
have immunodomulatory effects (103, 307). 
Epidemiological studies provide a fairly strong evidence base that fish consumption 
by pregnant women is protective against atopy development in their offspring (103). It is 
recommended that pregnant women and women of reproductive age should consume two 
portions of  fish per week, of  which at  least one should  be oily,  in order to achieve a 
minimum intake of 450 mg/day of EPA plus DHA (11). While it is widely considered that 
the protective effect of fish is due to the provision of LC n-3 PUFA, fish also provide other 
nutrients such as vitamin D and selenium. It is possible that it is these nutrients or the 
combination  of  these  nutrients  with  LC  n-3  PUFA  that  is  important. To  examine  this 
further, early intervention with fish is required. 
There are no published intervention trials with fish during pregnancy. The Salmon in 
Pregnancy Study (SIPS) is the first single blind (investigator) randomised controlled trial 
with oily fish (in this case farmed salmon) in pregnant women. SIPS specifically focuses 
on pregnant women whose offspring are at risk of developing atopic disease, with one aim 
being  to  identify  whether  there  is  an  effect  on  atopy  outcomes  in  the  offspring.  The 
overarching SIPS hypothesis, is that “increased consumption of oily fish during pregnancy 
by women at risk of having offspring who will develop atopy will increase their LC n-3 
PUFA and antioxidant status and that of their developing baby and will ameliorate the 
development of atopic markers and manifestations in the infants”. 
The  present thesis  focused  only  on  part of  the  SIPS  data.  The  aims  of  the  work 
described in this thesis were: a) to increase oily fish consumption from a habitually low   268 
intake (≤ 2 portions/month) to the recommended maximum level of intake (two portions/ 
week) between week 20 gestation to delivery, in women whose offspring is at a risk of 
developing atopic disease; b) to investigate the effect of increased oily fish consumption 
on  maternal  blood and tissue  LC  n-3 PUFA status; and c) to investigate the effect of 
increased oily fish consumption on maternal immunity, which may potentially influence 
the developing foetal immune system and atopy risk of the offspring. 
The research hypotheses examined on this thesis were that increased consumption of 
salmon during pregnancy (week 20 gestation to delivery) by women with high risk of 
having an atopic offspring will:  
d)  increase maternal LC n-3 PUFA intake; 
e)  increase maternal LC n-3 PUFA status;  
f)  alter maternal  immunity, which  may potentially  influence the developing 
foetal  immune  system,  in  a  way  that  would  decrease  atopy  risk  for  the 
offspring  
The data obtained allowed the first two hypotheses to be accepted (Chapters 3 and 4), 
whereas  there  was  limited  impact  of  the  salmon  intervention  on  the  third  hypothesis 
(chapter 5), and thus it cannot be accepted. The main findings of the present thesis are 
outlined below and further discussed in the context of the currently available literature. 
A total of 123 pregnant women whose baby had a high risk of being atopic and with a 
self-reported  low habitual  intake of oily  fish  were randomly  assigned to consume two 
portions of oily fish (farmed salmon) per week or to continue their habitual diet low in oily 
fish,  from  week  20  gestation  until  the  end  of  their  pregnancy.  For  study  design  and 
recruitment details see chapter 2. Briefly, subjects were seen at 20 (n = 61 control group; n 
= 62 salmon group), 32-34 (n = 110), and 38 weeks of pregnancy (n = 91). Up to delivery, 
the withdrawal rate was 14.5% for the salmon arm and 11.5% for the control arm, and 13% 
for the total of the subjects. Birth samples were collected from 101 subjects. A total of 88 
(n = 41 control group;  n = 47  salmon group) 3  month postpartum appointments were 
completed. 
Main findings from the dietary and nutrient analysis. The salmon intervention was 
successful  in  achieving  consumption  of  2  portions  of  study  salmon  per  week  in  the 
intervention  group,  whereas  the  control  group  maintained  their  habitually  low  intake. 
According to the food frequency questionnaire (FFQ) at 34 weeks gestation all subjects 
(100%) assigned in the salmon group reported having oily fish 1-2 times per week. The   269 
fish  diaries  showed  that the  median  consumption  frequency  of  study  salmon  from  the 
salmon group was 1.94 portions per week. Also, it was shown that, 79.6% of the volunteers 
in the salmon group were having 2 or more portions of study salmon per week for the 
81.25% of intervention period. The control group had a very low intake of oily fish and 
total  fish  and  this  was  significantly  lower  than  the  salmon  group.  These  data  prove 
compliance to the intervention. The median intake of LC n-3 PUFA from total fish for the 
salmon group during intervention was 402.6 mg/day EPA plus DHA according to FFQ at 
34 weeks (or 490.9 mg/day according to fish diaries), which was significantly higher from 
that of the control group (30.1 mg/day from FFQ, or 24.4 mg/day from fish diaries). This 
intake  covers  the  recommendation  for  minimum  intake  of  EPA  plus  DHA  during 
pregnancy (108% of 450 mg/day). Also, DHA intake in the salmon group covered more 
than  the  minimum  recommended  intake  for  DHA  (200  mg/day)  (19).  Interestingly, 
according to the 34 week FFQ, study salmon intake resulted in higher total diet selenium 
and vitamin D intake in the salmon group compared to control (selenium 58.2 µg/day vs. 
49 µg/day; vitamin D 5.75 µg/day vs. 2.9 µg/day, for salmon vs. control groups). 
Main  findings  on  maternal  fatty  acid  status.  It  was  hypothesised  that  increased 
provision of LC n-3 PUFA from study salmon will result in increased status of these fatty 
acids in the mother. SIPS findings agreed well with the findings of previous studies on the 
pregnancy-associated changes in the concentrations of blood lipids and in the fatty acid 
components of these lipids (i.e. the changes seen in the control group). Interestingly, it was 
shown  for  the  first  time  that  pregnancy  results  in  lower  content  of  LC  n-3  PUFA  in 
maternal  peripheral  blood  mononuclear  cells  (PBMC),  suggesting  depletion  of  LC  n-3 
PUFA in this pool during pregnancy. The salmon intervention had a significant effect on 
maternal  EPA,  DHA,  and  DPA  status  which  was  differentiated  from  the  effect  of 
pregnancy on fatty acid status. It was shown that the increased intake of EPA and DHA 
from two portions of oily fish per week prevented the decline in LC n-3 PUFA seen in 
plasma lipids and immune cells with pregnancy and resulted in increased amounts of these 
fatty acids in plasma lipids and in immune cells. This could be of significant importance 
since the mother is not totally depleted and the foetus is potentially provided with greater 
amounts of these fatty acids. What is more, placenta and umbilical cord tissue had also 
higher content of LC n-3 PUFA in the salmon group compared to control. The implications 
of these results are that increased EPA and DHA concentrations in maternal plasma may 
facilitate better transfer of key fatty acids to the foetus, and that increased EPA and DHA 
concentrations  in  maternal  plasma  and  cells  may  modulate  the  immune  system  of  the   270 
mother  during  pregnancy.  These  effects  either  alone  or  together  may  influence  the 
developing foetal immune system in a way that may reduce the risk of developing atopy. 
Main findings on maternal immune system. It was considered that the increased intake 
of EPA plus DHA during pregnancy which resulted in increased status of these fatty acids 
in  the  mother,  and  especially  in  maternal  immune  cells,  will  have  immunomodulatory 
effects  for  the  mother  which  could  consequently  affect  the  developing  foetal  immune 
system in a protective way. The results did not support the hypotheses that the salmon 
intervention will result in altered maternal immune cell phenotypes during pregnancy, in 
altered  maternal  innate  and  adaptive  immune  responses,  measured  as  Th1,  Th2,  and 
regulatory cytokine expression by mononuclear cells cultured with various stimulants, and 
in lower production of PGE2 by mononuclear cells cultured with various stimulants. The 
results obtained indicate that, while there were some effects of salmon intake on certain 
immune parameters, these  hypotheses cannot be accepted (i.e.  increased salmon  intake 
during pregnancy had only a limited impact on maternal immunity, at least as measured 
here). However, significant alterations of the immune system associated with pregnancy, in 
line with the existing literature, occurred and were not affected by the salmon intervention.  
According  to the  above  SIPS  is  the  first  randomised  control  trial  to  show  that  if 
pregnant women who do not habitually consume oily fish, eat two portions of oily fish 
(salmon) per week, from week 20 gestation to delivery, they will significantly increase: 
  their intake of LC n-3 PUFA (achieving recommended intake), vitamin D, and 
selenium, and 
  their status in LC n-3 PUFA 
The increased maternal LC n-3 PUFA status did not result in maternal immune system 
changes.  
These  main  outcomes  along  with  secondary  outcomes  described  in  this  thesis  will  be 
discussed in the context of existing literature in the following paragraphs. 
SIPS intervention was conducted between mid pregnancy to delivery. This period of 
intervention  was  chosen  based  upon  previous  fish  oil  supplementation  studies  which 
focused on similar periods of gestation indicating that this is a critical window for early life 
intervention (22, 184, 186, 188). Also, the demand in LC n-3 PUFA increases dramatically 
during the last trimester of pregnancy (245, 258).    271 
In SIPS, the combination of the FFQ with the fish diary is considered as a strength as 
it allows control over compliance, and also provides the information required to investigate 
dietary patterns and nutrient intake and changes in these. Although the SIPS sample size 
was  small,  because  of  the  primary  interest  in  fish  intake  and  the  long  period  of 
intervention,  it  seemed  appropriate  to  use  a  FFQ  especially  developed  for  use  in  the 
Southampton population. The FFQ was developed for use in the Southampton Women’s 
Survey (SWS); this  FFQ  included questions on  consumption  frequency of distinct  fish 
categories and reflected diet over the previous three  months. The SWS  FFQ  has  been 
validated for use to assess nutrient intakes in pregnant women in Southampton (214-219). 
Although  weighed  food  diaries  are  considered  to  be  more  accurate  when  determining 
nutrient intake for a small number of volunteers, compared to FFQ, they cannot reflect a 
long period of time which was of interest in SIPS (103, 214). Also, prospective, open-
ended dietary methods such as food diaries are demanding to fill in (12). Epidemiological 
studies  investigating  the  effect  of  maternal  fish  intake  during  pregnancy  on  atopic 
outcomes  in  the  offspring  have  also  used  FFQ  as  a  method  for  determining  intake  of 
different types of fish (154-159). 
The macronutrient intake calculated here for the SIPS subjects is very close to the that 
reported by SWS (219), showing that the FFQ was a reliable tool to estimate nutrient 
intake although the study group had a small size. Also, these similarities along with the 
fact that SIPS correlation coefficients from principal component analysis (PCA) correlated 
very well with the SWS coefficients shows that, apart from the SIPS subjects having a low 
intake  of  oily  fish  and  being  atopic,  they  were  very  similar  to  the  average  female 
Southampton population of this age and representative of that.  
A limitation of the FFQ, as with most FFQ, is that it had an ordinal scale of distinct 
consumption frequency categories, rather than an interval scale providing a ‘true’ measure 
(220). As such, consumption of salmon twice per week was recorded as consumption 1-2 
times per week, and was interpreted as 1.5 times per week for nutrient calculations. The 
fish diaries were important in determining a more precise consumption frequency. Also, 
volunteers filled in the diaries on a daily bases and so the recall bias associated with the 
FFQ was minimised. The use of fish diaries as a compliance measure was essential and can 
be considered as a strength of SIPS. The slight difference in the findings on consumption 
frequencies and nutrient intakes between FFQ and fish diaries may be again attributed to 
the limitation of the FFQ to identify small differences because of the distinct consumption 
frequency categories.    272 
Also, a limitation of this specific FFQ is that it has not been validated to calculate total 
diet EPA and DHA. However, the main sources of EPA and DHA are fish and fish oil 
supplements or functional foods. The FFQ indicated that no subject was consuming fish oil 
containing supplements during pregnancy. Thus, it can be suggested that intake of EPA 
and DHA from total fish would be a very good estimate of total intake of these LC n-3 
PUFA from the whole diet. The use of FFQ to assess micronutrient intake and especially 
LC  n-3 PUFA  has  been  validated  in studies on pregnant (232, 233) and  non-pregnant 
subjects (234, 235) and has also been reviewed (236). These studies support that the intake 
of EPA and DHA can be adequately estimated by FFQ. 
The use of the FFQ allowed the investigation of other changes that may have occurred 
in the dietary pattern of the subjects associated with the intervention. However, a too long 
FFQ may be a limitation especially when conducting larger studies. The use of a shorter 
FFQ may be helpful when there is interest in only one aspect of the diet, such as vitamin D 
or  fat  (237),  or  fish  intake  and  LC  n-3  PUFA.  Generally,  a  shorter  FFQ,  especially 
designed to determine consumption of food rich in the nutrients that are of interest can be 
less time consuming and equally efficient.  
A disadvantage of the  fish diaries  is that they  have  not been  validated. Also, fish 
diaries may have been subject to over or under reporting, as with any other dietary record 
method, especially when filled in for such a long period of time (12). Finally, the fish 
diaries were returned by a subset of subjects and not by the whole study group (77% in the 
control group, and 79% in the salmon group returned completed fish diaries). 
There  have  been  no  studies  of  fish  intervention  during  pregnancy.  However  the 
current study may be compared to other studies which investigated the effect of increased 
fish  consumption  on  different  health  outcomes  and  on  different  populations  (238-241, 
243). Unlike the current study, these studies used food diaries as a method for measuring 
compliance and dietary intake.  
The baseline difference in intakes of fish and nutrients from fish between the two 
SIPS groups, despite the fact that subjects were randomly assigned to the two arms, is a 
limitation of the current study. This was further reflected by the findings of the fatty acid 
analysis.  At  baseline  (20  weeks  gestation),  the  salmon  group  had  significantly  higher 
percentages of EPA, DHA, and total n-3 PUFA, and a lower percentage of arachidonic 
(ARA) in plasma phosholipids (PC) and in the other plasma lipid fractions, compared to 
the control group. Fasting plasma lipid fatty acids reflect fairly short-term changes in the   273 
diet since they are associated, mainly, with continuous lipoprotein synthesis from the liver. 
However,  cell  fatty  acid  composition  (especially  red  blood  cells  but  also  mononuclear 
cells) is affected in the long-term because of the long period of life of the cells (red blood 
cells  have  a  half  life  of  about  4  months).  There  were  no  baseline  differences  in  the 
peripheral  blood  mononuclear cell (PBMC)  fatty acid composition  between the groups 
which may reflect that the salmon group consumed more fish closer to the start of the 
intervention (20 weeks) rather than habitually for a longer period.  
The baseline differences in fish consumption and plasma LC PUFA levels between the 
two groups may be considered as a limitation of the current study. For this reason between 
group comparisons of the change in intake and in the fatty acid content between before and 
after starting the intervention were conducted. The increase in oily fish consumption, and 
in  EPA  and  DHA  intake,  in  the  salmon  group  was  significantly  different  from  the 
consistently low intake in the control group (increase by 1.2 portions/week and by 269.3 
mg/day, respectively). 
Apart from increasing significantly EPA and DHA intake, the salmon intervention 
resulted in higher intake of vitamin D, selenium, and total n-3 PUFA from oily fish and 
total  fish at 34 weeks gestation compared to the control group. More importantly, this 
increased intake from fish was reflected in an increased intake of these nutrients from total 
diet (estimated by FFQ). Total diet selenium intake was 58.2 µg/day for the salmon group 
(97% of Reference Nutrient Intake (RNI; 60 µg/day)) and 49 µg/day for the control group 
(82%  RNI) (p  =  0.005)  (18).  The  contribution  of  study  salmon  to total  diet  intake  of 
selenium was 20% which is quite substantial. The intake of selenium in the control group 
was fairly close to the average intake that has been recently reported by the National Diet 
and Nutrition Survey (NDNS) in the UK (39 µg/day) (13). It has to be noted that total diet 
selenium intake should be treated as a rough estimate, since the content of selenium in 
foods depends on soil content and data are not completely reliable (222). Total diet vitamin 
D intake was 5.75 µg/day for the salmon group (57% RNI; RNI for pregnant women is 10 
µg/day) and 2.9 µg/day for the control group (29% RNI) (p < 0.001) (18). It is worth 
noting  that, the  study  salmon  contributed  to  68% of  the  total  vitamin  D  intake  in  the 
salmon group. Total diet vitamin D intake in the control group was very comparable to that 
reported by NDNS (2.7 µg/day) (13). These findings agree with the findings of other fish 
intervention  trials  (238,  243).  In  SIPS,  it  would  be  expected  that  the  blood  levels  of 
selenium and vitamin D would be higher in the salmon group compared to the control 
group based on the fact that intake was significantly and substantially higher. Early fish 
and  vitamin  D  exposure  improves  bone  health  in  infancy  and  childhood  (207,  208).   274 
Maternal vitamin D intake during pregnancy has been associated with decreased risk of 
sensitization to food allergens in the offspring (209) and evidence shows the importance of 
vitamin D and selenium in reducing risk of atopic disease development (92, 210-213). 
Consumption  of  two  portions  of  oily  fish  per  week  would  provide  more  than  the 
minimum recommended intake of DHA and of EPA plus DHA (450 mg/day) (11), DHA 
(200 mg/day) (19) , 40% of the recommended intake of vitamin D for pregnant women (10 
µg/day), and 20% of the recommended intake of selenium (60 µg/day). According to the 
findings of the fish diaries, consumption of two portions of study salmon per week (oily 
fish data  including  study  salmon) provided 158.3  mg EPA, 322.2  mg DHA, 11.94 µg 
selenium,  and  3.89  µg  vitamin  D  per  day.  This  would  mean  that  consumption  of  two 
portions of oily fish per week would cover approximately 40% of the amount of vitamin D 
and selenium, 260% of the amount of EPA, 106% of the DHA, and 133% of total EPA 
plus  DHA  provided  from  a  typical  pregnancy  supplement.  This  is  the  first  study  in 
pregnant women to provide this information, supporting the importance of oily fish during 
pregnancy  as  they  can  be  an  excellent  source  of  a  combination  of  nutrients.  This,  in 
relation to the fact that increased oily fish consumption resulted in lower meat intake, can 
provide strong evidence in order to support public health messages and interventions that 
target increased consumption of oily fish (at least two portions) instead of the use of fish 
oil supplements during pregnancy. Of course all considerations about limiting contaminant 
intake during pregnancy should be taken into account when choosing the source of fish. 
The dietary intake of LC n-3 PUFA was reflected by the fatty acid analysis not only at 
baseline, as mentioned above, but also at 34 and 38 weeks during intervention. It has to be 
noted  that  fatty  acid  status  in  the  current  study  was  expressed  in  two  different  ways 
(percentage levels and absolute concentrations). This is a strength of the current study as 
there is no indication for any expression being more advantageous than the other. The 
combination of the two expressions gives a better picture of the changes that occur. Also, 
fatty acid analysis in the four plasma lipid fractions is another strength of the study which 
allowed for more specific changes to be observed.  
The current study showed that there is an effect of pregnancy on fatty acid status of 
the mother, and this was differentiated from the effect of the salmon intervention. It was 
observed that pregnancy resulted in increased total plasma concentrations within each lipid 
fraction. The  hyperlipidemia of pregnancy  has been well established  in  literature (245, 
255) and was seen in both groups in the current study without being affected by the salmon 
intervention. The increased concentration of lipids in maternal plasma during pregnancy,   275 
especially of non-esterified fatty acids (NEFA) and triglycerides (TAG), is important for 
ensuring supply of fatty acids to the foetus via the placenta.  
Specific pregnancy associated changes in fatty acid status were observed in the control 
group.  In  total  plasma,  ARA,  EPA,  DPA  and  DHA  concentrations  decreased  during 
pregnancy. Changes were also observed within each lipid fraction. More specifically, ARA 
and LC n-3 PUFA concentrations decreased in plasma phospholipid (PC) whereas they 
increased in plasma NEFA, and either increased or remained stable in cholesteryl esters 
(CE) and TAG. On the other hand, expressed as percentages these fatty acids decreased in 
almost  all  lipid  fractions.  The  current  findings  agree  with  existing  literature  that  the 
absolute  concentrations  of  ARA  and  DHA  increase  during  pregnancy  but  that  their 
percentages in various plasma lipids decrease (260, 261, 265, 270, 271). The agreement 
between fatty acid levels in the current study, which was conducted on a UK population of 
low  intake  of  oily  fish,  with  studies  from  other  North  Western  European  countries 
(Germany, the Netherlands, Belgium) may imply similar dietary patterns in these ‘western-
type’ environments and may also be associated to the similarity of the ethnic groups. Also, 
these  results  suggest  that  the  mother  is  progressively  depleted  in  these  fatty  acids 
(especially DHA and ARA) during pregnancy as they are transported to the foetus to be 
used for foetal growth, visual and neuronal development (245, 251). The decrease in EPA 
is also associated to the fact that it is metabolised to DPA and eventually to DHA which is 
highly demanded by the foetus (47, 245, 251). The pregnancy associated LC n-3 PUFA 
and ARA depletion observed in the control group also reflects its very low intake of fish 
and thus of EPA and  DHA. Low  intake of these LC  n-3 PUFA results  in remarkable 
depletion of these fatty acids during pregnancy and may lead to alterations in the function 
of the maternal immune system and have implications on the provision of these fatty acids 
to  the  foetus,  especially  in  multiparus  women  whose  LC  n-3  PUFA  status  has  been 
progressively depleted throughout previous pregnancies (7, 47, 121). 
The  current  study  showed  for  the  first  time  that  consumption  of  two  portions  of 
salmon  per  week  from  week  20  of  pregnancy  until  delivery  reversed  the  pregnancy 
associated decrease in plasma EPA, DPA and DHA, resulting in an increase of these fatty 
acids  in  all  plasma  lipid  fractions.  In  contrast,  the  salmon  intervention  enhanced  the 
pregnancy associated ARA decrease in maternal plasma lipids. The ratios of fatty acids of 
interest  (ARA/EPA,  ARA/DHA,  ARA/(EPA+DHA),  and  n-6/n-3)  were  lower  in  the 
salmon group compared to control at 34 and at 38 weeks gestation for all plasma lipid 
fractions.  The  data  show  that  increased  maternal  intake  of  EPA  and  DHA  through 
consumption of two portions of salmon per week increased their status in LC n-3 PUFA   276 
which was compensated by a lower status of ARA. The lower ARA/DHA ratio in the 
salmon group may have an impact on the relative transfer of these fatty acids to the foetus 
via fatty acid transport proteins on the placenta for which these fatty acids may compete 
(189, 258). It can be speculated that the increased maternal status in EPA and DHA may 
have  resulted  in  higher  provision  of  these  fatty  acids  to  the  foetus  which  may  have 
beneficial  implications  for  the  foetal  growth,  visual  and  brain  development,  and  also 
immune system development. In addition to that, the reversal of the decrease in LC n-3 
PUFA may be associated to benefits for the mother herself and for her immune system.  
Consumption of two portions of salmon per week during pregnancy resulted in higher 
EPA, DPA, and DHA content in maternal plasma NEFA. This reflects a higher adipose 
tissue storage of these fatty acids which was achieved by the salmon intervention. This is 
of high importance not only for foetal supply with LC n-3 PUFA during pregnancy but 
also for infant supply through breast milk after birth. It has been well established that fatty 
acids  in  breast  milk  originate  from  maternal  adipose  tissue  fatty  acids  stored  during 
pregnancy (160, 272). A higher supply of these fatty acids to the infant during the critical 
window of the initial post-partum period is also vital for its growth and development and 
potentially for its immune system modulation.  
The fish intervention studies of Vidgren et al. (243), Pot et al. (241), and Din et al. 
(238), although not conducted on pregnant women, showed a higher level of EPA and 
DHA in fish consuming subjects and a lower level of ARA compared to control subjects. 
The current study adds to this body of literature as it is a novel study of fish intervention on 
pregnant women, showing that increased oily fish consumption can increase status of LC 
n-3 PUFA even during pregnancy when the maternal LC n-3 PUFA stores are normally 
depleted for the benefit of the foetus. 
Zhang et al. (274) investigated maternal dietary intake of EPA and DHA and levels of 
these  fatty acids  in plasma PC of pregnant women and their  neonates  from river/lake, 
coastal, and inland regions of China. Dietary intake was assessed using a validated semi-
quantitative FFQ. Median daily intake of EPA and DHA was higher in the river/lake and 
coastal  regions  compared  to  inland,  probably  due  to  higher  intake  of  fish  and  other 
seafood. The  median  maternal plasma PC  levels of DHA and EPA were higher  in the 
river/lake and coastal regions compared to the inland region. These findings agree with the 
current study showing a close association between dietary intake of EPA and DHA and the 
corresponding levels of these fatty acids in maternal plasma PC. Also, De Vriese et al.   277 
(266)  showed  that  maternal  plasma  PC  EPA  and  DHA  percentages  were  positively 
associated with intake of these fatty acids during pregnancy. 
A novel finding of the current study is that pregnancy had an effect on the fatty acid 
composition  of  immune  cells.  Maternal  PBMC  EPA,  DPA,  DHA  and  ARA  content 
decreased during pregnancy. The pregnancy-associated decrease in PBMC LC n-3 PUFA 
and ARA suggests that immune cells ‘give up’ these fatty acids in order for them to be 
transferred to the foetus through the placenta. The current data support that these fatty 
acids essential for foetal growth and development are mobilised from the maternal cells to 
plasma lipoprotein CE and TAG fractions, and eventually plasma NEFA, that play a key 
role in transporting fatty acids to the foetus. Whether the change in fatty acid composition 
of  PBMC  is  important  in  influencing  (or  regulating)  pregnancy-associated  changes  in 
immune function is not clear, but this is an intriguing possibility since EPA, DHA and 
ARA all play a role in immune cell function. 
It was shown that consumption of two portions of salmon per week not only prevented 
the pregnancy associated decrease in PBMC EPA and DHA status, but it also resulted in an 
increase of PBMC DHA. Moreover, the salmon intervention resulted in further decrease of 
maternal PBMC ARA content during pregnancy. The decrease of maternal immune cell 
content in EPA and DHA during pregnancy, and its reversal by the salmon intervention 
was  considered  to  potentially  have  an  impact  on  the  function  of  the  immune  cells, 
including  cytokine  and  eicosanoid  production,  which  was  further  investigated  and  is 
discussed here later on. 
The  current  findings  on  increased  maternal  LC  n-3  PUFA  status  agree  with  the 
findings of fish oil supplementation studies. The study of Damsgaard et al. (275) showed 
that fish oil supplementation in healthy men resulted in higher levels of EPA and DHA, 
and lower levels of ARA in PBMC, as seen in the current study in the salmon group. 
Hawkes et al. (276) conducted a trial with DHA-rich tuna oil in healthy mothers from day 
3 post-partum. After 4 weeks of supplementation, DHA concentrations in maternal plasma, 
PBMC, breast milk and breast milk cell PC increased in a linear manner in response to 
dietary DHA. In the high DHA intake group, percentages of PBMC PC EPA and DHA 
were significantly higher than those of the placebo group. This finding agrees with the 
current findings in the salmon group. In the study of Dunstan et al. (180) pregnant women 
were supplemented with a high dose of fish oil or placebo between week 20 gestation and 
delivery. At 30 and 37 weeks gestation, fish oil supplementation significantly increased 
maternal  erythrocyte  PC  EPA  and  DHA  percentages  and  significantly  decreased  the   278 
percentages of all n-6 PUFA including ARA compared to baseline. The current study did 
not examine erythrocyte lipids. In the European multi-center study of Krauss-Etschmann et 
al. (184), pregnant women received a supplement providing 500 mg/day DHA plus 150 
mg/day EPA or placebo from week 22 of gestation to delivery. Maternal plasma PC DHA 
and EPA levels increased from 20 weeks to 30 weeks and at delivery in the fish oil group. 
In the current study salmon increased plasma PC EPA and DHA compared with baseline 
and  compared  with  control,  although  the  increases  seen  were  not  as  great  as those  of 
Krauss-Etschmann et al. (184). Krauss-Etschmann et al. (184) showed that the intervention 
also increased DHA  levels  in cord plasma PC.  In the same  study, Larque et al. (189) 
showed that fish oil supplementation increased the levels of DHA in placenta PC, whereas 
ARA levels remained unchanged. In the current study placenta DHA (and EPA) increased, 
but ARA declined.  
Houwelingen et al. (264) found that maternal plasma PC fatty acids expressed as a 
percentage  were  highly  significantly  correlated  with  foetal  plasma  PC  fatty  acids. 
Vlaardingerbroek  &  Hornstra  (265)  concluded  that  maternal  fatty  acid  percentages  at 
delivery in red blood cell and plasma PC were highly correlated with neonatal fatty acid 
percentages at birth. Also, De Vriese et al. (266) showed that EPA and total n-6 PUFA 
levels in cord plasma PC were positively correlated with maternal dietary intake of these 
fatty acids during pregnancy. Zhang et al. (274) showed that neonates in inland regions of 
China (where fish consumption is lower) had higher levels of ARA and lower levels of 
EPA and DHA in their plasma PC compared to those in the lake/river and coastal regions 
and  that  maternal  plasma  EPA  and  DHA  were  also  positively  associated  with  the 
corresponding  levels  in  cord  plasma  PC.  Krauss-Etschmann  et  al.  (184)  showed  that 
maternal fish oil supplementation in pregnancy increased DHA levels in cord plasma PC. 
These studies may support that the increased maternal LC n-3 PUFA status observed in the 
current study might be reflected also in the foetus benefiting its growth and development.  
Placenta  fatty  acid  content  might  reflect the  nutrient  supply  to the  foetus,  and  its 
analysis may be a good indicator of placental fatty acid transfer (247, 248). The increased 
provision of LC n-3 PUFA to the foetus in the current study is supported by the fact that 
consumption of two portions of salmon per week, between mid pregnancy to delivery, 
resulted  in  higher  LC  n-3  PUFA  content  in  placenta  and  umbilical  cord  tissue.  The 
placenta  will  have  been  built  up  using  those  fatty  acids  available  from  the  maternal 
bloodstream  and  thus  some  relationship  or  similarity  between  placental  and  maternal 
plasma  fatty  acid  compositions  might  be  expected.  Furthermore,  in  the  current  study 
percentages of ARA, EPA and DHA in total placental lipids in the control group were in   279 
good agreement with studies in Germany and UK (16, 247). Placental PC from a Spanish 
population had higher proportions of EPA and DHA and a slightly lower proportion of 
ARA compared to the control group of the current study. These differences might reflect 
differences  in  maternal  diet  including  differences  in  fish  intake (273).  In  the  study  of 
Krauss-Etschmann et al. (184), Larque et al. (189) showed that fish oil supplementation 
during  pregnancy  increased  the  levels  of  DHA  in  placenta  PC,  whereas  ARA  levels 
remained unchanged. In the current study placenta DHA (and EPA) increased, but ARA 
declined. 
Based on the findings discussed above, increased intake of salmon during pregnancy 
resulted in higher n-3 PUFA status in maternal plasma and immune cells. Thus, it was 
considered that salmon intake in pregnancy could influence maternal immunity that could 
impact on development of the foetal immune system and predisposition to atopy. Fatty 
acid-derived  mediators  might  play  a  role  in  the  immune  changes  that  occur  during 
pregnancy and in setting up the foetal immune system (93). The results obtained, indicate 
that, while there were some effects of salmon intake on certain immune parameters, the 
hypothesis that the fish intervention will alter maternal immunity cannot be accepted (i.e. 
increased  salmon  intake  during  pregnancy  had  only  a  limited  impact  on  maternal 
immunity, at least as measured here). Furthermore the data obtained show that the effect of 
progression through pregnancy on immune function is of a much greater magnitude than 
the  effect  of  salmon:  a  number  of  immune  measures  were  significantly  affected  by 
progression through pregnancy. 
Pregnancy  is  known  to  be  associated  with  changes  in  maternal  immune  function, 
believed to be  important to prevent rejection of the  foetus which  could  be  seen  as an 
allograft (i.e. transplant) that would normally elicit an immune response resulting in its 
rejection (64, 65, 277). Thus the immune changes that occur allow a successful pregnancy 
to  ensue.  At  birth  several  aspects  of  the  foetal  immune  response  are  like  those  in  the 
mother. Some foetal immune responses indicate a predisposition to atopy (291, 292). 
The immune cell subset analysis showed that the percentage of B-cells in lymphocytes 
decreased during pregnancy, whereas the percentage of helper T-cells in total leukocytes 
(and their number in blood) increased during pregnancy. Also, in the current study it was 
shown that the number of cytotoxic T-cells in blood increased during pregnancy (but not 
their percentage).These findings are supported by other studies and are consistent with the 
immune  shifts  observed  during  normal  pregnancy  (64,  65,  315-317).  Moreover,  the 
percentage of T-regulatory cells in total leukocytes (and their number in blood) increased   280 
during pregnancy. This finding is in accordance with previous literature findings on T-
regulatory cell pool expansion (i.e. increase in number) during normal pregnancy (318-
320).  The  percentage  of  toll-like  receptor-2  positive  (TLR-2
+)  monocytes  in  total 
leukocytes,  as  well  as  their  number,  increased  during  pregnancy.  This  indicates  an 
upregulation  of  innate  immunity  during  pregnancy  which  is  in  agreement  with  current 
literature that the innate immune system is important during pregnancy (322-324). 
In the current study the increase in helper T-cells (as a % of leukocytes) was greater in 
the salmon group compared to the control group. There appears to be no literature on fish 
or fish oil intake and maternal immune cell subsets in pregnancy with which to compare 
this finding. Since an increase in helper T-cells as a % of leukocytes is normally seen 
during pregnancy and this finding may indicate better progression to successful pregnancy 
with increased salmon intake.  
Also it was found that the percentage of lymphocytes as natural killer (NK) cells (% 
lymphocytes) decreased in the salmon group but not in the control group. An increase in 
number and/or activity of NK cells and their subsets (CD56
+/CD16
+) has been observed in 
women with recurrent spontaneous abortions (RSA) (282). Also, it has been shown that the 
percentage of NK cells is lower in pregnant compared to non-pregnant women (315). This 
would  suggest  that  a  suppression  in  NK  cell  numbers  and  activity  would  promote 
successful pregnancy. Thus this effect of salmon may be an important and beneficial one. 
However,  what  happens  in  the  maternal  periphery  may  not  necessarily  reflect  what 
happens in the materno-foetal interface. The only study available with which to compare 
these findings with NK cells in the salmon group is that of Krauss-Etschmann et al. (72) 
which  showed  that  fish  oil  supplementation  during  pregnancy  was  associated  with 
decreased frequencies of NK cells and CCR3
+CD8
+
 T-cells in cord blood. However, that 
study did not investigate the effect of fish oil intervention on maternal immune cell subsets 
during  pregnancy.  There  are  no  previous  studies  on  fish  oil  supplementation  or  fish 
consumption during pregnancy that have reported results on maternal immune cell subsets.  
One limitation of the current study is that intracellular markers that would characterise 
the functional properties of immune cell subsets and differentiate them into T-helper type 1 
(Th1) or T-helper type 2 (Th2) phenotypes were not investigated. However, the current 
study  did  examine  production  of  Th1  and  Th2-type  cytokines  by  unstimulated  and 
stimulated  mononuclear  cells,  a  measure  that  does  provide  insight  into  the  functional 
phenotype  of  the  cells  present.  Also,  it  has  to  be  noted  that  distinguishing  between 
immunological changes that occur locally in the uterus and systemically in the maternal   281 
circulation is important (322). Whether the salmon intervention affected frequencies and/or 
functionality of immune cell subsets in the materno-foetal interface is unknown and was 
not investigated here.  
A strength of the current study is the use of different (ex vivo) stimulants in order to 
investigate  different  aspects of  the  immune  system  including  both  innate  and  adaptive 
immunity, using allergens, a mitogen, and TLR ligands. Also, a strength was the method of 
cytokine determination. They were measured using a flow cytometry based assay termed 
cytometric bead array, which measures a range of cytokines characteristic for different 
responses: Th1 (interleukin (IL)-2, tumour necrosis factor (TNF)-α, interferon (IFN)-γ), 
Th2 (IL-4, IL-2) and regulatory (IL-10). 
The production of all cytokines determined (IL-10, TNF-α, IFN-γ, IL-2, IL-4, IL-5) by 
maternal PBMC stimulated with mitogen (PHA) decreased during the course of pregnancy, 
as did the production of IL-10 in response to allergens. These observations suggest T cell 
reactivity decreases as pregnancy proceeds. Furthermore, the production of IFN-γ by TLR 
(-2, -3, -4) ligand stimulated PBMC decreased during pregnancy. The ratio of prototypical 
Th1 to Th2 cytokines (IFN-γ/IL-4) produced in response to PHA and the ratio of Th1 to T-
regulatory cytokines (IFN-γ/IL-10) both decreased significantly during pregnancy. These 
changes  signify  a  polarisation  of  the  helper  T-cells  towards the  Th2  and  T-regulatory 
phenotype during pregnancy which is in agreement with current literature (277, 278, 329). 
Ho et al. (325) found that the proportion of IL-4 secreting cells exceeded IFN-γ secreting 
cells in peripheral blood and in decidua of normal pregnancies. Langer-Gould et al. (326) 
showed that IFN-γ producing CD8
+ T-cells decreased during the course of pregnancy. The 
findings of the current study are consistent with these studies. The findings of the current 
study also partly agree with those of Breckler et al. (287). It was shown that for both 
allergic and non-allergic women, although the regulatory responses (IL-10) did not change 
during pregnancy, Th1 responses (IFN-γ) were suppressed compared to postpartum. Non-
allergic women downregulated Th2 responses (IL-13) during pregnancy, while allergic 
women failed to do so and continued to exhibit high Th2 responses. The authors suggested 
that these peripheral responses in allergic women may also skew the cytokine milieu at the 
maternal-foetal  interface  towards  the  Th2  phenotype,  contributing  to  increased  risk  of 
atopy in the offspring of allergic mothers. This partly agrees with the current findings that 
Th1, Th2, and T-regulatory responses to PHA decreased during pregnancy in both groups. 
Although results of the current study indicate that maternal immune responses during 
pregnancy  were  suppressed and polarised towards the Th2/T-regulatory phenotype, the   282 
hypothesis that increased oily fish intake will alter cytokine expression by maternal PBMC 
during  pregnancy  was  not  supported.  There  were  no  major  or  consistent  statistically 
significant  differences  between  the  two  groups  in  terms  of  cytokine  production.  IL-10 
production  from  salmon  paralbumin  stimulated  PBMC  decreased  significantly  in  the 
control  group  whereas  it  remained  stable  in  the  salmon  group.  The  same  pattern  was 
observed for IL-10 production in response to ovalbumin. This observation may be related 
to the increased salmon consumption of the intervention group which increased exposure 
of the subjects to salmon antigens. The levels of this regulatory cytokine (IL-10) may be 
pivotal for the regulation of the immune system of the foetus with increased exposure to 
salmon antigen through the materno-fetal unit, and may result in better tolerance of the 
offspring  to  salmon  antigen  (i.e.  reduced  likelihood  of  mounting  an  active  immune 
response). Although the study of Breckler et al. (287) did not show any difference between 
during  and  after  pregnancy  for  IL-10  production,  other  studies  have  shown  that  this 
cytokine is essential in regulating immune responses in pregnancy and that it is higher in 
the plasma of pregnant compared to non-pregnant women (330). The only study showing 
that fish oil supplementation affected maternal T-cell responses is the study of Krauss-
Etschmann et al. (183). It was shown that fish oil supplementation during pregnancy was 
associated with lower mRNA expression of IL-1 and IFN-γ and higher mRNA expression 
of  the  regulatory  cytokine  transforming  growth  factor-β  (TGF-β)  in  maternal  blood  at 
delivery. Thus, it appeared that fish oil supplementation during pregnancy downregulates 
Th1  responses  in  the  mother  (183).  This  agrees  with  the  current  observation  that  the 
maternal  immune  system  was  suppressed  and  polarised  towards  Th2/T-regulatory 
responses during pregnancy  in  both groups. Warstedt et al. (188) conducted a  fish oil 
supplementation  trial  during  pregnancy  and  lactation.  No  differences  in  secretion  of 
chemokines and cytokines (IL-1, TNF, IL-6, IL-10, IL-12, IFN-γ) were observed in the 
mothers with fish oil supplementation which agrees with the findings of the current study. 
In the current study, TNF-α production in response to TLR-2 ligand was not affected in the 
control  group,  but  it  increased  and  then  it  decreased  in  the  salmon  group.  This  may 
indicates a greater upregulation of innate immunity in the salmon group during pregnancy. 
Since innate immune system is important during pregnancy (322-324) this may indicate a 
better progression to successful pregnancy in the salmon group. 
Both in vitro and animal feeding studies showed that LC n-3 PUFA inhibit T-cell 
proliferation and production of IL-2 and IFN-γ (126, 128). However, the results of human 
supplementation  studies  are  heterogeneous  (105,  112,  132,  331,  332).  These  studies, 
although not conducted on pregnant women, have shown an effect of increased EPA and   283 
DHA intake on T-cell function which was not observed in the current study. The lack of 
effect in the current study may be due to the lower dose of EPA and DHA provided here. 
Studies  of  maternal  fish  oil  supplementation  during  pregnancy  or  lactation  have 
shown effects on immune markers (including cytokine production in cord blood) in the 
offspring consistent with decreased risk of developing atopy (22, 178, 183, 185). Also, it 
has been shown that fish oil supplementation during pregnancy resulted in decreased risk 
of  developing  clinical  signs  of  atopy  in  the  offspring (186,  187).  Moreover,  there  are 
various studies of fish oil supplementation in infancy or childhood showing that fish oil 
supplementation in early life may affect immune function in a protective way (196, 197, 
199), although the evidence is inconsistent (103). 
According to the above (22, 178, 183, 185-188, 196, 197, 199), although studies of 
maternal  fish  oil  supplementation  have  not  reported  major  changes  on  maternal  T-cell 
function (apart from the study of Krauss-Etschmann et al.), they showed that early fish oil 
provision is associated with T-cell function changes in cord blood which may be consistent 
with decreased risk of developing atopy. Thus, the finding that maternal T-cell responses 
were  not  altered  by  the  salmon  intervention  cannot  exclude  the  possibility  that  the 
intervention might have affected foetal T-cell responses and subsequently immune system 
changes  in  the  offspring.  Also,  the  evidence  available  suggests  that  maternal  fish  oil 
supplementation may have a protective effect against the development of atopy clinical 
outcomes in the offspring early in life with a possible persistence until adolescence (103). 
It  may  be  proposed  that  immune  function  changes  observed  in  the  offspring  are  not 
associated  with  immune  function  changes  in  the  maternal  blood  periphery  but  in  the 
decidua.  Also,  production  of  lipid  mediators,  such  as  eicosanoids,  and  the  increased 
provision of LC n-3 PUFA from the study salmon through the placenta to the foetus may 
be more important in programming the immune system of the offspring.  
As discussed earlier, changes in PBMC fatty acid composition were observed as an 
effect  of  pregnancy  and  also  as  an  effect  of  the  salmon  intervention.  Pregnancy  was 
associated with PBMC ARA decrease in both groups. ARA from the cell membrane lipids 
is converted by COX to prostaglandin (PG) E2. PGE2 production from unstimulated and 
PHA-stimulated  PBMC  decreased  during  pregnancy.  Thus  the  effect  of  pregnancy  on 
PGE2 production may simply relate to reduced ARA availability. In agreement with this, it 
was shown that PBMC ARA content correlated significantly and positively with PGE2 
production, whereas there was a significant and negative correlation between PBMC EPA 
and DHA, and PGE2 production. Why PGE2 production in response to lipopolysaccharide   284 
(LPS; TLR-4 ligand) was not affected by pregnancy is not clear. There are no previous 
studies that have looked at PGE2 production from cultured PBMC during pregnancy. At 34 
weeks  gestation  PGE2  expression  by  unstimulated  mononuclear  cells  was  lower  in  the 
salmon group. The pregnancy associated reduction in PGE2 production by unstimulated 
PBMC occurred more quickly in the salmon group, probably associated with the lower 
PBMC ARA levels observed in the salmon group compared to the control group. One 
limitation in further interpreting these results is that other lipid mediators such as PGE3, 
leukotriene (LT) B4, LTB5, resolvins, and protectins were not measured. The determination 
of other mediators would help in showing that higher EPA and DHA content in PBMC, 
due to salmon intake, leads to the production of less potent mediators.  
In accordance to the current findings, it has been shown that fish oil supplementation 
results in decreased production of PGE2 (112, 313). Warstedt et al. (188) conducted a fish 
oil supplementation trial during pregnancy (from week 25) and lactation. They showed a 
tendency towards decreased LPS-induced PGE2 secretion from whole blood cultures in the 
fish oil group. No differences in secretion of LTB4 were observed in the mothers with fish 
oil supplementation (188). These results partly agree with the current findings supporting 
the idea that increased intake of EPA and DHA may result in lower PGE2 production in the 
maternal periphery but also in the materno-foetal interface resulting in a less inflammatory 
environment for the foetus, independently of cytokine production, and thus reduction of the 
risk of developing atopy in the offspring. The study of Prescott & Dunstan (182) showed 
that  fish  oil  supplementation  during  pregnancy  resulted  in  lower  LTB4  production  and 
higher LTB5 production by cord blood neutrophils. It could be speculated that also in SIPS 
increased provision of EPA and DHA to the foetus will result in decreased production of 
ARA derived lipid mediators and increased production of the less potent EPA and DHA 
derived lipid mediators (PGE3, LTB5) from the offspring’s immune cells. This may affect 
the  offspring’s  T-cell  function  and  polarisation  and  it  may  also  predispose  to  a  less 
inflammatory environment during early life, contributing to lower risk of developing atopy 
in the offspring related to increased maternal oily fish intake during pregnancy. 
One limitation of the current study is the criterion used to determine pregnant women 
whose offspring were at high risk of developing atopy. This was based on self-reported 
clinical signs of atopy for the mother, the father, or sibling. Maternal and paternal atopy 
was also examined using skin prick testing (SPT), but only after the end of the intervention 
when this had been approved by the ethics committee. It was shown that the majority of 
the subjects who reported atopy also had positive SPT to at least one allergen, however it 
was not possible to examine all subjects since some of them had already dropped out. It   285 
would have been more appropriate to perform the SPT at baseline and to include this to the 
selection  criteria  of  the  study.  However,  this  was  not  possible  because  of  constraints 
associated with obtaining ethics approval. 
Finally, in order to explore whether the salmon intervention affected other parameters 
of the diet, the FFQ provided information on dietary patterns during and after the end of 
the intervention. These are discussed in the following paragraphs. 
The PCA results described showed that the salmon group had a statistically significant 
higher ‘prudent’ diet z-score than the control group, indicating a ‘healthier’ dietary pattern 
for the salmon group, at baseline and at 34 weeks gestation. The higher ‘prudent’ diet 
scores in the salmon group, reflecting ‘healthier’ dietary patterns, are in accordance with 
the higher fish consumption both at baseline and at 34 weeks. It may be considered that 
volunteers in the salmon group made an effort to eat more healthily as they were aware of 
the fact that they were taking part in a nutrition intervention, and they belonged to the 
salmon  group.  Many  volunteers  reported  verbally  during  appointments  that  they  were 
trying  to  combine  salmon  with  ‘healthier’  dietary  choices,  such  as  cooking  it  with 
vegetables, and generally taking care of their diet in total, as they realised that this would 
be good for themselves and the baby.  
An interesting question to be addressed, through the dietary information available in 
SIPS, was whether the salmon intervention resulted in changes of dietary patterns during 
the intervention. The data showed that increased salmon consumption was compensated by 
a decreased consumption of other  fish (non-oily  fish  and  fish dishes  according to fish 
diaries) and also by a decrease in red meat, chicken, and total meat intake. Another fish 
intervention did not observe any changes in meat intake, which is difficult to explain but 
may be related to that study using food diaries which do not reflect long term consumption 
(241, 242).  
The information from the 3 month post-partum FFQ was used to investigate whether 
the intervention had an impact on fish consumption habits after its end. For the majority of 
the  volunteers  this  increase  was  not  sustained  after  the  end  of  the  intervention,  as 
volunteers returned to their habitually low intake of oily fish. Interestingly, at 3 months 
post-partum 17% of the salmon group continued having oily fish more or equal to 1.5 
times per week (i.e. ≥ 1-2 times per week) compared to 0% before intervention. This may 
suggest that, there was a sustained effect beyond the intervention period for only for a 
small number of volunteers. Similarly, the fish intervention study of Din et al. showed that   286 
the nutrient  intake differences observed during the study due to the intervention were not 
sustained after the end of the intervention (238). Borland et al. (215) examined the stability 
of dietary patterns in young women over a 2-year period. The study was performed on a 
subgroup of the SWS and it was concluded that dietary patterns were reasonably stable. 
This may explain the difficulty in changing dietary patterns and why high oily fish intake 
was not sustained after the end of SIPS intervention for the majority of the subjects in the 
salmon group. Investigating the factors that may help increase intake of oily and total fish 
by women of reproductive age in a sustainable way is an important issue that needs further 
exploration in order to be able to plan and implement successfully interventions that target 
increased fish intake. 
In summary, SIPS is the first randomised control trial that successfully increased oily 
fish  intake  during  pregnancy  to  the  recommended  level  of  intake  (2  portions/week), 
showing that increased consumption of oily fish during pregnancy results in significantly 
increased intake of LC n-3 PUFA, vitamin D, and selenium. Consumption of two portions 
of oily fish per week provided more than the minimum recommended intake of DHA and 
of EPA plus DHA (109%), 60% of the recommended intake of vitamin D, and 20% of the 
recommended intake of selenium. The salmon intervention not only resulted in reversal of 
the  maternal  pregnancy-associated  depletion  in  LC  n-3  PUFA,  but  it  also  increased 
maternal status in LC n-3 PUFA, as measured in plasma lipids, immune cells and maternal 
tissues at birth. The implications of these results are that increased maternal EPA and DHA 
status may facilitate better transfer of these key fatty acids to the foetus which is vital for 
its growth and development. Although salmon intake resulted in increased maternal LC n-3 
PUFA status this had only a limited impact on maternal immunity (at least as measured 
here).  As  a  number  of  immune  measures  were  significantly  affected  by  progression 
through pregnancy, the effect of progression through pregnancy on immune function is of a 
much greater  magnitude than the effect of  salmon. Only a  few  immune  markers were 
affected by the salmon  intervention  and these seem to  indicate a  better progression to 
successful pregnancy with increased salmon intake. Also, the salmon intervention resulted 
in different pattern of maternal regulatory cytokine (IL-10) responses to salmon and egg 
allergen which may be pivotal for the regulation of the immune system of the foetus with 
increased exposure to salmon antigen through the materno-fetal unit, and may result in 
better tolerance of the offspring to salmon antigen (i.e. reduced likelihood of mounting an 
active immune response). Immune effects at the materno-foetal interface which may have 
an important role in immune system development of the foetus were not investigated, and 
the possibility that the salmon intervention may have resulted in local immune alterations   287 
cannot be excluded. The salmon intervention may have resulted in programming of the 
immune system of the foetus and the developing offspring, mediated, not through changes 
in  maternal  immune  cell  phenotype  and  function,  but  through  the  provision  of  higher 
amounts of LC n-3 PUFA and lipid mediator alterations in the decidua. It was shown that 
there was a tendency for lower inflammatory eicosanoid production (PGE2) in the salmon 
group  which  was  associated  with  the  lower  ARA  content  in  PBMC.  This  may  be 
accompanied by increased eicosanoid and lipid mediators from EPA and DHA which have 
less inflammatory potency. This may potentially affect the offspring’s T-cell function and 
polarisation and it may also predispose to a less inflammatory environment during early 
life, contributing to lower risk of developing atopy in the offspring related to increased 
maternal oily fish intake during pregnancy.  
In conclusion, if pregnant women who do not habitually consume oily fish, eat two 
portions of oily fish (salmon) per week, from week 20 gestation to delivery, they will 
significantly  increase  their  intake  of  LC  n-3  PUFA  (achieving  recommended  intake), 
vitamin D, and selenium, and they will also increase their status in LC n-3 PUFA. This 
may suggest increased availability of these fatty acids to the foetus which would facilitate 
its growth and development. The salmon intervention had only limited impact on maternal 
immunity  as  measured  here,  and  thus  it  cannot  be  concluded  whether  the  intervention 
would  have  an  effect  on  the  immune  system  of  the  offspring.  Further  investigation  is 
needed  on  the  mechanisms  through  which  increased  maternal  fish  consumption  during 
pregnancy may affect the developing foetal immune system in a protective way against 
atopic disease development in the offspring later on in life. 
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6.1  Future work 
The Salmon in Pregnancy Study (SIPS) design and findings presented in this thesis add 
valuable and novel information to the existing literature and encourage further future work 
on this area to be conducted. The present thesis focused on the effects of the intervention 
on maternal outcomes, although the main outcome measure of SIPS was the clinical signs 
of atopic disease manifestation in the offspring. Clinical follow-up of the offspring at 6 
months  of  age  has  been  completed.  Findings  from  cord  blood  and  from  the  6  month 
clinical follow-up will be reported by Maria Vlachava in her PhD thesis. It was shown that 
the salmon intervention increased offspring long chain (LC) n-3 polyunsaturated fatty acid 
(PUFA)  status  at  birth  (i.e.  in  cord  blood).  Pro-inflammatory  prostaglandin  (PG)  E2 
production by cord blood mononuclear cells was lower in the salmon group indicating 
exposure to a less inflammatory environment early in life which could be related to lower 
risk  of  developing  atopy.  Differences  between  the  two  groups  were  also  observed  in 
cytokine production from cord blood mononuclear cells which could be consistent with a 
less  atopy-prone phenotype. However, at 6  months of age, clinical  examination of the 
infants (skin prick testing (SPT) and eczema score) did not show any effects of the salmon 
intervention. Future follow-up of this cohort is essential as clinical manifestations of atopy 
may  be  more  pronounced  later  on  in  life  and  thus  differences  in  atopic  disease 
development between the groups may be more evident as the children become older. A 
possible time point would be when the infants are 2.5 years of age (summer 2010-summer 
2011). Apart from clinical signs on atopy, it would be of great interest to assess cognitive 
and visual development of the children. Although SIPS was not designed to assess these 
outcomes, it would be worth doing since there are no other randomised controlled trials 
(RCT) with fish during pregnancy. Subject to the findings at the 2.5 years of age follow-
up, a next follow-up when children are 5 years old would be appropriate.  
As  mentioned  repeatedly  in  this  thesis,  SIPS  is  the  first  fish  intervention  during 
pregnancy and this is partly related to the difficulties and practical implications of such an 
intervention. A larger RCT of increased oily fish consumption during pregnancy would be 
more  adequately  powered  to  detect  differences  in  atopic  outcomes,  but  also  outcomes 
related to development such as length of gestation, cognition, and vision. An appropriate 
follow-up would be when the offspring are 6 months of age and later on at 1, 2.5, and 5 
years.  This  would  provide  clearer  evidence  in  support,  or  not,  of  the  epidemiological 
studies which show a protective effect of fish consumption during pregnancy on atopic 
disease development. Such a study would require follow-up of the subjects’ diet similar to 
the  present  study  (a  shorter  and  more  focused  food  frequency  questionnaire  would  be   289 
equally effective) in order to prove compliance. However, maternal blood collection would 
not  be  necessary,  making  the  study  more  easy  to  conduct,  since  it  was  shown  by  the 
present study that increased oily fish consumption (2 portions/week) increases maternal LC 
n-3 PUFA status (and  had  no  major effect on maternal  immunity). This would enable 
completion and increase feasibility of a larger RCT with fish during pregnancy. As it is 
vital to determine the mechanisms through which increased early exposure to nutrients 
from oily fish could be protective against atopic disease development, it may be worth 
investigating  immunological  changes  that  happen  in  the  materno-foetal  interface  (e.g. 
immune markers in placenta, cytokines produced by immune cells in the placenta) rather 
than  the  maternal  periphery,  as  this  may  show  predisposition  of  the  foetus  to  a  less 
inflammatory  environment  as  a  result  of  increased  maternal  oily  fish  consumption. 
Examining the hypothesis that increased oily fish intake during pregnancy alters the foetal 
immune system during gestation is very difficult in humans. However, analysis of immune 
markers in cord blood at birth may provide an indication of changes in foetal immunity 
during gestation. Possible variations in the methodology and design of such a larger study 
in  order  to  clarify  the  effect  of  increased  oily  fish  during  pregnancy  would  include: 
different  levels  of  fish  consumption  (portions/week),  different  types  of  fish  (including 
types  of  oily  and  non-oily  fish),  different  early  life  critical  windows  (duration  of 
intervention and period of gestation), different levels of baseline exposure to fish (never or 
<1/month,  1-2  times/month,  2/month).  Also,  determining  the  study  population 
characteristics in relation to atopy risk at baseline more strictly than in SIPS would be an 
advantage. An example would be to include only pregnant women who had self-reported 
atopy and had a positive SPT to at least one allergen. It is obvious that a safe source of fish 
low in contaminants should be used. Such a study would require a significant amount of 
time and effort and would demand strong support and funding. Finally, within such a study 
or in a separate one, investigating the factors that may help to increase intake of oily and 
total  fish  by  women  of  reproductive  age  in  a  sustainable  way  is  important  and  needs 
exploration in order to be able to plan and implement successful interventions that target 
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Appendix A: Initial information 
sheet for pregnant women 
 
Salmon In Pregnancy Study (SIPS): 
The effects of oily fish in pregnancy 
on signs of allergic diseases in 
infants at high risk of developing 
allergies 
 
Ethical approval number 07/Q1704/43 
Co-ordinator: Dr Liz Miles 
  
Chief Investigator: Prof Philip Calder 
 
Telephone: 023 8079 6925 or 023 8079 5252 or 
07864 831283 
Email: sips@soton.ac.uk  
 





We would like to invite you to participate in a research 
study about a mother’s nutrition and her baby’s 
development of allergies and growth. Before you agree 
to participate it is important for you to understand why 
the research is being done and what it will involve. 
Please take time to read the following information 
carefully and discuss it with others if you wish. Ask us 
if there is anything that is not clear or if you would like 
more information. Take time to decide whether or not 
you wish to take part. 
 
1 What is the purpose of this study? 
The purpose is to study how a mother’s nutrition may 
influence their baby’s development in the womb and the 
likelihood of allergies in later childhood. We wish to 
select a group of pregnant women who would be suitable 
to help us in research into the possible protective 
effects of eating oily fish (salmon) in pregnancy on 
development of allergies in babies. 
 
2 Why have I been chosen? 
We are looking for women aged from 18-40 years who 
are in the early stages of pregnancy (about 14 weeks or 
less) who may be able to assist us in our research.  
 
3 Do I have to take part? 
You are under no obligation to take part. If you take 
part you are still free to withdraw at any time and 
without giving a reason. If you wish to withdraw you can 
request that your data and samples be destroyed. A 
decision to withdraw at any time, or a decision not to 
take part, will not affect the standard of care you 
receive. If you are interested in having more 
information about the study please complete the 
‘interested in study’ form (found at reception) and give 
it to the receptionist at your 13 week ultrasound scan 
appointment. Alternatively you can contact us on the 
telephone numbers or email address shown in this 
leaflet. A member of the research team will then 
discuss the study with you and answer any questions 
you may have. If you are satisfied with the explanation 
and would like to help us with our research we will ask 
you to sign a consent form. We will give you a copy of 
the consent form and this information leaflet to keep. 
 
4 What will happen to me if I take part? 
If you are happy to take part in this first stage of the 
study we wish to gather 3 pieces of information about 
you.  
Firstly, we would like you to complete a few questions 
about your health and any allergies which you or your 
family may have. 
 
Secondly, we would like to assess the growth and 
development of your baby in pregnancy. This will mean 
that during your routine ultrasound scans (13 & 20 
weeks) a few extra measurements will be made of the 
baby’s size and of the size and blood flow in some of its 
organs, including the heart and liver.  
 
T h i r d l y ,  w e  w o u l d  l i k e  t o  g a t h e r  s o m e  i n f o r m a t i o n  o n  
how your body adapts to the pregnancy. To do this we 
would like to measure your height, your weight and your 
body composition (i.e. amount of muscle and fat). We 
use specialised weighing scales, which measure your 
weight and use a tiny electrical current to assess your 
body composition. This is a harmless procedure and has 
been used to assess the body composition of pregnant 
mothers in previous studies. 
When we have gathered this information we would like 
to use it to select mothers who are suitable to help 
with assessing the possible benefits of eating salmon in 
pregnancy. If you were suitable for this, we would 
provide more details for you and invite you to take part. 
Once again you would be under no obligation to take 
part, and a decision to withdraw at any time, or a 
decision not to take part, would not affect the 
standard of care you receive.   2 
 
5 What is an ultrasound scan? 
Ultrasound uses sound waves to produce pictures of 
your body and baby.  Ultrasound has been used for 
many years to help us know if the baby is developing 
normally and growing properly. 
  
6 What do I need to do for the scan? 
A moderately full bladder is needed to allow us to 
obtain good views of your pregnancy.  Please drink a 
pint of water, squash or 3 cups of tea / coffee about an 
hour before your scan appointment.  Do not empty your 
bladder until after your scan. This is a medical 
examination and an important antenatal screening test. 
For your comfort, health and safety please ensure only 
one adult accompanies you for your scan. We would 
advise you not to bring young children as this can cause 
delays and distraction to the medical team. However if 
it is unavoidable we ask that any young children you 
wish to bring with you are supervised in the waiting 
area by another adult while the scan is in progress. 
7 What are the possible benefits of taking part? 
By participating in this study you may be able to help 
other children in the future from developing allergies. 
Suitable mothers will be offered the additional scan 
and will be given scan pictures of their baby in the 
womb. 
 
8 What are the possible disadvantages and risks of taking part? 
None, other than the giving up of your time to help us 
with our research.  This will include an extra ultrasound 
scan appointment at the Princess Anne Hospital which 
w i l l  t a k e  n o  l o n g e r  t h a n  1  h o u r  a n d  s o m e  e x t r a  
measurements and questions asked at your routine NHS 
13 and 20 week ultrasound appointments which will take 
approximately 1 hour. 
9 What will happen if anything goes wrong? 
If you have a concern about any aspect of the study 
you should speak to the researchers who will do their 
best to answer your questions (telephone 023 8079 
6925). If you remain unhappy and wish to complain 
formally you should contact the Wellcome Trust Clinical 
Research Facility in the first instance (telephone 023 
8079 4989). Any complaint about the way that you have 
been dealt with during the study or any possible harm 
you might suffer will be addressed. In the unlikely 
event that you are harmed due to someone’s negligence, 
then you may have grounds for a legal action for 
compensation but you may have to pay your legal costs.  
 
10 Will my taking part in this study be kept 
confidential? 
All information which is collected about you during the 
course of the research will be kept strictly 
confidential.  
 
11 What will happen to the study results? 
The results from this first part of the study will be 
used to identify pregnant women suitable to help us 
with assessing the possible benefits of eating salmon in 
pregnancy. The results may be submitted for 
publication in medical literature. If you wish to see 
copies of any reports and publications, please contact 
the researchers listed and they will be happy to supply 
these for you.  
 
12 Who is funding the study? 
T h i s  s t u d y  i s  f u n d e d  b y  t h e  E u r o p e a n  C o m m i s s i o n  
(website: http://ec.europa.eu/index_en.htm). 
 
13 Who has reviewed the study? 
The Southampton and South West Hampshire Local 
Research Ethics Committees. 
14 Contact for further information 
If you have any questions then please contact the SIPS 
Project Team on Tel: 023 8079 6925 or 023 8079 
5252 or 07864 831283. There is an answer phone 
available and all calls will be returned. Alternatively 
email us on sips@soton.ac.uk 
Thank you for taking the time to read this   3
Appendix B: Volunteer initial consent form  
 
Thank you for reading the information about our research project. If 
you would like to take part, please read and sign this form. 
 
Title of study: The effects of oily fish in pregnancy on signs of allergic 
diseases in infants at high risk of developing allergies 
Local ethical committee submission number……………………….. 
Chief Investigator: Professor Philip Calder, Tel: 023 8079 5250 
Contact details for research team: Dr Liz Miles, Tel: 023 8079 6925 or 023 
80 79 5252 
 
PLEASE INITIAL THE BOXES IF YOU AGREE WITH EACH SECTION: 
 
1.  I am not taking part in any other study (i.e. Southampton Women’s Survey). 
 
2.  I have read the initial information sheet dated 8/05/07 (version 2) for the above study 
and have been given a copy to keep. I have had the opportunity to ask questions, 
understand why the research is being done and any possible risks which have been 
explained to me. 
 
3.  I understand that my participation in this study is voluntary and that I am free to 
decline entry into the study, and that during the study I am free to withdraw at any 
time without giving a reason and that withdrawal will not affect any future medical care. 
 
4.  Data to be collected. I agree to have my weight, body composition and height measured 
for research in this project (delete as appropriate).  
 
5.  I agree to have additional measurements made of the growth and development of 
my baby and allow a sample of my afterbirth (placenta) to be collected. 
 
6.  Information to be collected. I agree to complete a short questionnaire on my health and 
I give permission for someone from the research team to look at my medical notes to 
get information pertinent to the study. I understand that the information will be kept 
confidential. 
 
7.  I agree to take part in the above study 
 
 
_____________________      ___________  ______________________ 
Name  of  Patient    Date    Signature 
 
_____________________      ___________  _______________________ 
Name of Person taking consent  Date      Signature 
 
 
1 for patient, 1 for researcher, 1 to be kept with hospital notes. 
Version 2, 08 May 2007  Ethics Number: 07/Q1704/43   4
Appendix C: SIPS initial questionnaire (< 14 weeks gestation) 
 
Volunteer Number    P 
 
Date informed consent given 
 
Initial visit check list (please tick when sample/data collected): 
 
a Ultrasound  scan 
 
b Body  composition 
 
c Initial  questionnaire 
 










Telephone – home/work 
 









   5
 
 Personal  Details 
 






Date of last menstrual period 
 




Community midwife & clinic 
 
Health visitor & clinic 
 






 Eligible  for  SIPS? 
 
 
 Yes  No 
Atopy (1
o relative of baby affected by atopy)     
Habitual oily fish intake ≤ 2 portions per month?     
Aged 18-40 year?     
Not consuming fish oil supplements?     
Yes to all above question = eligible for SIPS     
   6
 
















(Note – individuals with indwelling medical devices must not have 
bioelectrical impedance measurements taken 
 
4. Do you have any indwelling electrical devices (i.e. pacemakers)? 
 







Ask volunteer to empty bladder. Take measurements and attach print off 
securely to this page. 
 
IF INELIGIBLE FOR SIPS – END QUESTIONNAIRE HERE 
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5. Medication/supplements/vitamins (taken in the last 4 weeks) 
Therapy  Dose route and regimen  Date started/stopped 
 
 
   
 
 
   
 
 
   
 
 
   
 
 
   
 
 
6. Number of pregnancies (including this pregnancy) 
 
7. Number of children 
 
8. History of smoking Never / Past smoker / current smoker 
 




9. Current alcohol intake in drinks per week (1 beer or 1 glass of wine or 1 
shot of spirits). 
 





   8
  Family History of Atopy (within the last 5 years) 
10. Have any of the following persons had asthma? 
Mother Father  Any  sibling 
Yes  No  Not sure  Yes  No  Not sure  Yes  No  Not sure 
 
 
              
 







11. Have any of the following persons had hayfever? 
Mother Father  Any  sibling 
Yes  No  Not sure  Yes  No  Not sure  Yes  No  Not sure 
 
 
              
 







12. Have any of the following persons had an itchy rash persisting (even 
sporadically) over 6 months? 
Mother Father  Any  sibling 
Yes  No  Not sure  Yes  No  Not sure  Yes  No  Not sure 
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13. Have any of the following persons had wheezing when breathing? 
Mother Father  Any  sibling 
Yes  No  Not sure  Yes  No  Not sure  Yes  No  Not sure 
 
 
              
 







14. Have any of the following persons had itchy stuffy nose or swollen, 
itchy eyes when not with a cold? 
Mother Father  Any  sibling 
Yes  No  Not sure  Yes  No  Not sure  Yes  No  Not sure 
 
 
              
 






15. Do you have pets in the home? 
 Yes  No  Details 
Cat     
Dog     
Other      
 
16. Do you regularly visit a home where there are pets? 
 Yes  No  Details 
Cat     
Dog     
Other      
   10
 
  Habitual intake of fish 






18. Which types of fish do you eat (i.e. cod, mackerel, sole, kipper, 





19. How often do you eat each of these (i.e. number of time per week or 











Thank you for giving us this information 
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Salmon in Pregnancy Study (SIPS): 
The effects of oily fish in pregnancy on signs of allergic diseases in 
infants at high risk of developing allergies 
  
 
Ethics Number: 07/Q1704/43  
 
Co-ordinator: Dr Liz Miles 
  
Chief Investigator: Prof Philip Calder 
 
Telephone: 023 8079 5250 or 023 8079 6925  
or 023 8079 5252 
(Mobile - 07864 831283) 
Email sips@soton.ac.uk  
 
Version 4, 7
th May 2008 
 
We would like to invite you to participate in research studying whether eating salmon in pregnancy can prevent allergy 
in children. Before you agree to participate it is important for you to understand why the research is being done and 
what it will involve. Please take time to read the following information carefully and discuss it with others if you wish. 
Ask us if there is anything that is not clear or if you would like more information. Take time to decide whether or not 
you wish to take part. 
1 What is the purpose of this study? 
The reason for the large increase in allergies in the last 30 years is not understood. One suggestion is that changes in 
the fats we eat are making us more susceptible to allergies. People in the UK with a typical ‘modern’ diet eat very little 
oily fish. We are interested in studying possible benefits of eating oily fish in pregnancy on development of allergies in 
children. We know that babies who later get allergies show some slight changes in their immune response at birth. 
These changes do not allow us to accurately predict which babies will get allergies, but do tell us that a tendency to do 
so may partly originate before the baby is born. Therefore we wish to study the effect of eating oily fish during 
pregnancy on signs of allergy in the baby. We will start our study in 2007 and it will finish in 2010. 
2 Why have I been chosen? 
We are looking for women aged 18-40 who are in the early stages of pregnancy and who have allergies themselves or 
whose partner, or any other children, suffer from allergies (i.e. hayfever, eczema, asthma or food allergies). This 
increases your baby’s risk of developing allergies him/herself. We wish to investigate the effect of eating oily fish 
(salmon) in pregnancy and need a group of mothers who are happy to eat 2 portions of salmon per week but who usually 
do not eat oily fish more than twice per month. We will provide this salmon for you and your partner. However, we need 
to compare mothers who have eaten salmon with a group of mothers who have not (i.e. mothers who carry on eating 
their normal diet). Thus we will allocate those happy to join our study into the salmon or no salmon group randomly (i.e. 
by chance). Current government guidelines advise that we should all eat more oily fish but that pregnant women should 
not eat more than 2 oily fish meals per week [www.eatwell.gov.uk/healthydiet/nutritionessentials/fishandshellfish/].   12
Our salmon group women will be eating the amount of oily fish recommended by the government but the no salmon 
group, who will continue with their normal diet, will be eating less oily fish than is currently recommended. We are 
hoping that 100 women will agree to take part. 
3 Do I have to take part? 
You are under no obligation to take part. If you take part you are still free to withdraw at any time and without giving 
a reason. If you wish to withdraw you can request that your data and samples be destroyed. A decision to withdraw at 
any time, or a decision not to take part, will not affect the standard of care you receive. If you decide to take part you 
will be given this information sheet to keep and will be asked to sign a consent form. 
 
4 What will happen to me if I take part? 
You and (ideally) your partner will be invited to attend the Southampton Women’s Survey Unit at the Princess Anne 
Hospital at about 20 weeks of pregnancy to meet a member of the research team. The research study will be explained 
fully and you will be given the opportunity to ask questions.  
We will ask both of you some questions about your health, lifestyle and allergies. We will take some blood (30 ml, about 
2 tablespoonfuls from you and ask you to provide a urine sample. We will measure your weight and your body 
composition (i.e. amount of muscle and fat). We use specialised weighing scales which measure your weight and by 
sending a very small electrical current through your body can assess your body composition. This is a harmless 
procedure and has been used to assess the body composition of pregnant mothers in previous studies. 
The sonographer will perform an ultrasound scan (this will replace your normal 20 week NHS ultrasound scan) and give 
you pictures of your baby from the scan to keep. On this morning we will ask you not to eat or drink (except water) 
before your appointment and we will give you breakfast at the appointment. We will complete a questionnaire with you 
about your normal diet. This appointment will take approximately 1 hour. At this time we will allocate you to either the 
group of mothers asked to eat salmon or to the no salmon group. If you are in the salmon eating group we will supply 
you (and your partner) with frozen salmon portions sufficient for you to have 2 portions per week. We will give you one 
month’s supply every month from when you join the study until your baby is born. We will ask mothers in the no-salmon 
group not to eat more than 2 portions of oily fish (salmon, tuna, pilchards, sardines) per month whilst on this study 
(tinned tuna is OK).  
We would like to see you for 2 more appointments during your pregnancy (weeks 34 and 38). On each visit we will ask 
you some questions about your health, take a blood sample, measure body composition and ask you to provide a urine 
sample. We will provide breakfast and also offer you an ultrasound scan of your baby at 34 weeks. These appointments 
will take approximately 1-1½ hours.  
At week 38 we would like you to collect a small stool sample for us. This is to compare with the development of 
‘friendly bacteria’ in your baby’s bowel. We are interested in this because it has been suggested that some ‘friendly 
bacteria’ normally found in babies bowels may be protective against the development of allergies. 
At the birth of your baby we will collect a blood sample from the umbilical cord. This is a harmless procedure and does 
not involve the newborn baby at all and is carried out by the midwife present at the birth or a researcher. We will also 
collect a sample of umbilical cord and of placenta (which are normally disposed of). A research nurse will measure the 
size of your baby whilst you are in hospital 
If you decide to breast feed your baby we would like you to provide us with a sample (5 ml, about 1 teaspoonful) of 
your breast milk on the first day of breast feeding and then days 5, 14 and 28 after your baby is born (if you are still 
breastfeeding your baby at this time).  
We would like you to measure your body composition at home daily for the first 2 weeks after your baby is born with 
specialised weighing scales which we will provide. This will take less than 5 minutes each day.  
We would like to measure your body composition as before and your bone mineral density by DEXA scan within 2 weeks 
of you giving birth. The appointment will last, at most, 45 minutes. During this time we will measure your height and 
weight and perform a bone density scan. 
The bone density scan does not work if you are wearing any metal objects like buckles, zips or rings, so we do ask you 
to wear tracksuit bottoms and a T-shirt, if possible. The bone density scan involves lying on a table and a small scanning 
arm will pass over, about two feet in the air; it does not touch you. The dose of x-rays is equivalent to about three 
day’s natural background x-rays (or a day trip to Cornwall). The scan will not cause any pain or harm.  
We would like to follow your baby for his/her first 6 months of life. You will receive a separate information sheet 
about this and you will have the opportunity to discuss this further and to ask any questions that you might have 
before deciding if you wish to help with this research.  
At the follow up appointment (or at a mutually convenient time) we would like to perform some skin prick testing on you 
and your partner. This is to confirm the allergies you told us about when we first met you. Skin prick testing is   13
performed by placing a drop of clear solution on the arm and pricking the skin through the solution. From your partner 
we would like to take a blood sample (10mls, about 2 teaspoonfuls). 
All blood and breast milk samples donated for this research study will be frozen and stored for analyses related to the 
development of allergy. 
5 What are the possible benefits of taking part? 
By participating in this study you may be able to help other children in the future from developing allergies. 
6 What are the possible disadvantages and risks of taking part? 
Taking blood can occasionally cause some discomfort and bruising. Skin prick testing can cause some local itching which 
may last for about 15-30 minutes and can be relieved by using some calamine lotion. You will be giving up your time to 
help us with research including a longer appointment at your routine 20 week NHS ultrasound scan appointment and 2 
extra appointments at the Princess Anne Hospital at 34 and 38 weeks of pregnancy (approximately 1-1½ hours). In 
addition, we would like you to record your consumption of fish, provide breast milk samples (on 4 days over the first 
month), collect your baby’s stools (on 4 days over the first three months), measure your own body composition at home 
by standing on a specialised weighing scale (daily for the first two weeks after you give birth – each weighing will take 
no more than 5 minutes), and if possible allow your bone density to be measured within two weeks of giving birth (this 
will require a visit to the Princess Anne Hospital for a 45 minute appointment). 
7 What will happen if anything goes wrong? 
If you have a concern about any aspect of the study you should speak to the researchers who will do their best to 
answer your questions (telephone 023 8079 6925). If you remain unhappy and wish to complain formally you should 
contact the Wellcome Trust Clinical Research Facility in the first instance (telephone 023 8079 4989). Any complaint 
about the way that you have been dealt with during the study or any possible harm you might suffer will be addressed.  
In the unlikely event that you are harmed due to someone’s negligence, then you may have grounds for a legal action 
for compensation but you may have to pay your legal costs.  
8 Will my taking part in this study be kept confidential? 
All information which is collected about you during the course of the research will be kept strictly confidential. We 
will inform your GP that we have approached you and will notify them of your participation. 
9 What will happen to the study results? 
The results will be submitted for publication in medical literature. If you wish to see copies of any reports and 
publications, please contact the researchers listed and they will be happy to supply these for you. Once the study is 
complete, an open meeting will be arranged so that participants may discuss outcomes and get a summary of the 
results. 
10 Will I be reimbursed? 
We will reimburse you your travel expenses and parking fee at each appointment. 
11 Who is funding the study? 
This study is funded by the European Commission (website: http://ec.europa.eu/index_en.htm). 
12 Who has reviewed the study? 
The Southampton and South West Hampshire Local Research Ethics Committees. 
13 Contact for further information 
If you have any questions then please contact the SIPS Project Research Team on the numbers/email given on the 
front of this leaflet. 
Thank you for taking the time to read this   14
Appendix E: SIPS power calculation  
 
The overall SIPS study was powered according to three outcomes, fatty acid composition 
of maternal plasma phospholipids, infant sensitisation to at least one common allergen, 
and maternal body composition. 
  
Fatty acid composition of plasma phospholipids. Based upon previous work, the content 
of EPA in plasma phospholipids in these women was expected to be approx. 1% of fatty 
acids. Two salmon meals per week were anticipated to provide a total of approximately 4 
g EPA + DHA/week; of this about 2.8 g will be EPA, equivalent to an increased intake of 
0.4 g EPA/day (background intake was expected to be approx. 0.1 g/day). This was 
expected to increase the EPA content of plasma phospholipids by 50% to about 1.5% of 
fatty acids. Using known standard deviations for the EPA content of plasma 
phospholipids in adult women in the Southampton area, a sample size of 50 per group 
was anticipated to have a 99% power to detect this difference with p < 0.05 (90% power 
to detect with p < 0.001). 
 
Sensitisation to at least one common allergen. Infants born to women recruited into the 
study will be at high risk of becoming sensitized to allergens. Based upon previous 
studies of such cohorts of infants in Southampton it was anticipated that 45% of infants 
would be sensitized at 6 months of age. It was estimated that infants of women in the oily 
fish group will be 30% less likely to have been sensitized (this is based upon data from 
Dunstan et al. using fish oil in at risk pregnant women). A sample size of 50 per group 
will have a 70% power to detect this difference with p < 0.05.  
  
Maternal body composition. A sample size of 100 subjects was proposed to be sufficient 
to establish prediction equations at each stage of pregnancy. If unified measurements 
made at each of three stages of pregnancy are pooled this would involve 300 pregnancy 
measurements. A sample size of 100 at each time point would be sufficient to establish a 
correlation as low as 0.26 (r
2 = 0.07) between bioelectrical impedance indices and birth 
weight, with 80% power and p< 0.05. The same sample size is sufficient to detect a 7 
ohm difference in reactance between the control and intervention group (mean in late 
pregnancy ~60 + 12 ohms) with p = 0.05 and power of 80%.   15
Appendix F: SIPS Consent form for pregnant women 
 
Thank you for reading the information about our research project. If you would like to 
take part, please read and sign this form. 
Title of study: The effects of oily fish in pregnancy on signs of allergic diseases in 
infants at high risk of developing allergies 
Study ID Number………………………………………………………………………….. 
Chief Investigator: Professor Philip Calder, Tel: 023 8079 5250 
Contact details for research team: Dr Liz Miles, Tel: 023 8079 6925 or 023 8079 5252 
PLEASE INITIAL THE BOXES IF YOU AGREE WITH EACH SECTION: 
 
8.  I have read the information sheet dated 15/05/07 (version 2) for the above study and 
have been given a copy to keep. I have had the opportunity to ask questions, understand 
why the research is being done and any possible risks which have been explained to me. 
 
9.  I understand that my participation in this study is voluntary and that I am free to 
decline entry into the study, and that during the study I am free to withdraw at any 
time without giving a reason and that withdrawal will not affect any future medical care. 
 
10.  Samples to be collected. I agree to give a sample of my blood, urine, umbilical cord 
blood, umbilical cord, placenta, stool and breast milk (if applicable) for research in this 
project (delete as appropriate). I agree to be skin prick tested. I understand how the 
samples will be collected and how these procedures will be performed and that they will 
be used for the purposes if this investigation and will then be disposed of. I understand 
that my name will not be linked to these samples. 
 
11.  I agree to have my body composition measured by bioelectrical impedence and 
bone mineral density measured by DEXA scan.   
       
12.  Information to be collected. I give permission for someone from the research team to 
look at my medical notes to get information pertinent to the study. I understand that 
the information will be kept confidential. 
 
13.  I understand that my Doctor will be informed of my participation in the study. 
 
7.   I agree to take part in the above study 
 
 
_________________ _              ___________           ___________________ 
Name  of  Patient    Date    Signature 
 
 
_________________ _              ___________           ___________________ 
Name of Person taking consent   D a t e     S i g n a t u r e  
 
1 for patient, 1 for researcher, 1 to be kept with hospital notes. 
Version 3, 12
th October 2007    Ethics Number: 07/Q1704/43   16





Date informed consent given 
 
19 week visit check list (please tick when sample/data collected): 
 
a Urine  sample 
 
b Blood  sample 
 
c  Food frequency questionnaire 
 
d Ultrasound  scan 
 
e Body  composition 
 










Telephone – home/work 
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 Personal  Details 
 








Community midwife & clinic 
 
Health visitor & clinic 
 
Doctor & surgery 
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4. Medication/supplements/vitamins (taken in the last 4 weeks) 
Therapy  Dose route and regimen  Date started/stopped 
 
 
   
 
 
   
 
 
   
 
 
   
 
 
   
 
 
5. Number of pregnancies (including this pregnancy) 
 
6. Number of children 
 
7. History of smoking Never / Past smoker / current smoker 
 






8. Current alcohol intake in drinks per week (1 beer or 1 glass of wine or 1 
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  Activity and Exercise 
 
Can I firstly ask you about your activity and exercise patterns over the last three months? As 
before, we would like you to divide up a “typical” day into three types of activity. These are: 
    (1) sleeping or lying,    (2) sitting,  (3) standing or walking. 
 
 
10.1  Over a typical 24 hour day how many hours have you generally 
spent sleeping or lying with your feet up?                  
      
     hrs            mins    
  
(ask time usually go to bed & wake up, including any at work!) 
 
  This would indicate xx hours sitting or on your feet. 
 
10.2  Of those hours how many on a typical day have you spent sitting  
down?  (e.g. includes sitting at work, mealtimes,  driving, reading, 
watching TV)                                                                                      
                         
    hrs              mins 
                                                                                               
10.3  This would mean that you have spent about xx hours a day on your 
feet.  Does this sound about right? 
                                                                                                                                      
           
            hrs                 mins 
 
10.4  Out of these xx hours spent on your feet, about how much of the 
time were you actively on the move (rather than standing fairly still)? 
 
  1.  Very  little  10% 
  2.  Some   30% 
    3. About  half  50% 
  4.  Most   70% 
  5.  Almost  all  90% 
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10.5  During the past three months, how often have you done the 
following kinds of exercise or activities? 
 
a)   strenuous exercise which made your heart beat rapidly AND left 
you breathless e.g. jogging, vigorous swimming or cycling, aerobics. 
      
                 FFQ categories 1-7               >x1              
        
and on average about how long did each period of activity last?    
    
 
            hrs               mins 
 
b) moderate  exercise  which left you exhausted but not breathless, 
e.g. brisk walking, dancing, easy swimming or cycling, badminton, 
sailing. 
 
     FFQ categories 1-7                   >x1 
 
 
and on average  about how long did each period of activity last?  
 
            
    hrs                      mins         
 
c)  gentle exercise  which left you tired but not exhausted, e.g. 
walking, heavy housework (including washing windows and polishing), 
gardening, DIY, golf. 
 
  FFQ categories 1-7                     >x1 
 
 
and on average  about how long did each period of activity last?  
 
         hrs     mins 
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10.6  Which of the following best describes your walking speed at 
present? 
  1.  Very  slow 
    2.  Stroll at an easy pace 
  3.  Normal  speed 
  4.  Fairly  brisk 
  5 .   F a s t  
 
Family Social History 
 
18. Mothers’ occupation 
 
19. Fathers’ occupation 
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Bioelectrical impedance 
(Note – individuals with indwelling medical devices must not have 
bioelectrical impedance measurements taken 
 
22. Do you have any indwelling electrical devices (i.e. pacemakers)? 
 








Ask volunteer to empty bladder. Take measurements and attach print off 














Thank you for giving us this information 
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Appendix H: SIPS Food Frequency Questionnaire for Women  
 





Volunteer Number        
Name 







Version 1, 1 September 2006           Ethics Number: 07/Q1704/43 
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2:   DIETARY QUESTIONS 
2.1  Now I am going to ask you about the foods you have eaten over the past 3 months. To do this I have a list of foods and I would like you to tell me how often 
you have eaten each food.  As before the list may include foods you never ate or you may find foods which you eat a lot are missing.  These can be added on at the 
end. (Define the 3 month period) 
 
 
 FOOD  DESCRIPTION  FREQUENCY EATEN 
FOOD 
CODE 











































When you ate bread/toast/sandwiches, how many slices/rolls did you eat at 
a typical meal? 
                                                                                                     . 
Rolls (count as 2 slices) 




















              
 
 
How many slices/rolls did you eat at a typical meal? 
                                                                                                     . 























































   25 
 
 FOOD  DESCRIPTION  FREQUENCY EATEN 
FOOD 
CODE 
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 FOOD  DESCRIPTION  FREQUENCY EATEN 
FOOD 
CODE 













































































When you ate these how many potatoes did you  
eat at a typical meal? 
                                                                                                          . 























When you ate these how many potatoes did you 
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 FOOD  DESCRIPTION  FREQUENCY EATEN 
FOOD 
CODE 
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 FOOD  DESCRIPTION  FREQUENCY EATEN 
FOOD 
CODE 
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 FOOD  DESCRIPTION  FREQUENCY EATEN 
FOOD 
CODE 
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 FOOD  DESCRIPTION  FREQUENCY EATEN 
FOOD 
CODE 









































Soft drinks not including diet drinks 
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 FOOD  DESCRIPTION  FREQUENCY EATEN 
FOOD 
CODE 
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 FOOD  DESCRIPTION  FREQUENCY EATEN 
FOOD 
CODE 
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 FOOD  DESCRIPTION  FREQUENCY EATEN 
FOOD 
CODE 
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 FOOD  DESCRIPTION  FREQUENCY EATEN 
FOOD 
CODE 

































































































Spreading fat (1) 



















Spreading fat (2) 



















Spreading fat (3) 



















Frying fat  or oil (1) 



















Frying fat or oil (2) 
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Frying fat or oil (3) 
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 FOOD  DESCRIPTION  FREQUENCY EATEN 
FOOD 
CODE 



















once a day 
 
99 
Other vegetable oil (1) 



















Other vegetable oil (2) 


















 2.2  Are there food or drinks which you have eaten or drunk once a week or more which are not on the list? Include breakfast bars such as Nutrigrain and 
Kellogg’s       0.No/1.  Yes 
 
If Yes, name of food/drink 
 































Now I would like to ask in more detail about some specific foods 
 
2.3:  Which types of milk have you used regularly in drinks and added to breakfast cereals 
over the last 3 months? 
  0.  None 
  1.  Whole  pasteurised 
  2.  Semi-skimmed  pasteurised 
  3.  Skimmed  pasteurised 
  4.  Whole  UHT 
 5.  Semi-skimmed  UHT 
  6.  Skimmed  UHT 
  7.  Other 
 
            Milk 1                    Other (specify)___________________________________   
 
  
                        Milk 2                    Other (specify)___________________________________   
                      
                          
            Milk 3                    Other (specify)___________________________________   
  
 
2.4  On average over the last 3 months how much 
 *     of each milk have you consumed per day?                      
  
    Milk 1                                                           .                   pints                                    
     
  
      Milk 2                            .         pints 
  
  
       Milk 3                      .         pints   
      
2.5  Have you added sugar to breakfast cereals, tea & coffee,    
     puddings etc.?         
  0.  No  go to 2.7   
    1. Yes                       
                                                              
2.6  Approximately how many teaspoons of sugar have you                                  
     added each day?                                
                                                        
 
2.7   When you eat meat, how much of the fat have you           
      usually cut off (including chicken skin)?               
                 1. all       100%                                            
        2. most      60%                                            
        3. some     30%                                            
        4. none        0%                                            
          9. not applicable                  
                                       37
2.8  Just thinking about the past week how many servings did you eat of: 
Vegetables and vegetable-containing dishes (excluding potatoes)?   
fruit and pure fruit juices?   
 meat and fish and their dishes?   
 
3: FOOD  SUPPLEMENTS & DIETARY CHANGES 
 
3.1  During the past three months have you taken any pills, tonics or tablets to supplement 
your diet?  (e.g. vitamins, minerals, iron tablets, folic acid, fish oils etc.)  
  0. No     1. Yes                     
           If yes, please state which:  











Did you start taking this: 
1: Less than 1 month ago 
2: 1-2 months ago 
3: More than 2 months ago 
 
     
 
     
 
     
 
     
 
     
 
 
5: ALCOHOL  CONSUMPTION 
 
I’d like to ask you a few questions about your drinking and smoking habits. 
    
5.1  Do you ever drink alcohol? 
 0.  No  go to section 6 
  1. Yes 
 
5.2  During the past three months: 
 
  a) How often have you drunk                                      
        Shandy or Low Alcohol Beer/Lager/Cider?   FFQ 1-7         >x1 
  (don't  include  alcohol  free lager etc)  
                                                                
  b) When you drank these how many pints did you  
    normally have?                                                                               . 
     (if range given code mid-point)                     
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5.3  a) How often have you drunk                                         
  Beer/Stout/Lager/Cider/Alcopops?                FFQ 1-7           >x1  
                                                                                                     
  b) When you drank these how many pints did you  
    normally have?                                                                               . 
     (if range given code mid-point)               
 
 5.4  a) How often have you drunk                                     
        Low alcohol wine?                                FFQ 1-7            >x1     
                                                         
  b) When you drank this how many glasses did you  
    normally have?                                                                               . 
  (if range given code mid-point)                                                                         
 
5.5  a) How often have you drunk                               
        Wine/Sherry/Martini/Cinzano?               FFQ 1-7             > x1  
                                                                
  b) When you drank these how many glasses did you  
    normally have?                                                                                 . 
  (if range given code mid-point)                                                                                              
           
5.5  a)  How often have you drunk                               
        Spirits/Liqueurs?                      FFQ 1-7              > x1 
 
    b) When you drank these how many measures did you  
    normally have?                                                                                 . 
  (if range given code mid-point)                                                                                              
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DIETARY QUESTIONS ON FOOD ITEMS FORTIFIED WITH ESSENTIAL FATTY ACIDS, PROBIOTICS, PREBIOTICS 
 
We are particularly interested in your consumption of food items with added omega-3, omega-6, probiotics or prebiotics.  I have a list of food items 
that have these things added to help you remember the specific products you may consume. Are there foods or drinks with added omega-3, omega-6, 
probiotics or prebiotics that you have eaten or drunk once a week or more?  
 
                                  0.No/1. Yes   
If Yes 
Name of food/drink  Code  Portion  Number of days per week  More than 
once a day 
    
1 2 3 4 5 6 7 
 
    
1 2 3 4 5 6 7 
 
    
1 2 3 4 5 6 7 
 
    
1 2 3 4 5 6 7 
 
    
1 2 3 4 5 6 7 
 
    
1 2 3 4 5 6 7 
 
    
1 2 3 4 5 6 7 
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Appendix I: SIPS Salmon consumption diary during pregnancy 
Volunteer Number 
 
Volunteer Name   
Please tick the days on which you eat your salmon. This should be twice per week. Could you 
also include any other fish you eat (which type and how it is cooked). Thank you. SIPS 
research team (tel: 02380 796925 or 02380 795252). 
Month 5 / date started…………………….  Fish eaten 
Week 21 – day 1   
Week 21 – day 2   
Week 21 – day 3   
Week 21 – day 4   
Week 21 – day 5   
Week 21 – day 6   
Week 21 – day 7   
Week 22 – day 1   
Week 22 – day 2   
Week 22 – day 3   
Week 22 – day 4   
Week 22 – day 5   
Week 22 – day 6   
Week 22 – day 7   
Week 23 – day 1   
Week 23 – day 2   
Week 23 – day 3   
Week 23 – day 4   
Week 23 – day 5   
Week 23 – day 6   
Week 23 – day 7   
Week 24 – day 1   
Week 24 – day 2   
Week 24 – day 3   
Week 24 – day 4   
Week 24 – day 5   
Week 24 – day 6   
Week 24 – day 7     41
Appendix J: SIPS Fish consumption dairy during pregnancy 
 
Please tick the days on which you eat fish and write what type of fish it is and how it 
is cooked, i.e., baked cod in crumbs; smoked haddock, poached; fresh tuna, fried; 
tinned tuna; fresh trout, grilled. 
During your pregnancy, while you are on the study (i.e. from the 20
th week until 
delivery) please could you avoid eating more than 1 portion of oily fish per month. We 
have listed some examples of oily fish below. You can eat as much non-oily fish as you 
usually like to. We have listed some examples of non-oily fish below. Thank you. SIPS 
research team (tel: 023 8079 6925 or 023 8079 5252). 
Oily Fish  Non-oily/white fish 
Please eat no more than once per month  Eat as much as usual 
















Cod    
Tinned tuna                       
Haddock                   
Plaice                       
Coley                                           











     Marlin         
    Sea bream                    
    Lemon sole  
    Halibut 
    Shark 
    Pollack 
    Monk fish 
   Cat fish                  
    Red snapper 
    Seabass    
    Dover sole 
    Crab 
 




Volunteer Name   
Please tick the days on which you eat fish and write which type and how it is cooked. Thank 
you. SIPS research team (tel: 023 8079 6925 or 023 8079 5252). 
Month 5 / date started…………………….  Fish eaten 
Week 21 – day 1   
Week 21 – day 2   
Week 21 – day 3   
Week 21 – day 4   
Week 21 – day 5   
Week 21 – day 6   
Week 21 – day 7   
Week 22 – day 1   
Week 22 – day 2   
Week 22 – day 3   
Week 22 – day 4   
Week 22 – day 5   
Week 22 – day 6   
Week 22 – day 7   
Week 23 – day 1   
Week 23 – day 2   
Week 23 – day 3   
Week 23 – day 4   
Week 23 – day 5   
Week 23 – day 6   
Week 23 – day 7   
Week 24 – day 1   
Week 24 – day 2   
Week 24 – day 3   
Week 24 – day 4   
Week 24 – day 5   
Week 24 – day 6   
Week 24 – day 7   
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34 week visit check list (please tick when sample/data collected): 
 
a Urine  sample 
 
b Blood  sample 
 
c  Food frequency questionnaire 
 
d Ultrasound  scan 
 
e Body  composition 
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4. Medication/supplements/vitamins (taken in the last 4 weeks) 
Therapy  Dose route and regimen  Date started/stopped 
 
 
   
 
 
   
 
 
   
 
 
   
 
 
   
 
5. Do you currently smoke? Yes / No 
 






6. How many alcoholic beverages per week do you drink at the moment (1 
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  Activity and Exercise 
Can I firstly ask you about your activity and exercise patterns over the last three months? As 
before, we would like you to divide up a “typical” day into three types of activity. These are: 
    (1) sleeping or lying,    (2) sitting,  (3) standing or walking. 
 
 
10.1  Over a typical 24 hour day how many hours have you generally 
spent sleeping or lying with your feet up?                  
      
     hrs            mins    
  
(ask time usually go to bed & wake up, including any at work!) 
 
  This would indicate xx hours sitting or on your feet. 
 
10.2  Of those hours how many on a typical day have you spent sitting  
down?  (e.g. includes sitting at work, mealtimes,  driving, reading, 
watching TV)                                                                                      
                         
    hrs              mins 
                                                                                               
10.3  This would mean that you have spent about xx hours a day on your 
feet.  Does this sound about right? 
                                                                                                                                      
           
            hrs                 mins 
 
10.4  Out of these xx hours spent on your feet, about how much of the 
time were you actively on the move (rather than standing fairly still)? 
 
  1.  Very  little  10% 
  2.  Some   30% 
    3. About  half  50% 
  4.  Most   70% 
  5.  Almost  all  90% 
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10.5  During the past three months, how often have you done the 
following kinds of exercise or activities? 
 
a)   strenuous exercise which made your heart beat rapidly AND left 
you breathless e.g. jogging, vigorous swimming or cycling, aerobics. 
      
                 FFQ categories 1-7               >x1              
        
and on average about how long did each period of activity last?    
    
 
            hrs               mins 
 
b) moderate  exercise  which left you exhausted but not breathless, 
e.g. brisk walking, dancing, easy swimming or cycling, badminton, 
sailing. 
 
     FFQ categories 1-7                   >x1 
 
 
and on average  about how long did each period of activity last?  
 
            
    hrs                      mins         
 
d)  gentle exercise  which left you tired but not exhausted, e.g. 
walking, heavy housework (including washing windows and polishing), 
gardening, DIY, golf. 
 
  FFQ categories 1-7                     >x1 
 
 
and on average  about how long did each period of activity last?  
 
         hrs     mins 
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10.6  Which of the following best describes your walking speed at 
present? 
  1.  Very  slow 
    2.  Stroll at an easy pace 
  3.  Normal  speed 
  4.  Fairly  brisk 
  5 .   F a s t  
 
 







(Note – individuals with indwelling medical devices must not have 
bioelectrical impedance measurements taken 
 
9. Do you have any indwelling electrical devices (i.e. pacemakers)? 
 







Ask volunteer to empty bladder. Take measurements and attach print off 
securely to this page. 
 
 
Thank you for giving us this information 
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38 week visit check list (please tick when sample/data collected): 
 
a Urine  sample 
 
b Blood  sample 
 
c Stool  sample 
 
 
 General  Health 
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 4. Medication/supplements/vitamins (taken in the last 4 weeks) 
Therapy  Dose route and regimen  Date started/stopped 
 
 
   
 
 
   
 
 
   
 
 
   
 
 
   
 
5. Do you currently smoke? Yes / No 
 






6. How many alcoholic beverages per week do you drink at the moment (1 
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  Activity and Exercise 
Can I firstly ask you about your activity and exercise patterns over the last three months? As before, we 
would like you to divide up a “typical” day into three types of activity. These are: 




10.1  Over a typical 24 hour day how many hours have you generally 
spent sleeping or lying with your feet up?                  
      
     hrs            mins    
  
(ask time usually go to bed & wake up, including any at work!) 
 
  This would indicate xx hours sitting or on your feet. 
 
10.2  Of those hours how many on a typical day have you spent sitting  
down?  (e.g. includes sitting at work, mealtimes,  driving, reading, 
watching TV)                                                                                      
                         
    hrs              mins 
                                                                                               
10.3  This would mean that you have spent about xx hours a day on your 
feet.  Does this sound about right? 
                                                                                                                                      
           
            hrs                 mins 
 
10.4  Out of these xx hours spent on your feet, about how much of the 
time were you actively on the move (rather than standing fairly still)? 
 
  1.  Very  little  10% 
  2.  Some   30% 
    3. About  half  50% 
  4.  Most   70% 
  5.  Almost  all  90% 
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10.5  During the past three months, how often have you done the 
following kinds of exercise or activities? 
 
a)   strenuous exercise which made your heart beat rapidly AND left 
you breathless e.g. jogging, vigorous swimming or cycling, aerobics. 
      
                 FFQ categories 1-7               >x1              
        
and on average about how long did each period of activity last?    
    
 
            hrs               mins 
 
b) moderate  exercise  which left you exhausted but not breathless, 
e.g. brisk walking, dancing, easy swimming or cycling, badminton, 
sailing. 
 
     FFQ categories 1-7                   >x1 
 
 
and on average  about how long did each period of activity last?  
 
            
    hrs                      mins         
 
e)  gentle exercise  which left you tired but not exhausted, e.g. 
walking, heavy housework (including washing windows and polishing), 
gardening, DIY, golf. 
 
  FFQ categories 1-7                     >x1 
 
 
and on average  about how long did each period of activity last?  
 
         hrs     mins 
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10.6  Which of the following best describes your walking speed at 
present? 
  1.  Very  slow 
    2.  Stroll at an easy pace 
  3.  Normal  speed 
  4.  Fairly  brisk 
  5 .   F a s t  
 
 










Thank you for giving us this information 
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Appendix M: Institute of Human Nutrition fatty acid methyl 
ester standard mix for gas chromatography 
 
Fatty acid methyl ester  Concentration in mixture 
(mg/mL) 
Lauric 12:0  1 
Myristic 14:0  2 
Palmitic 16:0  1 
Palmitoleic 16:1n-7  2 
Stearic 18:0  1 
Oleic 18:1n-9  2 
Linoleic 18:2n-6  1 
γ-linolenic 18:3n-6  1 
α-linolenic 18:3n-3  2 
Arachidic 20:0  2 
Eicosenoic 20:1n-9  1 
Eicosadienoic 20:2n-6  1 
Dihomo-γ-linolenic 20:3n-6  1 
Arachidonic 20:4n-6  2 
Behenic 22:0  2 
Lignoceric 24:0  1 
Nervonic 24:1n-9  2 
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Appendix N: Gas chromatography settings for analysis of 
fatty acid methyl esters using a BPX-70 column 
 
 
1.  Oven 
Max temperature   250ºC 
Equilibration time   1 min 
Initial temperature   115ºC 
Initial time     2 min 
 
Ramp  1    Rate    10ºC/min 
  Final  temperature  200ºC 
  Final  time   18.5  min 
 
Ramp  2 Rate    60ºC/min 
  Final  temperature  245ºC 
  Final  time   8  min 
 
Run time  37.75 min 
 
 
2.  Front inlet  Temperature    300ºC 
Pressure   14.75psi 
Gas saver    on 
Saver flow    20mL/min 
Saver time    2 min 
Gas type    Helium 
 
3.  Column  Length    30m 
Diameter   220μm 
Film thickness   0.25μm 
Initial flow    0.1mL/min 
Average velocity  31cm/min 
Outlet pressure  ambient 
 
4.  Detector Temperature    300ºC 
Hydrogen flow  40mL/min 
Air flow    184mL/min 
 
Constant makeup flow 
Makeup flow    45L/min 
Makeup gas    Helium 
Electrometer   on 
Lit offset    2 
 